



(51) International Patent Classification:
Not classified

(21) International Application Number:
PCT/US2023/065552

(22) International Filing Date:
07 April 2023 (07.04.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/329,003 08 April 2022 (08.04.2022) US

(71) Applicant: **2SEVENTY BIO, INC.** [US/US]; 60 Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: **JARJOUR, Jordan**; 11014 37th Avenue SW, Seattle, Washington 98146 (US). **LELEUX, Jardin Alexandra**; 12711 Evanston Ave N., Seattle, Washington 98133 (US). **POGSON, Mark**; 3122 SE 16th Street, North Bend, Washington 98045 (US).

(74) Agent: **GASTONGUAY, Adam** et al.; c/o 2seventy bio, Inc., 60 Binney Street, Cambridge, Massachusetts 02142 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,

(54) Title: MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES




FIG. 1D

(57) Abstract: The present disclosure provides adoptive T cell therapies that have improved architectures for targeting antigens and recruiting multimeric immune signaling complexes for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.

SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

MULTIPARTITE RECEPTOR AND SIGNALING COMPLEXES

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 63/329,003, filed April 8, 2022, which is incorporated by reference herein in its
5 entirety.

BACKGROUND

Technical Field

The present disclosure relates to improved adoptive cell therapies. More particularly, the disclosure relates to improved immune receptor signaling molecules, cells, and methods
10 of using the same for modulating spatial and/or temporal control of immune receptor signal initiation and downstream responses during adoptive immunotherapy.

Description of the Related Art

The global burden of cancer doubled between 1975 and 2000. Cancer is the second leading cause of morbidity and mortality worldwide, with approximately 14.1 million new
15 cases and 8.2 million cancer related deaths in 2012. The number of new cancer cases is projected to rise to 22 million within the next two decades.

Although chemotherapies and subsequently biologics have been the standard of care for decades now, adoptive cellular therapy is emerging as a powerful paradigm for delivering complex biological signals to treat cancer. In contrast to small molecule and biologic drug
20 compositions, adoptive cell therapies have the potential to execute unique therapeutic tasks owing to their myriad sensory and response programs and increasingly defined mechanisms of genetic control. To achieve such therapeutic value, cells need to be outfitted with machinery for sensing and integrating chemical and/or biological information associated with local physiological environments.

25 In recent years, outfitting cells with chimeric antigen receptors (CARs) or transgenic T cell receptors (TCRs) have proven to be a potent way to target immune cells to a particular

antigen (*e.g.*, a tumor antigen), stimulate T cell activating signal transduction, and ultimately attack and kill the antigen-associated cell (*e.g.*, cancer cell). Despite these successes there remains fundamental differences and limitations between the two architectures including i) sensitivity ii) antigen recognition, iii) antigen independent signaling activity, and iv) lack of
5 regulatability. Accordingly, there remains a need for improved targeting and signaling machinery that more potently sense and respond to target antigens and associated cells.

BRIEF SUMMARY

The present disclosure generally relates, in part, to engineered immunoreceptor complexes that can both recognize a target antigen and recruit and activate a natural or a
10 transgenic immunoreceptor signaling complex, *e.g.*, a T cell receptor (TCR) signaling complex, polynucleotides and polypeptides encoding the same, compositions thereof, and methods of making and using the same to treat a disorder or disease (*e.g.*, cancer or autoimmune).

In one aspect, disclosed herein is a non-natural cell, comprising a signaling
15 component comprising (i) a first multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (ii) a first polypeptide linker, and (iii) a CD3 ϵ polypeptide or variant thereof; and a targeting component comprising (i) an anti-CLL1 scFv or single domain antibody (sdAb), (ii) an anti-CD33 scFv or single domain antibody (sdAb), (iii) a second polypeptide linker, (iv) a second multimerization domain
20 comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (v) a CD4 hinge polypeptide, (vi) a CD4 transmembrane polypeptide, and (vii) a truncated CD4 intracellular polypeptide.

In some embodiments, the targeting component does not comprise a functional intracellular domain or costimulatory domain having signaling capabilities. In some
25 embodiments, the CD4 hinge polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 41. In one embodiment, the CD4 hinge polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 41.

In some embodiments, the CD3 ϵ polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 32. In one
30 embodiment, the CD3 ϵ polypeptide comprises an amino acid sequence as set forth in SEQ ID

NO: 32. In some embodiments, the CD3ε polypeptide comprises both extracellular and intracellular portions.

In some embodiments, the FRB and FKBP polypeptides localize extracellularly when the signaling and targeting components are expressed. In some embodiments, the first and second multimerization domains are different. In some embodiments, the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP12 polypeptide or variant thereof. In some embodiments, the first multimerization domain comprises an FKBP12 polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof. In one embodiment, the FRB polypeptide is an FRB T2098L variant. In some embodiments, the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 1. In some embodiments, the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 2. In some embodiments, the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 3. In some embodiments, the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 4.

In some embodiments, the multimerization domains of the signaling component and the targeting component associate with a bridging factor. In some embodiments, the bridging factor is selected from the group consisting of: rapamycin or a rapalog thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A or a derivative thereof, trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof, wherein the bridging factor promotes the formation of a polypeptide complex, with the bridging factor associated with and disposed between the multimerization domains of the signaling and targeting components. In some embodiments, the bridging factor is AP1903, AP20187, AP21967 (also known as C16-(S)-7-methylindolerapamycin), everolimus, novolimus, pimecrolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus, umirolimus, zotarolimus, or BPC015.

In some embodiments, the first polypeptide linker is a linker of 2 to 40 amino acids in length. In some embodiments, the first polypeptide linker is selected from the group

consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, 5xG4S, and any combination thereof. In one embodiment, the first polypeptide linker is a 3xG4S linker. In some embodiments, the second polypeptide linker is a linker of 2 to 40 amino acids in length. In some embodiments, the second polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof. In one embodiment, the second polypeptide linker is a G4S linker. In some embodiments, the anti-CLL1 scFv or sdAb and the anti-CD33 scFv or sdAb are separated by a third polypeptide linker. In some embodiments, the third polypeptide linker is a linker of 2 to 40 amino acids in length. In some embodiments, the third polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof. In some embodiments, the third polypeptide linker is a G4S linker.

In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 45. In some embodiments, the CD4 transmembrane polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 45. In some embodiments, the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 48. In one embodiment, the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 49.

In some embodiments, the anti-CLL1 and anti-CD33 antibodies are each a sdAb. In some embodiments, the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb). In one embodiment, the sdAb is a camelid VHH. In some embodiments, the scFv or sdAb is human or humanized. In some embodiments, the anti-CLL1 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 92, 93, and 94, respectively. In some embodiments, the anti-CLL1 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 75. In some embodiments, the anti-CLL1 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 75. In some embodiments, the anti-CD33 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 89, 90, and 91, respectively. In some embodiments, the anti-CD33 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the anti-CD33 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 72.

In some embodiments, the signaling component further comprises a signal sequence. In some embodiments, the signal sequence is a CD8 signal sequence. In some embodiments, the CD8 signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In one embodiment, the CD8 signal sequence

5 comprises an amino acid sequence set forth as SEQ ID NO: 96. In some embodiments, the targeting component further comprises a signal sequence. In some embodiments, the signal sequence is an IgK signal sequence. In some embodiments, the IgK signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 95. In one embodiment, the IgK signal sequence comprises an amino

10 acid sequence set forth as SEQ ID NO: 95. In some embodiments, the signaling component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 111. In one embodiment, the signaling component comprises a sequence set forth as SEQ ID NO: 111. In some embodiments, the targeting component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth as SEQ

15 ID NO: 122. In one embodiment, the targeting component comprises a sequence set forth as SEQ ID NO: 122.

In some embodiments, the non-natural cell comprises a fusion polypeptide which comprises the targeting component and the signaling component. In some embodiments, the fusion polypeptide comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 151. In one embodiment, the fusion polypeptide comprises a

20 sequence set forth as SEQ ID NO: 151.

In some embodiments, the cell comprises a first nucleic acid molecule encoding the signaling component. In some embodiments, the cell comprises a second nucleic acid molecule encoding the targeting component. In some embodiments, the cell comprises a

25 nucleic acid molecule that encodes both the signaling component and the targeting component.

In some embodiments, the cell further expresses an exogenous costimulatory factor, immunomodulatory factor, agonist for a costimulatory factor, antagonist for an immunosuppressive factor, immune cell engager, flip receptor, or any combination thereof. In

30 some embodiments, the cell further expresses an exogenous lymphocyte receptor or co-receptor. In some embodiments, the exogenous lymphocyte receptor or co-receptor is selected from the group consisting of: TCR alpha (TCR α), TCR beta (TCR β), TCR gamma (TCR γ), TCR delta (TCR δ), CD4, CD8, pre T cell receptor α (pT α), Fc receptor alpha

(FcR α), Fc receptor beta (FcR β), Fc receptor gamma (FcR γ), natural killer group 2 member D (NKG2D), CD79A, CD79B, and any combination thereof. In some embodiments, the cell further expresses an exogenous TCR. In some embodiments, the exogenous TCR binds a target antigen selected from the group consisting of: α -fetoprotein (AFP), B Melanoma

5 Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-

10 8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human Epidermal Growth Factor Receptor 2 (HER-2), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3,

15 MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X

20 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, Wilms tumor protein (WT-1), X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2). In some embodiments, the exogenous TCR is an $\alpha\beta$ -TCR or $\gamma\delta$ -TCR.

In some embodiments, the cell further expresses a CAR, CCR, or flip receptor. In

25 some embodiments, the cell further expresses a zetakine, immune cell engager, or BiTE. In one embodiment, the cell is a hematopoietic cell. In some embodiments, the cell is a T cell, an $\alpha\beta$ -T cell, or a $\gamma\delta$ -T cell. In some embodiments, the cell is a CD3⁺, CD4⁺, and/or CD8⁺ cell. In some embodiments, the cell is an immune effector cell. In some embodiments, the cell is a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell. In

30 some embodiments, the cell is a natural killer (NK) cell or natural killer T (NKT) cell. In some embodiments, the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors. In one embodiment, the non-natural cell is an

isolated non-natural cell. In one embodiment, the non-natural cell is obtained from a subject. In one embodiment, the non-natural cell is a human cell. In some embodiments, the cell further comprises a polypeptide having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 137. In one embodiment, the cell further comprises an amino acid sequence as set forth in SEQ ID NO: 137. In some embodiments, the cell further comprises a polypeptide having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 138. In some embodiments, the cell further comprises an amino acid sequence as set forth in SEQ ID NO: 138.

In one aspect, disclosed herein is a fusion polypeptide comprising a signaling component comprising (i) a first multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (ii) a first polypeptide linker, and (iii) a CD3 ϵ polypeptide or variant thereof; and a targeting component comprising (i) an anti-CLL1 scFv or single domain antibody (sdAb), (ii) an anti-CD33 scFv or single domain antibody (sdAb), (iii) a second polypeptide linker, (iv) a second multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (v) a CD4 hinge polypeptide, (vi) a CD4 transmembrane polypeptide, and (vii) a truncated CD4 intracellular polypeptide.

In some embodiments, the targeting component does not comprise a functional intracellular domain or costimulatory domain having signaling capabilities. In some embodiments, the CD4 hinge polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 41. In one embodiment, the CD4 hinge polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 41.

In some embodiments, the CD3 ϵ polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 32. In one embodiment, the CD3 ϵ polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 32. In some embodiments, the CD3 ϵ polypeptide comprises both extracellular and intracellular portions.

In some embodiments, the FRB and FKBP polypeptides localize extracellularly when the signaling and targeting components are expressed. In some embodiments, the first and second multimerization domains are different. In some embodiments, the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP12 polypeptide or variant thereof. In some

embodiments, the first multimerization domain comprises an FKBP12 polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof. In one embodiment, the FRB polypeptide is an FRB T2098L variant. In some embodiments, the FRB polypeptide comprises an amino acid sequence having at least 90%,
 5 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 1. In some embodiments, the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 2. In some embodiments, the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a
 10 sequence set forth as SEQ ID NO: 3. In some embodiments, the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 4.

In some embodiments, the multimerization domains of the signaling component and the targeting component associate with a bridging factor. In some embodiments, the bridging
 15 factor is selected from the group consisting of: rapamycin or a rapalog thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A or a derivative thereof, trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof, wherein the bridging factor promotes the formation of a polypeptide
 20 complex, with the bridging factor associated with and disposed between the multimerization domains of the signaling and targeting components. In some embodiments, the bridging factor is AP1903, AP20187, AP21967 (also known as C16-(S)-7-methylindolerapamycin), everolimus, novolimus, pimecrolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus, umirolimus, zotarolimus, or BPC015.

In some embodiments, the first polypeptide linker is a linker of 2 to 40 amino acids in length. In some embodiments, the first polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, 5xG4S, and any combination thereof. In one embodiment, the first polypeptide linker is a 3xG4S linker. In some embodiments, the second polypeptide linker is a linker of 2 to 40
 30 amino acids in length. In some embodiments, the second polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof. In some embodiments, the second polypeptide linker is a G4S linker. In some embodiments, the anti-CLL1 scFv or sdAb and the anti-CD33 scFv or

sdAb are separated by a third polypeptide linker. In some embodiments, the third polypeptide linker is a linker of 2 to 40 amino acids in length. In some embodiments, the third polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof. In one
 5 embodiment, the third polypeptide linker is a G4S linker.

In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 45. In one embodiment, the CD4 transmembrane polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 45. In one embodiment, the truncated intracellular CD4 polypeptide
 10 comprises an amino acid sequence as set forth in SEQ ID NO: 48. In one embodiment, the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 49. In some embodiments, the anti-CLL1 and anti-CD33 antibodies are each a sdAb. In some embodiments, the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb). In one embodiment, the sdAb is a camelid VHH. In some embodiments,
 15 the scFv or sdAb is human or humanized. In some embodiments, the anti-CLL1 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 92, 93, and 94, respectively. In some embodiments, the anti-CLL1 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 75. In some embodiments, the anti-CLL1 scFv or sdAb comprises a sequence as set forth SEQ ID
 20 NO: 75. In some embodiments, the anti-CD33 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 89, 90, and 91, respectively. In some embodiments, the anti-CD33 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the anti-CD33 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 72.

25 In some embodiments, the signaling component further comprises a signal sequence. In some embodiments, the signal sequence is a CD8 signal sequence. In some embodiments, the CD8 signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In one embodiment, the CD8 signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 96. In some embodiments, the
 30 targeting component further comprises a signal sequence. In some embodiments, the signal sequence is an IgK signal sequence. In some embodiments, the IgK signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 95. In one embodiment, the IgK signal sequence comprises an amino

acid sequence set forth as SEQ ID NO: 95. In some embodiments, the signaling component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 111. In one embodiment, the signaling component comprises a sequence set forth as SEQ ID NO: 111. In some embodiments, the targeting component comprises a sequence
5 having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth as SEQ ID NO: 122. In one embodiment, the targeting component comprises a sequence set forth as SEQ ID NO: 122.

In some embodiments, the fusion polypeptide comprises a fusion polypeptide which comprises the targeting component and the signaling component. In some embodiments,
10 fusion polypeptide comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 151. In one embodiment, the fusion polypeptide comprises a sequence set forth as SEQ ID NO: 151.

In some embodiments, the polypeptide cleavage signal is a viral self-cleaving polypeptide. In some embodiments, the polypeptide cleavage signal is a viral self-cleaving
15 2A polypeptide.

In one aspect, the disclosure provides a nucleic acid molecule that encodes any one of the fusion polypeptides disclosed herein.

In another aspect, the disclosure provides a cell comprising any one of the fusion polypeptides disclosed herein.

20 In another aspect, the disclosure provides a cell comprising any one of the nucleic acid molecules disclosed herein.

In some embodiments, the cell further expresses an exogenous costimulatory factor, immunomodulatory factor, agonist for a costimulatory factor, antagonist for an immunosuppressive factor, immune cell engager, flip receptor, or any combination thereof. In
25 some embodiments, the cell further expresses an exogenous lymphocyte receptor or co-receptor. In some embodiments, the exogenous lymphocyte receptor or co-receptor is selected from the group consisting of: TCR alpha (TCR α), TCR beta (TCR β), TCR gamma (TCR γ), TCR delta (TCR δ), CD4, CD8, pre T cell receptor α (pT α), Fc receptor alpha (FcR α), Fc receptor beta (FcR β), Fc receptor gamma (FcR γ), natural killer group 2 member D
30 (NKG2D), CD79A, CD79B, and any combination thereof. In some embodiments, the cell further expresses an exogenous TCR. In some embodiments, the exogenous TCR binds a target antigen selected from the group consisting of: α -fetoprotein (AFP), B Melanoma

Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human Epidermal Growth Factor Receptor 2 (HER-2), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, Wilms tumor protein (WT-1), X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2). In some embodiments, the exogenous TCR is an $\alpha\beta$ -TCR or $\gamma\delta$ -TCR.

In some embodiments, the cell further expresses a CAR, CCR, or flip receptor. In some embodiments, the cell further expresses a zetakine, immune cell engager, or BiTE. In some embodiments, the cell is a hematopoietic cell. In some embodiments, the cell is a T cell, an $\alpha\beta$ -T cell, or a $\gamma\delta$ -T cell. In some embodiments, the cell is a CD3⁺, CD4⁺, and/or CD8⁺ cell. In some embodiments, the cell is an immune effector cell. In some embodiments, the cell is a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell. In some embodiments, the cell is a natural killer (NK) cell or natural killer T (NKT) cell. In some embodiments, the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors. In one embodiment, the cell is an isolated cell. In one embodiment, the cell is obtained from a subject. In one embodiment the cell is a human cell.

In one aspect, disclosed herein is a polypeptide complex, comprising a signaling component comprising (i) a first multimerization domain comprising an FRB polypeptide or

variant thereof or a FKBP polypeptide or variant thereof, (ii) a first polypeptide linker, and (iii) a CD3 ϵ polypeptide or variant thereof; and a targeting component comprising (i) an anti-CLL1 scFv or single domain antibody (sdAb), (ii) an anti-CD33 scFv or single domain antibody (sdAb), (iii) a second polypeptide linker, (iv) a second multimerization domain

5 comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (v) a CD4 hinge polypeptide, (vi) a CD4 transmembrane polypeptide, and (vii) a truncated CD4 intracellular polypeptide.

In some embodiments, the targeting component does not comprise a functional intracellular domain or costimulatory domain having signaling capabilities. In some

10 embodiments, the CD4 hinge polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 41. In some embodiments, the CD4 hinge polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 41. In some embodiments, the CD3 ϵ polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 32. In one embodiment, the

15 CD3 ϵ polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 32. In some embodiments, the CD3 ϵ polypeptide comprises both extracellular and intracellular portions.

In some embodiments, the FRB and FKBP polypeptides localize extracellularly when the signaling and targeting components are expressed. In some embodiments, the first and second multimerization domains are different. In some embodiments, the first

20 multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP12 polypeptide or variant thereof. In some embodiments, the first multimerization domain comprises an FKBP12 polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof. In one embodiment, the FRB polypeptide is an FRB T2098L variant. In some

25 embodiments, the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 1. In some embodiments, the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 2. In some embodiments, the FKBP12 polypeptide comprises an amino acid

30 sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 3. In some embodiments, the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 4.

In some embodiments, the multimerization domains of the signaling component and the targeting component associate with a bridging factor. In some embodiments, the bridging factor is selected from the group consisting of: rapamycin or a rapalog thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A or a derivative thereof, trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof, wherein the bridging factor promotes the formation of a polypeptide complex, with the bridging factor associated with and disposed between the multimerization domains of the signaling and targeting components. In some embodiments, the bridging factor is AP1903, AP20187, AP21967 (also known as C16-(S)-7-methylindolerapamycin), everolimus, novolimus, pimecrolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus, umirolimus, zotarolimus, or BPC015. In some embodiments, the first polypeptide linker is a linker of 2 to 40 amino acids in length. In some embodiments, the first polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, 5xG4S, and any combination thereof. In one embodiment, the first polypeptide linker is a 3xG4S linker. In some embodiments, the second polypeptide linker is a linker of 2 to 40 amino acids in length. In some embodiments, the second polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof. In one embodiment, the second polypeptide linker is a G4S linker. In some embodiments, the anti-CLL1 scFv or sdAb and the anti-CD33 scFv or sdAb are separated by a third polypeptide linker. In some embodiments, the third polypeptide linker is a linker of 2 to 40 amino acids in length. In some embodiments, the third polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof. In one embodiment, the third polypeptide linker is a G4S linker.

In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 45. In one embodiment, the CD4 transmembrane polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 45. In one embodiment, the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 48. In one embodiment, the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 49.

In some embodiments, the anti-CLL1 and anti-CD33 antibodies are each a sdAb. In some embodiments, the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb). In one embodiment, the sdAb is a camelid VHH. In some embodiments, the scFv or sdAb is human or humanized. In some embodiments, the anti-CLL1 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 92, 93, and 94, respectively. In some embodiments, the anti-CLL1 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 75. In some embodiments, the anti-CLL1 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 75. In some embodiments, the anti-CD33 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 89, 90, and 91, respectively. In some embodiments, the anti-CD33 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72. In some embodiments, the anti-CD33 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 72.

In some embodiments, the signaling component further comprises a signal sequence. In some embodiments, the signal sequence is a CD8 signal sequence. In some embodiments, the CD8 signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96. In one embodiment, the CD8 signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 96. In some embodiments, the targeting component further comprises a signal sequence. In some embodiments, the signal sequence is an IgK signal sequence. In some embodiments, the IgK signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 95. In one embodiment, the IgK signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 95. In some embodiments, the signaling component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 111. In one embodiment, the signaling component comprises a sequence set forth as SEQ ID NO: 111. In some embodiments, the targeting component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth as SEQ ID NO: 122. In one embodiment, the targeting component comprises a sequence set forth as SEQ ID NO: 122. In some embodiments, the polypeptide complex comprises a fusion polypeptide which comprises the targeting component and the signaling component. In some embodiments, the fusion polypeptide comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 151. In one embodiment, the fusion polypeptide comprises a sequence set forth as SEQ ID NO: 151.

In one aspect, the disclosure provides a nucleic acid molecule that encodes both the signaling component and the targeting component of any one of the polypeptide complexes disclosed herein.

In another aspect, the disclosure provides a cell comprising any one of the polypeptide
5 complexes disclosed herein.

In another aspect, the disclosure provides a cell comprising any one of the nucleic acid molecules disclosed herein.

In some embodiments, the cell further expresses an exogenous costimulatory factor, immunomodulatory factor, agonist for a costimulatory factor, antagonist for an
10 immunosuppressive factor, immune cell engager, flip receptor, or any combination thereof. In some embodiments, the cell further expresses an exogenous lymphocyte receptor or co-receptor. In some embodiments, the exogenous lymphocyte receptor or co-receptor is selected from the group consisting of: TCR alpha (TCR α), TCR beta (TCR β), TCR gamma (TCR γ), TCR delta (TCR δ), CD4, CD8, pre T cell receptor α (pT α), Fc receptor alpha
15 (FcR α), Fc receptor beta (FcR β), Fc receptor gamma (FcR γ), natural killer group 2 member D (NKG2D), CD79A, CD79B, and any combination thereof. In some embodiments, the cell further expresses an exogenous TCR. In some embodiments, the exogenous TCR binds a target antigen selected from the group consisting of: α -fetoprotein (AFP), B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS),
20 Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV)
25 non-structure protein 3 (NS3), Human Epidermal Growth Factor Receptor 2 (HER-2), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells
30 (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X

3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, Wilms tumor protein (WT-1), X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2). In some embodiments, the exogenous TCR is an $\alpha\beta$ -TCR or $\gamma\delta$ -TCR.

5 In some embodiments, the cell further expresses a CAR, CCR, or flip receptor. In some embodiments, the cell further expresses a zetakine, immune cell engager, or BiTE. In one embodiment, the cell is a hematopoietic cell. In some embodiments, the cell is a T cell, an $\alpha\beta$ -T cell, or a $\gamma\delta$ -T cell. In some embodiments, the cell is a CD3⁺, CD4⁺, and/or CD8⁺ cell. In some embodiments, the cell is an immune effector cell. In some embodiments, the cell is a
10 cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell. In some embodiments, the cell is a natural killer (NK) cell or natural killer T (NKT) cell. In some embodiments, the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors. In one embodiment, the cell is an isolated cell. In
15 one embodiment, cell is obtained from a subject. In one embodiment, the cell is a human cell.

In one aspect, the disclosure provides a polynucleotide encoding the signaling and targeting component of any one of the fusion polypeptides or polypeptide complexes disclosed herein.

In another aspect, the disclosure provides a cDNA encoding the signaling and
20 targeting component of any one of the fusion polypeptides or polypeptide complexes disclosed herein.

In another aspect, the disclosure provides an RNA encoding any one of the signaling and targeting components, or any one of the fusion polypeptides, or any one of the polypeptide complexes disclosed herein.

25 In another aspect, the disclosure provides a vector comprising any one of the polynucleotides disclosed herein.

In some embodiments, the vector is an expression vector. In one embodiment, the vector is a transposon. In some embodiments, the vector is a piggyBAC transposon or a Sleeping Beauty transposon. In some embodiments, the vector is a viral vector. In some
30 embodiments, the vector is an adenoviral vector, an adeno-associated viral (AAV) vector, a herpes virus vector, a vaccinia virus vector, or a retroviral vector. In some embodiments, the retroviral vector is a lentiviral vector. In some embodiments, the lentiviral vector is selected

from the group consisting of: human immunodeficiency virus 1 (HIV-1); human immunodeficiency virus 2 (HIV-2), visna-maedi virus (VMV) virus; caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus
5 (SIV).

In one aspect, the disclosure provides a cell comprising any one of the fusion polypeptides, polynucleotides, or the vectors disclosed herein.

In one embodiment, the cell is a hematopoietic cell. In some embodiments, the cell is an immune effector cell. In some embodiments, the cell is a T cell, an $\alpha\beta$ T cell, or a $\gamma\delta$ T
10 cell. In some embodiments, the cell expresses CD3⁺, CD4⁺, CD8⁺, or a combination thereof. In some embodiments, the cell is a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell. In some embodiments, the cell is a natural killer (NK) cell or natural killer T (NKT) cell.

In one aspect, the disclosure provides a composition comprising any one of the cells
15 or vectors disclosed herein.

In another aspect, the disclosure provides a composition comprising a physiologically acceptable carrier and any one of the cells or vectors disclosed herein.

In another aspect, the disclosure provides a method of treating a subject in need thereof comprising administering the subject an effective amount of any one of the
20 compositions disclosed herein.

In another aspect, the disclosure provides a method of treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith, comprising administering to the subject an effective amount of any one of the compositions disclosed
25 herein.

In another aspect, the disclosure provides a method of treating a solid cancer comprising administering to the subject an effective amount of any one of the compositions disclosed herein.

In some embodiments, the solid cancer is selected from the group consisting of lung
30 cancer, squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer

endometrial cancer, or brain cancer. In some embodiments, the solid cancer is a non-small cell lung carcinoma, head and neck squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, gliomas, glioblastomas, or

5 oligodendroglioma.

In one aspect, the disclosure provides a method of treating a hematological malignancy comprising administering to the subject an effective amount of any one of the compositions disclosed herein. In some embodiments, the hematological malignancy is a leukemia, lymphoma, or multiple myeloma. In one embodiment, the hematological

10 malignancy is acute myelogenous leukemia (AML).

BRIEF DESCRIPTION OF SEVERAL VIEWS OF THE DRAWINGS

Figures 1A-1H show the architecture of representative engineered immune receptors and fusion constructs. In particular, **Figures 1A-1C** depict expression constructs and components of a few exemplary engineered immune receptors and fusion constructs of the invention. **Figures**

15 **1D-1H** are cartoons depicting how representative engineered immune receptors comprising a signaling component and a targeting component may form a complex with an immune receptor (*e.g.*, a TCR) to activate receptor signaling when a target cell expressing the target antigen is present, and, in certain embodiments, when a bridging factor is present. As one non-limiting example, in **Figure 1D**, construct SR022/SR001 comprises a signaling component comprising an

20 FRB multimerization domain, a linker, and a CD3 ϵ actuator domain; and a targeting component comprising a CD4 transmembrane domain, a CD4 hinge, an FKBP multimerization domain, a linker, and a CD33 VHH targeting domain. When a cell expressing CD33 is present, the CD33 VHH targeting domain binds to the target cell, bringing it in close contact with the immune cell expressing the engineered immune receptor, *e.g.*, a T cell. When a bridging factor is present, the

25 multimerization domains then interact, allowing the signaling component to activate the immune receptor (*e.g.*, TCR).

Figure 2 shows the percent positive and median fluorescence intensity of SR024 components on T cells as measured by flow cytometry.

Figure 3 shows IFN γ , IL2, IL4 and TNF secretion from untransduced and SR024-T cells

30 cocultured with a high CD33 expressing cancer cell line, and in the presence of rapamycin.

Figure 4 shows IFN γ secretion from untransduced and SR024-T cells cultured alone, with and without rapamycin.

Figures 5A and **5B** show cytotoxicity and proliferation, respectively, of control and SR024 T cells, each cocultured with a high CD33 expressing cancer cell line.

5 **Figure 6** shows the percent positive and median fluorescence intensity of SR020, SR022, and SR024 components on T cells as measured by flow cytometry.

Figure 7A shows IFN γ , IL2, IL4 and TNF secretion from untransduced, SR020-T cells, SR022-T cells, and SR024-T cells, each cocultured with a high CD33 expressing cancer cell line, and in the presence of rapamycin.

10 **Figure 7B** shows IFN γ secretion from untransduced, SR020-T cells, SR022-T cells, and SR024-T cells, each co-cultured with high, medium, and low CD33 expressing cancer cell lines, and in the presence of rapamycin.

15 **Figures 7C** shows IL2 secretion from untransduced, SR020-T cells, SR022-T cells, and SR024-T cells, each co-cultured with high, medium, and low CD33 expressing cancer cell lines, and in the presence of rapamycin.

Figure 8 shows IFN γ secretion from untransduced, SR020-T cells, SR022-T cells, and SR024-T cells alone, e with and without rapamycin.

20 **Figures 9A** and **9B** show cytotoxicity and proliferation, respectively, of control, SR020-T cells, SR022-T cells, and SR024-T cells, each cocultured with a high CD33 expressing cancer cell line.

Figure 10 shows the percent positive and median fluorescence intensity of SR021 components on T cells as measured by flow cytometry.

Figure 11 shows IFN γ , IL2, IL4 and TNF secretion from untransduced and SR021-T cells cocultured with a high CD33 expressing cancer cell line, and in the presence of rapamycin.

25 **Figure 12** shows IFN γ secretion from untransduced and SR021-T cells cocultured with a high CD33 expressing cancer cell line, alone with and without rapamycin.

Figures 13A and **13B** show cytotoxicity and proliferation, respectively, of control and SR021-T cells cocultured with a high CD33 expressing cancer cell line.

30 **Figure 14** shows the percent positive and median fluorescence intensity of SR022 and SR001 components on T cells as measured by flow cytometry.

Figure 15 shows IFN γ , IL2, and TNF secretion from untransduced, SR022- and SR001-T cells, each cocultured with a high CD33 expressing cancer cell line, and in the presence of rapamycin.

5 **Figure 16** shows IFN γ secretion from untransduced, SR022- and SR001-T cells, each cocultured with a high CD33 expressing cancer cell line, with and without rapamycin.

Figures 17A and 17B show cytotoxicity and proliferation, respectively, of control and SR001-T cells, each cocultured with a high CD33 expressing cancer cell line.

Figure 18 shows the percent positive and median fluorescence intensity of SR028 components on T cells as measured by flow cytometry.

10 **Figure 19** shows IFN γ , IL2, IL4 and TNF secretion from untransduced and SR028-T cells cocultured with a high CD33 expressing cancer cell line, and in the presence of rapamycin.

Figure 20 shows IFN γ secretion from untransduced and SR028-T cells cocultured with a high CD33 expressing cancer cell line, with and without rapamycin.

15 **Figures 21A and 21B** show cytotoxicity and proliferation, respectively, of control and SR028-T cells, each cocultured with a high CD33 expressing cancer cell line.

Figure 22 shows the percent positive and median fluorescence intensity of SR004 and SR006 components on T cells as measured by flow cytometry.

20 **Figure 23** shows IFN γ , IL2, IL4 and TNF secretion from untransduced, SR004- and SR006-T cells, each cocultured with a high CD33 expressing cancer cell line, and in the presence of rapamycin.

Figure 24 shows IFN γ secretion from untransduced, SR004- and SR006-T cells, each cocultured with a high CD33 expressing cancer cell line, with and without rapamycin.

Figures 25A and 25B show cytotoxicity and proliferation, respectively, of control, SR004- and SR006-T cells, each cocultured with a high CD33 expressing cancer cell line.

25 **Figures 26A and 26B** show the percent positive and median fluorescence intensity of SR008 and SR030 components on T cells as measured by flow cytometry.

Figures 26C and 26D show the phenotypes of CD4⁺ and CD8⁺ T cells transduced with vectors encoding the indicated constructs.

Figures 27A and 27B show IFN γ , IL2, IL4 and TNF secretion from untransduced, SR008-T cells, and SR030-T cells, each cocultured with either a high CD33 expressing cancer cell line or a high CLL1 expressing cancer cell line, and in the presence of rapamycin.

Figure 27C shows IFN γ secretion of untransduced, SR008-T cells, and SR030-T cells alone, with or without rapamycin.

Figures 28A and 28B show cytotoxicity of untransduced, SR008-T cells, and SR030-T cells, each cocultured with a high CD33 expressing cancer cell line or a high CLL1 expressing cancer cell line, respectively.

Figure 29 shows the percent positive and median fluorescence intensity of SR001 and SR001-28 components on T cells as measured by flow cytometry.

Figure 30 shows IFN γ , IL2, IL4 and TNF secretion from untransduced, SR001- and SR001-28-T cells, each cocultured with a high CD33 expressing cancer cell line and in the presence of rapamycin.

Figures 31A and 31B show cytotoxicity and proliferation, respectively, of control, SR001- and SR001-28-T cells, each cocultured with a high CD33 expressing cancer cell line.

Figures 32A and 32B show *in vivo* tumor growth in NSG mouse xenografts and control following administration of 10E6 SR001 $\pm$ 41BB or CD28 costimulation domains. All tumor control is regulated by rapamycin.

Figures 32C and 32D show *in vivo* tumor growth in NSG mouse xenografts and control following administration of 3E6 SR001 $\pm$ 41BB or CD28 costimulation domains with rapamycin present.

Figures 33A and 33B show the percent positive and median fluorescence intensity of SR022 $\pm$ CD4 or CD8 coreceptor signaling domains as measured by flow cytometry.

Figure 34 show IFN γ and IL2 secretion from untransduced, SR022-T cells $\pm$ CD4 or CD8 coreceptor signaling domains, each cocultured with a high CD33 expressing cancer cell line, with or without rapamycin.

Figures 35A-35C show the vector copy number, percent positive, and geometric mean fluorescence intensity of a tetramer and TCR beta chain staining for an untransduced TCR, a transgenic TCR, SR001, or the combination of a transgenic TCR and SR001 as measured by flow cytometry.

Figures 35D and 35E show the percent positive and geometric mean fluorescence intensity of an anti-VHH staining for an untransduced TCR, a transgenic TCR, SR001, or the combination of a transgenic TCR and SR001 as measured by flow cytometry.

Figures 36A and 36B show IFN γ , IL2 and TNF α secretion from untransduced, 5 transgenic TCR, SR001, or the combination of a transgenic TCR and SR001, each cocultured with a high HLA-A2+TCR epitope+ or CD33+ expressing cancer cell line and in the absence and presence of rapamycin.

Figure 36C shows cytotoxicity of untransduced, transgenic TCR cells, SR001-T cells, or the combination of transgenic TCR and SR001, cocultured with cancer cells high HLA-A2+TCR 10 epitope+ or CD33+ expressing cancer cell lines in the absence or presence of rapamycin.

Figures 37A and 37B show IL2 secretion from untransduced or SR001, each cocultured with a very low CD33- or CLL1-expressing cancer cell line in the presence of rapamycin.

Figure 38 shows *in vivo* tumor growth in NSG mouse xenografts and control following administration of 10E6 SR007 or comparator regulated CAR T cells (targeting either CD33 or 15 CLL1). All tumor control is regulated by rapamycin.

Figures 39A-39C show the vector copy number, percent positive FRB and VHH staining for expression in the absence or presence of rapamycin.

Figures 40A and 40B show IFN γ secretion of SR10167 or SR10168-T cells alone $\pm$ rapamycin, compared with regulated CAR controls.

20 **Figures 41A and 41B** show IFN γ secretion of SR10167 or SR10168-T cells $\pm$ rapamycin, compared with regulated CAR controls, when cultured with a CD19+ target cell line.

Figures 42A-42D show IL2 and TNF α secretion of SR10167 or SR10168-T cells $\pm$ rapamycin, compared with regulated CAR controls, when cultured with a CD19+ target cell line.

25 **Figures 43A and 43B** show cytotoxicity of control, SR10167-T cells, and Regulated CAR comparator-T cells, each cocultured with either CD19+ Jeko-1 or Daudi cell lines. All tumor control is regulated by rapamycin.

Figure 44 shows cartoons of representative constitutively active (non-regulatable) engineered immune receptors and fusion constructs.

30 **Figures 45A and 45B** show the percent positive and median fluorescence intensity of VHH staining for expression of SR292, SR293, SR296, SR001 and relevant comparator

molecules including a non-regulated CAR, regulated CAR, and non-regulated TCR-based architecture comparator.

Figures 46A and 46B show IFN γ and IL2 secretion of SR292, SR293, SR296, SR001 and relevant comparator molecules including a non-regulated CAR, regulated CAR, and non-regulated TCR-based architecture comparator, when cultured with a CD33+ target cell line.

Figure 47 shows IFN γ secretion of T cells alone expressing SR292, SR293, SR296, SR001 and relevant comparator molecules including a non-regulated CAR, regulated CAR, and non-regulated TCR-based architecture comparator.

Figures 48A and 48B show cytotoxicity and T cell proliferation of control, SR292, SR293, SR296 and one non-regulated CAR, following coculture with a CD33+ target line.

Figure 49 shows the percent positive and median fluorescence intensity of FRB staining for expression of SR001 $\pm$ IL7-receptor- α , common γ chain, IL2-receptor- β , or both common γ chain, and IL2-receptor- β .

Figures 50A-50D show IFN γ and IL2 secretion of SR001 $\pm$ IL7-receptor- α , common γ chain, IL2-receptor- β , or both common γ chain and IL2-receptor- β , when cultured with a CD33+ target cell line with and without rapamycin.

Figure 51 shows T cell proliferation of control or SR001 $\pm$ IL7-receptor- α , common γ chain, IL2-receptor- β , or both common γ chain and IL2-receptor- β , following coculture with a CD33+ target line.

Figure 52 shows the median fluorescence intensity of FRB or PD-1 staining of T cells expressing either SR300 (affinity enhanced PD1) or SR301 (wild-type PD1).

Figures 53A-53D show cytotoxicity of T cells expressing SR300 or SR301 when cultured with a PDL1+ target cell line or the same cell line with PDL1 and PDL2 knocked out, with and without rapamycin.

Figure 54 shows the percent positive and median fluorescence intensity of VHH staining for expression of SR354 construct.

Figures 55A and 55B show IFN γ secretion of NK cells expressing SR354 when cultured with a CD33+ target cell line or the same cell line with CD33 knocked out.

Figures 55C and 55D show cytotoxicity of NK cells expressing SR354 when cultured with a CD33+ target cell line or the same cell line with CD33 knocked out.

Figure 56 shows the percent positive of SR303 components on T cells as measured by flow cytometry.

Figures 57A and 57B show IFN γ secretion of SR303 cells when cultured with an ROR1+ target cell line with and without rapamycin.

5 **Figure 57C** shows IFN γ secretion of T cells alone expressing SR303 molecules.

BRIEF DESCRIPTION THE SEQUENCE IDENTIFIERS

SEQ ID NOs: 1-4 set forth the amino acid sequences of exemplary FRB and FKBP12 polypeptides.

10 **SEQ ID NOs: 5-10** set forth the amino acid sequences of exemplary antibody derived heterodimerization domains.

SEQ ID NOs: 11-31 set forth amino acid sequences of exemplary linkers.

SEQ ID NOs: 32-40 set forth the amino acid sequences of exemplary actuator domains.

SEQ ID NOs: 41-44 set forth the amino acid sequences of illustrative hinge domains.

15 **SEQ ID NOs: 45-47** set forth the amino acid sequences of exemplary transmembrane polypeptides.

SEQ ID NOs: 48 and 49 set forth the amino acid sequences of illustrative truncated intracellular CD4 polypeptides. **SEQ ID NOs: 50-94** set forth the amino acid sequences of illustrative targeting domains.

20 **SEQ ID NOs: 95-97** sets forth the amino acid sequences of illustrative signal sequences.

SEQ ID NOs: 98-106 set forth the amino acid sequences of exemplary intracellular signaling domains.

25 **SEQ ID NOs: 107-115** set forth the amino acid sequences of exemplary signaling components.

SEQ ID NOs: 116-136 set forth the amino acid sequences of exemplary targeting components.

SEQ ID NOs: 137 and 138 set forth the amino acid sequences of exemplary co-signaling components.

SEQ ID NOs: 139-170 set forth the amino acid sequences of illustrative fusion polypeptides.

5 **SEQ ID NOs: 171-192** set forth the amino acid sequence of protease cleavage sites and self-cleaving polypeptide cleavage sites.

SEQ ID NO: 193 sets forth a spacer amino acid sequence.

SEQ ID NO: 194 sets forth a furin recognition amino acid sequence.

SEQ ID NOs: 195-197 set forth TEV (tobacco etch virus) protease cleavage sites.

10 **SEQ ID NO: 198** sets forth a kozak amino acid sequence.

In the foregoing sequences, X, if present, refers to any amino acid or the absence of an amino acid.

DETAILED DESCRIPTION

A. OVERVIEW

15 Cancer is among the leading causes of death worldwide. Although adoptive cell therapy is being used to successfully treat some hematological malignancies, treatment of solid tumors with both chimeric antigen receptor (CAR) T cells and T cells that express T cell receptors (TCR) against tumor antigens still remains largely ineffective.

20 Additionally, while TCRs are known to be exquisitely sensitive to low levels of target antigen, they lack the ability to see non-MHC presented antigens. On the other hand, while CARs can be engineered to target almost any extracellular antigen through their antibody-like binding domains, they are generally less sensitive to low levels of target antigen and are prone to tonic and/or antigen-independent signaling. Moreover, T cells engineered to express a CAR or TCR generally lack spatial and temporal control of T cell activity and/or
25 demonstrate insufficient activation of T cell signaling pathways.

Lack of control over engineered T cell activity can trigger a range of side effects, many of which begin subtly but can rapidly worsen. A particularly severe complication is cytokine release syndrome (CRS) or “cytokine storm” where CAR T cells induce massive

and potentially fatal cytokine release. CRS can produce dangerously high fevers, extreme fatigue, difficulty breathing, and a sharp drop in blood pressure. CRS can also produce a second wave of side effects that involve the nervous system, including neurotoxicity, tremors, headaches, confusion, loss of balance, trouble speaking, seizures, and hallucinations.

- 5 Insufficient activation of T cell signaling pathways can result in failure to eradicate a cancer and/or lead to a cancer that becomes refractory to treatment. The compositions and methods contemplated herein offer solutions to these and other problems plaguing adoptive cell therapies.

Thus, the disclosure generally relates to improved compositions and methods for
10 regulating the antigen recognition capabilities, sensitivity, and/or spatial and temporal control of adoptive cell therapies by using engineered immunoreceptor complexes that bind a selected target antigen and that can recruit and activate a natural or transgenic immunoreceptor signaling complex.

Without wishing to be bound by any particular theory, the engineered immune
15 receptor compositions and methods contemplated herein provide numerous advantages over CAR T cell and TCR T cell therapies existing in the art, including but not limited to, both spatial and temporal control over immune effector cell signal transduction, binding and signaling activities, and activating signaling pathways without requiring MHC complex recognition. In some embodiments, temporal control primes the engineered immune receptor
20 machinery for signaling through bridging factor mediated association of a targeting component to a signaling component. In other embodiments, the machinery is primed by association of multimerization domains, without the need for a bridging factor. Spatial control engages the signaling machinery through recognition of a target antigen by an extracellular or targeting domain of a targeting component, whereas the signaling component
25 comprises an actuator domain that forms a complex with a lymphocyte immune receptor. In this manner, immune effector cells activate receptor signaling when a target cell expressing the target antigen is present, and, in certain embodiments, when a bridging factor is present.

In various embodiments, the disclosure contemplates signaling and targeting
components that generate an immune receptor-based response against cells that express a
30 target antigen without recognition of the natural immune receptor target antigen. In various embodiments, the disclosure contemplates signaling and targeting components that generate an immune receptor-based anti-cancer response against cancers that express a target antigen

without requiring MHC complex recognition of the target antigen and/or the lymphocytic immune receptor's natural or engineered target antigen.

In particular embodiments, the engineered immune receptor complexes include a signaling component that comprises a multimerization domain polypeptide or variant thereof and an actuator domain or variant thereof (*e.g.*, a CD3 ϵ , CD3 δ , CD3 γ , Fc ϵ R1 γ , Ig α /CD79a, Ig β /CD79b, DAP10, or DAP12 polypeptide); and a targeting component that comprises an extracellular domain that comprises a targeting domain that binds a target antigen expressed on a target cell, a multimerization domain polypeptide or variant thereof, a transmembrane domain, and optionally a hinge domain disposed between the multimerization domain and the transmembrane domain. In some embodiments, in the presence of a bridging factor, the signaling and binding/targeting components associate with one another through the bridging factor to form a functionally active immune receptor. In some embodiments, the components associate without the need for a bridging factor.

In particular embodiments, the multimerization domains of the signaling and targeting components are positioned extracellularly. Extracellular position of the multimerization domains provides numerous advantages over intracellular positioning including, but not limited to, more efficient positioning of the targeting domain, higher temporal sensitivity to bridging factor regulation, and less toxicity due to ability to use non-immunosuppressive doses of particular bridging factors.

Polynucleotides encoding the engineered immune receptors, targeting components, signaling components, protein/polypeptide complexes, and fusion proteins; polypeptides comprising the engineered immune receptors, targeting components, signaling components, protein/polypeptide complexes, and fusion proteins; cells comprising polynucleotides encoding the engineered immune receptors, targeting components, and signaling components and/or expressing the same; vectors encoding the engineered immune receptors, targeting components, signaling components, protein/polypeptide complexes, and fusion proteins; and methods of using the same to treat a disease or disorder (*e.g.*, cancer or an immune disorder) are contemplated herein.

Techniques for recombinant (*i.e.*, engineered) DNA, peptide and oligonucleotide synthesis, immunoassays, tissue culture, transformation (*e.g.*, electroporation, lipofection), enzymatic reactions, purification and related techniques and procedures may be generally performed as described in various general and more specific references in microbiology,

- molecular biology, biochemistry, molecular genetics, cell biology, virology and immunology as cited and discussed throughout the present specification. See, *e.g.*, Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 3d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; *Current Protocols in Molecular Biology* (John Wiley and Sons, updated July 5 2008); *Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology*, Greene Pub. Associates and Wiley-Interscience; Glover, *DNA Cloning: A Practical Approach*, vol. I & II (IRL Press, Oxford Univ. Press USA, 1985); *Current Protocols in Immunology* (Edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strober 2001 John Wiley & Sons, NY, NY); *Real-Time PCR: Current Technology and Applications*, Edited by Julie Logan, Kirstin Edwards and Nick Saunders, 2009, Caister Academic Press, Norfolk, UK; Anand, *Techniques for the Analysis of Complex Genomes*, (Academic Press, New York, 1992); Guthrie and Fink, *Guide to Yeast Genetics and Molecular Biology* (Academic Press, New York, 1991); *Oligonucleotide Synthesis* (N. Gait, Ed., 1984); *Nucleic Acid The Hybridization* (B. Hames & S. Higgins, Eds., 1985); 10 *Transcription and Translation* (B. Hames & S. Higgins, Eds., 1984); *Animal Cell Culture* (R. Freshney, Ed., 1986); Perbal, *A Practical Guide to Molecular Cloning* (1984); *Next-Generation Genome Sequencing* (Janitz, 2008 Wiley-VCH); *PCR Protocols* (Methods in Molecular Biology) (Park, Ed., 3rd Edition, 2010 Humana Press); *Immobilized Cells And Enzymes* (IRL Press, 1986); the treatise, *Methods In Enzymology* (Academic Press, Inc., N.Y.); *Gene Transfer Vectors For Mammalian Cells* (J. H. Miller and M. P. Calos eds., 1987, Cold Spring Harbor Laboratory); 20 Harlow and Lane, *Antibodies*, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998); *Immunochemical Methods In Cell And Molecular Biology* (Mayer and Walker, eds., Academic Press, London, 1987); *Handbook Of Experimental Immunology*, Volumes I-IV (D. M. Weir and CC Blackwell, eds., 1986); Roitt, *Essential Immunology*, 6th Edition, (Blackwell Scientific Publications, Oxford, 1988); *Current Protocols in Immunology* (Q. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach and W. Strober, eds., 1991); *Annual Review of Immunology*; as well as monographs in journals such as *Advances in Immunology*.

B. DEFINITIONS

- Prior to setting forth this disclosure in more detail, it may be helpful to an understanding 30 thereof to provide definitions of certain terms to be used herein.

Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by those of ordinary skill in the art to which the invention

belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of particular embodiments, preferred embodiments of compositions, methods and materials are described herein. For the purposes of the present disclosure, the following terms are defined below.

5 The articles “a,” “an,” and “the” are used herein to refer to one or to more than one (*i.e.*, to at least one, or to one or more) of the grammatical object of the article. By way of example, “an element” means one element or one or more elements.

 The use of the alternative (*e.g.*, “or”) should be understood to mean either one, both, or any combination thereof of the alternatives.

10 The term “and/or” should be understood to mean either one, or both of the alternatives.

 As used herein, the term “about” or “approximately” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2% or 1% to a reference quantity, level,
15 value, number, frequency, percentage, dimension, size, amount, weight or length. In one embodiment, the term “about” or “approximately” refers a range of quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length $\pm 15\%$, $\pm 10\%$, $\pm 9\%$, $\pm 8\%$, $\pm 7\%$, $\pm 6\%$, $\pm 5\%$, $\pm 4\%$, $\pm 3\%$, $\pm 2\%$, or $\pm 1\%$ about a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

20 In one embodiment, a range, *e.g.*, 1 to 5, about 1 to 5, or about 1 to about 5, refers to each numerical value encompassed by the range. For example, in one non-limiting and merely illustrative embodiment, the range “1 to 5” is equivalent to the expression 1, 2, 3, 4, 5; or 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, or 5.0; or 1.0, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4.0,
25 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, or 5.0.

 As used herein, the term “substantially” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that is 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or higher compared to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or
30 length. In one embodiment, “substantially the same” refers to a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that produces an

effect, *e.g.*, a physiological effect, that is approximately the same as a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

Throughout this specification, unless the context requires otherwise, the words “comprise,” “comprises,” and “comprising” will be understood to imply the inclusion of a
 5 stated step or element or group of steps or elements but not the exclusion of any other step or element or group of steps or elements. By “consisting of” is meant including, and limited to, whatever follows the phrase “consisting of.” Thus, the phrase “consisting of” indicates that the listed elements are required or mandatory, and that no other elements may be present. By “consisting essentially of” is meant to include any elements listed after the phrase and limited
 10 to other elements that do not interfere with or contribute to the activity or action specified in the disclosure for the listed elements. Thus, the phrase “consisting essentially of” indicates that the listed elements are required or mandatory, but that no other elements are present that materially affect the activity or action of the listed elements.

Reference throughout this specification to “one embodiment,” “an embodiment,” “a
 15 particular embodiment,” “a related embodiment,” “a certain embodiment,” “an additional embodiment,” or “a further embodiment” or combinations thereof means that a particular feature, structure or characteristic described in connection with the embodiment is included in at least one embodiment. Thus, the appearances of the foregoing phrases in various places throughout this specification are not necessarily all referring to the same embodiment.
 20 Furthermore, the particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. It is also understood that the positive recitation of a feature in one embodiment, serves as a basis for excluding the feature in a particular embodiment.

As used herein, the term “TCR complex” refers to a complex formed by the
 25 association of CD3 with a TCR. For example, a TCR complex can be composed of a CD3 γ chain, a CD3 δ chain, two CD3 ϵ chains, a homodimer of CD3 ζ chains, a TCR α chain, and a TCR β chain. In some embodiments, a TCR complex can be composed of a CD3 γ chain, a CD3 δ chain, two CD3 ϵ chains, a homodimer of CD3 ζ chains, a TCR γ chain, and a TCR δ chain.

30 A “component of a TCR complex,” as used herein, refers to a TCR chain (*i.e.*, TCR α , TCR β , TCR γ or TCR δ), a CD3 chain (*i.e.*, CD3 γ , CD3 δ , CD3 ϵ or CD3 ζ), or a complex formed by two or more TCR chains or CD3 chains (*e.g.*, a complex of TCR α and TCR β , a

complex of TCR γ and TCR δ , a complex of CD3 ϵ and CD3 δ , a complex of CD3 γ and CD3 ϵ , or a sub-TCR complex of TCR α , TCR β , CD3 γ , CD3 δ , and two CD3 ϵ chains).

An “actuator polypeptide”, “actuator domain”, or “actuator” as used herein, refer to a polypeptide that, associates, integrates, or complexes, either directly or indirectly, with a
 5 multimeric immune receptor complex to promote signaling and does not itself contain direct antigen-binding properties. In certain embodiments, the actuator domain is part of a protein or protein complex that signals when bound to a target molecule. The actuator domain may directly contribute to a cellular response when it contains signaling domains or motifs, such as an immunoreceptor tyrosine-based activation motif (ITAM). In other embodiments, an actuator
 10 domain will indirectly promote a cellular response by associating with one or more other proteins that directly signal and thus promote a cellular response. Illustrative actuator domains include, *e.g.*, a CD3 polypeptide, Fc ϵ R1 γ polypeptide, Ig α /CD79a polypeptide, Ig β /CD79b polypeptide, DAP10 polypeptide, or DAP12, polypeptide, or any combination thereof.

A “multimerization domain,” or “multimerization domain polypeptide” as used herein,
 15 refers to a polypeptide that preferentially interacts or associates with another different polypeptide directly or via a bridging molecule, *e.g.*, a chemically inducible dimerizer, wherein the interaction of different multimerization domains substantially contributes to or efficiently promotes multimerization (*i.e.*, the formation of a dimer, trimer, or multipartite complex, which may be a homodimer, heterodimer, homotrimer, heterotrimer, homomultimer, heteromultimer). A
 20 multimerization domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source.

Illustrative examples of multimerization domains suitable for use in particular embodiments contemplated herein include an FK506 binding protein (FKBP) polypeptide or variants thereof, an FKBP-rapamycin binding (FRB) polypeptide or variants thereof, a
 25 calcineurin polypeptide or variants thereof, a cyclophilin polypeptide or variants thereof, a bacterial dihydrofolate reductase (DHFR) polypeptide or variants thereof, a PYR1-like 1 (PYL1) polypeptide or variants thereof, an abscisic acid insensitive 1 (ABI1) polypeptide or variants thereof, a GIB1 polypeptide or variants thereof, or a GAI polypeptide or variants thereof.

As used herein, the term “FKBP-rapamycin binding polypeptide” refers to an FRB
 30 polypeptide. In particular embodiments, the FRB polypeptide is an FKBP12-rapamycin binding polypeptide. FRB polypeptides suitable for use in particular embodiments contemplated herein generally contain at least about 85 to about 100 amino acid residues. In certain embodiments, the

FRB polypeptide comprises a 93 amino acid sequence Ile-2021 through Lys -2113 and a mutation of T2098L (T82L is equivalent position in 93 amino acid FRB polypeptide), with reference to GenBank Accession No. L34075.1. The terms “FRB star”, FRBstar”, or “FRB*” as used herein refer to such FRB T2098L (T82L) mutants. An FRB polypeptide contemplated
 5 herein binds to an FKBP polypeptide through a bridging factor, thereby forming a ternary complex.

As used herein, the term “FK506 binding protein” refers to an FKBP polypeptide. In particular embodiments, the FKBP polypeptide is an FKBP12 polypeptide or an FKBP12 polypeptide comprising an F36V mutation. In certain embodiments, an FKBP domain may also
 10 be referred to as a “rapamycin binding domain”. Information concerning the nucleotide sequences, cloning, and other aspects of various FKBP species is known in the art (*see, e.g.,* Staendart *et al.*, *Nature* 346:671, 1990 (human FKBP12); Kay, *Biochem. J.* 314:361, 1996). An FKBP polypeptide contemplated herein binds to an FRB polypeptide through a bridging factor, thereby forming a ternary complex.

A “bridging factor” refers to a molecule that associates with and that is disposed between two or more multimerization domains. In particular embodiments, multimerization domains substantially contribute to or efficiently promote formation of a polypeptide complex only in the presence of a bridging factor. In particular embodiments, multimerization domains do not contribute to or do not efficiently promote formation of a polypeptide complex in the absence of a
 20 bridging factor. Illustrative examples of bridging factors suitable for use in particular embodiments contemplated herein include, but are not limited to AP21967, rapamycin (sirolimus) or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FKCsA or a derivative thereof, trimethoprim (Tnp)-
 25 synthetic ligand for FKBP (SLF) or a derivative thereof, or any combination thereof.

Rapamycin analogs (rapalogs) include, but are not limited to, those disclosed in U.S. Pat. No. 6,649,595, which rapalog structures are incorporated herein by reference in their entirety. In certain embodiments, a bridging factor is a rapalog with substantially reduced immunosuppressive effect as compared to rapamycin. In a preferred embodiment, the rapalog is
 30 AP21967 (also known as C-16-(S)-7-methylindolerapamycin, $IC_{50} = 10nM$, a chemically modified non-immunosuppressive rapamycin analogue). Other illustrative rapalogs suitable for use in particular embodiments contemplated herein include, but are not limited to, AP1903,

AP20187, everolimus, novolimus, pimecrolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus, umirolimus, zotarolimus, and BPC015.

5 A “substantially reduced immunosuppressive effect” refers to at least less than 0.1 to 0.005 times the immunosuppressive effect observed or expected for the same dose measured either clinically or in an appropriate *in vitro* (e.g., inhibition of T cell proliferation) or *in vivo* surrogate of human immunosuppressive activity.

A “transmembrane domain” or “TM domain” is a domain that anchors a polypeptide to the plasma membrane of a cell. The TM domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source.

10 As used herein, the term “extracellular domain” refers to a domain or portion of a polypeptide which is situated or present outside of a cell. The extracellular domain of a targeting component, as disclosed herein, comprises at least one targeting domain, which re-directs activation of an immune receptor complex, e.g., a TCR, to one or more selected target antigens, e.g., on a target cell, such as a cancer cell, when the targeting component is associated with the
15 signaling component, e.g., by a bridging factor connecting the multimerization domains of the targeting component and the signaling component, or by association of multimerization domains of the targeting component and the signaling component without the need for a bridging factor.

The term “effector function” or “effector cell function” refers to a specialized function of an immune effector cell. Effector function includes, but is not limited to, activation,
20 cytokine production, proliferation and cytotoxic activity, including the release of cytotoxic factors, or other cellular responses elicited with antigen binding to the receptor expressed on the immune effector cell. An “intracellular signaling domain” or “endodomain” refers to the portion of a protein which transduces the effector function signal and that directs the cell to perform a specialized function. While usually the entire intracellular signaling domain can be
25 employed, in many cases it is not necessary to use the entire domain. To the extent that a truncated portion of an intracellular signaling domain is used, such truncated portion may be used in place of the entire domain as long as it transduces an effector function signal. The term intracellular signaling domain is meant to include any truncated portion of an intracellular signaling domain necessary or sufficient to transduce an effector function signal.

30 It is known that signals generated through the TCR alone are insufficient for full activation of the T cell and that a secondary or costimulatory signal is also required. Thus, T cell activation can be said to be mediated by two distinct classes of intracellular signaling

domains: primary signaling domains that initiate antigen-dependent primary activation through the TCR (*e.g.*, a TCR/CD3 complex) and costimulatory signaling domains that act in an antigen-independent manner to provide a secondary or costimulatory signal.

As used herein, the term, “costimulatory signaling domain,” or “costimulatory domain” refers to an intracellular signaling domain of a costimulatory molecule. Costimulatory molecules are cell surface molecules other than antigen receptors or Fc receptors that provide a second signal required for efficient activation and function of T lymphocytes upon binding to antigen. Illustrative examples of such costimulatory molecules from which costimulatory domains may be isolated include, but are not limited to: Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD3 ϵ , CD3 γ , CD3 δ , CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DNAX-Activation Protein 10 (DAP10), FYN, Linker for activation of T-cells family member 1 (LAT), SH2 Domain-Containing Leukocyte Protein Of 76 kD (SLP76), LCK, T cell receptor associated transmembrane adaptor 1 (TRAT1), TNFR2, TNF receptor superfamily member 14 (TNFRS14; HVEM), TNF receptor superfamily member 18 (TNFRS18; GITR), TNF receptor superfamily member 25 (TNFRS25; DR3), and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).

A “hinge domain,” refers to a polypeptide that plays a role in spatially positioning a domain away from the effector cell surface to enable proper cell/cell contact, antigen binding and activation. In particular embodiments, polypeptides may comprise one or more hinge domains between the extracellular domain and the transmembrane domain (TM), between the multimerization domain and the transmembrane domain, or between the multimerization domain and the actuator domain. The hinge domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source. The hinge domain can include the amino acid sequence of a naturally occurring immunoglobulin hinge region or an altered immunoglobulin hinge region.

A “linker” or “linker polypeptide” refers to a plurality of amino acid residues between the various polypeptide domains added for appropriate spacing and conformation of the molecule. In particular embodiments, the linker is a variable region linking sequence. A “variable region linking sequence,” is an amino acid sequence that connects the V_H and V_L domains and provides a spacer function compatible with interaction of the two sub-binding domains so that the resulting polypeptide retains a specific binding affinity to the same target molecule as an antibody that

comprises the same light and heavy chain variable regions. In particular embodiments, a linker separates one or more heavy or light chain variable domains, hinge domains, multimerization domains, transmembrane domains, costimulatory domains, and/or primary signaling domains.

Illustrated examples of linkers suitable for use in particular embodiments contemplated herein include, but are not limited to the following amino acid sequences: GGG; DGGGS (SEQ ID NO: 16); TGEKP (SEQ ID NO: 17) (see, *e.g.*, Liu *et al.*, PNAS 5525-5530 (1997)); GGRR (SEQ ID NO: 18) (Pomerantz *et al.* 1995, *supra*); (GGGS)_n wherein n = 1, 2, 3, 4 or 5 (SEQ ID NOS: 11-15) (Kim *et al.*, PNAS 93, 1156-1160 (1996.)); EGKSSGSGSESKVD (SEQ ID NO: 19) (Chaudhary *et al.*, 1990, Proc. Natl. Acad. Sci. U.S.A. 87:1066-1070);

10 KESGSVSSEQLAQFRSLD (SEQ ID NO: 20) (Bird *et al.*, 1988, Science 242:423-426), GGRRGGGS (SEQ ID NO: 21); LRQRDGERP (SEQ ID NO: 22); LRQKDGGGSERP (SEQ ID NO: 23); LRQKD(GGGS)₂ ERP (SEQ ID NO: 24). Alternatively, flexible linkers can be rationally designed using a computer program capable of modeling both DNA-binding sites and the peptides themselves (Desjarlais & Berg, PNAS 90:2256-2260 (1993), PNAS 91:11099-11103

15 (1994) or by phage display methods. In one embodiment, the linker comprises the following amino acid sequence: GSTSGSGKPGSGEGSTKG (SEQ ID NO: 25) (Cooper *et al.*, Blood, 101(4): 1637-1644 (2003)).

A “spacer domain,” refers to a polypeptide that separates two domains. In one embodiment, a spacer domain moves a or targeting domain away from the effector cell surface to enable proper cell/cell contact, antigen binding and activation (Patel *et al.*, Gene Therapy, 1999; 6: 412-419). In particular embodiments, a spacer domain separates one or more heavy or light chain variable domains, multimerization domains, transmembrane domains, costimulatory domains, and/or primary signaling domains. The spacer domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source. In certain embodiments, a spacer

20 domain is a portion of an immunoglobulin, including, but not limited to, one or more heavy chain constant regions, *e.g.*, CH2 and CH3. The spacer domain can include the amino acid sequence of a naturally occurring immunoglobulin hinge region or an altered immunoglobulin hinge region.

An “antigen (Ag)” refers to a compound, composition, or substance that can stimulate the production of antibodies or a T cell response in an animal, including compositions (such as one that includes a cancer-specific protein) that are injected or absorbed into an animal. Exemplary

30 antigens include but are not limited to lipids, carbohydrates, polysaccharides, glycoproteins, peptides, or nucleic acids. An antigen reacts with the products of specific humoral or cellular immunity, including those induced by heterologous antigens, such as the disclosed antigens.

A “target antigen” or “target antigen of interest” refers to a molecule expressed on the cell surface of a target cell that a binding or targeting domain contemplated herein, is designed to bind. In particular embodiments, the target antigen is an epitope of a polypeptide expressed on the surface of a cancer cell.

5 As used herein, the term, “targeting domain” refers to a domain, *e.g.*, a domain of a targeting component, that provides the polypeptide with the ability to specifically bind to a target antigen of interest. The targeting domain may be derived either from a natural, synthetic, semi-synthetic, or recombinant source. A targeting domain may, *e.g.*, comprise an antibody, or an antigen-binding fragment thereof or, *e.g.*, an ectodomain.

10 The terms “specific binding affinity” or “specifically binds” or “specifically bound” or “specific binding” or “specifically targets” as used herein, describe binding of a targeting domain to a target antigen at greater binding affinity than background binding. A targeting domain “specifically binds” to a target antigen, if it binds to or associates with the antigen with an affinity or K_a (*i.e.*, an equilibrium association constant of a particular binding interaction with units of
15 $1/M$) of, for example, greater than or equal to about $10^5 M^{-1}$. In certain embodiments, a targeting domain (or a fusion protein comprising the same) binds to a target with a K_a greater than or equal to about $10^6 M^{-1}$, $10^7 M^{-1}$, $10^8 M^{-1}$, $10^9 M^{-1}$, $10^{10} M^{-1}$, $10^{11} M^{-1}$, $10^{12} M^{-1}$, or $10^{13} M^{-1}$. “High affinity” targeting domains (or single chain fusion proteins thereof) refer to those targeting domains with a K_a of at least $10^7 M^{-1}$, at least $10^8 M^{-1}$, at least $10^9 M^{-1}$, at least $10^{10} M^{-1}$, at least
20 $10^{11} M^{-1}$, at least $10^{12} M^{-1}$, at least $10^{13} M^{-1}$, or greater.

The terms “selectively binds” or “selectively bound” or “selectively binding” or “selectively targets” and describe preferential binding of one molecule to a target molecule (on-target binding) in the presence of a plurality of off-target molecules.

25 An “antibody” refers to a binding agent that is a polypeptide comprising at least a light chain or heavy chain immunoglobulin variable region which specifically recognizes and binds an epitope of an antigen, such as a lipid, carbohydrate, polysaccharide, glycoprotein, peptide, or nucleic acid containing an antigenic determinant, such as those recognized by an immune cell.

An “epitope” or “antigenic determinant” refers to the region of an antigen to which a binding agent binds.

30 Antibodies include antigen binding fragments thereof, such as a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a $F(ab')_2$ fragment, a bispecific Fab dimer (Fab2), a trispecific Fab trimer (Fab3), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)₂, a

minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (sdAb, a camelid VHH, Nanobody) and portions of full length antibodies responsible for antigen binding. The term also includes genetically engineered forms such as chimeric antibodies (for example, humanized murine antibodies), heteroconjugate antibodies
 5 (such as, bispecific antibodies) and antigen binding fragments thereof. *See also*, Pierce Catalog and Handbook, 1994-1995 (Pierce Chemical Co., Rockford, IL); Kuby, J., Immunology, 3rd Ed., W. H. Freeman & Co., New York, 1997.

As used herein, the term “cancer” relates generally to a class of diseases or conditions in which abnormal cells divide without control and can invade nearby tissues.

10 As used herein, the term “malignant” refers to a cancer in which a group of tumor cells display one or more of uncontrolled growth (*i.e.*, division beyond normal limits), invasion (*i.e.*, intrusion on and destruction of adjacent tissues), and metastasis (*i.e.*, spread to other locations in the body via lymph or blood). As used herein, the term “metastasize” refers to the spread of cancer from one part of the body to another. A tumor formed by cells
 15 that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor.

As used herein, the term “benign” or “non-malignant” refers to tumors that may grow larger but do not spread to other parts of the body. Benign tumors are self-limited and typically do not invade or metastasize.

20 A “cancer cell” refers to an individual cell of a cancerous growth or tissue. Cancer cells include both solid cancers and liquid cancers. A “tumor” or “tumor cell” refers generally to a swelling or lesion formed by an abnormal growth of cells, which may be benign, pre-malignant, or malignant. Most cancers form tumors, but liquid cancers, *e.g.*, leukemia, do not necessarily form tumors. For those cancers that form tumors, the terms
 25 cancer (cell) and tumor (cell) are used interchangeably. The amount of a tumor in an individual is the “tumor burden” which can be measured as the number, volume, or weight of the tumor.

The term “relapse” refers to the diagnosis of return, or signs and symptoms of return, of a cancer after a period of improvement or remission.

30 “Remission,” is also referred to as “clinical remission,” and includes both partial and complete remission. In partial remission, some, but not all, signs and symptoms of cancer have

disappeared. In complete remission, all signs and symptoms of cancer have disappeared, although cancer still may be in the body.

“Refractory” refers to a cancer that is resistant to, or non-responsive to, therapy with a particular therapeutic agent. A cancer can be refractory from the onset of treatment (*i.e.*, non-responsive to initial exposure to the therapeutic agent), or as a result of developing resistance to the therapeutic agent, either over the course of a first treatment period or during a subsequent treatment period.

“Antigen negative” refers to a cell that does not express antigen or expresses a negligible amount of antigen that is undetectable. In one embodiment, antigen negative cells do not bind receptors directed to the antigen. In one embodiment, antigen negative cells do not substantially bind receptors directed to the antigen.

As used herein, the terms “individual” and “subject” are often used interchangeably and refer to any animal that exhibits a symptom of cancer or other immune disorder that can be treated with the compositions and methods contemplated elsewhere herein. Suitable subjects (*e.g.*, patients) include laboratory animals (such as mouse, rat, rabbit, or guinea pig), farm animals, and domestic animals or pets (such as a cat or dog). Non-human primates and, preferably, human patients, are included. Typical subjects include human patients that have, have been diagnosed with, or are at risk of having, cancer or another immune disorder.

As used herein, the term “patient” refers to a subject that has been diagnosed with cancer or another immune disorder that can be treated with the compositions and methods disclosed elsewhere herein.

As used herein “treatment” or “treating,” includes any beneficial or desirable effect on the symptoms or pathology of a disease or pathological condition, and may include even minimal reductions in one or more measurable markers of the disease or condition being treated. Treatment can involve optionally either the reduction of the disease or condition, or the delaying of the progression of the disease or condition, *e.g.*, delaying tumor outgrowth. “Treatment” does not necessarily indicate complete eradication or cure of the disease or condition, or associated symptoms thereof.

As used herein, “prevent,” and similar words such as “prevented,” “preventing” *etc.*, indicate an approach for preventing, inhibiting, or reducing the likelihood of the occurrence or recurrence of, a disease or condition. It also refers to delaying the onset or recurrence of a disease or condition or delaying the occurrence or recurrence of the symptoms of a disease or

condition. As used herein, “prevention” and similar words also includes reducing the intensity, effect, symptoms and/or burden of a disease or condition prior to onset or recurrence of the disease or condition.

As used herein, the phrase “ameliorating at least one symptom of” refers to decreasing one or more symptoms of the disease or condition for which the subject is being treated. In particular embodiments, the disease or condition being treated is a cancer, wherein the one or more symptoms ameliorated include, but are not limited to, weakness, fatigue, shortness of breath, easy bruising and bleeding, frequent infections, enlarged lymph nodes, distended or painful abdomen (due to enlarged abdominal organs), bone or joint pain, fractures, unplanned weight loss, poor appetite, night sweats, persistent mild fever, and decreased urination (due to impaired kidney function).

By “enhance” or “promote,” or “increase” or “expand” refers generally to the ability of a composition contemplated herein to produce, elicit, or cause a greater physiological response (*i.e.*, downstream effects) compared to the response caused by either vehicle or a control molecule/composition. A measurable physiological response may include an increase in T cell expansion, activation, persistence, cytokine secretion, and/or an increase in cancer cell killing ability, among others apparent from the understanding in the art and the description herein. An “increased” or “enhanced” amount is typically a “statistically significant” amount, and may include an increase that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (*e.g.*, 500, 1000 times) (including all integers and decimal points in between and above 1, *e.g.*, 1.5, 1.6, 1.7, 1.8, *etc.*) the response produced by vehicle or a control composition.

By “decrease” or “lower,” or “lessen,” or “reduce,” or “abate” refers generally to the ability of composition contemplated herein to produce, elicit, or cause a lesser physiological response (*i.e.*, downstream effects) compared to the response caused by either vehicle or a control molecule/composition. A “decrease” or “reduced” amount is typically a “statistically significant” amount, and may include a decrease that is 1.1, 1.2, 1.5, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 30 or more times (*e.g.*, 500, 1000 times) (including all integers and decimal points in between and above 1, *e.g.*, 1.5, 1.6, 1.7, 1.8, *etc.*) the response (reference response) produced by vehicle, a control composition, or the response in a particular cell lineage.

By “maintain,” or “preserve,” or “maintenance,” or “no change,” or “no substantial change,” or “no substantial decrease” refers generally to the ability of a composition

contemplated herein to produce, elicit, or cause a substantially similar or comparable physiological response (*i.e.*, downstream effects) in a cell, as compared to the response caused by either vehicle, a control molecule/composition, or the response in a particular cell lineage. A comparable response is one that is not significantly different or measurable
5 different from the reference response.

Additional definitions are set forth throughout this disclosure.

C. ENGINEERED IMMUNE RECEPTOR ARCHITECTURES

In particular embodiments, one or more engineered immune receptors that redirect cytotoxicity of immune effector cells toward cells expressing a target antigen and that recruit
10 and an immune receptor complex are contemplated. As used herein, the terms “engineered immune receptor”, “engineered immune receptor complex”, or “engineered immune receptor system” refer to one or more non-naturally occurring polypeptides that facilitates transduction of an immunostimulatory signal in an immune effector cell upon exposure to a pre-defined or selected target antigen and association/multimerization with an immune
15 receptor complex. In some embodiments, a multimerizing agent or bridging factor is required to promote multimerization of the non-naturally occurring polypeptides and thereby stimulating immune effector cell activity and function through activation of an immune receptor complex. In preferred embodiments, an engineered immune receptor or system is a multi-chain chimeric receptor comprising a signaling component that associates with a
20 member of an immune receptor complex, and a targeting component that redirects or complements the antigen specificity of the receptor/complex.

In one embodiment, a signaling component and a targeting component are expressed from the same cell. In another embodiment, a signaling component and a targeting component are expressed from different cells. In another embodiment, a signaling
25 component is expressed from a cell and a targeting component is supplied exogenously, as a polypeptide. In a particular embodiment, a targeting component pre-loaded with a bridging factor is supplied exogenously to a cell expressing a signaling component.

I. SIGNALING COMPONENT

A “signaling component” refers to a polypeptide comprising one or more
30 multimerization domains (*e.g.*, FRB or FKBP polypeptides) or variants thereof, and a CD3ε

domain/polypeptide, or functional fragment or variant thereof, that is capable of recruiting an immune receptor complex (*e.g.*, a TCR complex).

In various embodiments, the CD3 ϵ peptide or a functional fragment or variant thereof comprising an amino acid sequence having at least 90% identity to SEQ ID NO: 32. In some
 5 embodiments, the CD3 ϵ peptide or a functional fragment or variant thereof comprising an amino acid sequence having at least 95% identity to SEQ ID NO: 32. In some embodiments, the CD3 ϵ peptide or a functional fragment or variant thereof comprising an amino acid sequence having at least 96% identity to SEQ ID NO: 32. In some embodiments, the CD3 ϵ peptide or a functional fragment or variant thereof comprising an amino acid sequence having
 10 at least 97% identity to SEQ ID NO: 32. In some embodiments, the CD3 ϵ peptide or a functional fragment or variant thereof comprising an amino acid sequence having at least 98% identity to SEQ ID NO: 32. In some embodiments, the CD3 ϵ peptide or a functional fragment or variant thereof comprising an amino acid sequence having at least 99% identity to SEQ ID NO: 32. In particular embodiments, the CD3 ϵ peptide comprising an amino acid
 15 sequence as set forth in SEQ ID NO: 32.

In various embodiments, the CD3 ϵ polypeptide is a human CD3 ϵ polypeptide.

In particular embodiments, a signaling component comprises an FRB or FRB T2098L multimerization domain/polypeptide, a linker polypeptide, and a CD3 ϵ polypeptide.

In various embodiments, a signaling component comprises an amino acid sequence
 20 having at least 90% identity to SEQ ID NO: 111. In various embodiments, a signaling component comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 111. In various embodiments, a signaling component comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 111. In various embodiments, a signaling component comprises an amino acid sequence having at least 97% identity to SEQ ID NO:
 25 111. In various embodiments, a signaling component comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 111. In various embodiments, a signaling component comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 111. In particular embodiments, a signaling component comprises an amino acid sequence as set forth in SEQ ID NO: 111.

30 In various embodiments, the multimerization domain (*e.g.*, FRB or FKBP) localizes extracellularly when the signaling component is expressed.

In particular embodiments, a signaling component comprises an FRB polypeptide or variant thereof. In various embodiments, a signaling component comprises an FRB polypeptide comprising a T2098L (T82L) mutation, or variant thereof. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 1. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 1. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 1. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 1. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 1. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 1. In particular embodiments, the FRB polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 1. In particular embodiments, the FRB polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 2. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 2. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 2. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 2. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 2. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 2. In particular embodiments, the FRB polypeptide comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 2. In particular embodiments, the FRB polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 2.

In particular embodiments, the signaling component comprises an FKBP12 polypeptide or variant thereof. In various embodiments, a signaling component comprises an FKBP12 polypeptide comprising a F36V mutation. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 3. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 3. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 3. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least

97% identity to SEQ ID NO: 3. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 3. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 3. In particular embodiments, the FKBP12 polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 3. In particular embodiments, the FKBP12 polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 4. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 4. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 4. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 4. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 4. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 4. In one embodiment, the FKBP12 polypeptide comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 4. In particular embodiments, the FKBP12 polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 4.

In various embodiments, the first multimerization domain (*e.g.*, FRB or FKBP) and the CD3ε domain/polypeptide are separated by a first polypeptide linker of 2 to 40 amino acids in length. In various embodiments, a short oligo- or poly-peptide linker, preferably between 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length links one or more domains in the signaling component. A glycine-serine based linker provides a particularly suitable linker. In some embodiments, the first polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, and any combination thereof. In some embodiments, the first polypeptide linker is a G4S (GGGGS; SEQ ID NO: 11) linker. In some embodiments, the first polypeptide linker is a 2xG4S (GGGGSGGGGS; SEQ ID NO: 12) linker. In some embodiments, the first polypeptide linker is a 3xG4S (GGGGSGGGGS; SEQ ID NO: 13) linker. In some embodiments, the first polypeptide linker is a 4xG4S (GGGGSGGGSGGGGS; SEQ ID NO: 14) linker. In some embodiments, the first polypeptide linker is a 5xG4S (GGGGSGGGSGGGSGGGGS; SEQ ID NO: 15) linker. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 16. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 17. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 18. In one embodiment, the linker has a

sequence set forth as SEQ ID NO: 19. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 20. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 21. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 22. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 23. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 24. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 25. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 26. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 27. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 28. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 29. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 30. In one embodiment, the linker has a sequence set forth as SEQ ID NO: 31.

In various embodiments, a signaling component contemplated herein comprises a signal peptide, *e.g.*, secretion signal polypeptide or signal sequence. Illustrative examples of signal peptides/sequences suitable for use in particular signaling components include but are not limited to an IgG1 heavy chain signal polypeptide, an Igk light chain signal polypeptide, a CD8 α signal polypeptide, or a human GM-CSF receptor alpha signal polypeptide. In various embodiments, a signaling component comprises a Igk light chain signal polypeptide. In some embodiments, the Igk light chain signal polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 95. In various embodiments, a signaling component comprises a CD8 α signal polypeptide. In some embodiments, the CD8 α light chain signal polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 96. In various embodiments, a signaling component comprises a PD1 signal polypeptide. In one embodiment, the PD1 signal polypeptide comprises an amino acid sequence set forth as SEQ ID NO: 97.

In particular embodiments, the signaling component comprises an FRB polypeptide or variant thereof, a 3xG4S linker, and a CD3 ϵ polypeptide or variant thereof. In particular embodiments, the signaling component comprises a signaling sequence, an FRB polypeptide or variant thereof, a 3xG4S linker, and a CD3 ϵ polypeptide or variant thereof. In particular embodiments, the signaling component comprises a CD8 signaling sequence, an FRB* polypeptide or variant thereof, a 3xG4S linker, and a CD3 ϵ polypeptide or variant thereof. In particular embodiments, the signaling component comprises a CD8 signaling sequence (*e.g.*, as set forth in SEQ ID NO: 96, an FRB* polypeptide or variant thereof (*e.g.*, as set forth in

SEQ ID NO: 1, a 3xG4S linker (*e.g.*, as set for in SEQ ID NO: 13), and a CD3 ϵ polypeptide (*e.g.*, as set for in SEQ ID NO: 32).

2. TARGETING COMPONENT

A “targeting component” refers to a polypeptide comprising an extracellular domain,
5 one or more multimerization domains, and a transmembrane domain, that in conjunction with a signaling component re-directs activation of an immune receptor complex to one or more selected target antigens. In some embodiments, the extracellular domain comprises one or more targeting domains that associate with and/or binds one or more target antigens. In particular embodiments, a targeting component comprises a first targeting domain, a second
10 multimerization domain, a hinge domain, and a transmembrane domain.

In particular embodiments, a targeting component comprises an extracellular domain comprising at least one targeting domain, wherein the targeting domain is an antibody or antigen binding fragment thereof directed against one or more target antigens. Antigen binding fragments directed against one or more target antigens suitable for use in particular
15 embodiments contemplated herein include those selected from the group consisting of: a Camel Ig, a Llama Ig, an Alpaca Ig, Ig NAR, a Fab' fragment, a F(ab')₂ fragment, a bispecific Fab dimer (Fab₂), a trispecific Fab trimer (Fab₃), an Fv, an single chain Fv protein (“scFv”), a bis-scFv, (scFv)₂, a minibody, a diabody, a triabody, a tetrabody, a disulfide stabilized Fv protein (“dsFv”), and a single-domain antibody (*e.g.*, sdAb, a camelid VHH, or Nanobody).

20 In various embodiments, the targeting domain comprises a single-chain variable fragment (scFv) or single domain antibody (sdAb). In various embodiments, the targeting domain comprise a single-chain variable fragment (scFv). In some embodiments, the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb). In some embodiments, the sdAb is a camelid VHH. In some embodiments, the scFv or sdAb is human or humanized.

25 In particular embodiments, the VHH is humanized.

The disclosure provides a platform technology which is applicable to numerous classes and fragments of targeting domains and should not be limited to, for example, one particular targeting domain, *e.g.*, antibody, antigen-binding fragment, ectodomain, *etc.*, for targeting a specific target antigen.

30 For example, in some embodiments, the target antigen is an antigen expressed on a target cell, including, for example, cancer cells. In some embodiments, the targeting domain binds a CD33 target antigen and/or a C-type lectin-like molecule-1 (CLL-1) target antigen.

In various embodiments, the targeting component comprises an extracellular domain that comprises a second targeting domain.

In various embodiments, the second targeting domain comprises a single-chain variable fragment (scFv) or single domain antibody (sdAb). In various embodiments, the
5 second targeting domain comprises a single-chain variable fragment (scFv). In some embodiments, the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb). In some embodiments, the sdAb is a camelid VHH. In some embodiments, the scFv or sdAb is human or humanized. In particular embodiments, the VHH is humanized.

The extracellular domains contemplated in particular embodiments comprise a second
10 targeting domain that binds a CD33 target antigen and/or a C-type lectin-like molecule-1 (CLL-1) target antigen. In one embodiment, the targeting domain comprises a CD33 targeting domain. In one embodiment, the CD33 targeting domain is a VHH. In one embodiment, the CD33 VHH comprises a CDR1 comprising SEQ ID NO: 89, a CDR2 comprising SEQ ID NO: 90, and a CDR3 comprising SEQ ID NO: 91. In one embodiment,
15 the targeting domain comprises a sequence having at least 90% identity to SEQ ID NO: 72. In one embodiment, the targeting domain comprises a sequence having at least 95% identity to SEQ ID NO: 72. In one embodiment, the targeting domain comprises a sequence having at least 96% identity to SEQ ID NO: 72. In one embodiment, the targeting domain comprises a sequence having at least 97% identity to SEQ ID NO: 72. In one embodiment, the targeting
20 domain comprises a sequence having at least 98% identity to SEQ ID NO: 72. In one embodiment, the targeting domain comprises a sequence having at least 99% identity to SEQ ID NO: 72. In one embodiment, the targeting domain comprises a sequence set forth as SEQ ID NO: 72.

In one embodiment, the targeting domain is a CLL1 targeting domain. In one
25 embodiment, the targeting domain comprises a CLL1 targeting domain. In one embodiment, the CLL1 targeting domain is a VHH. In one embodiment, the CD33 VHH comprises a CDR1 comprising SEQ ID NO: 92, a CDR2 comprising SEQ ID NO: 93, and a CDR3 comprising SEQ ID NO: 94. In one embodiment, the targeting domain comprises a sequence having at least 90% identity to SEQ ID NO: 75. In one embodiment, the targeting domain
30 comprises a sequence having at least 95% identity to SEQ ID NO: 75. In one embodiment, the targeting domain comprises a sequence having at least 96% identity to SEQ ID NO: 75. In one embodiment, the targeting domain comprises a sequence having at least 97% identity to SEQ ID NO: 75. In one embodiment, the targeting domain comprises a sequence having at

least 98% identity to SEQ ID NO: 75. In one embodiment, the targeting domain comprises a sequence having at least 99% identity to SEQ ID NO: 75. In one embodiment, the targeting domain comprises a sequence set forth as SEQ ID NO: 75.

5 In one embodiment, the targeting component comprises a first targeting domain and a second targeting domain. In one embodiment, the first targeting domain is a CD33 targeting domain, and the second targeting domain is a CLL1 targeting domain. In another embodiment, the first targeting domain is a CLL1 targeting domain, and the second targeting domain is a CD33 targeting domain.

10 In one embodiment, the first targeting domain is a CD33 VHH, wherein, the CD33 VHH comprises a CDR1 comprising SEQ ID NO: 89, a CDR2 comprising SEQ ID NO: 90, and a CDR3 comprising SEQ ID NO: 91; and the second targeting domain is a CLL1 VHH, wherein the CLL1 VHH comprises a CDR1 comprising SEQ ID NO: 92, a CDR2 comprising SEQ ID NO: 93, and a CDR3 comprising SEQ ID NO: 94.

15 In one embodiment, the second targeting domain is a CD33 VHH, wherein, the CD33 VHH comprises a CDR1 comprising SEQ ID NO: 89, a CDR2 comprising SEQ ID NO: 90, and a CDR3 comprising SEQ ID NO: 91; and the first targeting domain is a CLL1 VHH, wherein the CLL1 VHH comprises a CDR1 comprising SEQ ID NO: 92, a CDR2 comprising SEQ ID NO: 93, and a CDR3 comprising SEQ ID NO: 94.

20 In various embodiments, the first targeting domain and the second targeting domain are separated by a third polypeptide linker 2 to 40 amino acids in length. In some embodiments, the third polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, and any combination thereof.

25 In particular embodiments, a targeting component comprises one or more multimerization domains.

30 Illustrative examples of multimerization domains suitable for use in particular targeting components contemplated herein include, but are not limited to, an FK506 binding protein (FKBP) polypeptide or variants thereof, an FKBP-rapamycin binding (FRB) polypeptide or variants thereof, a calcineurin polypeptide or variants thereof, a cyclophilin polypeptide or variants thereof, a bacterial dihydrofolate reductase (DHFR) polypeptide or variants thereof, a PYR1-like 1 (PYL1) polypeptide or variants thereof and an abscisic acid insensitive 1 (ABI1) polypeptide or variants thereof.

In various embodiments, a targeting component comprises an FRB polypeptide. In various embodiments, a targeting component comprises an FRB polypeptide comprising a T2098L (T82L) mutation, or variant thereof. In particular embodiments, the FRB polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 1. In particular
 5 embodiments, the FRB polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 2.

In various embodiments, a targeting component comprises an FKBP12 polypeptide or variant thereof. In various embodiments, a targeting component comprises an FKBP12 polypeptide comprising a F36V mutation. In particular embodiments, the FKBP12
 10 polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 3. In particular embodiments, the FKBP12 polypeptide comprises the amino acid sequence as set forth in SEQ ID NO: 4.

Other illustrative examples of multimerization domains suitable for use in particular targeting components contemplated herein include antibody derived heterodimerization
 15 domains. Such antibody heterodimerization domains include, but are not limited to, lock and key, DEKK, SEEDbody, DuoBody, dual variable domain immunoglobulin (DVD-Ig), and Fabs-in-tandem immunoglobulin (FIT-Ig) multimerization domains (see, *e.g.*, Ma *et al.*, *Front Immunol.* 2021 May 5;12:626616.)

In various embodiments, the extracellular domain or first targeting domain, and the
 20 second multimerization domain, are separated by a second polypeptide linker 2 to 40 amino acids in length. In various embodiments, a short oligo- or poly-peptide linker, preferably between 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length links one or more domains in the targeting component. A glycine-serine based linker provides a particularly suitable linker. In some embodiments, the second polypeptide linker
 25 is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, and any combination thereof. In some embodiments, the second polypeptide linker is a G4S (GGGGS; SEQ ID NO: 11) linker. In some embodiments, the second polypeptide linker is a 2xG4S (GGGSGGGGS; SEQ ID NO: 12) linker. In some embodiments, the second polypeptide linker is a 3xG4S (GGGSGGGSGGGGS; SEQ ID
 30 NO: 13) linker. In some embodiments, the second polypeptide linker is a 4xG4S (GGGSGGGSGGGSGGGGS; SEQ ID NO: 14) linker. In some embodiments, the second polypeptide linker is a 5xG4S (GGGSGGGSGGGSGGGSGGGGS; SEQ ID

NO: 15) linker. In some embodiments, the second polypeptide linker comprises an amino acid sequence as set forth in any one or more of SEQ ID NOs: 16-31.

In various embodiments, the second multimerization domain and the transmembrane domain are separated by a hinge domain. In some embodiments, the hinge domain is a CD4 hinge. In some embodiments, the CD4 hinge comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 41. In some embodiments, the CD4 hinge comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 41. In some embodiments, the CD4 hinge comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 41. In some embodiments, the CD4 hinge comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 41. In some embodiments, the CD4 hinge comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 41. In some embodiments, the CD4 hinge comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 41. In some embodiments, the CD4 hinge comprises an amino acid sequence as set forth in SEQ ID NO: 41.

In some embodiments, the targeting component comprises a linker comprising an GGR amino acid sequence. In some embodiments, the targeting component comprises a linker comprising an amino acid sequence as set forth in SEQ ID NO: 13 or SEQ ID NO: 14.

In particular embodiments, a targeting component comprises a transmembrane domain.

Illustrative examples of transmembrane domains suitable for use in particular targeting components contemplated herein include, but are not limited to, the transmembrane region(s) of the alpha, beta, gamma, or delta chain of a T-cell receptor, CD3ε, CD3ζ, CD4, CD5, CD8α, CD9, CD 16, CD22, CD27, CD28, CD33, CD37, CD45, CD64, CD71, CD80, CD86, CD 134, CD137, CD152, CD 154, amnionless (AMN), and programmed cell death 1 (PDCD1). In a various embodiment, a targeting component comprises a CD4 transmembrane domain, CD28 transmembrane domain, or a CD8α transmembrane domain.

In a particular embodiment, a targeting component comprises a CD4 transmembrane domain. In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 45. In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 45. In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 45. In some embodiments,

the CD4 transmembrane domain comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 45. In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 45. In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 45. In some embodiments, the CD4 transmembrane domain comprises an amino acid sequence as set forth in SEQ ID NO: 45.

In particular embodiments, a targeting component comprises a truncated CD4 intracellular (CD4ic) domain. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 48. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 48. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 48. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 48. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 48. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 48. In various embodiments, the truncated CD4ic domain comprises an amino acid sequence as set forth in SEQ ID NO: 48. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 49. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 49. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 49. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 49. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 49. In one embodiment, the truncated CD4ic domain comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 49. In various embodiments, the truncated CD4ic domain comprises an amino acid sequence as set forth in SEQ ID NO: 49.

In particular embodiments, the targeting component does not comprise a primary signaling domain (*e.g.*, CD3z). In various embodiments, the targeting component does not comprise an intracellular signaling or costimulatory domain.

In various embodiments, the targeting component further comprises a truncated intracellular CD4 polypeptide. In some embodiments, the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 48. In some embodiments, the truncated intracellular CD4 polypeptide comprises an amino acid sequence
 5 as set forth in SEQ ID NO: 49.

In a preferred embodiment, a targeting component comprises an extracellular domain that comprises a first targeting domain comprising a VHH or scFv that binds a CLL1, a linker polypeptide, a second targeting domain comprising a VHH or scFv that binds CD33, a linker polypeptide, an FRB or FKBP12 multimerization domain, a CD4 hinge, a CD4
 10 transmembrane domain, and a truncated CD4ic domain. In a preferred embodiment, a targeting component comprises an extracellular domain that comprises a first targeting domain comprising a VHH or scFv that binds a CD33, a linker polypeptide, a second targeting domain comprising a VHH or scFv that binds CLL1, a linker polypeptide, an FRB or FKBP12 multimerization domain, a CD4 hinge, a CD4 transmembrane domain, and a
 15 truncated CD4ic domain.

In one embodiment, the targeting component comprises a sequence having at least 90% identity to SEQ ID NO: 122. In one embodiment, the targeting component comprises a sequence having at least 95% identity to SEQ ID NO: 122. In one embodiment, the targeting component comprises a sequence having at least 96% identity to SEQ ID NO: 122. In one
 20 embodiment, the targeting component comprises a sequence having at least 97% identity to SEQ ID NO: 122. In one embodiment, the targeting component comprises a sequence having at least 98% identity to SEQ ID NO: 122. In one embodiment, the targeting component comprises a sequence having at least 99% identity to SEQ ID NO: 122. In one embodiment, the targeting component comprises a sequence set forth as SEQ ID NO: 122.

25 In various embodiments, a targeting component contemplated herein comprises a signal peptide, *e.g.*, secretion signal polypeptide or sequence. Illustrative examples of signal polypeptides/sequences suitable for use in particular targeting components include but are not limited to an IgG1 heavy chain signal polypeptide, an Igκ light chain signal polypeptide, a CD8α signal polypeptide, or a human GM-CSF receptor alpha signal polypeptide.

30 In various preferred embodiments, a targeting component comprises a Igκ light chain signal polypeptide. In some embodiments, the Igκ light chain signal polypeptide comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 95. In some

embodiments, the Igk light chain signal polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 95. In some embodiments, the Igk light chain signal polypeptide comprises an amino acid sequence having at least 96% identity to SEQ ID NO: 95. In some embodiments, the Igk light chain signal polypeptide comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 95. In some embodiments, the Igk light chain signal polypeptide comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 95. In some embodiments, the Igk light chain signal polypeptide comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 95. In some embodiments, the Igk light chain signal polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 95.

In particular embodiments, the targeting component comprises a CLL1 targeting domain, a 3xG4S linker, a CD33 targeting domain, a 3xG4S linker, an FKBP polypeptide or variant thereof, a CD4 hinge domain, a CD4 transmembrane domain, and a truncated intracellular CD4 polypeptide. In particular embodiments, the targeting component comprises a signaling sequence, a CLL1 targeting domain, a 3xG4S linker, a CD33 targeting domain, a 3xG4S linker, an FKBP polypeptide or variant thereof, a CD4 hinge domain, a CD4 transmembrane domain, and a truncated intracellular CD4 polypeptide. In particular embodiments, the targeting component comprises an IgK signaling sequence, a CLL1 VHH targeting domain, a 3xG4S linker, a CD33 VHH targeting domain, a 3xG4S linker, an FKBP polypeptide or variant thereof, a CD4 hinge domain, a CD4 transmembrane domain, and a truncated intracellular CD4 polypeptide. In particular embodiments, the targeting component comprises an IgK signaling sequence (*e.g.*, as set forth as SEQ ID NO: 95), a CLL1 VHH targeting domain (*e.g.*, comprising a CDR1 as set forth as SEQ ID NO: 92, a CDR2 as set forth as SEQ ID NO: 93, and a SEQ ID NO: 94; and/or a VHH as set forth as SEQ ID NO: 75), a 3xG4S linker (*e.g.*, as set forth in SEQ ID NO: 13), a CD33 VHH targeting domain (*e.g.*, comprising a CDR1 set forth as SEQ ID NO: 89, a CDR2 set forth as SEQ ID NO: 90, a CDR3 set forth as SEQ ID NO: 91; and/or a VHH comprising SEQ ID NO: 72), a 3xG4S linker (*e.g.*, as set forth in SEQ ID NO: 13), an FKBP polypeptide or variant thereof (*e.g.*, as set forth as SEQ ID NO: 3), a CD4 hinge domain (*e.g.*, as set forth as SEQ ID NO: 41), a CD4 transmembrane domain (*e.g.*, as set forth as SEQ ID NO: 45), and a truncated intracellular CD4 polypeptide (*e.g.*, as set forth as SEQ ID NO: 48 or SEQ ID NO: 49).

3. *BRIDGING FACTOR*

Bridging factors contemplated in particular embodiments herein mediate or promote the association of one or more signaling components with one or more targeting components through multimerization domains in the respective components. A bridging factor associates with and is disposed between the multimerization domains to promote association of a signaling component and a targeting component. In the presence of a bridging factor, the targeting component and the signaling component associate with an immune receptor complex and initiate immune effector cell activity against a target cell when the targeting component is bound to a target antigen on the target cell. In the absence of a bridging factor, the targeting component does not associate with the signaling component, does not recruit an immune receptor complex and the engineered receptor is inactive against the target antigen of the targeting component.

In particular embodiments, a signaling component and a targeting component comprise a cognate pair of multimerization domains selected from the group consisting of: FKBP and FKBP12-rapamycin binding (FRB), FKBP and calcineurin, FKBP and cyclophilin, FKBP and bacterial dihydrofolate reductase (DHFR), calcineurin and cyclophilin, and PYR1-like 1 (PYL1) and abscisic acid insensitive 1 (ABI1).

In certain embodiments, the multimerization domains of signaling and targeting components associate with a bridging factor selected from the group consisting of: rapamycin or a rapalog thereof, coumermycin or a derivative thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A (FKCsA) or a derivative thereof, and trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof.

In particular embodiments, a signaling component and a targeting component comprise one or more FRB and/or FKBP multimerization domains or variants thereof. In certain embodiments, a signaling component comprises an FKBP12 multimerization domain or variant thereof and a targeting component comprises an FRB multimerization domain or variant thereof. In certain embodiments, a signaling component comprises an FRB multimerization domain or variant thereof and a targeting component comprises an FKBP12 multimerization domain or variant thereof. In particular preferred embodiments, a signaling component comprises an FKBP12 or FKBP12 F36V multimerization domain or variant

thereof, and a targeting component comprises an FRB T2098L multimerization domains or variant thereof. In particular preferred embodiments, a CD3 signaling component comprises an FRB T2098L (T82L) multimerization domain or variant thereof, and a targeting component comprises an FKBP12 or FKBP12 F36V multimerization domains or variant thereof.

Illustrative examples of bridging factors suitable for use in particular embodiments contemplated herein include, but are not limited to, AP1903, AP20187, AP21967 (also known as C-16-(S)-7-methylindolerapamycin), everolimus, novolimus, pimecrolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus, umirolimus, zotarolimus, and BPC015. In particular preferred embodiments, the bridging factor is AP21967. In certain preferred embodiments, the bridging factor is a non-immunosuppressive dose of sirolimus (rapamycin).

D. ANTIGEN RECEPTORS AND BINDING MOLECULES

In particular embodiments, immune effector cells contemplated herein further express an exogenous lymphocyte receptor or engineered antigen receptor and one or more components of an engineered immune receptor complex or system as described herein. In some embodiments, the exogenous lymphocyte receptor or engineered antigen receptor is a chimeric antigen receptor (CAR), a chimeric costimulatory receptor (CCR), a T cell receptor (TCR), an $\alpha\beta$ T cell receptor ($\alpha\beta$ -TCR), a $\gamma\delta$ T cell receptor ($\gamma\delta$ -TCR), zetakine, or flip receptor. In some embodiments, the immune effector cells contemplated herein further express an exogenous costimulatory factor, immunomodulatory factor, agonist for a costimulatory factor, antagonist for an immunosuppressive factor, immune cell engager, or any combination thereof. In some embodiments, the immune effector cells contemplated herein further express a BiTE.

In various embodiments, the exogenous lymphocyte receptor or engineered antigen receptor is an engineered $\alpha\beta$ or $\gamma\delta$ T cell receptor (TCR), a chimeric antigen receptor (CAR), or a chimeric costimulatory receptor (CCR). In particular embodiments, the exogenous lymphocyte receptor is an engineered $\alpha\beta$ or $\gamma\delta$ T cell receptor. In particular embodiments, the engineered antigen receptor is a chimeric antigen receptor (CAR). In particular embodiments, the engineered antigen receptor is a chimeric costimulatory receptor (CCR). In various embodiments, immune effector cells contemplated herein comprise an engineered/exogenous TCR, and an engineered immune receptor component(s) as described herein. Without wishing to be limited to any particular theory, the signaling components of

the engineered immune receptors components/systems contemplated herein comprise a multimerization domain fused to an actuator domain (*e.g.*, CD3 ϵ , CD3 δ , CD3 γ , or Fc γ subunit) that associates with a multimeric immune receptor complex, and thus, in the presence of bridging factor recruits an immune receptor complex by multimerizing with the

5 targeting component comprising a second multimerization domain.

In one embodiment, T cells are engineered by introducing a polynucleotide or vector encoding an engineered antigen receptor (*e.g.*, TCR, CAR, or CCR) and one or more components of an engineered immune receptor system separated by one or more polypeptide cleavage signals. In one embodiment, T cells are engineered by introducing a polynucleotide

10 or vector encoding an engineered antigen receptor and a polynucleotide or vector encoding one or more components of an immune receptor system. In one embodiment, T cells engineered to express an engineered immune receptor are further engineered by introducing a polynucleotide or vector encoding one or more components of an immune receptor system.

Naturally occurring T cell receptors comprise two subunits, an alpha chain and a beta chain subunit ($\alpha\beta$ TCR), or a gamma chain and a delta chain subunit ($\gamma\delta$ TCR), each of which

15 is a unique protein produced by recombination event in each T cell's genome. Libraries of TCRs may be screened for their selectivity to particular target antigens. In this manner, natural TCRs, which have a high-avidity and reactivity toward target antigens may be selected, cloned, and subsequently introduced into a population of T cells used for adoptive

20 immunotherapy. In one embodiment, the TCR is an $\alpha\beta$ TCR. In one embodiment, the TCR is a $\gamma\delta$ TCR.

In one embodiment, T cells are modified by introducing a TCR subunit that has the ability to form TCRs that confer specificity to T cells for cells expressing a target antigen. In particular embodiments, the subunits have one or more amino acid substitutions, deletions,

25 insertions, or modifications compared to the naturally occurring subunit, so long as the subunits retain the ability to form TCRs and confer upon transfected T cells the ability to home to target cells, and participate in immunologically-relevant cytokine signaling. The engineered TCRs preferably also bind target cells displaying the relevant peptide (*e.g.*, a tumor-associated peptide) with high avidity, and optionally mediate efficient killing of target

30 cells presenting the relevant peptide *in vivo*.

The nucleic acids encoding engineered TCRs are preferably isolated from their natural context in a (naturally-occurring) chromosome of a T cell, and can be incorporated

into suitable vectors as described elsewhere herein. Both the nucleic acids and the vectors comprising them can be transferred into a cell, preferably a T cell in particular embodiments. The modified T cells are then able to express one or more chains of a TCR encoded by the transduced nucleic acid or nucleic acids. In preferred embodiments, the TCR is an exogenous
 5 TCR because it is introduced into T cells that do not normally express the particular TCR. In particular embodiments, the essential aspect of the TCR is that it has high avidity for an antigen presented by a major histocompatibility complex (MHC) or similar immunological component. In contrast to TCRs, CARs are engineered to bind target antigens in an MHC independent manner.

10 The TCR can be expressed with additional polypeptides attached to the amino-terminal or carboxyl-terminal portion of the alpha chain or beta chain of a TCR, or of the gamma chain or delta chain of a TCR so long as the attached additional polypeptide does not interfere with the ability of the alpha chain or beta chain to form a functional T cell receptor and the MHC dependent antigen recognition.

15 Antigens that are recognized by the TCRs contemplated in particular embodiments include, but are not limited to cancer antigens, including antigens on both hematological cancers and solid tumors. Illustrative antigens include, but are not limited to α -fetoprotein (AFP), B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase
 20 IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human Epidermal Growth Factor Receptor 2
 25 (HER-2), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16
 30 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5

(SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, Wilms tumor protein (WT-1), X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).

5 In other embodiments, immune effector cells contemplated herein comprise a CAR and an and an engineered immune receptor component(s) as described herein. Chimeric antigen receptors (CARs) are molecules that combine antibody-based specificity for a target antigen (*e.g.*, tumor antigen) with a T cell receptor-activating intracellular domain to generate a chimeric protein that exhibits a specific anti-tumor cellular immune activity. As used herein, the term, “chimeric,” describes being composed of parts of different proteins or DNAs
10 from different origins.

In other embodiments, immune effector cells contemplated herein comprise a CCR and an engineered immune receptor component(s) as described herein. Unlike CARs, chimeric costimulatory receptors (CCRs) are molecules that combine antibody-based specificity for a desired antigen with a T cell receptor-costimulatory domain but that lacks a
15 primary signaling domain (see, *e.g.*, WO2020/252110 and WO2021/211948).

In other embodiments, immune effector cells contemplated herein express a bispecific T cell engager (BiTE) and an engineered immune receptor component(s) as described herein. BiTEs are molecules that comprise two different antibody fragments (*e.g.*, single-chain variable fragments (scFvs)) connected by a small linker peptide, wherein in one antibody
20 fragment binds a component of the T cell receptor (TCR) complex (*e.g.*, a CD3 chain), and the other antibody fragment binds another antigen (*e.g.*, a tumor associated antigen).

In other embodiments, immune effector cells contemplated herein comprise a flip receptor and an engineered immune receptor component(s) as described herein. A flip receptor comprises an extracellular portion of a receptor, a transmembrane domain, and an
25 intracellular signaling portion of a different receptor. Thus, a flip receptor “converts” the binding properties of one receptor type into the intracellular signaling event of another receptor type. See, *e.g.*, WO2018/094244, WO2016/122738, WO2014/172584, and WO2012/138858.

In certain embodiments, the CAR, CCR, immune cell engager, BiTE, or flip receptor
30 binds a target antigen selected from the group consisting of: alpha folate receptor (FR α), $\alpha_v\beta_6$ integrin, B cell maturation antigen (BCMA), B7-H3 (CD276), B7-H6, carbonic anhydrase IX (CAIX), CD16, CD19, CD20, CD22, CD30, CD33, CD37, CD38, CD44, CD44v6, CD44v7/8,

CD70, CD79a, CD79b, CD123, CD133, CD138, CD171, carcinoembryonic antigen (CEA), C-type lectin-like molecule-1 (CLL-1), CD2 subset 1 (CS-1), chondroitin sulfate proteoglycan 4 (CSPG4), cutaneous T cell lymphoma-associated antigen 1 (CTAGE1), epidermal growth factor receptor (EGFR), epidermal growth factor receptor variant III (EGFRvIII), epithelial glycoprotein 2 (EGP2), epithelial glycoprotein 40 (EGP40), epithelial cell adhesion molecule (EPCAM),
 5 ephrin type-A receptor 2 (EPHA2), fibroblast activation protein (FAP), Fc Receptor Like 5 (FCRL5), fetal acetylcholinesterase receptor (AChR), ganglioside G2 (GD2), ganglioside G3 (GD3), Glypican-3 (GPC3), EGFR family including ErbB2 (HER2), IGF2BP3/A3, IL-10R α , IL-13R α 2, Kappa, cancer/testis antigen 2 (LAGE-1A), K-Ras, K-Ras G12C, K-Ras G12D, K-Ras
 10 G12V, Lambda, Lewis-Y (LeY), L1 cell adhesion molecule (L1-CAM), melanoma antigen gene (MAGE)-A1, MAGE-A3, MAGE-A4, MAGE-A6, MAGEA10, melanoma antigen recognized by T cells 1 (MelanA or MART1), Mesothelin (MSLN), MUC1, MUC16, MHC class I chain related proteins A (MICA), MHC class I chain related proteins B (MICB), neural cell adhesion molecule (NCAM), cancer/testis antigen 1 (NY-ESO-1), polysialic acid; placenta-specific 1
 15 (PLAC1), preferentially expressed antigen in melanoma (PRAME), prostate stem cell antigen (PSCA), prostate-specific membrane antigen (PSMA), receptor tyrosine kinase-like orphan receptor 1 (ROR1), synovial sarcoma, X breakpoint 2 (SSX2), Survivin, tumor associated glycoprotein 72 (TAG72), transmembrane activator and CAML interactor (TACI), tumor endothelial marker 1 (TEM1/CD248), tumor endothelial marker 7-related (TEM7R), trophoblast
 20 glycoprotein (TPBG), UL16-binding protein (ULBP) 1, ULBP2, ULBP3, ULBP4, ULBP5, ULBP6, vascular endothelial growth factor receptor 2 (VEGFR2), and Wilms tumor 1 (WT-1).

In particular embodiments, the CAR or CCR binds a target antigen selected from the group consisting of: BCMA, CD33, CD20, CD79a, CD79b, CLL-1, IGF2BP3/A3, MUC16, NY-ESO, PRAME, TACI, and TP53.

25 In various embodiments, immune effector cells contemplated herein comprise one or more chains of a zetakine receptor and an engineered immune receptor component(s) as described herein. Zetakines are chimeric transmembrane immunoreceptors that comprise an extracellular domain comprising a soluble receptor ligand linked to a support region capable of tethering the extracellular domain to a cell surface, a transmembrane region and an
 30 intracellular signaling domain. Zetakines, when expressed on the surface of T lymphocytes, direct T cell activity to those cells expressing a receptor for which the soluble receptor ligand is specific. Zetakine chimeric immunoreceptors redirect the antigen specificity of T cells,

with application to treatment of a variety of cancers, particularly via the autocrine/paracrine cytokine systems utilized by human malignancy.

In other embodiments, immune effector cells are modified by introducing an Fc Receptor (FcR) subunit that has the ability to bind to the fragment crystallizable (Fc) portion/region of an antibody, and an engineered immune receptor component(s) as described herein. In some embodiments, the FcR subunit can be from an Fc-gamma receptor, an Fc-alpha receptor, or an Fc-epsilon receptor. See, *e.g.*, Mkaddem *et al.*, *Front Immunol.* 2019 Apr 12;10:811.

In other embodiments, immune effector cells are modified by introducing NKG2D receptor, and an engineered immune receptor component(s) as described herein.

E. POLYPEPTIDES

Various polypeptides are contemplated herein, including, but not limited to, an engineered immune receptor system, targeting components, signaling components, immune receptors and their associated subunits or adaptor molecules, exogenous lymphocyte receptor, engineered antigen receptors, TCRs, FcRs, CARs, CCRs, BiTEs, zetakines, flip receptors, exogenous costimulatory factors, immunomodulatory factors, agonist for a costimulatory factors, antagonist for an immunosuppressive factors, immune cell engagers, or any combination thereof. Also contemplated herein are fusion proteins comprising the foregoing polypeptides, and fragments thereof. In preferred embodiments, a polypeptide comprises an amino acid sequence set forth in any one of SEQ ID NOs: 107-115, 116-138, or 139-170.

“Polypeptide,” “peptide” and “protein” are used interchangeably, unless specified to the contrary, and according to conventional meaning, *i.e.*, as a sequence of amino acids. In one embodiment, a “polypeptide” includes fusion polypeptides and other variants. Polypeptides can be prepared using any of a variety of well-known recombinant and/or synthetic techniques. Polypeptides are not limited to a specific length, *e.g.*, they may comprise a full-length protein sequence, a fragment of a full-length protein, or a fusion protein, and may include post-translational modifications of the polypeptide, for example, glycosylations, acetylations, phosphorylations and the like, as well as other modifications known in the art, both naturally occurring and non-naturally occurring. In particular preferred embodiments, fusion polypeptides, polypeptides, fragments and other variants thereof are prepared, obtained, or isolated from one or more human polypeptides.

An “isolated peptide” or an “isolated polypeptide” and the like, as used herein, refer to *in vitro* isolation and/or purification of a peptide or polypeptide molecule from a cellular environment, and from association with other components of the cell, *i.e.*, it is not significantly associated with *in vivo* substances. In particular embodiments, an isolated
5 polypeptide is a synthetic polypeptide, a semi-synthetic polypeptide, or a polypeptide obtained or derived from a recombinant source.

Polypeptides include “polypeptide variants.” Polypeptide variants may differ from a naturally occurring polypeptide in one or more substitutions, deletions, additions and/or insertions. Such variants may be naturally occurring or may be synthetically generated, for
10 example, by modifying one or more of the above polypeptide sequences. For example, in particular embodiments, it may be desirable to improve the binding affinity and/or other biological properties of a polypeptide by introducing one or more substitutions, deletions, additions and/or insertions in the polypeptide. In particular embodiments, polypeptides include polypeptides having at least about 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%,
15 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 86%, 97%, 98%, or 99% amino acid identity to any of the reference sequences contemplated herein, typically where the variant maintains at least one biological activity of the reference sequence. In particular embodiments, the biological activity is binding affinity. In particular embodiments, the biological activity is enzymatic
20 activity.

In certain embodiments, an engineered immune receptor component(s) as described herein that recruits a multimeric immune receptor complex comprising (i) a signaling component, *e.g.*, first fusion polypeptide, having a first multimerization domain and an actuator domain and (ii) a targeting component, *e.g.*, second fusion polypeptide, having a second multimerization
25 domain, an extracellular domain, and a transmembrane domain. In particular embodiments, the multimerization domains are the same; in certain embodiments, the first multimerization domain is different than the second multimerization domain. The first and second multimerization domains substantially contribute to or efficiently promote formation of the polypeptide complex, *e.g.*, in the presence of a bridging factor. The interaction(s) between the first and second
30 multimerization domains substantially contributes to or efficiently promotes the multimerization of the first and second fusion polypeptides if there is a statistically significant reduction in the association between the first and second fusion polypeptides in the absence of the first multimerization domain, the second multimerization domain, or the bridging factor. In certain

embodiments, when the first and second fusion polypeptides are co-expressed, at least about 60%, for instance, at least about 60% to about 70%, at least about 70% to about 80%, at least about 80% to about 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%, and at least about 90% to about 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the first and second
 5 single chain polypeptides form multimers with each other in the presence of a bridging factor.

Polypeptide variants include biologically active “polypeptide fragments.” Illustrative examples of biologically active polypeptide fragments include binding domains, intracellular signaling domains, and the like. As used herein, the term “biologically active fragment” or “minimal biologically active fragment” refers to a polypeptide fragment that retains at least
 10 100%, at least 90%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40%, at least 30%, at least 20%, at least 10%, or at least 5% of the naturally occurring polypeptide activity. In certain embodiments, a polypeptide fragment can comprise an amino acid chain at least 5 to about 1700 amino acids long. It will be appreciated that in certain embodiments, fragments are at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30,
 15 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700 or more amino acids long.

In particular embodiments, the polypeptides set forth herein may comprise one or more amino acids denoted as “X.” “X” if present in an amino acid SEQ ID NO, refers to any one or
 20 more amino acids. In particular embodiments, SEQ ID NOs denoting a fusion protein comprise a sequence of continuous X residues that cumulatively represent any amino acid sequence.

As noted above, polypeptides may be altered in various ways including amino acid substitutions, deletions, truncations, and insertions. Methods for such manipulations are generally known in the art. For example, amino acid sequence variants of a reference polypeptide
 25 can be prepared by mutations in the DNA. Methods for mutagenesis and nucleotide sequence alterations are well known in the art. *See*, for example, Kunkel (1985, *Proc. Natl. Acad. Sci. USA*, 82: 488-492), Kunkel *et al.*, (1987, *Methods in Enzymol*, 154: 367-382), U.S. Pat. No. 4,873,192, Watson, J. D. *et al.*, (*Molecular Biology of the Gene*, Fourth Edition, Benjamin/Cummings, Menlo Park, Calif., 1987) and the references cited therein. Guidance as to
 30 appropriate amino acid substitutions that do not affect biological activity of the protein of interest may be found in the model of Dayhoff *et al.*, (1978) *Atlas of Protein Sequence and Structure* (*Natl. Biomed. Res. Found.*, Washington, D.C.).

In certain embodiments, a polypeptide variant comprises one or more conservative substitutions. A “conservative substitution” is one in which an amino acid is substituted for another amino acid that has similar properties, such that one skilled in the art of peptide chemistry would expect the secondary structure and hydrophobic nature of the polypeptide to be substantially unchanged. Modifications may be made in the structure of the polynucleotides and polypeptides contemplated in particular embodiments and still obtain a functional molecule that encodes a variant or derivative polypeptide with desirable characteristics. When it is desired to alter the amino acid sequence of a polypeptide to create an equivalent, or even an improved, variant polypeptide, one skilled in the art, for example, can change one or more of the codons of the encoding DNA sequence, *e.g.*, according to Table 1.

TABLE 1- Amino Acid Codons

Amino Acids	One letter code	Three letter code	Codons					
Alanine	A	Ala	GCA	GCC	GCG	GCU		
Cysteine	C	Cys	UGC	UGU				
Aspartic acid	D	Asp	GAC	GAU				
Glutamic acid	E	Glu	GAA	GAG				
Phenylalanine	F	Phe	UUC	UUU				
Glycine	G	Gly	GGA	GGC	GGG	GGU		
Histidine	H	His	CAC	CAU				
Isoleucine	I	Iso	AUA	AUC	AUU			
Lysine	K	Lys	AAA	AAG				
Leucine	L	Leu	UUA	UUG	CUA	CUC	CUG	CUU
Methionine	M	Met	AUG					
Asparagine	N	Asn	AAC	AAU				
Proline	P	Pro	CCA	CCC	CCG	CCU		
Glutamine	Q	Gln	CAA	CAG				
Arginine	R	Arg	AGA	AGG	CGA	CGC	CGG	CGU
Serine	S	Ser	AGC	AGU	UCA	UCC	UCG	UCU
Threonine	T	Thr	ACA	ACC	ACG	ACU		
Valine	V	Val	GUA	GUC	GUG	GUU		
Tryptophan	W	Trp	UGG					
Tyrosine	Y	Tyr	UAC	UAU				

Guidance in determining which amino acid residues can be substituted, inserted, or deleted without abolishing biological activity can be found using computer programs well known in the art, such as DNASTAR, DNA Strider, Geneious, Mac Vector, or Vector NTI software. Preferably, amino acid changes in the protein variants disclosed herein are

5 conservative amino acid changes, *i.e.*, substitutions of similarly charged or uncharged amino acids. A conservative amino acid change involves substitution of one of a family of amino acids which are related in their side chains. Naturally occurring amino acids are generally divided into four families: acidic (aspartate, glutamate), basic (lysine, arginine, histidine), non-polar (alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine,

10 tryptophan), and uncharged polar (glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine) amino acids. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. In a peptide or protein, suitable conservative substitutions of amino acids are known to those of skill in this art and generally can be made without altering a biological activity of a resulting molecule. Those of skill in this art recognize that, in

15 general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, *e.g.*, Watson *et al. Molecular Biology of the Gene*, 4th Edition, 1987, The Benjamin/Cummings Pub. Co., p.224).

In one embodiment, where expression of two or more polypeptides is desired, the polynucleotide sequences encoding them can be separated by an IRES sequence.

20 Polypeptides contemplated in particular embodiments include fusion polypeptides. In particular embodiments, fusion polypeptides and polynucleotides encoding fusion polypeptides are provided. Fusion polypeptides and fusion proteins refer to a polypeptide having at least two, three, four, five, six, seven, eight, nine, or ten, or more polypeptide segments. In preferred embodiments, a fusion polypeptide comprises one or more of the

25 components described herein. In other preferred embodiments, the fusion polypeptide comprises a targeting component and a signaling component.

In particular embodiments, two or more engineered immune receptor components and/or other polypeptides can be expressed as a fusion protein that comprises one or more self-cleaving peptide sequences between the polypeptides as disclosed elsewhere herein.

30 In particular embodiments, a fusion polypeptide comprises a targeting component and one or more signaling components.

Fusion polypeptides can comprise one or more polypeptide domains or segments including, but are not limited to signal peptides, cell permeable peptide domains (CPP), binding domains, signaling domains, *etc.*, epitope tags (*e.g.*, maltose binding protein (“MBP”), glutathione S transferase (GST), HIS6, MYC, FLAG, V5, VSV-G, and HA), polypeptide linkers, and polypeptide cleavage signals. Fusion polypeptides are typically linked C-terminus to N-terminus, although they can also be linked C-terminus to C-terminus, N-terminus to N-terminus, or N-terminus to C-terminus. In particular embodiments, the polypeptides of the fusion protein can be in any order. Fusion polypeptides or fusion proteins can also include conservatively modified variants, polymorphic variants, alleles, mutants, subsequences, and interspecies homologs, so long as the desired activity of the fusion polypeptide is preserved. Fusion polypeptides may be produced by chemical synthetic methods or by chemical linkage between the two moieties or may generally be prepared using other standard techniques. Ligated DNA sequences comprising the fusion polypeptide are operably linked to suitable transcriptional or translational control elements as disclosed elsewhere herein.

Fusion polypeptides may optionally comprise one or more linkers that can be used to link the one or more polypeptides or domains within a polypeptide. A peptide linker sequence may be employed to separate any two or more polypeptide components by a distance sufficient to ensure that each polypeptide folds into its appropriate secondary and tertiary structures so as to allow the polypeptide domains to exert their desired functions. Such a peptide linker sequence is incorporated into the fusion polypeptide using standard techniques in the art. Suitable peptide linker sequences may be chosen based on the following factors: (1) their ability to adopt a flexible extended conformation; (2) their inability to adopt a secondary structure that could interact with functional epitopes on the signaling component and targeting component; and (3) the lack of hydrophobic or charged residues that might react with the polypeptide functional epitopes. In particular embodiments, preferred peptide linker sequences contain Gly, Asn and Ser residues. Other near neutral amino acids, such as Thr and Ala may also be used in the linker sequence. Amino acid sequences which may be usefully employed as linkers include those disclosed in Maratea *et al.*, *Gene* 40:39-46, 1985; Murphy *et al.*, *Proc. Natl. Acad. Sci. USA* 83:8258-8262, 1986; U.S. Patent No. 4,935,233 and U.S. Patent No. 4,751,180. Linker sequences are not required when a particular fusion polypeptide segment contains non-essential N-terminal amino acid regions that can be used to separate the functional domains and prevent steric interference. In particular embodiments, preferred linkers are typically flexible amino acid subsequences which are synthesized as part of a recombinant fusion protein. Linker polypeptides can be

between 1 and 200 amino acids in length, between 1 and 100 amino acids in length, or between 1 and 50 amino acids in length, including all integer values in between.

Exemplary polypeptide cleavage signals include polypeptide cleavage recognition sites such as protease cleavage sites, nuclease cleavage sites (*e.g.*, rare restriction enzyme recognition sites, self-cleaving ribozyme recognition sites), and self-cleaving viral oligopeptides (*see* deFelipe and Ryan, 2004. *Traffic*, 5(8); 616-26).

Suitable protease cleavages sites and self-cleaving peptides are known to the skilled person (*see, e.g.*, in Ryan *et al.*, 1997. *J. Gener. Virol.* 78, 699-722; Scymczak *et al.* (2004) Nature Biotech. 5, 589-594). Exemplary protease cleavage sites include, but are not limited to the cleavage sites of potyvirus NIa proteases (*e.g.*, tobacco etch virus protease), potyvirus HC proteases, potyvirus P1 (P35) proteases, byovirus NIa proteases, byovirus RNA-2-encoded proteases, aphthovirus L proteases, enterovirus 2A proteases, rhinovirus 2A proteases, picorna 3C proteases, comovirus 24K proteases, nepovirus 24K proteases, RTSV (rice tungro spherical virus) 3C-like protease, PYVF (parsnip yellow fleck virus) 3C-like protease, heparin, thrombin, factor Xa and enterokinase. Due to its high cleavage stringency, TEV (tobacco etch virus) protease cleavage sites are preferred in one embodiment, *e.g.*, EXXYXQ(G/S) (SEQ ID NO: 195), for example, ENLYFQG (SEQ ID NO: 196) and ENLYFQS (SEQ ID NO: 197), wherein X represents any amino acid (cleavage by TEV occurs between Q and G or Q and S).

In particular embodiments, the polypeptide cleavage signal is a viral self-cleaving peptide or ribosomal skipping sequence.

Illustrative examples of ribosomal skipping sequences include but are not limited to: a 2A or 2A-like site, sequence or domain (Donnelly *et al.*, 2001. *J. Gen. Virol.* 82:1027-1041). In a particular embodiment, the viral 2A peptide is an aphthovirus 2A peptide, a potyvirus 2A peptide, or a cardiovirus 2A peptide.

In one embodiment, the viral 2A peptide is selected from the group consisting of: a foot-and-mouth disease virus (FMDV) 2A peptide, an equine rhinitis A virus (ERAV) 2A peptide, a *Thosea asigna* virus (TaV) 2A peptide, a porcine teschovirus-1 (PTV-1) 2A peptide, a Theilovirus 2A peptide, and an encephalomyocarditis virus 2A peptide.

Illustrative examples of 2A sites are provided in **Table 2**.

TABLE 2:

SEQ ID NO: 171	GSGATNFSLLKQAGDVEENPGP
----------------	------------------------

SEQ ID NO: 172	ATNFSLLKQAGDVEENPGP
SEQ ID NO: 173	LLKQAGDVEENPGP
SEQ ID NO: 174	GSGEGRGSLTTCGDVEENPGP
SEQ ID NO: 175	EGRGSLTTCGDVEENPGP
SEQ ID NO: 176	LLTCGDVEENPGP
SEQ ID NO: 177	GSGQCTNYALLKLAGDVESNPGP
SEQ ID NO: 178	QCTNYALLKLAGDVESNPGP
SEQ ID NO: 179	LLKLAGDVESNPGP
SEQ ID NO: 180	GSGVKQTLNFDLLKLAGDVESNPGP
SEQ ID NO: 181	VKQTLNFDLLKLAGDVESNPGP
SEQ ID NO: 182	LLKLAGDVESNPGP
SEQ ID NO: 183	LLNFDLLKLAGDVESNPGP
SEQ ID NO: 184	TLNFDLLKLAGDVESNPGP
SEQ ID NO: 185	LLKLAGDVESNPGP
SEQ ID NO: 186	NFDLLKLAGDVESNPGP
SEQ ID NO: 187	QLLNFDLLKLAGDVESNPGP
SEQ ID NO: 188	APVKQTLNFDLLKLAGDVESNPGP
SEQ ID NO: 189	VTELLYRMKRAETYCPRPLLAIHPTEARHKQKIVAPVKQT
SEQ ID NO: 190	LNFDLLKLAGDVESNPGP
SEQ ID NO: 191	LLAIHPTEARHKQKIVAPVKQTLNFDLLKLAGDVESNPGP
SEQ ID NO: 192	EARHKQKIVAPVKQTLNFDLLKLAGDVESNPGP

In particular embodiments, the self-cleaving polypeptides (*e.g.*, 2A peptides) comprise a SGSG (SEQ ID NO: 193) spacer sequence. In particular embodiments, the self-cleaving polypeptides (*e.g.*, 2A peptides) comprise a furin recognition site, *e.g.*, RAKR (SEQ ID NO: 194) spacer sequence.

- 5 In preferred embodiments, a polypeptide or fusion polypeptide comprises one or more engineered immune receptors or components. In preferred embodiments, a fusion polypeptide comprises one or more engineered immune receptors or components separated by one or more self-cleaving polypeptides.

- 10 In particular embodiments, a fusion polypeptide comprises a signaling component comprising a first multimerization domain and an actuator domain that forms a complex with and recruits an immune receptor complex (*e.g.*, a CD3 ϵ , CD3 δ or CD3 γ , domain; a viral self-cleaving

2A polypeptide; and a targeting component comprising an extracellular domain (comprising at least a first targeting domain (*e.g.*, an antibody or antigen binding fragment thereof, that binds to a target antigen)), a second multimerization domain, and a transmembrane domain.

In particular embodiments, a fusion polypeptide comprises a signaling component
 5 comprising a first multimerization domain and an actuator domain that forms a complex with and recruits an immune receptor complex (*e.g.*, a CD3 ϵ , CD3 δ or CD3 γ , domain; a viral self-cleaving 2A polypeptide; and a targeting component comprising an extracellular domain (comprising at least a first targeting domain (*e.g.*, an antibody or antigen binding fragment thereof, that binds to a target antigen)), a second multimerization domain, a CD4 hinge domain, and a CD4
 10 transmembrane domain.

In particular embodiments, a fusion polypeptide comprises a signaling component comprising a first multimerization domain and an actuator domain that forms a complex with and recruits an immune receptor complex (*e.g.*, a CD3 ϵ , CD3 δ or CD3 γ , domain; a viral self-cleaving 2A polypeptide; and a targeting component comprising an extracellular domain (comprising at
 15 least a first targeting domain (*e.g.*, an antibody or antigen binding fragment thereof, that binds to a target antigen)), a second multimerization domain, a CD4 hinge domain, a CD4 transmembrane domain, and a truncated CD4ic domain.

In particular embodiments, a fusion polypeptide comprises a signaling component comprising an FRB or FKBP12 multimerization domain and an actuator domain that forms a
 20 complex with and recruits an immune receptor complex (*e.g.*, a CD3 ϵ , CD3 δ or CD3 γ , domain; a viral self-cleaving 2A polypeptide; and a targeting component comprising an extracellular domain comprising a VHH or scFv that binds a target antigen, an FRB or FKBP12 multimerization domain, a CD4 hinge, a CD4 transmembrane domain, and a truncated CD4ic domain.

In particular embodiments, a fusion polypeptide comprises a signaling component comprising an antibody derived heterodimerization domain multimerization domain and an
 25 actuator domain that forms a complex with and recruits an immune receptor complex (*e.g.*, a CD3 ϵ , CD3 δ or CD3 γ , domain; a viral self-cleaving 2A polypeptide; and a targeting component comprising VHH or scFv that binds a target antigen, an antibody derived heterodimerization
 30 domain, a CD4 hinge, a CD4 transmembrane domain, a truncated CD4ic domain, and optionally, a costimulatory or cytokine receptor intracellular signaling domain.

In particular embodiments, the fusion polypeptides comprise an amino acid sequence as set forth in any one of SEQ ID NOs: 139-170.

5 In particular embodiments, a fusion polypeptide comprises a signaling component comprising a first multimerization domain and an actuator domain that forms a complex with and recruits an Fc receptor complex (*e.g.*, a Fc γ domain/polypeptide); a viral self-cleaving 2A polypeptide; and a targeting component comprising an extracellular domain (comprising at least a first targeting domain (*e.g.*, an antibody or antigen binding fragment thereof, that binds to a target antigen)), a second multimerization domain, optionally a hinge domain, and a transmembrane domain.

10 In particular embodiments, a fusion polypeptide comprises a signaling component comprising a first multimerization domain and an actuator domain that forms a complex with and recruits an Fc receptor complex (*e.g.*, a Fc γ domain/polypeptide); a viral self-cleaving 2A polypeptide; and a targeting component comprising an extracellular domain (comprising at least a first targeting domain (*e.g.*, an antibody or antigen binding fragment thereof, that binds to a target antigen)), a second multimerization domain, a CD4 hinge, and a CD4 transmembrane domain.

15 In particular embodiments, a fusion polypeptide comprises a signaling component comprising a first multimerization domain and an actuator domain that forms a complex with and recruits an Fc receptor complex (*e.g.*, a Fc γ domain/polypeptide); a viral self-cleaving 2A polypeptide; and a targeting component comprising an extracellular domain (comprising at least a first targeting domain (*e.g.*, an antibody or antigen binding fragment thereof, that binds to a target antigen)), a second multimerization domain, a CD4 hinge, a CD4 transmembrane domain, and a truncated CD4ic domain.

20 In particular embodiments, a fusion polypeptide comprises a signaling component comprising an FRB or FKBP12 multimerization domain and an actuator domain that forms a complex with and recruits an Fc receptor complex (*e.g.*, a Fc γ domain/polypeptide); a viral self-cleaving 2A polypeptide; and a targeting component comprising an extracellular domain comprising a VHH or scFv that binds a target antigen, an FRB or FKBP12 multimerization domain, a CD4 hinge, a CD4 transmembrane domain, and a truncated CD4ic domain.

25 In particular embodiments, a fusion polypeptide comprises a signaling component comprising an antibody derived heterodimerization domain and an actuator domain that forms a complex with and recruits an Fc receptor complex (*e.g.*, a Fc γ domain/polypeptide); a viral self-cleaving 2A polypeptide; and a targeting component comprising an extracellular domain

comprising a VHH or scFv that binds a target antigen, an antibody derived heterodimerization domain, a CD4 hinge, a CD4 transmembrane domain, a truncated CD4ic domain, and optionally, a costimulatory or cytokine receptor intracellular signaling domain.

5 In particular embodiments, the fusion polypeptides comprise an amino acid sequence as set forth in any one of SEQ ID NOs: 139-170.

In one embodiment, the fusion polypeptide comprises an amino acid sequence having at least 90% identity to SEQ ID NO: 151. In one embodiment, the fusion polypeptide comprises an amino acid sequence having at least 95% identity to SEQ ID NO: 151. In one embodiment, the fusion polypeptide comprises an amino acid sequence having at least 96% identity to SEQ ID
10 NO: 151. In one embodiment, the fusion polypeptide comprises an amino acid sequence having at least 97% identity to SEQ ID NO: 151. In one embodiment, the fusion polypeptide comprises an amino acid sequence having at least 98% identity to SEQ ID NO: 151. In one embodiment, the fusion polypeptide comprises an amino acid sequence having at least 99% identity to SEQ ID NO: 151. In one embodiment, the fusion polypeptide comprises an amino acid sequence as set
15 forth as SEQ ID NO: 151.

In one embodiment, the fusion polypeptide comprises a sequence having at least 90% identity to SEQ ID NO: 137. In one embodiment, the fusion polypeptide comprises a sequence having at least 95% identity to SEQ ID NO: 137. In one embodiment, the fusion polypeptide comprises a sequence having at least 96% identity to SEQ ID NO: 137. In one
20 embodiment, the fusion polypeptide comprises a sequence having at least 97% identity to SEQ ID NO: 137. In one embodiment, the fusion polypeptide comprises a sequence having at least 98% identity to SEQ ID NO: 137. In one embodiment, the fusion polypeptide comprises a sequence having at least 99% identity to SEQ ID NO: 137. In one embodiment, the fusion polypeptide comprises a sequence set forth as SEQ ID NO: 137.

25 In one embodiment, the fusion polypeptide comprises a sequence having at least 90% identity to SEQ ID NO: 138. In one embodiment, the fusion polypeptide comprises a sequence having at least 95% identity to SEQ ID NO: 138. In one embodiment, the fusion polypeptide comprises a sequence having at least 96% identity to SEQ ID NO: 138. In one embodiment, the fusion polypeptide comprises a sequence having at least 97% identity to
30 SEQ ID NO: 138. In one embodiment, the fusion polypeptide comprises a sequence having at least 98% identity to SEQ ID NO: 138. In one embodiment, the fusion polypeptide

comprises a sequence having at least 99% identity to SEQ ID NO: 138. In one embodiment, the fusion polypeptide comprises a sequence set forth as SEQ ID NO: 138.

F. POLYNUCLEOTIDES

In particular embodiments, polynucleotides encoding an engineered immune receptor system, one or more engineered immune receptor components, signaling components, targeting components, exogenous lymphocyte receptors, engineered TCRs, CARs, CCRs, BiTEs, zetakines, flip receptors, exogenous costimulatory factors, immunomodulatory factors, agonist for a costimulatory factors, antagonist for an immunosuppressive factors, immune cell engagers, fusion proteins comprising the foregoing polypeptides, and fragments thereof.

As used herein, the terms “polynucleotide” or “nucleic acid” refer to deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and DNA/RNA hybrids. Polynucleotides may be single-stranded or double-stranded and either recombinant, synthetic, or isolated. Polynucleotides include, but are not limited to: pre-messenger RNA (pre-mRNA), messenger RNA (mRNA), RNA, short interfering RNA (siRNA), short hairpin RNA (shRNA), microRNA (miRNA), ribozymes, genomic RNA (gRNA), plus strand RNA (RNA(+)), minus strand RNA (RNA(-)), tracrRNA, crRNA, single guide RNA (sgRNA), synthetic RNA, synthetic mRNA, genomic DNA (gDNA), PCR amplified DNA, complementary DNA (cDNA), synthetic DNA, or recombinant DNA. Polynucleotides refer to a polymeric form of nucleotides of at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, at least 100, at least 200, at least 300, at least 400, at least 500, at least 1000, at least 5000, at least 10000, or at least 15000 or more nucleotides in length, either ribonucleotides or deoxyribonucleotides or a modified form of either type of nucleotide, as well as all intermediate lengths. It will be readily understood that “intermediate lengths,” in this context, means any length between the quoted values, such as 6, 7, 8, 9, *etc.*, 101, 102, 103, *etc.*; 151, 152, 153, *etc.*; 201, 202, 203, *etc.* In particular embodiments, polynucleotides or variants have at least or about 50%, 55%, 60%, 65%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% sequence identity to a reference sequence.

As used herein, “isolated polynucleotide” refers to a polynucleotide that has been purified from the sequences which flank it in a naturally-occurring state, *e.g.*, a DNA fragment that has been removed from the sequences that are normally adjacent to the fragment. In particular embodiments, an “isolated polynucleotide” also refers to a

complementary DNA (cDNA), a recombinant DNA, or other polynucleotide that does not exist in nature and that has been made by the hand of man. In particular embodiments, an isolated polynucleotide is a synthetic polynucleotide, a semi-synthetic polynucleotide, or a polynucleotide obtained or derived from a recombinant source.

5 In various embodiments, a polynucleotide comprises an mRNA encoding a polypeptide contemplated herein. In certain embodiments, the mRNA comprises a cap, one or more nucleotides, and a poly(A) tail.

 In particular embodiments, polynucleotides described herein, including polynucleotides encoding one or more engineered immune receptor components, may be codon-optimized. As
10 used herein, the term “codon-optimized” refers to substituting codons in a polynucleotide encoding a polypeptide in order to increase the expression, stability and/or activity of the polypeptide. Factors that influence codon optimization include, but are not limited to one or more of: (i) variation of codon biases between two or more organisms or genes or synthetically constructed bias tables, (ii) variation in the degree of codon bias within an organism, gene, or set
15 of genes, (iii) systematic variation of codons including context, (iv) variation of codons according to their decoding tRNAs, (v) variation of codons according to GC %, either overall or in one position of the triplet, (vi) variation in degree of similarity to a reference sequence for example a naturally occurring sequence, (vii) variation in the codon frequency cutoff, (viii) structural properties of mRNAs transcribed from the DNA sequence, (ix) prior knowledge about the
20 function of the DNA sequences upon which design of the codon substitution set is to be based, (x) systematic variation of codon sets for each amino acid, and/or (xi) isolated removal of spurious translation initiation sites.

 As used herein the term “nucleotide” refers to a heterocyclic nitrogenous base in N-glycosidic linkage with a phosphorylated sugar. Nucleotides are understood to include natural
25 bases, and a wide variety of art-recognized modified bases. Such bases are generally located at the 1' position of a nucleotide sugar moiety. Nucleotides generally comprise a base, sugar and a phosphate group. In ribonucleic acid (RNA), the sugar is a ribose, and in deoxyribonucleic acid (DNA) the sugar is a deoxyribose, *i.e.*, a sugar lacking a hydroxyl group that is present in ribose.

 Illustrative examples of polynucleotides include, but are not limited to, polynucleotides
30 encoding polypeptides set forth in SEQ ID NOs: 107-170.

 In various illustrative embodiments, polynucleotides contemplated herein include, but are not limited to polynucleotides encoding one or more engineered immune receptor components,

engineered antigen receptors, exogenous lymphocyte receptors, fusion polypeptides, and expression vectors, viral vectors, and transfer plasmids comprising polynucleotides contemplated herein.

As used herein, the terms “polynucleotide variant” and “variant” and the like refer to polynucleotides displaying substantial sequence identity with a reference polynucleotide sequence or polynucleotides that hybridize with a reference sequence under stringent conditions that are defined hereinafter. These terms also encompass polynucleotides that are distinguished from a reference polynucleotide by the addition, deletion, substitution, or modification of at least one nucleotide. Accordingly, the terms “polynucleotide variant” and “variant” include polynucleotides in which one or more nucleotides have been added or deleted, or modified, or replaced with different nucleotides. In this regard, it is well understood in the art that certain alterations inclusive of mutations, additions, deletions and substitutions can be made to a reference polynucleotide whereby the altered polynucleotide retains the biological function or activity of the reference polynucleotide.

The recitations “sequence identity” or, for example, comprising a “sequence 50% identical to,” as used herein, refer to the extent that sequences are identical on a nucleotide-by-nucleotide basis or an amino acid-by-amino acid basis over a window of comparison. Thus, a “percentage of sequence identity” may be calculated by comparing two optimally aligned sequences over the window of comparison, determining the number of positions at which the identical nucleic acid base (*e.g.*, A, T, C, G, I) or the identical amino acid residue (*e.g.*, Ala, Pro, Ser, Thr, Gly, Val, Leu, Ile, Phe, Tyr, Trp, Lys, Arg, His, Asp, Glu, Asn, Gln, Cys and Met) occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison (*i.e.*, the window size), and multiplying the result by 100 to yield the percentage of sequence identity. Included are nucleotides and polypeptides having at least about 50%, 55%, 60%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 86%, 97%, 98%, or 99% sequence identity to any of the reference sequences described herein.

The term “nucleic acid cassette” or “expression cassette” as used herein refers to genetic sequences within the vector which can express an RNA, and subsequently a polypeptide. In one embodiment, the nucleic acid cassette contains a gene(s)-of-interest, *e.g.*, a polynucleotide(s)-of-interest. In another embodiment, the nucleic acid cassette contains one or more expression control sequences, *e.g.*, a promoter, enhancer, poly(A) sequence, and a gene(s)-of-interest, *e.g.*, a

polynucleotide(s)-of-interest. Vectors may comprise 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or more nucleic acid cassettes. The nucleic acid cassette is positionally and sequentially oriented within the vector such that the nucleic acid in the cassette can be transcribed into RNA, and when necessary, translated into a protein or a polypeptide, undergo appropriate post-translational modifications
5 required for activity in the transformed cell, and be translocated to the appropriate compartment for biological activity by targeting to appropriate intracellular compartments or secretion into extracellular compartments. Preferably, the cassette has its 3' and 5' ends adapted for ready insertion into a vector, *e.g.*, it has restriction endonuclease sites at each end. The cassette can be removed and inserted into a plasmid or viral vector as a single unit.

10 Polynucleotides include polynucleotide(s)-of-interest. As used herein, the term "polynucleotide-of-interest" refers to a polynucleotide encoding a polypeptide or fusion polypeptide or a polynucleotide that serves as a template for the transcription of an inhibitory polynucleotide, as contemplated herein.

The polynucleotides contemplated herein, regardless of the length of the coding
15 sequence itself, may be combined with other DNA sequences, such as promoters and/or enhancers, untranslated regions (UTRs), signal sequences, Kozak sequences, polyadenylation signals, additional restriction enzyme sites, multiple cloning sites, internal ribosomal entry sites (IRES), recombinase recognition sites (*e.g.*, LoxP, FRT, and Att sites), termination codons, transcriptional termination signals, and polynucleotides encoding self-cleaving
20 polypeptides, epitope tags, as disclosed elsewhere herein or as known in the art, such that their overall length may vary considerably. It is therefore contemplated that a polynucleotide fragment of almost any length may be employed, with the total length preferably being limited by the ease of preparation and use in the intended recombinant DNA protocol.

Polynucleotides can be prepared, manipulated, expressed and/or delivered using any of a
25 variety of well-established techniques known and available in the art. In order to express a desired polypeptide, a nucleotide sequence encoding the polypeptide, can be inserted into appropriate vector.

Illustrative examples of vectors include, but are not limited to plasmid, autonomously replicating sequences, and transposable elements, *e.g.*, Sleeping Beauty, PiggyBac.

30 Additional illustrative examples of vectors include, without limitation, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosome (YAC),

bacterial artificial chromosome (BAC), or P1-derived artificial chromosome (PAC), bacteriophages such as lambda phage or M13 phage, and animal viruses.

Illustrative examples of viruses useful as vectors include, without limitation, retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpesvirus (*e.g.*, herpes simplex virus), poxvirus, baculovirus, papillomavirus, and papovavirus (*e.g.*, SV40).

Illustrative examples of expression vectors include, but are not limited to, pCIneo vectors (Promega) for expression in mammalian cells; pLenti4/V5-DEST™, pLenti6/V5-DEST™, and pLenti6.2/V5-GW/lacZ (Invitrogen) for lentivirus-mediated gene transfer and expression in mammalian cells. In particular embodiments, coding sequences of polypeptides disclosed herein can be ligated into such expression vectors for the expression of the polypeptides in mammalian cells.

In particular embodiments, the vector is an episomal vector or a vector that is maintained extrachromosomally. As used herein, the term “episomal” refers to a vector that is able to replicate without integration into host’s chromosomal DNA and without gradual loss from a dividing host cell also meaning that said vector replicates extrachromosomally or episomally.

“Expression control sequences,” “control elements,” or “regulatory sequences” present in an expression vector are those non-translated regions of the vector including an origin of replication, selection cassettes, promoters, enhancers, translation initiation signals (Shine Dalgarno sequence or Kozak sequence) introns, a polyadenylation sequence, 5' and 3' untranslated regions, all of which interact with host cellular proteins to carry out transcription and translation. Such elements may vary in their strength and specificity. Depending on the vector system and host utilized, any number of suitable transcription and translation elements, including ubiquitous promoters and inducible promoters may be used.

In particular embodiments, a polynucleotide comprises a vector, including but not limited to expression vectors and viral vectors. A vector may comprise one or more exogenous, endogenous, or heterologous control sequences such as promoters and/or enhancers. An “endogenous control sequence” is one which is naturally linked with a given gene in the genome. An “exogenous control sequence” is one which is placed in juxtaposition to a gene by means of genetic manipulation (*i.e.*, molecular biological techniques) such that transcription of that gene is directed by the linked enhancer/promoter. A “heterologous control sequence” is an exogenous sequence that is from a different species than the cell being genetically manipulated. A “synthetic” control sequence may comprise elements of one more endogenous and/or exogenous

sequences, and/or sequences determined *in vitro* or *in silico* that provide optimal promoter and/or enhancer activity for the particular therapy.

The term “promoter” as used herein refers to a recognition site of a polynucleotide (DNA or RNA) to which an RNA polymerase binds. An RNA polymerase initiates and
5 transcribes polynucleotides operably linked to the promoter. In particular embodiments, promoters operative in mammalian cells comprise an AT-rich region located approximately 25 to 30 bases upstream from the site where transcription is initiated and/or another sequence found 70 to 80 bases upstream from the start of transcription, a CNCAAT region where N
may be any nucleotide.

10 The term “enhancer” refers to a segment of DNA which contains sequences capable of providing enhanced transcription and in some instances can function independent of their orientation relative to another control sequence. An enhancer can function cooperatively or additively with promoters and/or other enhancer elements. The term “promoter/enhancer” refers to a segment of DNA which contains sequences capable of providing both promoter
15 and enhancer functions.

The term “operably linked”, refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner. In one embodiment, the term refers to a functional linkage between a nucleic acid expression control sequence (such as a promoter, and/or enhancer) and a second polynucleotide sequence, *e.g.*, a
20 polynucleotide-of-interest, wherein the expression control sequence directs transcription of the nucleic acid corresponding to the second sequence.

As used herein, the term “constitutive expression control sequence” refers to a promoter, enhancer, or promoter/enhancer that continually or continuously allows for transcription of an operably linked sequence. A constitutive expression control sequence
25 may be a “ubiquitous” promoter, enhancer, or promoter/enhancer that allows expression in a wide variety of cell and tissue types or a “cell specific,” “cell type specific,” “cell lineage specific,” or “tissue specific” promoter, enhancer, or promoter/enhancer that allows expression in a restricted variety of cell and tissue types, respectively.

Illustrative ubiquitous expression control sequences suitable for use in particular
30 embodiments include, but are not limited to, a cytomegalovirus (CMV) immediate early promoter, a viral simian virus 40 (SV40) (*e.g.*, early or late), a Moloney murine leukemia virus (MoMLV) LTR promoter, a Rous sarcoma virus (RSV) LTR, a herpes simplex virus

(HSV) (thymidine kinase) promoter, H5, P7.5, and P11 promoters from vaccinia virus, an elongation factor 1-alpha (EF1a) promoter, early growth response 1 (EGR1), ferritin H (FerH), ferritin L (FerL), Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), eukaryotic translation initiation factor 4A1 (EIF4A1), heat shock 70kDa protein 5 (HSPA5), heat shock protein 90kDa beta, member 1 (HSP90B1), heat shock protein 70kDa (HSP70), β -kinesin (β -KIN), the human ROSA 26 locus (Irions *et al.*, *Nature Biotechnology* 25, 1477 - 1482 (2007)), a Ubiquitin C promoter (UBC), a phosphoglycerate kinase-1 (PGK) promoter, a cytomegalovirus enhancer/chicken β -actin (CAG) promoter, a β -actin promoter and a myeloproliferative sarcoma virus enhancer, negative control region deleted, dl587rev primer-binding site substituted (MND) U3 promoter (Haas *et al. Journal of Virology*. 2003;77(17): 9439-9450).

In one embodiment, a vector comprises an MNDU3 promoter.

In one embodiment, a vector comprises an EF1a promoter comprising the first intron of the human EF1a gene.

15 In one embodiment, a vector comprises an EF1a promoter that lacks the first intron of the human EF1a gene.

In a particular embodiment, it may be desirable to use a cell, cell type, cell lineage or tissue specific expression control sequence to achieve cell type specific, lineage specific, or tissue specific expression of a desired polynucleotide sequence (*e.g.*, to express a particular nucleic acid encoding a polypeptide in only a subset of cell types, cell lineages, or tissues or during specific stages of development).

In a particular embodiment, it may be desirable to express a polynucleotide a T cell specific promoter.

As used herein, "conditional expression" may refer to any type of conditional expression including, but not limited to, inducible expression; repressible expression; expression in cells or tissues having a particular physiological, biological, or disease state, *etc.* This definition is not intended to exclude cell type or tissue specific expression. Certain embodiments provide conditional expression of a polynucleotide-of-interest, *e.g.*, expression is controlled by subjecting a cell, tissue, organism, *etc.*, to a treatment or condition that causes the polynucleotide to be expressed or that causes an increase or decrease in expression of the polynucleotide encoded by the polynucleotide-of-interest.

Illustrative examples of inducible promoters/systems include, but are not limited to, steroid-inducible promoters such as promoters for genes encoding glucocorticoid or estrogen receptors (inducible by treatment with the corresponding hormone), metallothionine promoter (inducible by treatment with various heavy metals), MX-1 promoter (inducible by interferon),
5 the “GeneSwitch” mifepristone-regulatable system (Sirin *et al.*, 2003, *Gene*, 323:67), the cumate inducible gene switch (WO 2002/088346), tetracycline-dependent regulatory systems, *etc.* Inducer agents include, but are not limited to glucocorticoids, estrogens, mifepristone (RU486), metals, interferons, small molecules, cumate, tetracycline, doxycycline, and variants thereof.

10 As used herein, an “internal ribosome entry site” or “IRES” refers to an element that promotes direct internal ribosome entry to the initiation codon, such as ATG, of a cistron (a protein encoding region), thereby leading to the cap-independent translation of the gene. *See, e.g.*, Jackson *et al.*, 1990, *Trends Biochem Sci* 15(12):477-83) and Jackson and Kaminski. 1995. *RNA* 1(10):985-1000. Examples of IRES generally employed by those of skill in the art include those
15 described in U.S. Pat. No. 6,692,736. Further examples of “IRES” known in the art include, but are not limited to IRES obtainable from picornavirus (Jackson *et al.*, 1990) and IRES obtainable from viral or cellular mRNA sources, such as for example, immunoglobulin heavy-chain binding protein (BiP), the vascular endothelial growth factor (VEGF) (Huez *et al.* 1998, *Mol. Cell. Biol.* 18(11):6178-6190), the fibroblast growth factor 2 (FGF-2), and insulin-like growth factor
20 (IGFII), the translational initiation factor eIF4G and yeast transcription factors TFIID and HAP4, the encephelomyocarditis virus (EMCV) which is commercially available from Novagen (Duke *et al.*, 1992, *J. Virol* 66(3):1602-9) and the VEGF IRES (Huez *et al.*, 1998, *Mol Cell Biol* 18(11):6178-90). IRES have also been reported in viral genomes of Picornaviridae, Dicistroviridae and Flaviviridae species and in HCV, Friend murine leukemia virus (FrMLV) and
25 Moloney murine leukemia virus (MoMLV).

In one embodiment, the IRES used in polynucleotides contemplated herein is an EMCV IRES.

In particular embodiments, the polynucleotides a consensus Kozak sequence. As used herein, the term “Kozak sequence” refers to a short nucleotide sequence that greatly facilitates the
30 initial binding of mRNA to the small subunit of the ribosome and increases translation. The consensus Kozak sequence is (GCC)RCCATGG (SEQ ID NO: 198), where R is a purine (A or G) (Kozak, 1986, *Cell*, 44(2):283-92, and Kozak, 1987, *Nucleic Acids Res.* 15(20):8125-48).

Elements directing the efficient termination and polyadenylation of the heterologous nucleic acid transcripts increases heterologous gene expression. Transcription termination signals are generally found downstream of the polyadenylation signal. In particular embodiments, vectors comprise a polyadenylation sequence 3' of a polynucleotide encoding a polypeptide to be expressed. The term "poly A site" or "poly A sequence" as used herein denotes a DNA sequence which directs both the termination and polyadenylation of the nascent RNA transcript by RNA polymerase II. Polyadenylation sequences can promote mRNA stability by addition of a poly A tail to the 3' end of the coding sequence and thus, contribute to increased translational efficiency. Cleavage and polyadenylation is directed by a poly(A) sequence in the RNA. The core poly(A) sequence for mammalian pre-mRNAs has two recognition elements flanking a cleavage-polyadenylation site. Typically, an almost invariant AAUAAA hexamer lies 20-50 nucleotides upstream of a more variable element rich in U or GU residues. Cleavage of the nascent transcript occurs between these two elements and is coupled to the addition of up to 250 adenosines to the 5' cleavage product. In particular embodiments, the core poly(A) sequence is an ideal poly A sequence (*e.g.*, AATAAA, ATTAAA, AGTAAA). In particular embodiments, the poly(A) sequence is an SV40 poly A sequence, a bovine growth hormone poly A sequence (BGHpA), a rabbit β -globin poly A sequence (r β gpA), variants thereof, or another suitable heterologous or endogenous poly A sequence known in the art. In particular embodiments, the poly(A) sequence is synthetic.

In particular embodiments, polynucleotides encoding one or more polypeptides, or fusion polypeptides may be introduced into immune effector cells, *e.g.*, T cells, by both non-viral and viral methods. In particular embodiments, delivery of one or more polynucleotides may be provided by the same method or by different methods, and/or by the same vector or by different vectors.

The term "vector" is used herein to refer to a nucleic acid molecule capable of transferring or transporting another nucleic acid molecule. The transferred nucleic acid is generally linked to, *e.g.*, inserted into, the vector nucleic acid molecule. A vector may include sequences that direct autonomous replication in a cell, or may include sequences sufficient to allow integration into host cell DNA. In particular embodiments, non-viral vectors are used to deliver one or more polynucleotides contemplated herein to a T cell.

Illustrative examples of non-viral vectors include, but are not limited to plasmids (*e.g.*, DNA plasmids or RNA plasmids), transposons, cosmids, and bacterial artificial chromosomes.

Illustrative methods of non-viral delivery of polynucleotides contemplated in particular embodiments include, but are not limited to: electroporation, sonoporation, lipofection, microinjection, biolistics, virosomes, liposomes, immunoliposomes, nanoparticles, polycation or lipid:nucleic acid conjugates, naked DNA, artificial virions, 5 DEAE-dextran-mediated transfer, gene gun, and heat-shock.

Illustrative examples of polynucleotide delivery systems suitable for use in particular embodiments contemplated in particular embodiments include, but are not limited to those provided by Amaxa Biosystems, Maxcyte, Inc., BTX Molecular Delivery Systems, and Copernicus Therapeutics Inc. Lipofection reagents are sold commercially (*e.g.*, Transfectam™ 10 and Lipofectin™). Cationic and neutral lipids that are suitable for efficient receptor-recognition lipofection of polynucleotides have been described in the literature. See *e.g.*, Liu *et al.* (2003) *Gene Therapy*. 10:180–187; and Balazs *et al.* (2011) *Journal of Drug Delivery*. 2011:1-12. Antibody-targeted, bacterially derived, non-living nanocell-based delivery is also contemplated in particular embodiments.

15 As will be evident to one of skill in the art, the term “viral vector” is widely used to refer either to a nucleic acid molecule (*e.g.*, a transfer plasmid) that includes virus-derived nucleic acid elements that typically facilitate transfer of the nucleic acid molecule or integration into the genome of a cell or to a viral particle that mediates nucleic acid transfer. Viral particles will typically include various viral components and sometimes also host cell 20 components in addition to nucleic acid(s). The term “viral vector” or “lentiviral vector” may refer either to a virus or viral particle capable of transferring a nucleic acid into a cell or to the transferred nucleic acid itself. Viral vectors and transfer plasmids contain structural and/or functional genetic elements that are primarily derived from a virus.

Viral vectors comprising polynucleotides contemplated in particular embodiments can 25 be delivered *in vivo* by administration to an individual patient, typically by systemic administration (*e.g.*, intravenous, intraperitoneal, intramuscular, subdermal, or intracranial infusion) or topical application, as described below. Alternatively, vectors can be delivered to cells *ex vivo*, such as cells explanted from an individual patient (*e.g.*, mobilized peripheral blood, lymphocytes, bone marrow aspirates, tissue biopsy, *etc.*) or universal donor 30 hematopoietic stem cells, followed by reimplantation of the cells into a patient.

In one embodiment, viral vectors comprising polynucleotides contemplated herein are administered directly to an organism or subject for transduction of cells *in vivo*. Alternatively,

naked DNA can be administered. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route.

Illustrative examples of viral vector systems suitable for use in particular embodiments contemplated in particular embodiments include, but are not limited to, adeno-associated virus (AAV), retrovirus, herpes simplex virus, adenovirus, and vaccinia virus vectors.

In various embodiments, one or more polynucleotides encoding one or more engineered immune receptor components and/or other polypeptides contemplated herein are introduced into an immune effector cell, *e.g.*, T cell, by transducing the cell with a recombinant adeno-associated virus (rAAV), comprising the one or more polynucleotides.

AAV is a small (~26 nm) replication-defective, primarily episomal, non-enveloped virus. AAV can infect both dividing and non-dividing cells and may incorporate its genome into that of the host cell. Recombinant AAV (rAAV) are typically composed of, at a minimum, a transgene and its regulatory sequences, and 5' and 3' AAV inverted terminal repeats (ITRs). The ITR sequences are about 145 bp in length. In particular embodiments, the rAAV comprises ITRs and capsid sequences isolated from AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10.

In some embodiments, a chimeric rAAV is used the ITR sequences are isolated from one AAV serotype and the capsid sequences are isolated from a different AAV serotype. For example, a rAAV with ITR sequences derived from AAV2 and capsid sequences derived from AAV6 is referred to as AAV2/AAV6. In particular embodiments, the rAAV vector may comprise ITRs from AAV2, and capsid proteins from any one of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, or AAV10. In a preferred embodiment, the rAAV comprises ITR sequences derived from AAV2 and capsid sequences derived from AAV6. In a preferred embodiment, the rAAV comprises ITR sequences derived from AAV2 and capsid sequences derived from AAV2.

In some embodiments, engineering and selection methods can be applied to AAV capsids to make them more likely to transduce cells of interest.

Construction of rAAV vectors, production, and purification thereof have been disclosed, *e.g.*, in U.S. Patent Nos. 9,169,494; 9,169,492; 9,012,224; 8,889,641; 8,809,058; and 8,784,799, each of which is incorporated by reference herein, in its entirety.

In various embodiments, one or more polynucleotides encoding one or more engineered immune receptor components and/or other polypeptides contemplated herein are introduced into an immune effector cell, *e.g.*, T cell, by transducing the cell with a retrovirus, *e.g.*, lentivirus, comprising the one or more polynucleotides.

As used herein, the term “retrovirus” refers to an RNA virus that reverse transcribes its genomic RNA into a linear double-stranded DNA copy and subsequently covalently integrates its genomic DNA into a host genome. Illustrative retroviruses suitable for use in particular embodiments, include, but are not limited to: Moloney murine leukemia virus (M-MuLV), Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend murine leukemia virus, Murine Stem Cell Virus (MSCV) and Rous Sarcoma Virus (RSV)) and lentivirus.

As used herein, the term “lentivirus” refers to a group (or genus) of complex retroviruses. Illustrative lentiviruses include, but are not limited to, HIV (human immunodeficiency virus; including HIV type 1, and HIV type 2); visna-maedi virus (VMV) virus; the caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV). In one embodiment, HIV based vector backbones (*i.e.*, HIV cis-acting sequence elements) are preferred.

In various embodiments, a lentiviral vector contemplated herein comprises one or more LTRs, and one or more, or all, of the following accessory elements: a cPPT/FLAP, a Psi (Ψ) packaging signal, an export element, poly (A) sequences, and may optionally comprise a WPRE or HPRE, an insulator element, a selectable marker, and a cell suicide gene, as discussed elsewhere herein.

In particular embodiments, lentiviral vectors contemplated herein may be integrative or non-integrating or integration defective lentivirus. As used herein, the term “integration defective lentivirus” or “IDLV” refers to a lentivirus having an integrase that lacks the capacity to integrate the viral genome into the genome of the host cells. Integration-incompetent viral vectors have

been described in patent application WO 2006/010834, which is herein incorporated by reference in its entirety.

Illustrative mutations in the HIV-1 pol gene suitable to reduce integrase activity include, but are not limited to: H12N, H12C, H16C, H16V, S81 R, D41A, K42A, H51A, Q53C, D55V,
 5 D64E, D64V, E69A, K71A, E85A, E87A, D116N, D116I, D116A, N120G, N120I, N120E, E152G, E152A, D35E, K156E, K156A, E157A, K159E, K159A, K160A, R166A, D167A, E170A, H171A, K173A, K186Q, K186T, K188T, E198A, R199c, R199T, R199A, D202A, K211A, Q214L, Q216L, Q221 L, W235F, W235E, K236S, K236A, K246A, G247W, D253A, R262A, R263A and K264H.

10 The term “long terminal repeat (LTR)” refers to domains of base pairs located at the ends of retroviral DNAs which, in their natural sequence context, are direct repeats and contain U3, R and U5 regions.

As used herein, the term “FLAP element” or “cPPT/FLAP” refers to a nucleic acid whose sequence includes the central polypurine tract and central termination sequences (cPPT and CTS)
 15 of a retrovirus, *e.g.*, HIV-1 or HIV-2. Suitable FLAP elements are described in U.S. Pat. No. 6,682,907 and in Zennou, *et al.*, 2000, *Cell*, 101:173.

As used herein, the term “packaging signal” or “packaging sequence” refers to psi [Ψ] sequences located within the retroviral genome which are required for insertion of the viral RNA into the viral capsid or particle, *see e.g.*, Clever *et al.*, 1995, *J. of Virology*, Vol. 69, No. 4; pp.
 20 2101–2109.

The term “export element” refers to a cis-acting post-transcriptional regulatory element which regulates the transport of an RNA transcript from the nucleus to the cytoplasm of a cell. Examples of RNA export elements include, but are not limited to, the human immunodeficiency virus (HIV) rev response element (RRE) (*see e.g.*, Cullen *et al.*, 1991, *J. Virol.* 65: 1053; and
 25 Cullen *et al.*, 1991, *Cell* 58: 423), and the hepatitis B virus post-transcriptional regulatory element (HPRE).

In particular embodiments, expression of heterologous sequences in viral vectors is increased by incorporating posttranscriptional regulatory elements, efficient polyadenylation sites, and optionally, transcription termination signals into the vectors. A variety of
 30 posttranscriptional regulatory elements can increase expression of a heterologous nucleic acid at the protein, *e.g.*, woodchuck hepatitis virus posttranscriptional regulatory element (WPRE; Zufferey *et al.*, 1999, *J. Virol.*, 73:2886); the posttranscriptional regulatory element present in

hepatitis B virus (HPRE) (Huang *et al.*, *Mol. Cell. Biol.*, 5:3864); and the like (Liu *et al.*, 1995, *Genes Dev.*, 9:1766).

Lentiviral vectors preferably contain several safety enhancements as a result of modifying the LTRs. “Self-inactivating” (SIN) vectors refers to replication-defective vectors, *e.g.*,
5 retroviral or lentiviral vectors, in which the right (3') LTR enhancer-promoter region, known as the U3 region, has been modified (*e.g.*, by deletion or substitution) to prevent viral transcription beyond the first round of viral replication. Self-inactivation is preferably achieved through the introduction of a deletion in the U3 region of the 3' LTR of the vector DNA, *i.e.*, the DNA used to produce the vector RNA. Thus, during reverse transcription, this
10 deletion is transferred to the 5' LTR of the proviral DNA. In particular embodiments, it is desirable to eliminate enough of the U3 sequence to greatly diminish or abolish altogether the transcriptional activity of the LTR, thereby greatly diminishing or abolishing the production of full-length vector RNA in transduced cells. In the case of HIV based lentivectors, it has been discovered that such vectors tolerate significant U3 deletions, including the removal of
15 the LTR TATA box (*e.g.*, deletions from -418 to -18), without significant reductions in vector titers.

An additional safety enhancement is provided by replacing the U3 region of the 5' LTR with a heterologous promoter to drive transcription of the viral genome during production of viral particles. Examples of heterologous promoters which can be used include, for example, viral
20 simian virus 40 (SV40) (*e.g.*, early or late), cytomegalovirus (CMV) (*e.g.*, immediate early), Moloney murine leukemia virus (MoMLV), Rous sarcoma virus (RSV), and herpes simplex virus (HSV) (thymidine kinase) promoters.

The terms “pseudotype” or “pseudotyping” as used herein, refer to a virus whose viral envelope proteins have been substituted with those of another virus possessing preferable
25 characteristics. For example, HIV can be pseudotyped with vesicular stomatitis virus G-protein (VSV-G) envelope proteins, which allows HIV to infect a wider range of cells because HIV envelope proteins (encoded by the *env* gene) normally target the virus to CD4⁺ presenting cells.

In certain embodiments, lentiviral vectors are produced according to known methods. See *e.g.*, Kutner *et al.*, *BMC Biotechnol.* 2009;9:10. doi: 10.1186/1472-6750-9-10; Kutner *et al.*
30 *Nat. Protoc.* 2009;4(4):495–505. doi: 10.1038/nprot.2009.22.

According to certain specific embodiments contemplated herein, most or all of the viral vector backbone sequences are derived from a lentivirus, *e.g.*, HIV-1. However, it is to be

understood that many different sources of retroviral and/or lentiviral sequences can be used, or combined and numerous substitutions and alterations in certain of the lentiviral sequences may be accommodated without impairing the ability of a transfer vector to perform the functions described herein. Moreover, a variety of lentiviral vectors are known in the art, *see* Naldini *et al.*, (1996a, 1996b, and 1998); Zufferey *et al.*, (1997); Dull *et al.*, 1998, U.S. Pat. Nos. 6,013,516; and 5,994,136, many of which may be adapted to produce a viral vector or transfer plasmid contemplated herein.

In various embodiments, one or more polynucleotides encoding one or more engineered immune receptor components and/or other polypeptides contemplated herein are introduced into an immune effector cell, by transducing the cell with an adenovirus comprising the one or more polynucleotides.

Adenoviral based vectors are capable of very high transduction efficiency in many cell types and do not require cell division. With such vectors, high titer and high levels of expression have been obtained. This vector can be produced in large quantities in a relatively simple system. Most adenovirus vectors are engineered such that a transgene replaces the Ad E1a, E1b, and/or E3 genes; subsequently the replication defective vector is propagated in human 293 cells that supply deleted gene function in trans. Ad vectors can transduce multiple types of tissues *in vivo*, including non-dividing, differentiated cells such as those found in liver, kidney and muscle. Conventional Ad vectors have a large carrying capacity.

Generation and propagation of the current adenovirus vectors, which are replication deficient, may utilize a unique helper cell line, designated 293, which was transformed from human embryonic kidney cells by Ad5 DNA fragments and constitutively expresses E1 proteins (Graham *et al.*, 1977). Since the E3 region is dispensable from the adenovirus genome (Jones & Shenk, 1978), the current adenovirus vectors, with the help of 293 cells, carry foreign DNA in either the E1, the D3 or both regions (Graham & Prevec, 1991). Adenovirus vectors have been used in eukaryotic gene expression (Levrero *et al.*, 1991; Gomez-Foix *et al.*, 1992) and vaccine development (Grunhaus & Horwitz, 1992; Graham & Prevec, 1992). Studies in administering recombinant adenovirus to different tissues include trachea instillation (Rosenfeld *et al.*, 1991; Rosenfeld *et al.*, 1992), muscle injection (Ragot *et al.*, 1993), peripheral intravenous injections (Herz & Gerard, 1993) and stereotactic inoculation into the brain (Le Gal La Salle *et al.*, 1993). An example of the use of an Ad vector in a clinical trial involved polynucleotide therapy for antitumor immunization with intramuscular injection (Sterman *et al.*, *Hum. Gene Ther.* 7:1083-9 (1998)).

In various embodiments, one or more polynucleotides encoding one or more engineered immune receptor components and/or other polypeptides contemplated herein are introduced into an immune effector cell by transducing the cell with a herpes simplex virus, *e.g.*, HSV-1, HSV-2, comprising the one or more polynucleotides.

5 The mature HSV virion consists of an enveloped icosahedral capsid with a viral genome consisting of a linear double-stranded DNA molecule that is 152 kb. In one embodiment, the HSV based viral vector is deficient in one or more essential or non-essential HSV genes. In one embodiment, the HSV based viral vector is replication deficient. Most replication deficient HSV vectors contain a deletion to remove one or more intermediate-early, early, or late HSV genes to
10 prevent replication. For example, the HSV vector may be deficient in an immediate early gene selected from the group consisting of: ICP4, ICP22, ICP27, ICP47, and a combination thereof. Advantages of the HSV vector are its ability to enter a latent stage that can result in long-term DNA expression and its large viral DNA genome that can accommodate exogenous DNA inserts of up to 25 kb. HSV-based vectors are described in, for example, U.S. Pat. Nos. 5,837,532,
15 5,846,782, and 5,804,413, and International Patent Applications WO 91/02788, WO 96/04394, WO 98/15637, and WO 99/06583, each of which are incorporated by reference herein in its entirety.

G. GENETICALLY MODIFIED CELLS

In various embodiments, cells are modified to express an engineered immune receptor
20 system, one or more engineered immune receptor components, signaling components, targeting components, engineered TCRs, CARs, CCRs, BiTEs, zetakines, flip receptors, exogenous costimulatory factor, immunomodulatory factor, agonist for a costimulatory factor, antagonist for an immunosuppressive factor, immune cell engager, and/or fusion proteins contemplated herein. In particular embodiments, the cells are for use in the treatment of
25 cancer. Cells may be non-genetically modified to express one or more of the polypeptides contemplated herein, or in particular preferred embodiments, cells may be genetically modified to express one or more of the polypeptides contemplated herein. As used herein, the term “genetically engineered” or “genetically modified” refers to the addition of extra genetic material in the form of DNA or RNA into the total genetic material in a cell. The
30 terms, “genetically modified cells,” “modified cells,” and “redirected cells,” are used interchangeably in particular embodiments.

In particular embodiments, one or more engineered immune receptor components that recruit an immune receptor complex, contemplated herein, are introduced and expressed in immune effector cells to improve the efficacy of the immune effector cells. In particular embodiments, one or more engineered immune receptor components that recruit an immune
5 receptor complex are introduced and expressed in immune effector cells that have been redirected to a target cell by virtue of co-expressing an exogenous lymphocyte receptor or engineered antigen receptor, *e.g.*, an engineered TCR or CAR, in the cell.

In particular embodiments, a dual targeting immune effector cell is contemplated where the target cell expresses a target antigen recognized by engineered immune receptor
10 and an MHC-antigen complex recognized by a TCR, *e.g.*, an engineered/exogenous TCR.

In particular embodiments, a dual targeting immune effector cell is contemplated where the target cell expresses CD33, CD123, CLL1, B7-H3, BCMA, CD19, CD20, CD22, CD79A, CD79B, EGFR, EGFRvIII, or an NKG2D ligand recognized by an engineered immune receptor, and a target antigen recognized by an exogenous lymphocyte receptor or
15 engineered antigen receptor, *e.g.*, an engineered/exogenous TCR or CAR.

An “immune effector cell,” is any cell of the immune system that has one or more effector functions (*e.g.*, cytotoxic cell killing activity, secretion of cytokines, induction of ADCC and/or CDC). The illustrative immune effector cells contemplated herein are T lymphocytes, including but not limited to cytotoxic T cells (CTLs; CD8⁺ T cells), TILs, and
20 helper T cells (HTLs; CD4⁺ T cells. In a particular embodiment, the cells comprise $\alpha\beta$ T cells. In a particular embodiment, the cells comprise $\gamma\delta$ T cells. In one embodiment, immune effector cells include natural killer (NK) cells. In one embodiment, immune effector cells include natural killer T (NKT) cells.

Immune effector cells can be autologous/autogeneic (“self”) or non-autologous (“non-self,” *e.g.*, allogeneic, syngeneic or xenogeneic). “Autologous,” as used herein, refers to cells
25 from the same subject. “Allogeneic,” as used herein, refers to cells of the same species that differ genetically to the cell in comparison. “Syngeneic,” as used herein, refers to cells of a different subject that are genetically identical to the cell in comparison. “Xenogeneic,” as used herein, refers to cells of a different species to the cell in comparison. In preferred
30 embodiments, the cells are human autologous immune effector cells.

Illustrative immune effector cells suitable for introducing one or more engineered immune receptor receptors or components contemplated herein include T lymphocytes. The

terms “T cell” or “T lymphocyte” are art-recognized and are intended to include thymocytes, immature T lymphocytes, mature T lymphocytes, resting T lymphocytes, or activated T lymphocytes. A T cell can be a T helper (Th) cell, for example a T helper 1 (Th1) or a T helper 2 (Th2) cell. The T cell can be a helper T cell (HTL; CD4⁺ T cell) CD4⁺ T cell, a
 5 cytotoxic T cell (CTL; CD8⁺ T cell), CD4⁺CD8⁺ T cell, CD4⁺CD8⁻ T cell, or any other subset of T cells. Other illustrative populations of T cells suitable for use in particular embodiments include naïve T cells and memory T cells. For example, populations of T cells suitable for use in particular embodiments include naïve T cells (T_N), T memory stem cells (T_{SCM}), central memory T cells (T_{CM}), effector memory T cells (T_{EM}), and effector T cells (T_{EFF}).

10 As would be understood by the skilled person, other cells may also be used as immune effector cells comprising one or more engineered immune receptor components contemplated herein. In particular embodiments, immune effector cells also include NK cells, NKT cells, neutrophils, and macrophages. Immune effector cells also include progenitors of effector cells wherein such progenitor cells can be induced to differentiate
 15 into immune effector cells *in vivo* or *in vitro*. Thus, in particular embodiments, immune effector cells include progenitors of immune effectors cells such as hematopoietic stem cells (HSCs) contained within the CD34⁺ population of cells derived from cord blood, bone marrow or mobilized peripheral blood which upon administration in a subject differentiate into mature immune effector cells, or which can be induced *in vitro* to differentiate into
 20 mature immune effector cells.

The term, “CD34⁺ cell,” as used herein refers to a cell expressing the CD34 protein on its cell surface. “CD34,” as used herein refers to a cell surface glycoprotein (*e.g.*, sialomucin protein) that often acts as a cell-cell adhesion factor and is involved in T cell entrance into lymph nodes. The CD34⁺ cell population contains hematopoietic stem cells (HSC), which
 25 upon administration to a patient differentiate and contribute to all hematopoietic lineages, including T cells, NK cells, NKT cells, neutrophils and cells of the monocyte/macrophage lineage.

Methods for making the immune effector cells which express one or more engineered immune receptor components contemplated herein are provided in particular embodiments.
 30 In one embodiment, the method comprises transfecting or transducing immune effector cells isolated from an individual such that the immune effector cells with one or more nucleic acids and/or vectors or combination thereof comprising one or more engineered immune

receptor components contemplated herein. In one embodiment, the method comprises transfecting or transducing immune effector cells isolated from an individual such that the immune effector cells express one or more engineered immune receptor components and an exogenous lymphocyte receptor or engineered antigen receptors contemplated herein (*e.g.*,
5 TCRs, CARs, CCRs, zetakines, or flip receptors). In certain embodiments, the immune effector cells are isolated from an individual and genetically modified without further manipulation *in vitro*. Such cells can then be directly re-administered into the individual. In further embodiments, the immune effector cells are first activated and stimulated to proliferate *in vitro* prior to being genetically modified. In this regard, the immune effector
10 cells may be cultured before and/or after being genetically modified.

In particular embodiments, the cells are human cells. In particular embodiments, prior to *in vitro* manipulation or genetic modification of the immune effector cells described herein, the source of cells is obtained from a subject. In particular embodiments, the modified immune effector cells comprise T cells.

15 T cells can be obtained from a number of sources including, but not limited to, peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments, T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled person, such as sedimentation, *e.g.*, FICOLL™
20 separation.

In other embodiments, an isolated or purified population of T cells is used. In some embodiments, after isolation of PBMC, both cytotoxic and helper T lymphocytes can be sorted into naïve, memory, and effector T cell subpopulations either before or after activation, expansion, and/or genetic modification.

25 In one embodiment, an isolated or purified population of T cells expresses one or more of the markers including, but not limited to a CD3⁺, CD4⁺, CD8⁺, or a combination thereof.

In certain embodiments, the T cells are isolated from an individual and first activated and stimulated to proliferate *in vitro* prior to being modified to express one or more engineered immune receptor components.

30 In order to achieve sufficient therapeutic doses of T cell compositions, T cells are often subjected to one or more rounds of stimulation, activation and/or expansion. In particular embodiments, T cells can be activated and expanded generally using methods as described, for

example, in U.S. Patents 6,352,694; 6,534,055; 6,905,680; 6,692,964; 5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869; 7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514; and 6,867,041, each of which is incorporated herein by reference in its entirety. In particular embodiments, T cells are activated and expanded for about 6 hours, about 12 hours, 5 about 18 hours or about 24 hours prior to introduction of vectors or polynucleotides encoding one or more engineered immune receptor components, optionally in combination with an exogenous lymphocyte receptor or engineered antigen receptor contemplated herein.

In one embodiment, T cells are activated at the same time that they are modified.

In various embodiments, a method of generating an immune effector cell comprises 10 activating a population of cells comprising T cells and expanding the population of T cells. T cell activation can be accomplished by providing a primary stimulation signal through the T cell TCR/CD3 complex and by providing a secondary costimulation signal through an accessory molecule, *e.g.*, CD28.

The TCR/CD3 complex may be stimulated by contacting the T cell with a suitable CD3 15 binding agent, *e.g.*, a CD3 ligand or an anti-CD3 monoclonal antibody. Illustrative examples of CD3 antibodies include, but are not limited to, OKT3, G19-4, BC3, and 64.1.

In addition to the primary stimulation signal provided through the TCR/CD3 complex, induction of T cell responses requires a second, costimulatory signal. In particular embodiments, a CD28 binding agent can be used to provide a costimulatory signal. Illustrative examples of 20 CD28 binding agents include but are not limited to: natural CD28 ligands, *e.g.*, a natural ligand for CD28 (*e.g.*, a member of the B7 family of proteins, such as B7-1(CD80) and B7-2 (CD86); and anti-CD28 monoclonal antibody or fragment thereof capable of crosslinking the CD28 molecule, *e.g.*, monoclonal antibodies 9.3, B-T3, XR-CD28, KOLT-2, 15E8, 248.23.2, and EX5.3D10.

25 In one embodiment, the molecule providing the primary stimulation signal, for example a molecule which provides stimulation through the TCR/CD3 complex and the costimulatory molecule are coupled to the same surface.

In certain embodiments, binding agents that provide stimulatory and costimulatory signals are localized on the surface of a cell. This can be accomplished by transfecting or 30 transducing a cell with a nucleic acid encoding the binding agent in a form suitable for its expression on the cell surface or alternatively by coupling a binding agent to the cell surface.

In another embodiment, the molecule providing the primary stimulation signal, for example a molecule which provides stimulation through the TCR/CD3 complex and the costimulatory molecule are displayed on antigen presenting cells.

5 In one embodiment, the molecule providing the primary stimulation signal, for example a molecule which provides stimulation through the TCR/CD3 complex and the costimulatory molecule are provided on separate surfaces.

In a certain embodiment, one of the binding agents that provides stimulatory and costimulatory signals is soluble (provided in solution) and the other agent(s) is provided on one or more surfaces. In a particular embodiment, the binding agents that provide stimulatory and costimulatory signals are both provided in a soluble form (provided in solution). In various 10 embodiments, the methods for making T cells contemplated herein comprise activating T cells with soluble anti-CD3 and/or soluble anti-CD28 antibodies, or fragments thereof. In various embodiments, the methods for making T cells contemplated herein comprise activating T cells with surface bound anti-CD3 and/or surface bound anti-CD28 antibodies, or fragments thereof. 15 In various embodiments, the methods for making T cells contemplated herein comprise activating T cells with bead-bound anti-CD3 and/or bead-bound anti-CD28 antibodies, or fragments thereof.

In one embodiment, expanding T cells activated by the methods contemplated herein further comprises culturing a population of cells comprising T cells for several hours (about 3 20 hours) to about 7 days to about 28 days or any hourly integer value in between. In another embodiment, the T cell composition may be cultured for 14 days. In a particular embodiment, T cells are cultured for about 21 days. In another embodiment, the T cell compositions are cultured for about 2-3 days. Several cycles of stimulation/activation/expansion may also be desired.

In particular embodiments, conditions appropriate for T cell culture include an 25 appropriate media (*e.g.*, Minimal Essential Media or RPMI Media 1640 or, X-vivo 15, (Lonza)) and one or more factors necessary for proliferation and viability including, but not limited to serum (*e.g.*, fetal bovine or human serum), interleukin-2 (IL-2), insulin, IFN- γ , IL-4, IL-7, IL-21, GM-CSF, IL-10, IL-12, IL-15, TGF β , and TNF- α or any other additives suitable for the growth of cells known to the skilled artisan.

30 Further illustrative examples of cell culture media include, but are not limited to RPMI 1640, Clicks, AIM-V, DMEM, MEM, a-MEM, IMDM, F-12, X-Vivo 15, and X-Vivo 20, Optimizer, with added amino acids, sodium pyruvate, and vitamins, either serum-free or

supplemented with an appropriate amount of serum (or plasma) or a defined set of hormones, and/or an amount of cytokine(s) sufficient for the growth and expansion of T cells.

Antibiotics, *e.g.*, penicillin and streptomycin, are included only in experimental cultures, not in cultures of cells that are to be infused into a subject. The target cells are maintained under
5 conditions necessary to support growth, for example, an appropriate temperature (*e.g.*, 37° C) and atmosphere (*e.g.*, air plus 5% CO₂).

In particular embodiments, PBMCs or isolated T cells are contacted with a stimulatory agent and costimulatory agent, such as anti-CD3 and anti-CD28 antibodies, generally attached to a bead or other surface, in a culture medium with appropriate cytokines, such as IL-2, IL-7,
10 and/or IL-15.

In other embodiments, artificial APC (aAPC) made by engineering K562, U937, 721.221, T2, and C1R cells to direct the stable expression and secretion, of a variety of costimulatory molecules and cytokines. In a particular embodiment K32 or U32 aAPCs are used to direct the display of one or more antibody-based stimulatory molecules on the aAPC cell surface.
15 Populations of T cells can be expanded by aAPCs expressing a variety of costimulatory molecules including, but not limited to, CD137L (4-1BBL), CD134L (OX40L), and/or CD80 or CD86. Finally, the aAPCs provide an efficient platform to expand genetically modified T cells and to maintain CD28 expression on CD8 T cells. aAPCs provided in WO 03/057171 and US2003/0147869 are hereby incorporated by reference in their entirety.

In a particular embodiment, a polynucleotide encoding one or more engineered immune receptor components is introduced into the population of T cells. In a particular embodiment, a polynucleotide encoding one or more engineered immune receptor components is introduced into a population of T cells that express an exogenous lymphocyte receptor or engineered antigen receptor. The polynucleotides may be introduced into the T cells by microinjection, transfection,
25 lipofection, heat-shock, electroporation, transduction, gene gun, microinjection, DEAE-dextran-mediated transfer, and the like.

In a preferred embodiment, polynucleotides are introduced into a T cell by viral transduction.

Illustrative examples of viral vector systems suitable for introducing a polynucleotide into
30 an immune effector cell or CD34⁺ cell include but are not limited to adeno-associated virus (AAV), retrovirus, herpes simplex virus, adenovirus, vaccinia virus vectors for gene transfer.

In one embodiment, polynucleotides are introduced into a T cell by AAV transduction. In one embodiment, polynucleotides are introduced into a T cell by retroviral transduction. In one embodiment, polynucleotides are introduced into a T cell by lentiviral transduction. In one embodiment, polynucleotides are introduced into a T cell by adenovirus transduction. In one
 5 embodiment, polynucleotides are introduced into a T cell by herpes simplex virus transduction. In one embodiment, polynucleotides are introduced into a T cell by vaccinia virus transduction.

H. COMPOSITIONS AND FORMULATIONS

The compositions contemplated herein may comprise one or more engineered immune receptor polypeptides, polynucleotides encoding engineered immune receptor
 10 polypeptides, vectors comprising same, genetically modified immune effector cells, bridging factors, *etc.* Compositions include, but are not limited to, pharmaceutical compositions. A “pharmaceutical composition” refers to a composition formulated in pharmaceutically-acceptable or physiologically-acceptable solutions for administration to a cell or an animal, either alone, or in combination with one or more other modalities of therapy. It will also be
 15 understood that, if desired, the compositions may be administered in combination with other agents as well, such as, *e.g.*, cytokines, growth factors, hormones, small molecules, chemotherapeutics, pro-drugs, drugs, antibodies, or other various pharmaceutically-active agents. There is virtually no limit to other components that may also be included in the compositions, provided that the additional agents do not adversely affect the ability of the
 20 composition to deliver the intended therapy.

The phrase “pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or
 25 complication, commensurate with a reasonable benefit/risk ratio.

The term “pharmaceutically acceptable carrier” refers to a diluent, adjuvant, excipient, or vehicle with which the bridging factors, polypeptides, polynucleotides, vectors comprising same, or genetically modified immune effector cells are administered. Illustrative examples of pharmaceutical carriers can be sterile liquids, such as cell culture media, water and oils, including
 30 those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical

excipients in particular embodiments, include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

In one embodiment, a composition comprising a pharmaceutically acceptable carrier is suitable for administration to a subject. In particular embodiments, a composition comprising a carrier is suitable for parenteral administration, *e.g.*, intravascular (intravenous or intraarterial), intraperitoneal or intramuscular administration. In particular embodiments, a composition comprising a pharmaceutically acceptable carrier is suitable for intraventricular, intraspinal, or intrathecal administration. Pharmaceutically acceptable carriers include sterile aqueous solutions, cell culture media, or dispersions. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the bridging factors, polypeptides, polynucleotides, vectors comprising same, or genetically modified immune effector cells, use thereof in the pharmaceutical compositions is contemplated.

In particular embodiments, compositions contemplated herein comprise genetically modified T cells and a pharmaceutically acceptable carrier. A composition comprising a cell-based composition contemplated herein can be administered separately by enteral or parenteral administration methods or in combination with other suitable compounds to effect the desired treatment goals.

In particular embodiments, compositions contemplated herein comprise a bridging factor and a pharmaceutically acceptable carrier.

The pharmaceutically acceptable carrier must be of sufficiently high purity and of sufficiently low toxicity to render it suitable for administration to the human subject being treated. It further should maintain or increase the stability of the composition. The pharmaceutically acceptable carrier can be liquid or solid and is selected, with the planned manner of administration in mind, to provide for the desired bulk, consistency, *etc.*, when combined with other components of the composition. For example, the pharmaceutically acceptable carrier can be, without limitation, a binding agent (*e.g.*, pregelatinized maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose, *etc.*), a filler (*e.g.*, lactose

and other sugars, microcrystalline cellulose, pectin, gelatin, calcium sulfate, ethyl cellulose, polyacrylates, calcium hydrogen phosphate, *etc.*), a lubricant (*e.g.*, magnesium stearate, talc, silica, colloidal silicon dioxide, stearic acid, metallic stearates, hydrogenated vegetable oils, corn starch, polyethylene glycols, sodium benzoate, sodium acetate, *etc.*), a disintegrant
5 (*e.g.*, starch, sodium starch glycolate, *etc.*), or a wetting agent (*e.g.*, sodium lauryl sulfate, *etc.*). Other suitable pharmaceutically acceptable carriers for the compositions contemplated herein include, but are not limited to, water, salt solutions, alcohols, polyethylene glycols, gelatins, amyloses, magnesium stearates, talcs, silicic acids, viscous paraffins, hydroxymethylcelluloses, polyvinylpyrrolidones and the like.

10 Such carrier solutions also can contain buffers, diluents and other suitable additives. The term “buffer” as used herein refers to a solution or liquid whose chemical makeup neutralizes acids or bases without a significant change in pH. Examples of buffers contemplated herein include, but are not limited to, Dulbecco’s phosphate buffered saline (PBS), Ringer’s solution, 5% dextrose in water (D5W), normal/physiologic saline (0.9%
15 NaCl).

The pharmaceutically acceptable carriers may be present in amounts sufficient to maintain a pH of the composition of about 7. Alternatively, the composition has a pH in a range from about 6.8 to about 7.4, *e.g.*, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, and 7.4. In still another embodiment, the composition has a pH of about 7.4.

20 Compositions contemplated herein may comprise a nontoxic pharmaceutically acceptable medium. The compositions may be a suspension. The term “suspension” as used herein refers to non-adherent conditions in which cells are not attached to a solid support. For example, cells maintained as a suspension may be stirred or agitated and are not adhered to a support, such as a culture dish.

25 In particular embodiments, compositions contemplated herein are formulated in a suspension, where the modified T cells are dispersed within an acceptable liquid medium or solution, *e.g.*, saline or serum-free medium, in an intravenous (IV) bag or the like. Acceptable diluents include, but are not limited to water, PlasmaLyte, Ringer’s solution, isotonic sodium chloride (saline) solution, serum-free cell culture medium, and medium
30 suitable for cryogenic storage, *e.g.*, Cryostor® medium.

In certain embodiments, a pharmaceutically acceptable carrier is substantially free of natural proteins of human or animal origin, and suitable for storing a composition

comprising a population of modified T cells. The therapeutic composition is intended to be administered into a human patient, and thus is substantially free of cell culture components such as bovine serum albumin, horse serum, and fetal bovine serum.

5 In some embodiments, compositions are formulated in a pharmaceutically acceptable cell culture medium. Such compositions are suitable for administration to human subjects. In particular embodiments, the pharmaceutically acceptable cell culture medium is a serum free medium.

Serum-free medium has several advantages over serum containing medium, including a simplified and better-defined composition, a reduced degree of contaminants, 10 elimination of a potential source of infectious agents, and lower cost. In various embodiments, the serum-free medium is animal-free, and may optionally be protein-free. Optionally, the medium may contain biopharmaceutically acceptable recombinant proteins. “Animal-free” medium refers to medium wherein the components are derived from non-animal sources. Recombinant proteins replace native animal proteins in animal-free medium 15 and the nutrients are obtained from synthetic, plant or microbial sources. “Protein-free” medium, in contrast, is defined as substantially free of protein.

Illustrative examples of serum-free media used in particular compositions includes, but is not limited to, QBSF-60 (Quality Biological, Inc.), StemPro-34 (Life Technologies), and X-VIVO 10.

20 In one embodiment, the compositions comprising modified T cells are formulated in PlasmaLyte.

In various embodiments, compositions comprising modified T cells are formulated in a cryopreservation medium. For example, cryopreservation media with cryopreservation agents may be used to maintain a high cell viability outcome post-thaw. Illustrative 25 examples of cryopreservation media used in particular compositions includes, but is not limited to, CryoStor CS10, CryoStor CS5, and CryoStor CS2.

In one embodiment, the compositions are formulated in a solution comprising 50:50 PlasmaLyte A to CryoStor CS10.

In particular embodiments, the composition is substantially free of mycoplasma, 30 endotoxin, and microbial contamination. By “substantially free” with respect to endotoxin is meant that there is less endotoxin per dose of cells than is allowed by the FDA for a

biologic, which is a total endotoxin of 5 EU/kg body weight per day, which for an average 70 kg person is 350 EU per total dose of cells. In particular embodiments, compositions contemplated herein contain about 0.5 EU/mL to about 5.0 EU/mL, or about 0.5 EU/mL, 1.0 EU/mL, 1.5 EU/mL, 2.0 EU/mL, 2.5 EU/mL, 3.0 EU/mL, 3.5 EU/mL, 4.0 EU/mL, 4.5 EU/mL, or 5.0 EU/mL.

In particular embodiments, formulation of pharmaceutically-acceptable carrier solutions is well-known to those of skill in the art, as is the development of suitable dosing and treatment regimens for using the particular compositions described herein in a variety of treatment regimens, including *e.g.*, enteral and parenteral, *e.g.*, intravascular, intravenous, intrarterial, intraosseously, intraventricular, intracerebral, intracranial, intraspinal, intrathecal, and intramedullary administration and formulation. It would be understood by the skilled artisan that particular embodiments contemplated herein may comprise other formulations, such as those that are well known in the pharmaceutical art, and are described, for example, in *Remington: The Science and Practice of Pharmacy*, volume I and volume II. 22nd Edition. Edited by Loyd V. Allen Jr. Philadelphia, PA: Pharmaceutical Press; 2012, which is incorporated by reference herein, in its entirety.

In particular embodiments, compositions comprise an amount of immune effector cells that express one or more engineered immune receptor components contemplated herein. In particular embodiments, compositions comprise an amount of immune effector cells that express an exogenous lymphocyte receptor or engineered antigen receptor and one or more engineered immune receptor components contemplated herein. As used herein, the term “amount” refers to “an amount effective” or “an effective amount” of cells comprising one or more engineered immune receptor components contemplated herein, *etc.*, to achieve a beneficial or desired prophylactic or therapeutic result in the presence of a bridging factor, including clinical results.

A “prophylactically effective amount” refers to an amount of cells comprising one or more engineered immune receptor components contemplated herein, *etc.*, effective to achieve the desired prophylactic result in the presence of a bridging factor. Typically, but not necessarily, since a prophylactic dose is used in subjects prior to or at an earlier stage of disease, the prophylactically effective amount is less than the therapeutically effective amount.

A “therapeutically effective amount” refers to an amount of cells comprising one or more engineered immune receptor components contemplated herein that is effective to “treat” a subject (*e.g.*, a patient) in the presence of a bridging factor. When a therapeutic amount is indicated, the precise amount of the compositions to be administered, cells, bridging factor, 5 *etc.*, can be determined by a physician with consideration of individual differences in age, weight, tumor size, extent of infection or metastasis, and condition of the patient (subject).

It can generally be stated that a pharmaceutical composition comprising the immune effector cells described herein may be administered at a dosage of 10^2 to 10^{10} cells/kg body weight, preferably 10^5 to 10^6 cells/kg body weight, including all integer values within those 10 ranges. The number of cells will depend upon the ultimate use for which the composition is intended as will the type of cells included therein. For uses provided herein, the cells are generally in a volume of a liter or less, can be 500 mLs or less, even 250 mLs or 100 mLs or less. Hence the density of the desired cells is typically greater than 10^6 cells/ml and generally is greater than 10^7 cells/ml, generally 10^8 cells/ml or greater. The clinically relevant number 15 of immune cells can be apportioned into multiple infusions that cumulatively equal or exceed 10^5 , 10^6 , 10^7 , 10^8 , 10^9 , 10^{10} , 10^{11} , or 10^{12} cells. In some embodiments, particularly since all the infused cells will be redirected to a particular target antigen, lower numbers of cells, in the range of 10^6 /kilogram (10^6 - 10^{11} per patient) may be administered.

If desired, the treatment may also include administration of mitogens (*e.g.*, PHA) or 20 lymphokines, cytokines, and/or chemokines (*e.g.*, IFN- γ , IL-2, IL-12, TNF- α , IL-18, and TNF- β , GM-CSF, IL-4, IL-13, Flt3-L, RANTES, MIP1 α , *etc.*) as described herein to enhance induction of the immune response.

Generally, compositions comprising the cells activated and expanded as described herein may be utilized in the treatment and prevention of diseases that arise in individuals 25 who are immunocompromised. In particular, compositions contemplated herein are used in the treatment of cancer. In particular embodiments, the immune effector cells may be administered either alone, or as a pharmaceutical composition in combination with carriers, diluents, excipients, and/or with other components such as IL-2 or other cytokines or cell populations.

30 In particular embodiments, pharmaceutical compositions comprise an amount of genetically modified T cells, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.

In particular embodiments, pharmaceutical compositions comprise an amount of bridging factor, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients.

5 In a particular embodiment, compositions comprise an effective amount of immune effector cells comprising one or more engineered immune receptor components contemplated herein, alone or in combination with a bridging factor and/or one or more therapeutic agents, such as radiation therapy, chemotherapy, transplantation, immunotherapy, hormone therapy, photodynamic therapy, *etc.* The compositions may also be administered in combination with antibiotics. Such therapeutic agents may be accepted in the art as a standard treatment for a
10 particular disease state as described herein, such as a particular cancer. Exemplary therapeutic agents contemplated include cytokines, growth factors, steroids, NSAIDs, DMARDs, anti-inflammatories, chemotherapeutics, radiotherapeutics, therapeutic antibodies, or other active and ancillary agents.

In a particular embodiment, a composition comprising an effective amount of immune
15 effector cells comprising one or more engineered immune receptor components contemplated herein is administered to a subject, and a composition comprising an effective amount of a bridging factor is administered to the subject, before, during, in combination with or subsequently to the cellular composition, and optionally repetitively administered to the subject.

20 In certain embodiments, compositions comprising immune effector cells comprising one or more engineered immune receptor components contemplated herein may be administered in conjunction with any number of chemotherapeutic agents.

A variety of other therapeutic agents may be used in conjunction with the compositions described herein. In one embodiment, the composition comprising immune
25 effector cells comprising one or more engineered immune receptor components contemplated herein is administered with an anti-inflammatory agent. Anti-inflammatory agents or drugs include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone), nonsteroidal anti-
30 inflammatory drugs (NSAIDs) including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF medications, cyclophosphamide and mycophenolate.

Illustrative examples of therapeutic antibodies suitable for combination treatment with the modified T cells comprising one or more engineered immune receptor components contemplated herein, include but are not limited to, atezolizumab, avelumab, bavituximab, bevacizumab (avastin), bivatuzumab, blinatumomab, conatumumab, daratumumab, 5 duligotumab, dacetuzumab, dalotuzumab, durvalumab, elotuzumab (HuLuc63), gemtuzumab, ibritumomab, indatuximab, inotuzumab, ipilimumab, lorvotuzumab, lucatumumab, milatuzumab, moxetumomab, nivolumab, ocaratuzumab, ofatumumab, pembrolizumab, rituximab, siltuximab, teprotumumab, and ublituximab.

In certain embodiments, the compositions described herein are administered in 10 conjunction with a cytokine. By “cytokine” as used herein is meant a generic term for proteins released by one cell population that act on another cell as intercellular mediators. Examples of such cytokines are lymphokines, monokines, and traditional polypeptide hormones.

I. THERAPEUTIC METHODS

15 Immune effector cells modified to express one or more engineered immune receptor components and/or an exogenous lymphocyte receptor or engineered antigen receptor contemplated herein provide improved methods of adoptive immunotherapy for use in the prevention, treatment, and amelioration of, or for preventing, treating, or ameliorating at least one symptom associated with an immune-related disease or disorder, *e.g.*, cancer, an 20 autoimmune disease, an immunodeficiency, an inflammatory disease, GVHD, or an infectious disease.

Immune effector cells comprising an engineered immune receptor system, *e.g.*, a targeting component and a signaling component, provide improved methods of adoptive immunotherapy for use in the prevention, treatment, and amelioration of, or for preventing, 25 treating, or ameliorating at least one symptom associated with an immune-related disease or disorder, *e.g.*, cancer, an autoimmune disease, an immunodeficiency, an inflammatory disease, GVHD, or an infectious disease.

In particular embodiments, immune effector cells modified to express one or more engineered immune receptor components provide improved methods of adoptive immunotherapy 30 to fine-tune the safety and efficacy of a cytotoxic response against target cells, *e.g.*, tumor cells, expressing target antigens while decreasing the risk of on-target antigen, off-target cell cytotoxicity (recognizing the target antigen on a normal, non-target cell).

In particular embodiments, a method of preventing, treating, or ameliorating at least one symptom of an immune-related disease or disorder (*e.g.*, cancer, an autoimmune disease, an immunodeficiency, an inflammatory disease, GVHD, or an infectious disease) comprises administering the subject an effective amount of modified immune effector cells or T cells comprising one or more components of a engineered immune receptor system and an engineered/exogenous TCR, CAR, or other therapeutic transgene to redirect the cells to a target cell. The genetically modified cells are a more efficacious and safe cellular immunotherapy by virtue of transducing a chemically regulatable immunostimulatory signal.

In particular embodiments, one or more immune effector cells, *e.g.*, T cells, are modified to express both a targeting component and a signaling component. In this case, the modified cells are administered to a subject in need thereof and home to the target cells via the interaction of the signaling component expressed on the immune effector cell and the target antigen expressed on the target cell. A bridging factor is administered to the subject before the modified cells, about the same time as the modified cells, or after the modified cells have been administered to the subject. In the presence of the bridging factor, a complex forms between the targeting component bound to the target antigen, the bridging factor, and the signaling component bound to an immune receptor complex. Upon formation of the complex, the signaling and targeting components transduce an immunostimulatory signal to the immune effector cell that synergizes with the immune receptor signal and in turn, elicits a cytotoxic response from the immune effector cell against the target cell.

In various embodiments, immune effector cells comprising one or more engineered immune receptor components and/or an exogenous lymphocyte receptor or engineered antigen receptor fine-tune the safety and efficacy of a cytotoxic response against target cells using a dual targeting strategy wherein one or more target cells express one or more target antigens recognized by the exogenous lymphocyte receptor or engineered antigen receptor and the engineered immune receptor.

In particular embodiments, one or more immune effector cells, *e.g.*, T cells, are modified to express both the targeting component and the signaling component and an exogenous lymphocyte receptor or engineered antigen receptor, *e.g.*, a TCR, CAR, CCR, or flip receptor. In this case, the modified cells are administered to a subject in need thereof and home to the target cells via the interaction of the targeting component that binds a first target antigen and the antigen receptor, which binds a second target antigen, wherein one or both target antigens are expressed on target cells or population of target cells. Interaction of the antigen receptor (*e.g.*, TCR) with a

target antigen on the target cell may elicit a cytotoxic response from the immune effector cell against the target cell. In some embodiments, a bridging factor is administered to the subject before the modified cells, about the same time as the modified cells, or after the modified cells have been administered to the subject. In the presence of the bridging factor, a complex forms
5 between the targeting component that binds a first target antigen, the bridging factor, and the signaling component, which binds an immune receptor complex. Upon formation of the complex, the signaling and targeting components transduce an immunostimulatory signal to the immune effector cell that synergizes with the immune receptor signal and in turn, elicits or augments a cytotoxic response from the immune effector cell against the target cell.

10 In particular embodiments, one or more immune effector cells, *e.g.*, T cells, are modified to express both a targeting component and a signaling component. In this case, the modified cells are administered to a subject in need thereof and home to the target cells via the interaction of the signaling component expressed on the immune effector cell and the target antigen expressed on the target cell. In some embodiments, a bridging factor is administered to the subject before the
15 modified cells, about the same time as the modified cells, or after the modified cells have been administered to the subject. In the presence of the bridging factor, a complex forms between the targeting component bound to the target antigen, the bridging factor, and a signaling component that comprises a multimerization domain, optionally a linker polypeptide, and an actuator domain (*e.g.*, Fc γ , CD3 ϵ , CD3 δ , or CD3 γ or fragment thereof). Upon formation of the
20 complex, the signaling and targeting components transduce an immunostimulatory signal to the immune effector cell that synergizes with the immune receptor signal and in turn, elicits a cytotoxic response from the immune effector cell against the target cell.

In particular embodiments, one or more immune effector cells, *e.g.*, T cells, are modified to express both the targeting component and the signaling component and an exogenous
25 lymphocyte receptor or engineered antigen receptor, *e.g.*, an engineered/exogenous TCR. In this case, the modified cells are administered to a subject in need thereof and home to the target cells via the interaction of the targeting component that binds a first target antigen and the immune receptor, which binds a second target antigen, wherein one or both target antigens are expressed on target cells or population of target cells. Interaction of the TCR with a target antigen on the
30 target cell may elicit a cytotoxic response from the immune effector cell against the target cell. A bridging factor is administered to the subject before the modified cells, about the same time as the modified cells, or after the modified cells have been administered to the subject. In the presence of the bridging factor, a complex forms between the targeting component that binds a first target

antigen, the bridging factor, and a signaling component that comprises a multimerization domain, optionally a linker polypeptide, and Fc γ , CD3 ϵ , CD3 δ or CD3 γ , or fragment thereof. Upon formation of the complex, the signaling and targeting components transduce an immunostimulatory signal to the immune effector cell that synergizes with the immune receptor
 5 signal and in turn, elicits or augments a cytotoxic response from the immune effector cell against the target cell.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers.

In particular embodiments, the modified immune effector cells contemplated herein are
 10 used in the treatment of solid tumors or cancers including, but not limited to: adrenal cancer, adrenocortical carcinoma, anal cancer, appendix cancer, astrocytoma, atypical teratoid/rhabdoid tumor, basal cell carcinoma, bile duct cancer, bladder cancer, bone cancer, brain/CNS cancer, breast cancer, bronchial tumors, cardiac tumors, cervical cancer, cholangiocarcinoma, chondrosarcoma, chordoma, colon cancer, colorectal cancer, craniopharyngioma, ductal
 15 carcinoma in situ (DCIS) endometrial cancer, ependymoma, esophageal cancer, esthesioneuroblastoma, Ewing's sarcoma, extracranial germ cell tumor, extragonadal germ cell tumor, eye cancer, fallopian tube cancer, fibrous histiosarcoma, fibrosarcoma, gallbladder cancer, gastric cancer, gastrointestinal carcinoid tumors, gastrointestinal stromal tumor (GIST), germ cell tumors, glioma, glioblastoma, head and neck cancer, hemangioblastoma, hepatocellular cancer,
 20 hypopharyngeal cancer, intraocular melanoma, kaposi sarcoma, kidney cancer, laryngeal cancer, leiomyosarcoma, lip cancer, liposarcoma, liver cancer, lung cancer, non-small cell lung cancer, lung carcinoid tumor, malignant mesothelioma, medullary carcinoma, medulloblastoma, meningioma, melanoma, Merkel cell carcinoma, midline tract carcinoma, mouth cancer, myxosarcoma, myelodysplastic syndrome, myeloproliferative neoplasms, nasal cavity and
 25 paranasal sinus cancer, nasopharyngeal cancer, neuroblastoma, oligodendroglioma, oral cancer, oral cavity cancer, oropharyngeal cancer, osteosarcoma, ovarian cancer, pancreatic cancer, pancreatic islet cell tumors, papillary carcinoma, paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pinealoma, pituitary tumor, pleuropulmonary blastoma, primary peritoneal cancer, prostate cancer, rectal cancer, retinoblastoma, renal cell
 30 carcinoma, renal pelvis and ureter cancer, rhabdomyosarcoma, salivary gland cancer, sebaceous gland carcinoma, skin cancer, soft tissue sarcoma, squamous cell carcinoma, small cell lung cancer, small intestine cancer, stomach cancer, sweat gland carcinoma, synovioma, testicular

cancer, throat cancer, thymus cancer, thyroid cancer, urethral cancer, uterine cancer, uterine sarcoma, vaginal cancer, vascular cancer, vulvar cancer, and Wilms Tumor.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers including, without limitation, non-small cell lung carcinoma, head and neck squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, gliomas, glioblastomas, and oligodendroglioma.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of solid tumors or cancers including, without limitation, non-small-cell lung cancer, metastatic colorectal cancer, glioblastoma, head and neck cancer, pancreatic cancer, and breast cancer.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of glioblastoma.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of liquid cancers or hematological cancers.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of B-cell malignancies, including but not limited to: leukemias, lymphomas, and multiple myeloma.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of liquid cancers including, but not limited to leukemias, lymphomas, and multiple myelomas: acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), myeloblastic, promyelocytic, myelomonocytic, monocytic, erythroleukemia, hairy cell leukemia (HCL), chronic lymphocytic leukemia (CLL), and chronic myeloid leukemia (CML), chronic myelomonocytic leukemia (CMML) and polycythemia vera, Hodgkin lymphoma, nodular lymphocyte-predominant Hodgkin lymphoma, Burkitt lymphoma, small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, marginal zone lymphoma, mycosis fungoides, anaplastic large cell lymphoma, Sézary syndrome, precursor T-lymphoblastic lymphoma, multiple myeloma, overt multiple myeloma, smoldering multiple myeloma, plasma cell leukemia, non-secretory myeloma, IgD myeloma, osteosclerotic myeloma, solitary plasmacytoma of bone, and extramedullary plasmacytoma.

In particular embodiments, the modified immune effector cells contemplated herein are used in the treatment of acute myeloid leukemia (AML).

Preferred cells for use in the methods contemplated herein include autologous/autogeneic ("self") cells, preferably hematopoietic cells, more preferably T cells,
5 and more preferably immune effector cells.

In particular embodiments, a method comprises administering a therapeutically effective amount of modified immune effector cells that express one or more engineered immune receptor components, and optionally an exogenous lymphocyte receptor or engineered antigen receptor or another targeting or signaling component, or a composition comprising the same, to a patient in
10 need thereof, and optionally also administering a bridging factor to the subject. In certain embodiments, the cells are used in the treatment of patients at risk for developing an immune disorder. Thus, particular embodiments comprise the treatment or prevention or amelioration of at least one symptom of an immune-related disease or disorder, *e.g.*, cancer or autoimmune disease, comprising administering to a subject in need thereof, a therapeutically effective amount
15 of the modified immune effector cells contemplated herein and, optionally, a bridging factor.

The quantity and frequency of administration of modified immune effector cells, targeting components, and/or bridging factor will be determined by such factors as the condition of the patient, and the type and severity of the patient's disease, although appropriate dosages and dose schedules may be determined by clinical trials.

20 In one illustrative embodiment, the effective amount of modified immune effector cells provided to a subject is at least 2×10^6 cells/kg, at least 3×10^6 cells/kg, at least 4×10^6 cells/kg, at least 5×10^6 cells/kg, at least 6×10^6 cells/kg, at least 7×10^6 cells/kg, at least 8×10^6 cells/kg, at least 9×10^6 cells/kg, or at least 10×10^6 cells/kg, or more cells/kg, including all intervening doses of cells.

25 In another illustrative embodiment, the effective amount of modified immune effector cells provided to a subject is about 2×10^6 cells/kg, about 3×10^6 cells/kg, about 4×10^6 cells/kg, about 5×10^6 cells/kg, about 6×10^6 cells/kg, about 7×10^6 cells/kg, about 8×10^6 cells/kg, about 9×10^6 cells/kg, or about 10×10^6 cells/kg, or more cells/kg, including all intervening doses of cells.

30 In another illustrative embodiment, the effective amount of modified immune effector cells provided to a subject is from about 2×10^6 cells/kg to about 10×10^6 cells/kg, about 3×10^6 cells/kg to about 10×10^6 cells/kg, about 4×10^6 cells/kg to about 10×10^6 cells/kg, about

5 5×10^6 cells/kg to about 10×10^6 cells/kg, 2×10^6 cells/kg to about 6×10^6 cells/kg, 2×10^6 cells/kg to about 7×10^6 cells/kg, 2×10^6 cells/kg to about 8×10^6 cells/kg, 3×10^6 cells/kg to about 6×10^6 cells/kg, 3×10^6 cells/kg to about 7×10^6 cells/kg, 3×10^6 cells/kg to about 8×10^6 cells/kg, 4×10^6 cells/kg to about 6×10^6 cells/kg, 4×10^6 cells/kg to about 7×10^6 cells/kg, 4×10^6 cells/kg to about 8×10^6 cells/kg, 5×10^6 cells/kg to about 6×10^6 cells/kg, 5×10^6 cells/kg to about 7×10^6 cells/kg, 5×10^6 cells/kg to about 8×10^6 cells/kg, or 6×10^6 cells/kg to about 8×10^6 cells/kg, including all intervening doses of cells.

One of ordinary skill in the art would recognize that multiple administrations of the compositions contemplated in particular embodiments may be required to affect the desired therapy. For example, a composition may be administered 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 or more times over a span of 1 week, 2 weeks, 3 weeks, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years, 5 years, 10 years, or more. Modified immune effector cells, engineered immune receptor components, and/or bridging factor may be administered in the same or different compositions; in one or more compositions at the same time; or more than one composition at different times. Modified immune effector cells, engineered immune receptor components (e.g., targeting components), and/or bridging factor may be administered through the same route of administration or different routes.

In certain embodiments, it may be desirable to administer activated T cells to a subject and then subsequently redraw blood (or have an apheresis performed), activate T cells therefrom, and reinfuse the patient with these activated and expanded T cells. This process can be carried out multiple times every few weeks. In certain embodiments, T cells can be activated from blood draws of from 10cc to 400cc. In certain embodiments, T cells are activated from blood draws of 20cc, 30cc, 40cc, 50cc, 60cc, 70cc, 80cc, 90cc, 100cc, 150cc, 200cc, 250cc, 300cc, 350cc, or 400cc or more. Not to be bound by theory, using this multiple blood draw/multiple reinfusion protocol may serve to select out certain populations of T cells.

In one embodiment, a method of treating a subject diagnosed with an immune-related disease or disorder (e.g., cancer or autoimmune disease), comprises removing immune effector cells from the subject, modifying the immune effector cells by introducing one or more vectors encoding one or more engineered immune receptor components into the cell and producing a population of modified immune effector cells, and administering the population of modified immune effector cells to the same subject. In a preferred embodiment, the immune effector cells comprise T cells.

In one embodiment, a method of treating a subject diagnosed with a cancer or autoimmune disease, comprises administering one or more vectors encoding one or more engineered immune receptor components to the subject. In a preferred embodiment, the immune effector cells comprise T cells.

5 In one embodiment, a method of treating a subject diagnosed with a cancer, comprises removing immune effector cells from the subject, modifying the immune effector cells by introducing one or more vectors encoding one or more engineered immune receptor components and optionally an exogenous lymphocyte receptor or engineered antigen receptor or another targeting or signaling component into the cell and producing a
10 population of modified immune effector cells, and administering the population of modified immune effector cells to the same subject. In a preferred embodiment, the immune effector cells comprise T cells.

In one embodiment, a method of treating a subject diagnosed with a cancer, comprises administering one or more vectors encoding one or more engineered immune receptor
15 components to the subject. In a preferred embodiment, the immune effector cells comprise T cells.

The methods for administering the cell compositions contemplated in particular embodiments include any method which is effective to result in reintroduction of *ex vivo* modified immune effector cells or reintroduction of modified progenitors of immune effector
20 cells that upon introduction into a subject differentiate into mature immune effector cells. One method comprises modifying peripheral blood T cells *ex vivo* by introducing one or more vectors encoding one or more engineered immune receptor components and optionally an exogenous lymphocyte receptor or engineered antigen receptor or another targeting or signaling component into the cell and returning the transduced cells into the
25 subject.

The methods for administering the cell compositions contemplated in particular embodiments include any method which is effective to result in reintroduction of *ex vivo* modified immune effector cells or reintroduction of modified progenitors of immune effector cells that upon introduction into a subject differentiate into mature immune effector cells.
30 One method comprises modifying peripheral blood T cells *ex vivo* by introducing one or more vectors encoding one or more engineered immune receptor components and optionally an exogenous lymphocyte receptor or engineered antigen receptor or another

targeting or signaling component into the cell and returning the transduced cells into the subject.

- The methods for administering the vector compositions contemplated in particular embodiments include any method which is effective to result in *in vivo* modified immune effector cells.

J. SEQUENCE LISTING

SEQ ID NO:	Description	Sequence
1	FRB*	ILWHEMWHEGLEEASRLYFGERNVKGMEFVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEQEWCRKYMKSGNVKDLLQAWDLYYHVFRISK
2	FRB	ILWHEMWHEGLEEASRLYFGERNVKGMEFVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEQEWCRKYMKSGNVKDLTQAWDLYYHVFRISK
3	FKBP12	GVQVETISPGDGRTFPKRGQTCVVHYTGMLDGKKFDSRDRNPKFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGH?GIIPPHATLVFDVELLKLE
4	FKBP12 F36V	GVQVETISPGDGRTFPKRGQTCVVHYTGMLDGKKVDSSRDRNPKFKFMLGKQEVIRGWEEGVAQMSVGQRAKLTISPDYAYGATGH?GIIPPHATLVFDVELLKLE
5	CH3-Ab (S354C T366W)	GQPREPQVYTLPPCRDELTKNQVSLWCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHREALHNHYTQKSLSLSPGK
6	CH3-IA (Y349C T366S L368A Y407V)	GQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLVSKLTVDKSRWQQGNVFSCSVMHREALHNHYTQKSLSLSPGK
7	CH3-DE (L351D L368E)	GQPREPQVYTDPPSRDELTKNQVSLTCEVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHREALHNHYTQKSLSLSPGK
8	CH3-KK (L351K T366K)	GQPREPQVYTKPPSRDELTKNQVSLKCLVKGFYPSDIAVEWESNGQPENNYKTTTPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHREALHNHYTQKSLSLSPGK
9	CH3-GA (SEED 1)	GQPREPQVYTLPPPSEELALNELVTLTCLVKGFYPSDIAVEWLQGSQELPREKYLTWAPVLDSDGSFFLYSILRVAEADWKKGDTFSCSVMHREALHNHYTQKSLSLDR
10	CH3-AG (SEED 2)	GQPFREPVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNGQPENNYKTTTPSRQEPSQGTTFFAVTSKLTVDKSRWQQGNWFSQSVMHREALHNHYTQKTISL
11	1xG4S linker	GGGGS
12	2xG4S linker	GGGSGGGGS
13	3xG4S linker	GGGSGGGSGGGGS
14	4xG4S linker	GGGSGGGSGGGSGGGGS
15	5xG4S linker	GGGSGGGSGGGSGGGSGGGGS
16	Linker	DGGGS
17	Linker	TGEKP
18	Linker	GGRR
19	Linker	EKGSSGSGSESKVD
20	Linker	KESGSVSSEQLAQFRSLD
21	Linker	GGRRGGGS
22	Linker	LRQRDGERP
23	Linker	LRQKDGGGGERP
24	Linker	LRQKDGGGSGGGGERP
25	Linker	GSTSGSGKPGSGEGSTKG
26	linker	GSTSGSGKSSEGSSTKG
27	linker	GSTSGSGKSSEGKG
28	linker	GSTSGSGKPGSGEGS
29	linker	GGGS
30	yuTCR linker (uLNK)	LEKT

31	uLNK + G4S linker	LEKTGGGGS
32	CD3ε	DGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNIG GDEDDKNIGSDEHDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYL RARVENCENMEMDVM SVATIVIVDICTTGGLLLLVYYWSKNRKA KAKPVTRGAGAGGRQGRGQNKERPPVPNPDYEPTRKQGQRDLYSGL NQRR
33	CD3γ	QSIKGNHLVKVYDYQEDGSVLLTCDAEAKNITWFKDGKMGIFLTE DKKKWNLGSNAKDPRGMYQCKGSKQKSKPLQVYYRMCQNCIELNA ATISGFLFAEIVSIFVLAVGVYFIAGQDGVQRSDRSDKQTLTND QLYQPLKDREDDQYSHLQGNQLRRN
34	CD3δ	EHSTFLSGLVLATLLSQVSPFKIPIEELEDVFNVCNTSITWVEG TVGTLLSDITRLDLGKRILDPRIYRCNGTDIYKDKESTVQVHYR MCQSCVELDPATVAGIIVTDVIATLLALGVFCFAGHETGRLSGA ADTQALLRNDQVYQPLRDRDDAQYSHLGGNWARNK
35	FcεR1γ - v1	GEPLCYILDAILFLYGIVLTLLYCRCLKIQVRKAAITSYEKSDGVY TGLSTRNQETYETLKHEKPPQ
36	FcεR1γ - v2	LGEPLCYILDAILFLYGIVLTLLYCRCLKIQVRKAAITSYEKSDG VYTGLSTRNQETYETLKHEKPPQ
37	Igα/CD79a (BCR)	LWMHKVPASLMVSLGEDAHFQCPHNSNNANVTWVRVLHGNYTWP PEFLGPGEDPNGTLIIQNVNKS HGGIYVCRVQEGNESYQQSCGT YLRVRQPPPRPFLDMGEGTKNRIITAEGIILLFCVAVPGTLLLFK RWQNEKLGLDAGDEYEDENLYEGLNLD DCSMYEDISRGLQGT YQDVGLNIGDVQLEK
38	Igβ/CD79b (BCR)	MARLALSPVPSHWMVALLLLLSGTEPTTRPVGFALISSCLGPAAL PPACSTLLCLSLFTACLPLMALGPGSVGVSTW
39	DAP10	QTTPGERSSLPFYPGTSGSCSGCSLSLPLLAGLVAADAVASLL IVGAVFLCARPRRSPAQEDGKVYINMPGRG
40	DAP12	LRPVQAQAQSDCSCSTVSPGVLAGIVMGDLVLTVLIALAVYFLGR LVPRGRGAEEAATRKQRI TETESPYQELQGRSDVYSLNTQRPY YK
41	Minimal CD4 hinge	SNIKVLPWTSTPVQP
42	Minimal CD28 hinge	KGKHLCPSPFLFPGPSKP
43	IgG4 hinge	ESKYGPPCPSCP
44	CD8 hinge	TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD
	Hinge linker	GGR
45	CD4 transmembrane	MALIVLGGVAGLLFLFIGLGIFF
46	CD28 transmembrane	FWVLVVVGVLACYSLLVTVAFIIFWV
47	CD8 transmembrane	AGTGSDIYIWAFLAGTCGVLLLSLVIT
48	Truncated intracellular CD4 - v1	CVRC
49	Truncated intracellular CD4 - v2	CVRCRHHRRQ
50	anti-BCMA_scFv_1	DIVLTQSPPSLAMS LGKRATISCRASESVTILGSHLIHWYQQKPG QPPTLLIQLASNVQTVGPARGSGSGSRTDFTLTIDPVEEDDVAVY YCLQSRITPRTFGGKLEIKGSTSGSGKPGSGEGSTKGQQLVQ SGPELKKPGETVKISCKASGYFTDYSINWVKRAPGKGLKWMGWI NTETREPAYAYDFRGRAFSLETSASTAYLQINNLYEDTATYFC ALDYSYAMDYWGQGSTVTVSS
51	anti-BCMA_scFv_2	DIVLTQSPASLAVSLGERATINCRASESVSVIGAHLIHWYQQKPG QPPKLLIYLASNLETGVPARGSGSGSRTDFTLTISLQAEDAAIY YCLQSRIFPRTFGQTKLEIKGSTSGSGKPGSGEGSTKGQQLVQ SGSELKKPGASVKVSCASGYFTDYSINWVRQAPGQGLEWMGWI NTETREPAYAYDFRGRFVSLDTSVSTAYLQISSLKAEDTAVYYC ARDYSYAMDYWGQGTLLVTVSS
52	anti-BCMA_scFv_3	DIQMTQSPSSLSASVGDRTITCRASQDIRNYLGWYQQKPKGAPK VLI FAASSLQSGVPSRFSGSGSGTDFTLTISLQPEDFATYYCLQ DYIYPWTFAGQTKVEIKGGGSGGGGSGGGGSGVQLVSGGGVQ PGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWVAIVSYDGRNK NYADSVKGRFTISRDNKNTLYLQMNSLRAEDTAVYYCAREGEAT YYDILTGFEDYWGQGTLLVTVSS
53	anti-CD19_scFv	DIQMTQTTSSLSASLGDRVTISCRASQDISKYNWYQQKPDGTVK LLIYHTSRHSGVPSRFSGSGSGTDYSLTISNLEQEDATYFCQQ GNTLPYTFGGGKLEITGGGSGGGGSGGGGSEVKLQESGGLVA PSQSLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGSETTY

		YNSALKSRSLTIKDNSKSQVFLKMNSLQTDITAIYYCAKHYYYGG SYAMDYWGQGTSTVTSS
54	anti-CD20_scFv_1	EVQLQQSGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGQGL EWIGAIYPNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSED SADYYCARSNYYGSSYWFDFVWGAGTTVTVSSGGGGSGGGSGGG GSDIVLTQSPAILSPGKVTMTCRASSSVNYMDWYQKKEGSSP KPWIYATSNLASGVPARFSGSGSGTSYSLTISRVEAEDAATYYCQ QWSFNPPTFGGGTKLEIK
55	anti-CD20_scFv_2	QVQLQQPGAELVKPGASVKMSCKASGYTFTSYNMHWVKQTPGRGL EWIGAIYPNGDTSYNQKFKGKATLTADKSSSTAYMQLSSLTSED SAVYYCARSTYYGGDWYFNVWGAGTTVTVSAGGGSGGGSGGGG SQIVLSQSPAILSPGKVTMTCRASSSVSYIHWYQKPGSSPK PWIYATSNLASGVPVRFSGSGSGTSYSLTISRVEAEDAATYYCQ WTSNPPTFGGGTKLEIKR
56	anti-CD20_scFv_3	QVQLVQSGAEVKKPGSSVKVSKASGYAFSYSWINWVRQAPGQGL EWMGRIFPGDGDITDNGKFKGRVTITADKSTSTAYMELSSLRSED TAVYYCARNVFDGYLVYWGQGLTVTVSSGGGGSGGGSGGGSD IVMTQTPLSLPVPTEGEPASISCRSSSKSLHNSGITYLYWYQKPG QSPQLLIYQMSNLVSGVPDRFSGSGSGTDFTLTKISRVEAEDVGVY YCAQNLELPYTFGGGTKVEIKRTV
57	anti-CD22_scFv	QVQLQQSGPGLVKPQSLTCAISGDSVSSNSAAWNRIQSPSR GLEWLGRTYYRSKWYNDYAVSVKSRITINPDTSKNQFSLQLNSVT PEDTAVYYCAREVTGLEDADFIDWGQGTMTVTVSSGGGGSDIQMTQ SPSSLSASVGDRTITCRASQTIWSYLNWYQRPKAPNLLIYAA SSLQSGVPSRFSGRSGTDFTLTISSLQAEDFATYYCQSYSIPO TFGQGTKEIK
58	anti-CD33_scFv	EIVLTQSPGSLAVSPGERVTMSCKSSQSVFFSSSQKNYLAWYQQI PGQSPRLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQPEDLA IYYCHQYLSSRTFGQGTKEIKGGGGSGGGSGGGSGVQLQQPG AEVVKPGASVKMSCKASGYTFTSYIHWIKQTPGQGLEWVGVIYP GNDDISYNQKFKGKATLTADKSSSTAYMQLSSLTSEDSAVYYCAR EVRRLRYFDVWGQGTMTVTVSS
59	anti-CD79A_scFv	DVLTMTQIPLSLPVSIGDQASISCRSSQSIHNSGNTYLEWYQKP GQSPKLLIYKVSNRFSGVPDRFSGSGSGTDFTLTKISRVEAEDLG VYCFQGSHPVFTFGSGTKLEIKRGGGGSGGGSGGGSGVQLQQS GPELVKPGASVKISCKASGYTFSTSWMNWVKQRPQGQLEWIGRIY PGDGDITNYNGKFKGKATLTADKSSNTAYMQLSSLTSDSAVYFCE RFYYGNTEAMDYWGQGTSTVTSS
60	anti-CD79B_scFv_1	QIQLVQSGPELKKPGETVKISCKASGYTFTDYSMHWVKQAPGEG LKWGWINTETGEPTYADDFKGRFAFSLTSASTAYLQINLNKNE TATYFCYYGSYWGQGLTVTVSAGGGSGGGSGGGSGDIIVLTQSP ASLAVSLGQRATISCKASQSVDDYDGDGYMDWYQKPGQPPKLLIF AASNLSKGIIPARFSGSGSGTDFTLNIHPVEEEDAATYYCQQTNEY PWTFGGGTKLEIK
61	Anti-CD79B_scFv_2	DIQLTQSPSSLSASVGDRTITCKASQSVDEGDSFLNHYQQKPG KAPKLLIYAASNLESVPSRFSGSGSGTDFTLTISLQPEDFATY YCQQSNEDPLTFGQGTKEIKRGGGGSGGGSGGGSEVQLVESG GGLVQPGGSLRLSCAASGYTFSSYWI EWVRQAPGKGLEWIGEILP GGGDTNYNEIFKGRATFSADTSKNTAYLQMNSLRAEDTAVYYCTR RVPRIRLDYWGQGLTVTVSS
62	anti-B7H3_scFv	DIVMTQSHKFMSTSIGARVSICTKASQDVRTAVAWYQKPGQSPK LLIYSASYRYTGVPDRFTGSGSGTDFTFTISSVQAEDLAVYYCQ HYGTPPWTFGGGTKEIKGGGGSGGGSGGGSEVQLVESGGGLV KPGGSLKLSCEASRTTFSSYAMSWVRQTPKRLWVAASGGGRY TYYPDSMKGRFTISRDNANKFLYLQMSSLRSEDTAMYYCARHYDG YLDYWGQGTTLTVSSTR
63	anti-Muc16_scFv	VKLQESGGGFVKPGGSLKVS CAASGTFSSYAMSWVRLSPEMRL EWWATISSAGGYIFYSDSVQGRFTISRDNANKTLHLQMGSLRSGDT AMYYCARQGFNGYGDYAMDYWGQGTMTVTVSSGGGGSGGGSGGG GSDIELTQSPSSLAVSAGEKVTMSCKSSQSLNSRTRKNQLAWYQ QKPGQSPPELLIYWASTRQSGVPDRFTGSGSGTDFTLTISVQAED LAVYYCQSYNLLTFGPGTKLEVKR
64	anti-HER2_scFv	DIQMTQSPSSLSASVGDRTITCRASQDVNTAVAWYQKPGKAPK LLIYSASFLYSGVPSRFSGSRSGTDFTLTISLQPEDFATYYCQ HYTTPPTFGQGTKEIKGSTSGSGKPGSGEGSGEVQLVESGGGLV QPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGY TRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGD GFYAMDVWGQGLTVTVSS

65	anti-EGFR_scFv	DILLTQSPVILSVSPGERVVSFSCRASQSIGTNIHWYQQRNGSPR LLIKYASESISGIPSRFSGSGSGTDFTLINSINSVESEDIADYYCQQ NNNWPPTTFAGAGTKLELKGGGGSGGGSGGGGSQVQLKQSGPGLVQ PSQSLSTICTVSGFSLTNYGVHWRQSPGKGLEWLGVIWSGNGTD YNTPTTSRLSINKDNSKSQVFFKMNSLQSNDAIYYCARALTYD YEFAYWGQGLTVTVSS
66	anti-FN-EDB_scFv	EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGL EWVSSISGSSGTTYADSVKGRFTISRDNKNTLYLQMNSLRAED TAVYYCAKPPFPYFDYWGQGLTVTVSSGDSSGGSGGASEIVLTQS PGLTSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLIIYYA SSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPP TFGQGTKEIK
67	anti-CLDN18.2_scFv	QIQLVQSGPELKKPGETVKISCKASGYFTFTNYGMNWVKQAPGKGL KWMGWINTNTGEPTYAEFEKGRFAFSLTSASTAYLQINNKNED TATYFCARLGFNGAMDYWGQGSTVTVSSGGGGSGGGSGGGSDI VMTQSPSSLTVTAGEKVTMSCKSSQSLNSGNQKNYLTWYQQKPG QPPKLLIYWASTRESGVPDRFTGSGSGTDFTLTISVQAEDLAVY YQNDYSYPLTFGAGTKLELK
68	anti-DLL3_scFv	QVQLQESGPGLVKPSSETLSLTCTVSGDSISSYWTWIRQPPGKGL EWIGYIYSGTTNYPNLSKSRVTISVDTSKSKQFSLKLSVTAADT AVYYCASIAVRGFFFDYWGQGLTVTVSSGGGGSGGGSGGGSEI VLTQSPGTLTSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRL LIYGASTRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQY GTSPLTFGGGTKEIK
69	anti-FLT3_scFv_1	QVTLKESGPVLVKPTETLTLTCTVSGFSLINARMGVSWIRQPPGK ALEWLAHIFSNAEKSYRTSLKSRLTISKDTSKSQVVLMTNMDPV DTATYYCARIPGYGGNGDYHYYGMDVWGQGTTVTVSSGGGGSGGG SGGGGGDIQMTQSPSSLSASLGDRVTITCRASQGIKRLDLGWYQQ KPGKAPKRLIYASSTLQSGVPSRFSGSGSGTEFTLTISLQPEDF ATYYCLQHNFPWTFGQGTKEIK
70	anti-FLT3_scFv_2	EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYGMHWVRQAPGKGL EWVAVISYDGSNKYYADSVKGRFTISRDNKNTLYLQMNSLRAED TAVYYCANLAPWAAAYWGQGLTVTVSSGGGGSGGGSGGGSEIVL TQSPSLSPVTPGEPASISCRSSQSLHNSNGYNLYLDWYLQKPGQSP QLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAEDVGVIYCM QALQTPHTFGQGTKEIK
71	anti-ROR1_scFv	DIQMTQSPSFLSASVGDRTVINCKASQNIIDRYLNWYQQKLGAPK RLLYNTNKLQGTGIPSRFSGSGSATDFTLTISLQPEDFATYFCLQ YNSLPLTFGSGTKLEIKGGGGSGGGSGGGGSEVQLVESGGGLVQ PGRSLKLSCAASGFI FSEHNMAWVRQAPKKGLEWVATISDDGRNT YYRDSMRGRFTISRANARSTLYLQLDSLRS EDTATYYCASHRYNL FDSWGQGVMTVSS
72	anti-CD33_VHH_1	EVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKER LVAEISGVGDTNYYAASLADRFTVSRDNKNTVYVLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGLTVTVK?
73	anti-CD33_VHH_2	EVQLVESGGGEVQPGGSLRLSCAASGRTFSGYIMGWFRQAPGKER ELVARISGNNLSTEYAESVKGRFTISRDNKNTLYLQMSSLRAED TAVYYCAAEDYSSGDFVYWGQGLTVTVK?
74	anti-CD33_VHH_3	EVQLVESGGGEVQPGGSLRLSCAASGSTLNIDHIGWYRQAPGKER ELVGVISSGAGPNYAESVKGRFTISRDNKNTVYVLQMSSLRAEDT AVYYCNAWIDYGSGLPQNYWGQGLTVTVK?
75	anti-CLL1_VHH_1	EVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKER EWVAGITNNGYSTAYAESVKGRFTISRDNKNTIYLQMSSLRAED TAVYYCHADLTAKAYDVEYAWGQGLTVTVK?
76	anti-CLL1_VHH_2	EVQLVESGGGEVQPGGSLRLSCAASGLLFSIYDMNWYRQAPGKER EWVAGITNNGYSTAYAESVKGRFTISRDNKNTVYVLQMSSLRAED TAVYYCHTDEWGREYWGQGLTVTVK?
77	anti-CD123_VHH_1	EVQLVESGGGEVQPGGSLRLSCTASGRAINMYAMGWFRQAPGKER EFVAAINWNGAYTQYAESVKGRFTISRDNKNTLYLQMSSLRAED TAVYYCSADADYNTYVSPNKRVS YWGQGLTVTVK?
78	anti-CD123_VHH_2	EVQLVESGGGLVQPGGSLRLSCAASGRAINMYAMGWFRQAPGKER EFVSAINWNAARTYAYAESVKGRFTISRDNKNTLYLQMSSLRAED TAVYYCAASGRWSAAVPSGEDQYNFWGQGLTVTVK?
79	anti-CD20_VHH	QVQLQESGGGLVQAGGSLRLSCAASGRTFSNYNMGWFRQAPGKER EFVAAIDWSSGSPYYAASVRGRFTISRDNKNTVYVLQMNSLK?ED TAVYYCAAPLSYGSTWLADYWGQGTQTVTVSS

80	anti-EGFR_VHH	QVKLEESGGGSVQTGGSLRLTCAASGRTSRSYGMGWFRQAPGKER EFVSGISWRGDSGTGYADSVKGRFTISRDNAKNTVDLQMNLSLK?ED TAIYYCAAAGSAWYGTLYEYDYWGQGTQVTVSS
81	anti-BCMA_VHH_1	QVKLEESGGGLVQAGRSLRLSCAASEHTFSSHVMGWFRQAPGKER ESVAVIGWRDISTSADSVKGRFTISRDNAKKTLYLQMNLSLK?ED TAVYYCAARRIDAADFDSWGQGTQVTVSS
82	anti-BCMA_VHH_2	EVQLVESGGGLVQAGGSLRLSCAASGRTFTMGWFRQAPGKEREFV AAISLSPTLAYYAESVKGRFTISRDNAKNTVVLQMNLSLKPEDTAL YYCAADRKSVMISIRPDYWGQGTQVTVSS
83	anti-CD19_VHH	QVKLEESGGELVQPGGPLRLSCAASGNI F SINRMGWYRQAPGKQR AFVASITVRGITNYADSVKGRFTISVDKSKNTIY LQMNALKPEDT AVYYCNAVSSNRDPDYWGQGTQVTVSS
84	PD1 ectodomain	NPPTFSPALLVVTGEDNATFTCSFSNTSESFVLNWRMSPSNQTD KLAAPFEDRSQPGQDSRFRTVQLPNGRDFHMSVVRARRNDSGYTL CGAISLAPKAQIKESLRAELRVTE
85	PD1 high affinity ectodomain	NPPTFSPALLVVTGEDNATFTCSFSNTSESFVLNWRMSPSNQTD KLAAPFEDRSQPGQDSRFRTVQLPNGRDFHMSVVRARRNDSGYTL CGAISLAPKVQIKESLRAELRVTE
86	Human A Proliferation- Inducing Ligand (APRIL)	SVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDA GVYLLYSQVLFQDVTFTMGQVVSREGQGRQETLFRICIRSMPSHPD RAYNSCYSAGVFHLHQGDILSVII PRARAKLNLS PHGTFLGFVKL
87	Trimerized human APRIL	SVLHLVPINATSKDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDA GVYLLYSQVLFQDVTFTMGQVVSREGQGRQETLFRICIRSMPSHPD RAYNSCYSAGVFHLHQGDILSVII PRARAKLNLS PHGTFLGFVKL GGGGSGGGSGGGSSVLHLVPINATSKDDSDVTEVMWQPALRRG RGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQVVSREGQGRQ ETLFRICIRSMPSHPDRAYNSCYSAGVFHLHQGDILSVII PRARAK LNLS PHGTFLGFVKLGGGGSGGGSGGGSSVLHLVPINATSKDD SDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVT FTMGQVVSREGQGRQETLFRICIRSMPSHPDRAYNSCYSAGVFHLH QGDILSVII PRARAKLNLS PHGTFLGFVKL
88	NKG2D membrane protein	FNQEVQIPLTESYCGPCPKNWICYKNNCYQFFDESKNWYESQASC MSQNASLLKVYSKEDQDILLKLVKSYHWMGLVHIPTNGSWQWEDGS ILSPNLLTIIEMQKGDICALYASSFKGYIENCSTPNTYICMQRTV
89	anti-CD33_VHH_1_CDR1	RSSGIDVMG
90	anti-CD33_VHH_1_CDR2	EISGVGDTN
91	anti-CD33_VHH_1_CDR3	HSFLDLVGA
92	anti-CLL1_VHH_1_CDR1	GFLEFSIYDMN
93	anti-CLL1_VHH_1_CDR2	GITNNGYSTA
94	anti-CLL1_VHH_1_CDR3	DLTKAYDVEYA
95	IgK signal sequence	ETPAQLLFLLLWLDPDTTG
96	CD8 signal sequence	ALPVTALLPLALLLHAAAP
97	PD1 signal sequence	QIPQAPWPVVWAVLQLGWRPGW
98	41BB intracellular signaling domain	KRGRKKLLYIFKQPFMRPVQTTEEDGCSCRFPEEEEGGCEL
99	CD28 intracellular signaling domain	RSKRSRLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS
100	CD4 coreceptor domain	CVRCRHHRRQAERMSQIKRLLEKKTQCPCPHRFQKTCSP I
101	CD8 coreceptor domain	LYCNHRNRRRVCKCPRPVVKSGDKPSLSARYV
102	LAT domain	HCHRLPGSYDSTSSDSLYPRGIQFKRHTVAPWPAYPPVTSYPP LSQPDLLPIPRSPQPLGGSHRTPSSRRSDGANSVASYENEGASG IRGAQAGWGVWGPSWTRLTPVSLPPEPACEDADEDEDDYHNPGYL VVLDPDSTPATSTAAPSAPALSTPGIRDSAFSMESIDYVNVPESG ESAEASLDGSREYVNVSQELHPGAAKTEPAALSSQEAEEVEEEGA PDYENLQELN
103	IL7 receptor alpha signaling domain	KKRIKPIVWPSLPDHKKTLEHLCKK?RKNLNVSFNPESFLDCQIH RVDDIQARDEVEGFLQDTFPQOLEESEKORLGGDVQSPNCPSEDV VITPESFGRDSSITCLAGNVSACDA?ILSSSRSLDCRESGKNGPH VYQDLLLSLGTNTSLTPPPFSLQSGILTLNPVAQQQPIILSLGSN QEEAYVTMSSFYQNQ
104	IL2 receptor beta signaling domain, truncated	NCRNTGPWLKKVLCNTPDPSKFFS QLSSEHGGDVQKWLSSPFPS SSFSPGGLAPEISPLEVLERDKVTQLL
105	IL2 receptor beta signaling domain	NCRNTGPWLKKVLCNTPDPSKFFS QLSSEHGGDVQKWLSSPFPS SSFSPGGLAPEISPLEVLERDKVTQLLQDDKVPAPASLSSNHS L

		TSCFTNQGYFFFHLPDALEIEACQVYFTYDPYSEEDPDEGVAGAP TGSSPQPLQPLSGEDDAYCTFPSRDDLLLFSPSLGSGSPSTAP GGSGAGEERMPPSLQERVPRDWDPPQ?LGPPTPGVPDLVDFQP?PE LVLRAGEEVPDAGPREGVSPFWSR?PGQGEFRALNARLPNTDA YLSLQELQGQDP?THLV
106	Common gamma chain signaling domain	ERTMPRIPTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDYSER LCLVSEIPPKGALGEGPGASPCNQHSPIYWAPPCTYTLKPET
107	FRB.3xG4S.CD3e	WHEMWHEGLEEASRLYFGERNVKGMFVLEPLHAMMERGPQTLKE TSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRIS KGGGSGGGGSGGGSGDNEEMGGITQTPYKVISISETTVILTCPQ YPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYY VCYPRGSKPEDANFYLYLRARVCENCMEMDVMSVATIVIVDICIT GGLLLLIVYYWSKNRKAKAKPVTRGAGAGGRQGRQNKERPPVP?NP DYEPIRKQORDLYSGLNQRRRI
108	FRB.3xG4S.CD3g	WHEMWHEGLEEASRLYFGERNVKGMFVLEPLHAMMERGPQTLKE TSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRIS KGGGSGGGGSGGGGSGSISGNHLVKVYDYQEDGSVLLTCDAAEAK NITWFKDGKMI?FLTEDKKKWNLGSNAKDPGRMYQCKGSGNSKSP LQVYYRMCQNCIELNAATISGFLFAEIVSIFVLAVGVYFIAGQDG VRQSRASDKQTL?LPNDQLYQPLKDREDDQYSHLQGNQLRRN
109	FKBP12.G4S.CD3e	QVETISPGDGRTPFKRGQTCVVHYTGMLLEDGKKFDSRRDNK?FK FMLGKQEVIRGWEEGVAQMSVQRAKLTISPDIYAGATGHPGIIP PHATLVFDVELLKLGGGSGDNEEMGGITQTPYKVISISETTVIL TCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQ SGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDVMSVATIVIVD ICITGGLLLLIVYYWSKNRKAKAKPVTRGAGAGGRQGRQNKER?PP VPNPDIYEPPIRKQORDLYSGLNQRRRI
110	FRB.G4S.CD3e	WHEMWHEGLEEASRLYFGERNVKGMFVLEPLHAMMERGPQTLKE TSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRIS KGGGSGDNEEMGGITQTPYKVISISETTVILTCPQYPGSEILWQH NDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPE DANFYLYLRARVCENCMEMDVMSVATIVIVDICTITGGLLLLIVYYW SKNRKAKAKPVTRGAGAGGRQGRQNKERPPVPNPDIYEPPIRKQOR DLYSGLNQRRRI
111	FRBstar.3xG4S.CD3e	WHEMWHEGLEEASRLYFGERNVKGMFVLEPLHAMMERGPQTLKE TSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRIS KGGGSGGGGSGGGSGDNEEMGGITQTPYKVISISETTVILTCPQ YPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYY VCYPRGSKPEDANFYLYLRARVCENCMEMDVMSVATIVIVDICIT GGLLLLIVYYWSKNRKAKAKPVTRGAGAGGRQGRQNKERPPVP?NP DYEPIRKQORDLYSGLNQRRRI
112	IACH3.3xG4S.CD3e	GQPREPQVCTLPSPRDELTKNQVSLSCAVKGFYPSDIAVEWESNG QPENNYKTT?PVLDSDGSFFLVSKLTVDKSRWQQGNVFS?CSVMHE ALHNHYTQKSLSLSPGKGGGSGGGGSGGGSGDNEEMGGITQTP YKVISISETTVILT?TCPQYPGSEILWQHNDKNIGGDEDDKNIGSDED HLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEM DVMSVATIVIVDICTITGGLLLLIVYYWSKNRKAKAKPVTRGAGAGG RQGRQNKERPPVPNPDIYEPPIRKQORDLYSGLNQRRRI
113	CH3AG.3xG4S.CD3e	GQPFREPVHLLPPSREEMTKNQVSLTCLARGFYPKDIAVEWESNG QPENNYKTT?SRQEPSQGTTF?FAVTSKLTVDKSRWQQGNWF?SCSV MHEALHNHYTQKTI?SLGGGSGGGGSGGGSGDNEEMGGITQTPY KVISISETTVILT?TCPQYPGSEILWQHNDKNIGGDEDDKNIGSDEDH LSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMD VMSVATIVIVDICTITGGLLLLIVYYWSKNRKAKAKPVTRGAGAGGR QGRQNKERPPVPNPDIYEPPIRKQORDLYSGLNQRRRI
114	CH3DE.3xG4S.CD3e	GQPREPQVYTDPPSPRDELTKNQVSLTCEVKGFYPSDIAVEWESNG QPENNYKTT?PVLDSDGSFFLYSKLTVDKSRWQQGNVFS?CSVMHE ALHNHYTQKSLSLSPGKGGGSGGGGSGGGSGDNEEMGGITQTP YKVISISETTVILT?TCPQYPGSEILWQHNDKNIGGDEDDKNIGSDED HLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEM DVMSVATIVIVDICTITGGLLLLIVYYWSKNRKAKAKPVTRGAGAGG RQGRQNKERPPVPNPDIYEPPIRKQORDLYSGLNQRRRI
115	FRBstar.2xG4S.FCER1G	WHEMWHEGLEEASRLYFGERNVKGMFVLEPLHAMMERGPQTLKE TSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRIS KGGGSGGGGSGEPLCYILDAILFLYGIVLTLLYCRLLKIQVRKAA ITSYEKSDGVYTGSTRNQET?YETLKHEKPPQ

116	antiCD33.G4S.FKBP.minCD28hinge.CD28tm.CD4ic	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTTLVTVKPGGGSGVQVETISPGDGRT FPKRGQTCVVHYTGMLLEDGKKFDS SRDRNKP FKFMLGKQEVIRGW EEGVAQMSVGQRAKLTI SPDYAYGATGHPGII PPHATLVFDVELL KLEKKGHLCPSP LFPGPSKPFWVLVVGVLACYSLLVTVAFIIF WVCVRCRHRRRQ
117	antiCD33.G4S.FKBP.minCD4hinge.CD4tm.CD4ic	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTTLVTVKPGGGSGVQVETISPGDGRT FPKRGQTCVVHYTGMLLEDGKKFDS SRDRNKP FKFMLGKQEVIRGW EEGVAQMSVGQRAKLTI SPDYAYGATGHPGII PPHATLVFDVELL KLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR HRRRQ
118	antiCD33.G4S.FKBP.GGR.CD4tm.CD4ic	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTTLVTVKPGGGSGVQVETISPGDGRT FPKRGQTCVVHYTGMLLEDGKKFDS SRDRNKP FKFMLGKQEVIRGW EEGVAQMSVGQRAKLTI SPDYAYGATGHPGII PPHATLVFDVELL KLEGGRMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
119	FRB.2xG4S.antiCD33.minCD4hinge.CD4tm.CD4ic	WHEMWHEGLEEASRLYFGERNVKGMFVLEPLHAMMERGPQTLKE TSFNQAYGRDLMEAEQEWCRKYMKSGNVKDLTQAWDLYYHVFRRI S KGGGGSGGGGSEVQLVESGGGEVQPGGSLRLSCAASRSGIDVMG WYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDNAKNTVYL QMSSLRAEDTAVYYCNAHSFLDLVGAWGQGTTLVTVKPSNIKVLPT WSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
120	FKBP.2xG4S.antiCD33.minCD4hinge.CD4tm.CD4ic	GVQVETISPGDGRTFPKRGQTCVVHYTGMLLEDGKKFDS SRDRNKP FKFMLGKQEVIRGWEEGVAQMSVGQRAKLTI SPDYAYGATGHPGI I PPHATLVFDVELL KLEGGGGSGGGGSEVQLVESGGGEVQPGGSL RLSCAASRSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLA DRFTVSRDNAKNTVYLQMSSLRAEDTAVYYCNAHSFLDLVGAWGQ GTLVTVKPSNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIF FCVRCRHRRRQ
121	antiCLL1.G4S.FKBP.minCD4hinge.CD4tm.CD4ic	EVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKER EWWAGITNNGYSTAYAESVKGRFTISRDNANTYILQMSSLRAED TAVYYCHADLT KAYDVEYAWGQGTTLVTVKPGGGSGVQVETISPG DGRTFPKRGQTCVVHYTGMLLEDGKKFDS SRDRNKP FKFMLGKQEV IRGWEEGVAQMSVGQRAKLTI SPDYAYGATGHPGII PPHATLVFD VELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFC VRCRHRRRQ
122	antiCLL1.G4S.antiCD33.G4S.FKBP.minCD4hinge.CD4tm.CD4ic	EVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKER EWWAGITNNGYSTAYAESVKGRFTISRDNANTYILQMSSLRAED TAVYYCHADLT KAYDVEYAWGQGTTLVTVKPGGGGSEVQLVESGGG EVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERELVAEISGVGDT NYAASLADRFTVSRDNAKNTVYLQMSSLRAEDTAVYYCNAHSFL DLVGAWGQGTTLVTVKPGGGSGVQVETISPGDGRTFPKRGQTCVV HYTGMLLEDGKKFDS SRDRNKP FKFMLGKQEVIRGWEEGVAQMSVG QRAKLTI SPDYAYGATGHPGII PPHATLVFDVELLKLESNIKVLPT WSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
123	FRB.2xG4S.antiCLL1.minCD4hinge.CD4tm.CD4ic	WHEMWHEGLEEASRLYFGERNVKGMFVLEPLHAMMERGPQTLKE TSFNQAYGRDLMEAEQEWCRKYMKSGNVKDLTQAWDLYYHVFRRI S KGGGGSGGGGSEVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDM NWYRQAPGKER EWWAGITNNGYSTAYAESVKGRFTISRDNANTY ILQMSSLRAEDTAVYYCHADLT KAYDVEYAWGQGTTLVTVKPSNIK VLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
124	antiCLL1.G4S.FRB.2xG4S.antiCD33.minCD4hinge.CD4tm.CD4ic	EVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKER EWWAGITNNGYSTAYAESVKGRFTISRDNANTYILQMSSLRAED TAVYYCHADLT KAYDVEYAWGQGTTLVTVKPGGGGSLWHEMWHEGL EEASRLYFGERNVKGMFVLEPLHAMMERGPQTLKETSFNQAYGR DLMEAEQEWCRKYMKSGNVKDLTQAWDLYYHVFRRI S KGGGGSGGG GSEVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKE RELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAED TAVYYCNAHSFLDLVGAWGQGTTLVTVKPSNIKVLPTWSTPVQPM ALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
125	antiCD33.G4S.FKBP.minCD4hinge.CD4tm.CD28	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTTLVTVKPGGGSGVQVETISPGDGRT FPKRGQTCVVHYTGMLLEDGKKFDS SRDRNKP FKFMLGKQEVIRGW

		EEGVAQMSVVGQRAKLTISPDIAYGATGHPGII PPHATLVFDVVELL KLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR SKRSRLHSDYMNMTFRRPGPTRKHYPYAPPRDFAAYRS
126	antiCD33.G4S.FKBP.mi nCD4hinge.CD4tm.4lBB	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDANKNTVYQLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQVETISPGDGR T FPKRGQTCVVHYTGMLEDGKKFDSSRDNRNPKFKFMLGKQEVIRGW EEGVAQMSVVGQRAKLTISPDIAYGATGHPGII PPHATLVFDVVELL KLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR RGRKLLLYIFKQPFMRPVQTTQEEEDGCSCRFP EEEEEGGCEL
127	antiCD33.G4S.AbCH3.m inCD4hinge.CD4tm.CD4 ic	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDANKNTVYQLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQPREPQVYTLPPC RDELTKNQVSLKCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSQSVMEALHNHYTQKSLSLS PGKSNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR HRRRQ
128	antiCD33.G4S.CH3GA.m inCD4hinge.CD4tm.CD4 ic	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDANKNTVYQLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQPREPQVYTLPP SEELALNELVLTCLVKGFYPSDIAVEWQGSQELPREKYLTPWAP VLDSDGSFFLYSILRVAEDWKKGDTFSCSVMEALHNHYTQKSL DRSNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR RRRQ
129	antiCD33.G4S.CH3KK.m inCD4hinge.CD4tm.CD4 ic	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDANKNTVYQLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQPREPQVYTKPS RDELTKNQVSLKCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLD SDGSFFLYSKLTVDKSRWQQGNVFSQSVMEALHNHYTQKSLLS PGKSNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR HRRRQ
130	antiCD33.G4S.FKBP.mi nCD4hinge.CD4tm.CD4i c-full	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDANKNTVYQLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQVETISPGDGR T FPKRGQTCVVHYTGMLEDGKKFDSSRDNRNPKFKFMLGKQEVIRGW EEGVAQMSVVGQRAKLTISPDIAYGATGHPGII PPHATLVFDVVELL KLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR HRRRQAERMSQIKRLLSEKKTCCPHRFQKTCSP
131	antiCD33.G4S.FKBP.mi nCD4hinge.CD4tm.CD8i c-full	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERE LVAEISGVGDTNYAASLADRFTVSRDANKNTVYQLQMSSLRAEDTA VYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQVETISPGDGR T FPKRGQTCVVHYTGMLEDGKKFDSSRDNRNPKFKFMLGKQEVIRGW EEGVAQMSVVGQRAKLTISPDIAYGATGHPGII PPHATLVFDVVELL KLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFLYCNH RNRVRVCKCPRPVVKSGDKPSLSARYV
132	CD19scFv.G4S.FKBP.mi nCD4hinge.CD4tm.CD4i c	DIQMTQTTSLSASLGDRVTISCRASQDISKYLNWYQQKPDGT VK LLIYHTSRLHSGVPSRFSGSGSGTDYSLTISNLEQEDIA TYFCQQ GNTLPYTFGGGTKEITGGGSGGGGSGGGSEVKLQESG PLVAPSQLSVTCTVSGVSLPDYGVSWIRQPPRKGLEWLGVIWGS SETTY YNSALKSRLTI IKDNSKSQVFLKMNSLQTDATAIYYCA KHYYGGSYAMDYWGQGTSTVSSGGGSGVQVETISPGDGRTPFKR GQTCV VHYTGMLEDGKKFDSSRDNRNPKFKFMLGKQEVIRGWEEG VAQMSV GQRAKLTISPDIAYGATGHPGII PPHATLVFDVVELL KLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR HRRRQ
133	PD1 (A132V) ex.G4S.FKB P.minCD4hinge.CD4tm. CD4ic	FLDSPDRPWNPTFSPALLVVTEDGNATFTCSFSNTSESFV LNWY RMSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMS VVRARRNDSGTYLCGAISLAPKVQIKESLRAELRVTERRAEVPTAH SP SPRPAGQFQTLVGGGSGVQVETISPGDGRTPFKRGQTCVVHYT G MLEDGKKFDSSRDNRNPKFKFMLGKQEVIRGWEEGVAQMSV GQRAKLTISPDIAYGATGHPGII PPHATLVFDVVELL KLESNIKVL PTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
134	PDlex.G4S.FKBP.minCD 4hinge.CD4tm.CD4ic	FLDSPDRPWNPTFSPALLVVTEDGNATFTCSFSNTSESFV LNWY RMSPSNQTDKLAAPEDRSQPGQDCRFRVTQLPNGRDFHMS VVRARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVPTAH SP SPRPAGQFQTLVGGGSGVQVETISPGDGRTPFKRGQTCVVHYT G MLEDGKKFDSSRDNRNPKFKFMLGKQEVIRGWEEGVAQMSV GQRAKLTISPDIAYGATGHPGII PPHATLVFDVVELL KLESNIKVL PTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ

135	antiCD33.G4S.FKBP.CD4htm.trIL2Rb	EVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSSLRAEDTAVYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQVETISPGDGRTFPRGQTCVVHYTGMLDGGKKFSSSRDRNKPFFKMLGKQEVIRGWE EVAQMSVQRAKLTISPDIYAGATGHPGIIPPHATLVFDVVELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFGLGIFFNCRNTGPWLKKVLKCNTPDPSKFFSLSSEHGGDVQKWLSSPFPSSSPSPGGLAPEISPLEVLERDKVTQLLPLNTDAYLSLQELQGGDPHTLV
136	antiROR1.G4S.FKBP.minCD4hinge.CD4tm.CD4ic	DIQMTQSPSFLSASVGDRTVINCKASQNIIDRYLNWYQQKLGEPKRLLYNTNKLQGTGIPSRFSGSGSATDFTLTISLQPEDFATYFCLQYNSLPLTFGSGTKLEIKGGGSGGGGSGGGGSEVQLVESGGGLVQPGRSLKLSAASGFI FSEHNMAWVRQAPKKGLEWVATISDDGRNTYYRDSMRGRFTISRENARSTLYLQDLSLSEDTATYYCASHRYNLFDSWGQGVMTVTVSSGGGSGVQVETISPGDGRTFPRGQTCVVHYTGMLDGGKKFSSSRDRNKPFFKMLGKQEVIRGWE EVAQMSVQRAKLTISPDIYAGATGHPGIIPPHATLVFDVVELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFGLGIFFCVRCRHRHQ
137	FRBstar.CD4htm.IIL7Ra	ILWHEMWHEGLEEASRLYFGERNVKGMEFVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRRI SKSNIKVLPTWSTPVQPMALIVLGGVAGLLLFGLGIFFKRIKPIVWPSLPDHKKTLLEHLCKKPRKNLNVSENPESFLDCQIHRVDDIQARDEVEGFLQDTFPQGLEESEQRLGGDVQSPNCPSEDVVITPESFGRDSSLTCLAGNVSAADAPILSSSSLDRESGKNGPVHYQDL LLSLGTNTNSTLPPPSLQSGILTLPVAQGPILTSLSGNQEEAYVTMSSFYQNG
138	FRBstar.CD4htm.IIL2Rg	ILWHEMWHEGLEEASRLYFGERNVKGMEFVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLLQAWDLYYHVFRRI SKSNIKVLPTWSTPVQPMALIVLGGVAGLLLFGLGIFFFERTMRIPTLKNLEDLVTEYHGNFSAWSGVSKLAESLQPDYSERLCLVSEIPPKGGALGEGPGASPCNQHSFYWAPPCTYLPKET
139	SR020 - CD8ss.FRB.CD3e.P2A.IgKss.antiCD33.FKBP.minCD28hinge.CD28tm.CD4ic	ALPVTALLPLALLHAARPGSILWHEMWHEGLEEASRLYFGERNVKGMEFVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRI SKGGGSGGGGSGGGGSDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNI GGDEDDKNIGSDEHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDMVMSVATIVIVDICTGGLLLVVYWSKNRKAKAPVTRGAGAGGRQRGQNKERPPVPNPDPYEPKRGQRDLYSGLNQRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLPDPTTGEVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSSLRAEDTAVYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQVETISPGDGRTFPRGQTCVVHYTGMLDGGKKFSSSRDRNKPFFKMLGKQEVIRGWE EVAQMSVQRAKLTISPDIYAGATGHPGIIPPHATLVFDVVELLKLEKKGHLCPSPLPFGPSKPFVVLVVGVLACYSLLVTVAFIIFWVCVRCRHRHQ
140	SR021 - CD8ss.FRB.CD3g.P2A.IgKss.antiCD33.FKBP.minCD28hinge.CD28tm.CD4ic	ALPVTALLPLALLHAARPGSILWHEMWHEGLEEASRLYFGERNVKGMEFVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRI SKGGGSGGGGSGGGGSDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNI GGDEDDKNIGSDEHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDMVMSVATIVIVDICTGGLLLVVYWSKNRKAKAPVTRGAGAGGRQRGQNKERPPVPNPDPYEPKRGQRDLYSGLNQRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLPDPTTGEVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSSLRAEDTAVYYCNAHSFLDLVGAWGQGTLTVTVKPGGGSGVQVETISPGDGRTFPRGQTCVVHYTGMLDGGKKFSSSRDRNKPFFKMLGKQEVIRGWE EVAQMSVQRAKLTISPDIYAGATGHPGIIPPHATLVFDVVELLKLEKKGHLCPSPLPFGPSKPFVVLVVGVLACYSLLVTVAFIIFWVCVRCRHRHQ
141	SR022 - CD8ss.FRB.CD3e.P2A.IgKss.antiCD33.FKBP.minCD4hinge.CD4tm.CD4ic	ALPVTALLPLALLHAARPGSILWHEMWHEGLEEASRLYFGERNVKGMEFVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRI SKGGGSGGGGSGGGGSDGNEEMGGITQTPYKVSISGTTVILTCPQYPGSEILWQHNDKNI GGDEDDKNIGSDEHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDMVMSVATIVIVDICTGGLLLVVYWSKNRKAKAPVTRGAGAGGRQRGQNKERPPVPNPDPYEPKRGQRDLYSGLNQRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLPDPTTGEVQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSSLRAEDTAV

		YYCNAHSFLDLVGAWGQGTLVTVKPGGGSGVQVETISPGDGRTF PKRGQTCVVHYTGMLDGGKFDSSRDNRKPFKFMGLGQEVIRGWE EGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLK LESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHR RRRQ
142	SR023 - CD8ss.FRB.CD3g.P2A.I gKss.antiCD33.FKBP.m inCD4hinge.CD4tm.CD4 ic	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKY MKSNGVKDLTQAWDLYYHVFRRI SKGGGSGGGGSGGGGSGQSIKG NHLVKVYDYQEDGSVLLTCDAAEKNI TWFKDGKMIGFLTEDKKKW NLGSNAKDPGRMYQCKGSONKSKPLQVYYRMCQNCIELNAATISG FLFAEIVSIFVLAVGVYFIAGQDGVQRSPASDKQTLLPNDQLYQP LKDREDDQYSHLQGNQLRRNSGSGATNFSLLKQAGDVEENPG3SM ETPAQLLFLLLLWLPD TTGEVQLVESGGGEVQPGGSLRLSCAASR SSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRD NAKNTVYLQMSLSLRAEDTAVYYCNAHSFLDLVGAWGQGTLVTVK PGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLDGGKFDSSR DRNKPFFKFMGLGQEVIRGWE EGVAQMSVGQRAKLTISPDYAYGAT GHPGIIPPHATLVFDVELLKLESNIKVLPTWSTPVQPMALIVLGG VAGLLLFIGLGIFFCVRCRHRRRQ
143	SR024 - CD8ss.FRB.CD3e.P2A.I gKss.antiCD33.FKBP.C D4tm.CD4ic	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKY MKSNGVKDLTQAWDLYYHVFRRI SKGGGSGGGGSGGGGSDGNEE MGGITQTTPYKVSISGTTVILTCPQYPGSEILWQHNDKNI GDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSVATIVIVDICTGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQRGQNKERPPVPNPDIYEP IRKGQRDLYSGLNQRR ISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLLWLPD TTGE VQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKEREL VAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSLSLRAEDTAV YYCNAHSFLDLVGAWGQGTLVTVKPGGGSGVQVETISPGDGRTF PKRGQTCVVHYTGMLDGGKFDSSRDNRKPFKFMGLGQEVIRGWE EGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLK LEGGRMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQ
144	SR026 - CD8ss.FKBP.CD3e.P2A. IgKss.FRB.antiCD33.m inCD4hinge.CD4tm.CD4 ic	ALPVTALLPLALLLHAARPGSGVQVETISPGDGRTFPKRGQTCV VHYTGMLDGGKFDSSRDNRKPFKFMGLGQEVIRGWE EGVAQMSV GQRAKLTISPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGSD GNEEMGGITQTTPYKVSISGTTVILTCPQYPGSEILWQHNDKNI G DEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLY LPRVCENCMEMDMVSVATIVIVDICTGGLLLVYYWSKNRKAK AKPVTRGAGAGGRQRGQNKERPPVPNPDIYEP IRKGQRDLYSGLN QRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLLWLPD TTGLWHEMWHEGLEEASRLYFGERNVKGMEFEVLEPLHAMMERGP QTLKETSFNQAYGRDLMEAQEWCRKYMKSNGVKDLTQAWDLYYHV FRRI SKGGGSGGGGSEVQLVESGGGEVQPGGSLRLSCAASRSSGI DVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAK NTVYLQMSLSLRAEDTAVYYCNAHSFLDLVGAWGQGTLVTVKPSN IKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQ
145	SR028 - CD8ss.FRB.CD3e.P2A.I gKss.FKBP.antiCD33.m inCD4hinge.CD4tm.CD4 ic	ALPVTALLPLALLLHAARPGSLWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKY KSGNVKDLTQAWDLYYHVFRRI SKGGGSGDNEEMGGITQTTPYK VSISGTTVILTCPQYPGSEILWQHNDKNI GDEDDKNIGSDEDHLS LKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDM VSVATIVIVDICTGGLLLVYYWSKNRKAKAKPVTRGAGAGGRQ RGQNKERPPVPNPDIYEP IRKGQRDLYSGLNQRRISGSGATNFSLL KQAGDVEENPGPSMETPAQLLFLLLLWLPD TTGGVQVETISPGDG RTFPKRGQTCVVHYTGMLDGGKFDSSRDNRKPFKFMGLGQEVIR GWE EGVAQMSVGQRAKLTISPDYAYGATGHPGIIPPHATLVFDVE LLKLEGGGSGGGGSEVQLVESGGGEVQPGGSLRLSCAASRSSGI DVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAK NTVYLQMSLSLRAEDTAVYYCNAHSFLDLVGAWGQGTLVTVKPSN IKVLPTWSTPVQPMALIVLGGVAGLLLFIGLGIFFCVRCRHRRRQ
146	SR001 - CD8ss.FRBstar.CD3e.P 2A.IgKss.antiCD33.FK BP.minCD4hinge.CD4tm .CD4ic	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKY MKSNGVKDLTQAWDLYYHVFRRI SKGGGSGGGGSGGGGSDGNEE MGGITQTTPYKVSISGTTVILTCPQYPGSEILWQHNDKNI GDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSVATIVIVDICTGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQRGQNKERPPVPNPDIYEP IRKGQRDLYSGLNQRR ISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLLWLPD TTGE

		VQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLRAEDTAVYYCNAHSFLDLVGAWGQGTLTVTVKPGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLDGGKFDSSRDRNKPFFKFM LGKQEVIRGWE EGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHR
147	SR003 - CD8ss.FRB.CD3e.P2A.IgKss.antiCLL1.FKBP.minCD4hinge.CD4tm.CD4ic	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKGGGGSGGGGSGGGGSDGNEEMGGITQTPYKVSISGTTVILTCPOYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDMVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPVPNPDYEPPIRKGQRDLYSGLNQRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLLWLPD TTGEVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNMYRQAPGKEREWVAGITNNGYSTAYAESVKGRFTISRDNANTYIYLQMSSLRAEDTAVYYCHADLT KAYDVEYAWGQGTLTVTVKPGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLDGGKFDSSRDRNKPFFKFM LGKQEVIRGWE EGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHR
148	SR004 - CD8ss.FRB.CD3e.P2A.IgKss.antiCLL1.antiCD33.FKBP.minCD4hinge.CD4tm.CD4ic	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKGGGGSGGGGSGGGGSDGNEEMGGITQTPYKVSISGTTVILTCPOYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDMVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPVPNPDYEPPIRKGQRDLYSGLNQRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLLWLPD TTGEVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNMYRQAPGKEREWVAGITNNGYSTAYAESVKGRFTISRDNANTYIYLQMSSLRAEDTAVYYCHADLT KAYDVEYAWGQGTLTVTVKPGGGGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLDGGKFDSSRDRNKPFFKFM LGKQEVIRGWE EGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHR
149	SR005 - CD8ss.FKBP.CD3e.P2A.IgKss.FRB.antiCLL1.minCD4hinge.CD4tm.CD4ic	ALPVTALLPLALLLHAARPGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLDGGKFDSSRDRNKPFFKFM LGKQEVIRGWE EGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSDGNEEMGGITQTPYKVSISGTTVILTCPOYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDMVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPVPNPDYEPPIRKGQRDLYSGLNQRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLLWLPD TTGLWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKGGGGSGGGGSEVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNMYRQAPGKEREWVAGITNNGYSTAYAESVKGRFTISRDNANTYIYLQMSSLRAEDTAVYYCHADLT KAYDVEYAWGQGTLTVTVKPSNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHR
150	SR006 - CD8ss.FKBP.CD3e.P2A.IgKss.antiCLL1.FRB.antiCD33.minCD4hinge.CD4tm.CD4ic	ALPVTALLPLALLLHAARPGSGVQVETISPGDGRTFPKRGQTCVVHYTGMLDGGKFDSSRDRNKPFFKFM LGKQEVIRGWE EGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVELLKLEGGGGSDGNEEMGGITQTPYKVSISGTTVILTCPOYPGSEILWQHNDKNIGGDEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRARVCENCMEMDMVMSVATIVIVDICITGGLLLLVYYWSKNRKAKAKPVTRGAGAGGRQRGQNKERPPVPNPDYEPPIRKGQRDLYSGLNQRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLLWLPD TTGEVQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNMYRQAPGKEREWVAGITNNGYSTAYAESVKGRFTISRDNANTYIYLQMSSLRAEDTAVYYCHADLT KAYDVEYAWGQGTLTVTVKPGGGGSLWHEMWHEGLEEASRLYFGERNVKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKYMKSGNVKDLTQAWDLYYHVFRRISKGGGGSGGGGSEVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSSLR

		AEDTAVYYCNAHSFLDLVGAWGQGTTLVTVKPSNIKVLPTWSTPVQ PMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
151	SR008 - CD8ss.FRBstar.CD3e.P 2A.IgKss.antiCLL1. antiCD33.FKBP.minCD4 hinge.CD4tm.CD4ic	ALPVTALLLPALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKY MKSGNVKDLLQAWDLYYHVFRRIKGGGSGGGGSGGGGSDGNEE MGGITQTPYKVSISGTTVILTC PQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDVMSVATIVIVDITGGLLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNPDYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLDPDTTGE VQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKERE WVAGITNNGYSTAYAESVKGRFTISRDNANTYIYLMSSSLRAEDT AVYYCHADLT KAYDVEYAWGQGTTLVTVKPGGGGSEVQLVESGGGE VQPGGSLRLSCAASRSGIDVMGWYRQAPGKERELVAEISGVGDT NYAASLADRFTVSRDNANTVYLMSSSLRAEDTAVYYCNAHSFLD LVGAWGQGTTLVTVKPGGGGSGVQVETISPGDGRTFPKRGQTCVVH YTGMLEDGKKFDSSDRNKP FKFMLGKQEVIRGWEEGVAQMSVGQ RAKLTI SPDYAYGATGHPGIIPPHATLVFDVLLKLESNIKVLPT WSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
152	SR030 - CD8ss.FRBstar.CD3e.P 2A.IgKss.antiCLL1. antiCD33.FKBP.minCD4 hinge.CD4tm.41BB	ALPVTALLLPALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKY MKSGNVKDLLQAWDLYYHVFRRIKGGGSGGGGSGGGGSDGNEE MGGITQTPYKVSISGTTVILTC PQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDVMSVATIVIVDITGGLLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNPDYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLDPDTTGE VQLVESGGGEVQPGGSLRLSCAASGFLFSIYDMNWYRQAPGKERE WVAGITNNGYSTAYAESVKGRFTISRDNANTYIYLMSSSLRAEDT AVYYCHADLT KAYDVEYAWGQGTTLVTVKPGGGGSEVQLVESGGGE VQPGGSLRLSCAASRSGIDVMGWYRQAPGKERELVAEISGVGDT NYAASLADRFTVSRDNANTVYLMSSSLRAEDTAVYYCNAHSFLD LVGAWGQGTTLVTVKPGGGGSGVQVETISPGDGRTFPKRGQTCVVH YTGMLEDGKKFDSSDRNKP FKFMLGKQEVIRGWEEGVAQMSVGQ RAKLTI SPDYAYGATGHPGIIPPHATLVFDVLLKLESNIKVLPT WSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRGRKKLLYIFK QPFMRPVQTTQEEDGCSCRFPEEEEGGCEL
153	SR001-28 - CD8ss.FRBstar.CD3e.P 2A.IgKss.antiCD33.FK BP.minCD4hinge.CD4tm .CD28	ALPVTALLLPALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKY MKSGNVKDLLQAWDLYYHVFRRIKGGGSGGGGSGGGGSDGNEE MGGITQTPYKVSISGTTVILTC PQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDVMSVATIVIVDITGGLLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNPDYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLDPDTTGE VQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKEREL VAEISGVGDTNYAASLADRFTVSRDNANTVYLMSSSLRAEDTAV YYCNAHSFLDLVGAWGQGTTLVTVKPGGGGSGVQVETISPGDGRTF PKRGQTCVVHYTGMLEDGKKFDSSDRNKP FKFMLGKQEVIRGWE EGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVLLK LESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRS KRSRLHSDYMNMTPRRP GPTRKHYQPYAPP R DFAAYRS
154	SR001-41BB - CD8ss.FRBstar.CD3e.P 2A.IgKss.antiCD33.FK BP.minCD4hinge.CD4tm .41BB	ALPVTALLLPALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAQEWCRKY MKSGNVKDLLQAWDLYYHVFRRIKGGGSGGGGSGGGGSDGNEE MGGITQTPYKVSISGTTVILTC PQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDVMSVATIVIVDITGGLLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNPDYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLDPDTTGE VQLVESGGGEVQPGGSLRLSCAASRSGIDVMGWYRQAPGKEREL VAEISGVGDTNYAASLADRFTVSRDNANTVYLMSSSLRAEDTAV YYCNAHSFLDLVGAWGQGTTLVTVKPGGGGSGVQVETISPGDGRTF PKRGQTCVVHYTGMLEDGKKFDSSDRNKP FKFMLGKQEVIRGWE EGVAQMSVGQRAKLTI SPDYAYGATGHPGIIPPHATLVFDVLLK LESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCR KRSRLHSDYMNMTPRRP GPTRKHYQPYAPP R DFAAYRS

155	SR292 - CD8ss.IACH3.CD3e.P2A .IgKss.antiCD33.AbCH 3.minCD4hinge.CD4tm. 41BB	ALPVTALLLPLALLLHAARPGSGQP PREPQVCTLPSSRDELTKNQV SLSCAVKGFYPSDIAVEWESNGQP PENNYKTPPVLDSDGSGFFLV SLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKGGG SGGGGGSDGNEEMGGITQTPYKVS ISGTTVILTCPPQYPGSEIL WQHNDKNIGGEDDDKNIGSDEDHLS LKEFSELEQSGYYVCYPRGS KPEDANFYLYLRARVCENCMEMDM MSVATIVIVDICTGGLLLLV YYWSKNRKAKAKPVTRGAGAGGRQ RGQNKERPPVPNPDYEP IRKGQRDLYSGLNQRRISGSGATN FSLKQAGDVEENPGPSMETPAQL LFLLLLWLPDTTGEVQLVESGGGEV QPGGSLRLSCAASRSSGIDV MGWYRQAPGKERELVAEISGVGDT NYAASLADRFTVSRD NAKNTVYLQMS SLRAEDTAVYYCNAHSFLDLVGAWG QGT LVT VKPGGGSGQ PREPQVYTLPPCRDELTKNQVSLWCL VKGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGSGFFLYSKLT VDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKSNIKV LPTWSTPVQPMALIVLGGVAGLL LFIGLGIFFCVRCHRRRQ
156	SR293 - CD8ss.CH3AG.CD3e.P2A .IgKss.antiCD33.CH3G A.minCD4hinge.CD4tm. CD4ic	ALPVTALLLPLALLLHAARPGSGQP FRPEVHLLPPSREEMTKNQW SLTCLARGFYPKDIAVEWESNGQP PENNYKTPSRQEPSQGTTF AVTSKLTVDKSRWQQGNWFSCSV MHEALHNHYTQKTSLSLGGGGSG GGSGGGSDGNEEMGGITQTPYKVS ISGTTVILTCPPQYPGSEILW QHNDKNIGGEDDDKNIGSDEDHLS LKEFSELEQSGYYVCYPRGSK PEDANFYLYLRARVCENCMEMDM MSVATIVIVDICTGGLLLLV YWSKNRKAKAKPVTRGAGAGGRQ RGQNKERPPVPNPDYEP IRKGQRDLYSGLNQRRISGSGATN FSLKQAGDVEENPGPSMETPAQL LFLLLLWLPDTTGEVQLVESGGGEV QPGGSLRLSCAASRSSGIDV MGWYRQAPGKERELVAEISGVGDT NYAASLADRFTVSRD NAKNTVYLQMS SLRAEDTAVYYCNAHSFLDLVGAWG QGT LVT VKPGGGSGQ PREPQVYTLPPSEELALNELVTLTCL VKGFYPSDIAVEW LGGSQELPREKYLTWAPVLDSDGSG FFLYSILRVA AEDWKKGDTFSCSV MH EALHNHYTQKSLDRS NIKVLP TWSTPVQPMALIVLGGVAGLL LFIGLGIFFCVRCHRRRQ
157	SR296 - CD8ss.CH3DE.CD3e.P2A .IgKss.antiCD33.CH3K K.minCD4hinge.CD4tm. CD4ic	ALPVTALLLPLALLLHAARPGSGQP PREPQVYTDPPSRDELTKNQV SLTCEVKGFYPSDIAVEWESNGQP PENNYKTPPVLDSDGSGFFLYS KLTVDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKGGG SGGGGGSDGNEEMGGITQTPYKVS ISGTTVILTCPPQYPGSEIL WQHNDKNIGGEDDDKNIGSDEDHLS LKEFSELEQSGYYVCYPRGS KPEDANFYLYLRARVCENCMEMDM MSVATIVIVDICTGGLLLLV YYWSKNRKAKAKPVTRGAGAGGRQ RGQNKERPPVPNPDYEP IRKGQRDLYSGLNQRRISGSGATN FSLKQAGDVEENPGPSMETPAQL LFLLLLWLPDTTGEVQLVESGGGEV QPGGSLRLSCAASRSSGIDV MGWYRQAPGKERELVAEISGVGDT NYAASLADRFTVSRD NAKNTVYLQMS SLRAEDTAVYYCNAHSFLDLVGAWG QGT LVT VKPGGGSGQ PREPQVYTKPPSRDELTKNQVSLKCL VKGFYPSDIAVEWESNGQ PENNYKTPPVLDSDGSGFFLYSKLT VDKSRWQQGNVFSCSV MHEALHNHYTQKSLSLSPGKSNIKV LPTWSTPVQPMALIVLGGVAGLL LFIGLGIFFCVRCHRRRQ
158	SR001-CD4 - CD8ss.FRB.CD3e.P2A.h uIgKss.CD33.FKBP.min CD4hinge.CD4tm.CD4ic -full	ALPVTALLLPLALLLHAARPGSILW HEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKET SFNQAYGRDLMEAEQWCRKY MKSGNVKDLTQAWDLYYHVFRRIS KGGGGSGGGSGGGGGSDGNEE MGGITQTPYKVSISGTTVILTCPPQ YPGSEILWQHNDKNIGGEDDD KNIGSDEDHLSLKEFSELEQSGYY VCYPRGSKPEDANFYLYLRAR VCENCMEMDMMSVATIVIVDICTG GLLLLVYYWSKNRKAKAKPV TRGAGAGGRQRGQNKERPPVPNP DYEP IRKGQRDLYSGLNQRRISGSGATN FSLKQAGDVEENPGPSMETPAQL LFLLLLWLPDTTGEVQLVESGGGEV QPGGSLRLSCAASRSSGIDV MGWYRQAPGKERELVAEISGVGDT NYAASLADRFTVSRD NAKNTVYLQMS SLRAEDTAVYYCNAHSFLDLVGAWG QGT LVT VKPGGGSGVQVETISPGDGRTF PKRGQTCVVHYTGML EDGKKFDSSRD RNP KPFKMLGKQEVIRGWE EGVAQMSVGQRAKL TISPDYAYGATGHPGIIPPHATL VFDV ELLK LESNIKVLP TWSTPVQPMALIVLGGVAGLL LFIGLGIFFCVRCHRRRQ AERMSQIKRL LSEKKTCQCPH RFQKTCSP
159	SR001-CD8 - CD8ss.FRB.CD3e.P2A.h uIgKss.antiCD33.FKBP .minCD4hinge.CD4tm.C D8ic-full	ALPVTALLLPLALLLHAARPGSILW HEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKET SFNQAYGRDLMEAEQWCRKY MKSGNVKDLTQAWDLYYHVFRRIS KGGGGSGGGSGGGGGSDGNEE MGGITQTPYKVSISGTTVILTCPPQ YPGSEILWQHNDKNIGGEDDD KNIGSDEDHLSLKEFSELEQSGYY VCYPRGSKPEDANFYLYLRAR VCENCMEMDMMSVATIVIVDICTG GLLLLVYYWSKNRKAKAKPV TRGAGAGGRQRGQNKERPPVPNP DYEP IRKGQRDLYSGLNQRRISGSGATN FSLKQAGDVEENPGPSMETPAQL LFLLLLWLPDTTGEVQLVESGGGEV QPGGSLRLSCAASRSSGIDV MGWYRQAPGKEREL

		VAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSLRAEDTAV YYCNAHSFLDLVGAWGQGTTLVTVKPGGGSGVQVETISPGDGRTE PKRGQTCVVHYTGMLDGGKFDSSRDRNKPFFKMLGKQEVIRGWE EGVAQMSVGGQRAKLTI SPDYAYGATGHPGII PPHATLVFDVLLK LESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFLYCNHR NRRRVCKCPRPVVKS GDKPSLSARYV
160	TCR-SR001 - TCR.T2A.SR001	GFRLLCCVAFCLL GAGPVDSGVTQT?KHLITATGQRTVLRCS?RS GDLSVYWYQQSLDQGLQFLIQYYNGEERAKGNILERFSAQQF?DL HSELNLSLELGD SALYFCASSGGDGDEQFFGPGTRTLTVLEDLKN VFPPFEVAVFEP SKAEIAHTQKATLVCLATGFYPDHVELSVAWVNGK EVHSGVSTDPQPLKEQPALNDSRYCLSSRLRV SATFWQNP RNHFR CQVQFYGLSENDEWTDRAKPV TQIVSAEAWGRADCGIT SASYHQ GVLSATILYEI LLGKATLYAVLV SALVLMAMVKRKDSRGRKRGS GATNFSLLKQAGDVEENPGPMSLSSLLKVVTASLWGPSIAQKIT QTQPGMFVQEK EAVTLDCTYDTS DPSYGLFWYKQ PSSGEMI FLIY QGSYDQQNATEGRYSLNFQKARKSANLVISASQLGDSAMYFCAMS GGYTGGFKTIFGAGTRLFVKANIQN?DPAVYQLRDSKSSDKSVCL FTDFDSQTNVSQSKSDSVYITDKTVLDMRSMDFKSN SAVAWSNK DFACANAFNNSIIP EDTFFPSSDVP CDVKLVEKS FETDTNLFQCN LLVIVLRILLKLVAGFNLLMTLRLWSSSGEGRGSLT CGDVEEN PGPMALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYF GERNVKGMFEVLEPLHAMMERGPQTLKETS FNQAYGRDLMEAEQEW CRKYMKS GNVKDLLQAWDLYYHVFRRI SKGGGSGGGSGGGSDGNEE GNEEMGGITQTPYKVSISGTTVILTC PQYPGSEI LWQHNDKNI GG DEDDKNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLY LRLARVCENCMEMDVMSVATIVIVD ICITGGLLLVYYWSKNRKAK AKPVTRGAGAGGRQRGQNKERPPVPNP DYEP IRKGQRDLYSGLN QRRISGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLPLD TTGEVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQA?GK ERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQMSLRAE DTAVYYCNAHSFLDLVGAWGQGTTLVTVKPGGGSGVQVETIS?GD GRTF PKRGQTCVVHYTGMLDGGKFDSSRDRNKPFFKMLGKQEVIR GWEEGVAQMSVGGQRAKLTI SPDYAYGATGHPGII PPHATLVFDV ELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCV RCRHRRRQ
161	SR007 - CD8ss.FRBstar.CD3e.P 2A.huIgKss.antiCLL1. FKBP.minCD4hinge.CD4 tm.CD4ic	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETS FNQAYGRDLMEAEQEWCRKY MKSGNVKDLLQAWDLYYHVFRRI SKGGGSGGGSGGGSDGNEE MGGITQTPYKVSISGTTVILTC PQYPGSEI LWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRLAR VCENCMEMDVMSVATIVIVD ICITGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQRGQNKERPPVPNP DYEP IRKGQRDLYSGLNQRRI SGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLPLD TTGE VQLVESGGGEVQPGGSLRLSCAASGTFLSIYDMNYYRQAPGKERE WVAGITNNGYSTAYAESVKGRFTISR DNAKNTIYLQMSLRAEDT AVYYCHADLT KAYDVEYAWGQGTTLVTVKPGGGSGVQVETIS?GD GRTF PKRGQTCVVHYTGMLDGGKFDSSRDRNKPFFKMLGKQEVIR GWEEGVAQMSVGGQRAKLTI SPDYAYGATGHPGII PPHATLVFDV ELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFGLGIFFCV RCRHRRRQ
162	SR10168 - CD8ss.FRBstar- CD3e.P2A.IgKss.CD19s cFv.FKBP.minCD4hinge .CD4tm.CD4ic	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETS FNQAYGRDLMEAEQEWCRKY MKSGNVKDLLQAWDLYYHVFRRI SKGGGSGGGSGGGSDGNEE MGGITQTPYKVSISGTTVILTC PQYPGSEI LWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRLAR VCENCMEMDVMSVATIVIVD ICITGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQRGQNKERPPVPNP DYEP IRKGQRDLYSGLNQRRI SGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWLPLD TTGD IQMTQTSSLSASLGDRVTISCRASQDISKYLNNWYQQKPDGTVKL LIYHTSRHSGVPSRFSGSGSGTDYSLTISNLEQEDIATYFCQQG NTLPYTFGGGKLEITGGGGSGGGSGGGSEVKLGSGGLVAP SQSLSVTCTVSGVSLPDYGVSWIRQ?PRKGLEWLGVWGSSETYY NSALKSRLTII KDN SKSQVFLKMNSLQTDDTAIYYCAKHHYYGGS YAMDYWGQGTSTVTVSSGGGGSGVQVETISPGDGRTPFKRGQTCV HYTGMLDGGKFDSSRDRNKPFFKMLGKQEVIRGWEEGVAQMSV GQRAKLTI SPDYAYGATGHPGII PPHATLVFDV LKLESNIKVLPT WSTPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
163	SR001+IL7a - CD8ss.FRBstar.CD3eP2	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETS FNQAYGRDLMEAEQEWCRKY

	A.huIgKss.FRBstar.CD4htm.IL7Ra.P2A.huIgKss.antiCD33.FKBP.minCD4hinge.CD4tm.CD4ic	MKSGNVKDLLQAWDLYYHVFRRI SKGGGSGGGGSGGGSGDNEE MGGITQTPYKVSISGTTVILTC PQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSATIVIVD ICITGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNP DYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWL PDDTGS LWHEMWHEGLEEASRLYFGERNVKG MFEVLEPLHAMMERGPQTLK ETSFNQAYGRDLMEAEQEWCRKYMKS GNVKDLLQAWDLYYHVFRRI SKSNIKVLPTWSTPVQPMALIVLGGVAGLLLF IGLGIFFKRKIKP I VWP SLPDHKKTLEHLCKKPRK NNLNV SFNPESFLDCQIHRVDDIQ ARDEVEGFLQDTFPQOLEESEKQRLGGDVQSPNCPS EDVVT?ES FGRDSSLTCLAGNVSACDAPILSSSRSLDCRESGKN GPHVYQDLL LSLGTNTNSTLPPFSLQSGILTLNPVAQGQPI L TSLG SNQEEAYV TMS SFYQNGSGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLL LWLPD TTGEVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYR QAPGKERELVAEISGVGDTNYAASLADRET VSRD NAKNTVYLQMS SLRAEDTAVYYCNAHSFLDLVGAWGQGT LVTVKPGGGSGVQVET ISP GDGRTFPKRGQTCVVHYTG MLEDGKKFDS SRDRNKPFKMLG KQEVIRGWEEGVAQMSVGQRAKL TISP DYAYGATGHPGIIPPHAT LVFDV ELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLF IGLG IFFCVR CRHRRRQ
164	SR001+gC - CD8ss.FRBstar.CD3e.P 2A.huIgKss.FRBstar.C D4htm.IL2Rg.P2A.huIg Kss.antiCD33.FKBP.CD 4htm.CD4ic	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEQEWCRKY MKSGNVKDLLQAWDLYYHVFRRI SKGGGSGGGGSGGGSGDNEE MGGITQTPYKVSISGTTVILTC PQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSATIVIVD ICITGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNP DYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWL PDDTGS LWHEMWHEGLEEASRLYFGERNVKG MFEVLEPLHAMMERGPQTLK ETSFNQAYGRDLMEAEQEWCRKYMKS GNVKDLLQAWDLYYHVFRRI SKSNIKVLPTWSTPVQPMALIVLGGVAGLLLF IGLGIF FERTMPR I PTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDY SERLCLVSE I PPKGALGEGPGASPCNQHS PYWA?PCYTLKPETS GSGGATNFS LQAGDVEENPGPSMETPAQLLFLLLWL PDDTGEVQLVESGGE VQPGGSLRLSCAASRSSGIDVMGWYRQAPGKERELVAEISGVGDT NYAASLADRET VSRD NAKNTVYLQMS SLRAEDTAVYYCNAHSFLD LVGAWGQGT LVTVKPGGGSGVQVETISP GDGRTFPKRGQTCVVH YTG MLEDGKKFDS SRDRNKPFKMLGKQEVIRGWEEGVAQMSVGQ RAKL TISP DYAYGATGHPGIIPPHATLVFDV ELLKLESNIKVLPT WSTPVQPMALIVLGGVAGLLLF IGLGIFCVR CRHRRRQ
165	SR001+IL2Rb - CD8ss.FRBstar.CD3e.P 2A.huIgKss.antiCD33. FKBP.CD4htm.trIL2Rb	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEQEWCRKY MKSGNVKDLLQAWDLYYHVFRRI SKGGGSGGGGSGGGSGDNEE MGGITQTPYKVSISGTTVILTC PQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSATIVIVD ICITGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNP DYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWL PDDTGE VQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGWYRQAPGKEREL VAEISGVGDTNYAASLADRET VSRD NAKNTVYLQMS SLRAEDTAV YYCNAHSFLDLVGAWGQGT LVTVKPGGGSGVQVETISP GDGRTF PKRGQTCVVHYTG MLEDGKKFDS SRDRNKPFKMLGKQEVIRGWE EGVAQMSVGQRAKL TISP DYAYGATGHPGIIPPHATLVFDV ELLK LESNIKVLPTWSTPVQPMALIVLGGVAGLLLF IGLGIF FNCNRTG PWLKKVLKCNTPDP SKFFSQLSSEHG GDVQKWLSSPFPSSSFSPG GLAPEISPLEVLERDKVTQLPLNTDAYLSLQELQGQDP THLV
166	SR001+IL2Rb+gC - CD8ss.FRBstar.CD3e.P 2A.huIgKss.FRBstar.C D4htm.IL2Rg.P2A.huIg Kss.antiCD33.FKBP.CD 4htm.trIL2Rb	ALPVTALLPLALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEQEWCRKY MKSGNVKDLLQAWDLYYHVFRRI SKGGGSGGGGSGGGSGDNEE MGGITQTPYKVSISGTTVILTC PQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSATIVIVD ICITGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNP DYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPMETPAQLLFLLLWL PDDTGS LWHEMWHEGLEEASRLYFGERNVKG MFEVLEPLHAMMERGPQTLK ETSFNQAYGRDLMEAEQEWCRKYMKS GNVKDLLQAWDLYYHVFRRI SKSNIKVLPTWSTPVQPMALIVLGGVAGLLLF IGLGIF FERTMPR I PTLKNLEDLVTEYHGNFSAWSGVSKGLAESLQPDY SERLCLVSE

		I PPKGGALGEGPGASPCNQHSFYWA?PCYTLKPETSGSGATNFSL LKQAGDVEENPGPSMETPAQLLFLLLWL P DTTGEVQLVESGGGE VQPGGSLRLSCAASRSSGIDVMGWYRQAPGKERELVAEISGVGDT NYAASLADRFTVSRDNAKNTVYLQMSLRAEDTAVYYCNAHSFLD LVGAWGQGTLLTVKPPGGGSGVQVETISPGDGRTPPKRGQTCVVH YTGMLLEDGKKFDSRDRNKPFFKMLGKQEVIRGWEEGVAQMSVGQ RAKLTISPDIYAGATGHPGII PPHATLVFDVELLKLESNIKVLPT WSTPVQPMALIVLGGVAGLLLFIFGLGIFFCNCRNTGPWLKKVLKCN TPDPSKFFSQLSSEHGGDVQKWLSS?FPSSSFSPGGLAPEIS?LE VLERDKVTQLPLNTDAYLSLQELQGQDPTHLV
167	SR300 - CD8ss.FRB.CD3e.P2A.P Dlss.PD1 (A132V) ex.FK BP.minCD4hinge.CD4tm .CD4ic	ALPVTALLLPALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEWCRKY MKSGNVKDLTQAWDLYYHVFRRIKGGGSGGGGSGGGSDGNEE MGGITQTPYKVSISGTTVILTCPQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSVATIVIVDICTGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNPDPYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPSMQIPQAPWPVWVAVLQLGWRP GWFLDSPDRPWNPTTFSPALLVVTEGDNATFTCSFSNTSESFVLN WYRMSPSNQTDKLAAPEDRSQPGQDCRFVTVQLPNGRDFHMSVV RARRNDSGTYLCGAISLAPKVQIKESLRAELRVTERRAEVP TAHP SPSPRPAQGFQTLVGGGSGVQVETISPGDGRTPPKRGQTCVVHY TGMLLEDGKKFDSRDRNKPFFKMLGKQEVIRGWEEGVAQMSVGQ AKLTISPDIYAGATGHPGII PPHATLVFDVELLKLESNIKVLPTW STPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
168	SR301 - CD8ss.FRB.CD3e.P2A.P Dlss.PDlex.FKBP.minC D4hinge.CD4tm.CD4ic	ALPVTALLLPALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEWCRKY MKSGNVKDLTQAWDLYYHVFRRIKGGGSGGGGSGGGSDGNEE MGGITQTPYKVSISGTTVILTCPQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSVATIVIVDICTGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNPDPYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPSMQIPQAPWPVWVAVLQLGWRP GWFLDSPDRPWNPTTFSPALLVVTEGDNATFTCSFSNTSESFVLN WYRMSPSNQTDKLAAPEDRSQPGQDCRFVTVQLPNGRDFHMSVV RARRNDSGTYLCGAISLAPKAQIKESLRAELRVTERRAEVP TAHP SPSPRPAQGFQTLVGGGSGVQVETISPGDGRTPPKRGQTCVVHY TGMLLEDGKKFDSRDRNKPFFKMLGKQEVIRGWEEGVAQMSVGQ AKLTISPDIYAGATGHPGII PPHATLVFDVELLKLESNIKVLPTW STPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ
169	SR354 - CD8ss.FRBstar.FCER1G .P2A.huIgKss.antiCD3 3.FKBP.CD4tm.CD4ic	ALPVTALLLPALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEWCRKY MKSGNVKDLTQAWDLYYHVFRRIKGGGSGGGGSGEPLCYILDA ILFLYGI VLTLLYCRKLIQVRKAAITSYEKSDGVYGLSTRNQET YETLKHEKPPQSGSGATNFSLLKQAGDVEENPGPSMETPAQLLFL LLWL P DTTGEVQLVESGGGEVQPGGSLRLSCAASRSSGIDVMGW YRQAPGKERELVAEISGVGDTNYAASLADRFTVSRDNAKNTVYLQ MSSLRAEDTAVYYCNAHSFLDLVGAWGQGTLLTVKPPGGGSGVQV ETISPGDGRTPPKRGQTCVVHYTGMLLEDGKKFDSRDRNKPFFKFM LGKQEVIRGWEEGVAQMSVGQRAKLTISPDIYAGATGHPGII PPH ATLVFDVELLKLESNIKVLPTWSTPVQPMALIVLGGVAGLLLFIFG LGIFFCVRCRHRRRQ
170	SR303 - CD8ss.FRBstar.CD3e.P 2A.huIgKss.antiROR1. FKBP.minCD4hinge.CD4 tm.CD4ic	ALPVTALLLPALLLHAARPGSILWHEMWHEGLEEASRLYFGERN VKGMEFEVLEPLHAMMERGPQTLKETSFNQAYGRDLMEAEWCRKY MKSGNVKDLTQAWDLYYHVFRRIKGGGSGGGGSGGGSDGNEE MGGITQTPYKVSISGTTVILTCPQY?GSEILWQHNDKNI GGDEDD KNIGSDEDHLSLKEFSELEQSGYYVCYPRGSKPEDANFYLYLRAR VCENCMEMDMVSVATIVIVDICTGGLLLVYYWSKNRKAKAKPV TRGAGAGGRQGRQNKERPPVPNPDPYEP IRKGQRDLYSGLNQRR SGSGATNFSLLKQAGDVEENPGPSMETPAQLLFLLLWL P DTTGD IQMTQSPSFLSASVGDRTINCKASQNI DRYLNWYQQKLGAE?KR LLYNTNKLQGTGIPSRFSGSGSATDFTLTISLQPEDFATYFCLQY NSLPLTFGSGTKLEIKGGGSGGGGSGGGSEVQLVESGGGLVQ GRSLKLSAASGFI FSEHNMAWVRQAPKKGLEWVATISDDGPNY YRDSMRGRFTISRENARSTLYLQLDLSRSEDATATYGCASHRYNLF DSWGQGVMTVSSGGGSGVQVETISPGDGRTPPKRGQTCVVHYT GMLLEDGKKFDSRDRNKPFFKMLGKQEVIRGWEEGVAQMSVGQRA KLTISPDIYAGATGHPGII PPHATLVFDVELLKLESNIKVLPTWS TPVQPMALIVLGGVAGLLLFIFGLGIFFCVRCRHRRRQ

All publications, patent applications, and issued patents cited in this specification are herein incorporated by reference as if each individual publication, patent application, or issued patent were specifically and individually indicated to be incorporated by reference.

5 Although the foregoing embodiments have been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be readily apparent to one of ordinary skill in the art in light of the teachings contemplated herein that certain changes and modifications may be made thereto without departing from the spirit or scope of the appended claims. The following examples are provided by way of illustration only and not by way of
10 limitation. Those of skill in the art will readily recognize a variety of noncritical parameters that could be changed or modified to yield essentially similar results.

EXAMPLES

EXAMPLE 1

CONSTRUCTION OF RAPAMYCIN-INDUCIBLE TCRs (T CELL RECEPTORS)

5 Lentiviral vectors comprising constructs that include at least a multimerization domain (*e.g.*, a rapamycin-inducible dimerization domain), a CD3 subunit, and an extracellular antigen targeting domain were designed, cloned, and sequence verified. The constructs comprise various combinations of the following units: a signal sequence (*e.g.*, a CD8 α or IgK derived signal sequence), one or more multimerization domains (*e.g.*, an FK506-binding protein (FKBP12 or FKBP) and an FKBP-rapamycin binding protein (FRB or FRB*)), a CD3 subunit, one or more viral self-cleaving peptides (*e.g.*, P2A or T2A self-cleaving peptides) one or more extracellular antigen targeting domains (*e.g.*, an antibody derived targeting domain or a natural ligand derived targeting domain, various hinges and transmembrane domains (*e.g.*, those derived from CD4 or CD28), one or more intracellular domains (*e.g.*, costimulatory domains), and one or more coreceptor or cytokine receptor domains (see **Figures 1A-1H**). Transgenic TCRs were also expressed alongside the above components in some constructs.

EXAMPLE 2

20 EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH NO HINGE DOMAIN ANCHORING FKBP12

T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process then evaluated for expression and biological activity against specific target antigens (see Leung *et al.*, *JCI Insight*. 2019 Apr 30;5(11)). Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with no hinge domain between the FKBP12 multimerization domain and the CD4 transmembrane domain (CD4_{tm}) of the targeting component (SR024) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system (Wilson Wolf) 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-

dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR024-T cells) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting domain (*e.g.* anti-CD33 VHH), FRB multimerization domain and FKBP12 multimerization domain, using a recombinant CD33-Fc fusion, anti-FRB antibody and anti-FKBP12 antibody, respectively. As shown in **Figure 2**, FRB and CD33 components were highly expressed compared to control cells that were untransduced.

SR024-T cells' rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ , IL2, IL4 and TNF α production was quantified using MSD from supernatants of cultures with SR024-T cells and a cell line engineered to express high levels of CD33 (**Figure 3**). SR024-T cells released each of these 4 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD). Additionally, T cells were cultured alone with no antigen present, both in the presence of and without 1 nM of rapamycin (**Figure 4**). In both cases, SR024-T cells produced 2 orders of magnitude less IFN γ than if they were cultured in the presence of antigen.

The cytotoxicity of SR024-T cells was assessed by incubating them with cells that express target antigen and a nuclear red fluorescent molecule. Cells expressing nuclear fluorescence (antigen positive target line) and cells not expressing nuclear fluorescence (SR-T cells) were both tracked over approximately 200 hours using an Incucyte® live cell imaging system (Sartorius). While SR024-T cells did not effectively kill CD33+ target cells (**Figure 5A**), they significantly expanded in these cultures compared to a T cell control (**Figure 5B**).

25

EXAMPLE 3

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH FKBP12 ANCHORED TO CD4 OR CD28 HINGE DOMAINS

T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, PBMCs were cultured in an IL-2

30

containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with an FKBP12 containing targeting component anchored to CD4 or CD28 hinge domains (CD4h or CD28h), or no hinge domain (SR022, SR020, and SR024), were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity; as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR022-, SR020-, and SR024-T cells) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting domain (*e.g.*, anti-CD33 VHH), FRB multimerization domain and FKBP12 multimerization domain, using a recombinant CD33-Fc fusion, anti-FRB antibody and anti-FKBP12 antibody, respectively. FRB and CD33 components were highly expressed compared to control cells that were untransduced (**Figure 6**).

The rapamycin-dependent, antigen-dependent activity of SR022-, SR020-, and SR024-T cells was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ , IL2, IL4 and TNF α production was quantified using MSD from supernatants of cultures with SR022-, SR020-, or SR024-T cells; and a cell line engineered to express high levels of CD33 (**Figure 7A**). Both SR022- and SR020-T cells released each of these 4 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD). SR020 showed decreased IFN γ , IL2, and TNF α compared with SR022, but comparable IL4. SR024-T cells had diminished cytokine release across all 4 cytokines compared to SR022- and SR020-T cells.

T cells were also co-cultured with CD33+ cell lines with high, medium and low antigen density. SR022- and SR020-T cells produce more IFN γ than SR024-T cells at all antigen densities, particularly at low antigen density (**Figure 7B**). Additionally, SR022- and SR020-T cells generate IL2 in cultures at all antigen densities, whereas SR024-T produced little to no IL2 (**Figure 7C**). SR022-T cells secrete more IFN γ and IL2 across high, medium and low CD33+ antigen density target lines. T cells were also cultured alone with no antigen present, both in the presence of and without 1nM of rapamycin (**Figure 8**). Without antigen present, SR024, SR022 and SR020-T cells generated 2 orders of magnitude less IFN γ than when antigen was present.

The cytotoxicity of SR024-, SR022- and SR020-T cells was assessed by incubating them with cells that express target antigen and a nuclear red stain. Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 200 hours using an Incucyte® live cell imaging system (Sartorius). While SR024-T cells displayed minimal killing of CD33+ target cells (**Figure 9A**), they significantly expanded in these cultures compared to a T cell control (**Figure 9B**). SR022-T cells were able to effectively kill CD33+ target cells (**Figure 9A**) and expand compared to a T cell control (**Figure 9B**). While SR020-T cells expanded well compared to control (**Figure 9B**), they performed intermediately in the cytotoxicity assay (**Figure 9A**). Overall, SR022-T cells performed significantly better in a cytotoxicity assay compared to SR020- or SR024-T cells.

Figures 7A-7C, 8, and 9A-9B demonstrate that SR020 and SR022, which comprise a hinge domain, exhibit improved cytokine release profiles and increased killing of CD33+ target cells as compared to SR024, which lacks a hinge domain (see **Figures 1A and 1D**). Without wishing to be bound by any particular theory, it is contemplated that the addition of the hinge domain to the signaling components improves the function of the architecture by allowing the first multimerization domain of the signaling component to spatially align better with the multimerization domain of the targeting component, surprisingly increasing the efficacy of the targeting components that comprise a hinge domain compared to targeting components lacking a hinge domain.

EXAMPLE 4

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH FRB APPENDED TO CD3 γ

T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with FRB appended to CD3 γ instead of CD3 ϵ (SR021) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated

for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR021-T cells) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting domain (*e.g.*, anti-CD33 VHH), FRB dimerization domain and FKBP12 dimerization domain, using recombinant CD33-Fc fusion, anti-FRB antibody and anti-FKBP12 antibody, respectively. FRB and CD33 components were highly expressed compared to control cells that were untransduced (**Figure 10**).

The rapamycin-dependent, antigen-dependent activity of SR021-T cells was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ , IL2, IL4 and TNF α production was quantified using MSD from supernatants of cultures with SR021-T cells and a cell line engineered to express high levels of CD33 (**Figure 11**). SR021-T cells released each of these 4 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD). Additionally, T cells were cultured alone with no antigen present, both without and in the presence of 1 nM of rapamycin (**Figure 12**). Without antigen present, SR021-T cells generated 2 orders of magnitude less IFN γ than when antigen was present.

The cytotoxicity of SR021-T cells to cells that express target antigen was assessed using a target line that expressed a nuclear red stain and tracked over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 200 hours. SR021-T cells displayed a trend toward killing CD33+ cells (**Figure 13A**) and significantly expanded compared to a T cell control (**Figure 13B**).

EXAMPLE 5

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH FRB* (T2098L)

T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible

TCRs with either FRB or a mutant FRB—FRB (T2098L)—that allows for the binding of certain rapamycin analogs (denoted FRB*) (SR022 and SR001, respectively) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were
5 evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR022-T cells and SR001-T cells for FRB and FRB*, respectively) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting
10 domain (*e.g.*, anti-CD33 VHH) and FRB multimerization domain, using recombinant CD33-Fc fusion and anti-FRB antibodies, respectively. FRB and CD33 components were highly expressed compared to control cells that were untransduced (**Figure 14**).

The rapamycin-dependent, antigen-dependent activity of SR022-T cells and SR001 T cells was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1
15 nM rapamycin. Specifically, IFN γ , IL2, and TNF α production was quantified using MSD from supernatants of cultures with SR022- or SR001-T cells, and a cell line engineered to express high levels of CD33 (**Figure 15**). Both SR022- and SR001-T cells released each of these 3 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD). Additionally, T cells were cultured alone with no antigen present, both
20 without and in the presence of 1 nM of rapamycin (**Figure 16**). Without antigen present, SR022- and SR001-T cells generated 3 orders of magnitude less IFN γ than when antigen was present.

The cytotoxicity of SR001-T cells to cells that express target antigen was assessed using a target line that expressed a nuclear red stain and tracked over time using an
25 Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 160 hours. SR001-T cells effectively killed CD33+ target cells (**Figure 17A**) and significantly expanded compared to a T cell control (**Figure 17B**).

EXAMPLE 6

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH FKBP12 DISTAL TO ANTIGEN TARGETING DOMAINS

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge (CD4h), transmembrane (CD4tm) and minimal intracellular (CD4ic) domains anchoring an antigen targeting domain followed by an FKBP12 multimerization domain (SR028) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR028-T cells) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting domain (*e.g.*, anti-CD33 VHH), FRB multimerization domain and FKBP12 multimerization domain, using a recombinant CD33-Fc fusion, anti-FRB antibody and anti-FKBP12 antibody, respectively. FRB, FKBP12 and CD33 components were highly expressed compared to control cells that were untransduced (**Figure 18**).

SR028-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ , IL2, IL4 and TNF α production was quantified using MSD from supernatants of cultures with SR028-T cells and a cell line engineered to express high levels of CD33 (**Figure 19**). SR028-T cells released each of these 4 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD). Additionally, T cells were cultured alone with no antigen present, both without and in the presence of 1 nM of rapamycin. While SR028-T cells produced no IFN γ when rapamycin was absent, when 1 nM of rapamycin was added to the SR028-T cells with no antigen present, IFN γ was released at levels comparable to when antigen was present (**Figure 20**). SR028-T cells produced a

significant amount of IFN γ without antigen present, comparable to what was produced in the presence of antigen.

The cytotoxicity of SR028-T cells to cells that express target antigen was assessed using a target line that expressed a nuclear red stain and tracked over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 200 hours. SR028-T cells effectively killed CD33+ target cells (**Figure 21A**) and significantly expanded compared to a T cell control (**Figure 21B**).

10

EXAMPLE 7

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH MULTI-ANTIGEN TARGETING

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge, transmembrane and intracellular domains anchoring a FKBP12 or FRB multimerization domain and two antigen targeting domains (SR004 and SR006) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system (Wilson Wolf) 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR004-T cells and SR006-T cells) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting domains (*e.g.*, anti-CD33 and anti-CLL1 VHH) and an FRB multimerization domain, using a recombinant CD33-Fc fusion, recombinant CLL1-Fc fusion and anti-FRB antibody, respectively. FRB, anti-CD33 and anti-CLL1 components were highly expressed compared to control cells that were untransduced (**Figure 22**).

SR0004- and SR0006-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ , IL2, IL4 and TNF α production was quantified using MSD from supernatants of cultures with SR004- and SR006-T cells and a cell line engineered to express high levels of CD33 and CLL1. SR004- and SR006-T cells released each of these 4 cytokines at levels that were distinguishable from baseline (untransduced control; UTD). SR004-T cells trended toward showing increased IFN γ and IL2 release over SR006-T cells, and displayed significantly more TNF α release (**Figure 23**). Additionally, T cells were cultured alone with no antigen present, both without and in the presence of 1 nM of rapamycin. While SR004-T cells and SR006-T cells produced no IFN γ when rapamycin was absent, when 1 nM of rapamycin was added to the SR004-T cells with no antigen present, IFN γ was released at levels below that observed with antigen present, but above baseline (**Figure 24**).

The cytotoxicity of SR004 and SR006-T cells to cells that express both target antigens was assessed using a target line that expressed a nuclear red stain and tracked over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 250 hours. SR004- and SR006-T cells effectively kill CD33+CLL1+ target cells (**Figure 25A**) and significantly expanded in these cultures compared to an untransduced T cell control (**Figure 25B**).

EXAMPLE 8

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH 4-1BB COSTIMULATORY DOMAIN

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge and transmembrane domains anchoring a FKBP12 multimerization domain and two antigen targeting domains, with and without a 4-1BB costimulatory domain (SR030 and SR008, respectively) were used to transduce the PBMCs

one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

5 SR-T cells transduced with lentiviral vectors described above (SR008-T cells and SR030-T cells) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting domains (*e.g.*, anti-CD33 and anti-CLL1 VHH) and an FRB multimerization domain, using a recombinant CD33-Fc fusion, recombinant CLL1-Fc fusion and anti-FRB antibody, respectively. Additionally, an
10 antigen agnostic anti-VHH antibody was used to detect any targeting domain with a VHH format. FRB, anti-CD33 and anti-CLL1 components were highly expressed compared to control cells that were untransduced (**Figures 26A and 26B**). This was validated using anti-VHH.

Additionally, SR008- and SR030-T cells were stained using antibodies against
15 CD62L and CD45RA and expression of each molecule was determined using flow cytometry. Cells were then differentiated into CD62L+CD45RA+ (T naive), CD62L+CD45RA- (T central memory), CD62L-CD45RA+ (T effector memory) and CD62L-CD45RA- (T effector) populations using Flowjo to gate stained cells. While SR008-T cells resembled an untransduced cell in phenotype, the addition of 4-1BB costimulation
20 altered the T cell phenotype to be skewed towards effector memory differentiation compared to untransduced controls in CD4+ (**Figure 26C**) and CD8+ (**Figure 26D**) T-cell compartments.

SR008- and SR030-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM
25 rapamycin. Specifically, IFN γ , IL2, IL4 and TNF α production was quantified using MSD from supernatants of cultures with SR008- and SR030-T cells and a cell line engineered to express high levels of CD33 and CLL1 (**Figures 27A and 27B**, respectively). SR008- and SR030-T cells released each of these 4 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD). Furthermore, SR030-T cells produced more
30 IFN γ and TNF α compared to SR008-T cells that lacked 4-1BB costimulation.

SR008- and SR030-T cell rapamycin-dependent, antigen-independent activity was evaluated in cultures with 1 nM rapamycin alone. Specifically, IFN γ production was

quantified using MSD from supernatants of cultures with SR008- and SR030-T cells alone, with and without rapamycin (**Figure 27C**). SR030-T cells released significantly more IFN γ than SR008-T cells with and without rapamycin and with no antigen stimulation.

The cytotoxicity of SR008 and SR030-T cells to cells that express both target antigens was assessed using a target line that expressed a nuclear red stain and tracked over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 250 hours. SR008 and SR030-T cells effectively killed CD33+ target cells, with SR030-T cells controlling tumor growth for a longer duration of time (**Figure 28A**). Similarly, in a co-culture with CLL1+ target cells, SR030-T cells controlled tumor cell growth for longer compared to SR008-T cells (**Figure 28B**).

EXAMPLE 9

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH CD28 COSTIMULATORY DOMAIN

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge and transmembrane domains anchoring an FKBP12 multimerization domain and one antigen targeting domain, with and without a CD28 costimulatory domain (SR001-28 and SR001, respectively) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR001-T cells and SR001-28-T cells) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting domains (*e.g.*, anti-CD33) and FRB multimerization domains, using a recombinant CD33-Fc fusion and anti-

FRB antibody, respectively. FRB and anti-CD33 components were highly expressed compared to control cells that were untransduced (**Figure 29**).

SR001- and SR001-28-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ , IL2, IL4 and TNF α production was quantified using MSD from supernatants of cultures with SR001- and SR001-28-T cells and a cell line endogenously expressing high levels of CD33 (**Figure 30**). SR001- and SR001-28-T cells released each of these 4 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD).

The cytotoxicity of SR001 and SR001-28-T cells to cells that express both target antigens was assessed using a target line that expressed a nuclear red stain and tracked over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 150 hours. SR001 and SR001-28-T cell effectively killed CD33+ target cells (**Figure 31A**) and significantly expanded in these cultures compared to an untransduced T cell control (**Figure 31B**).

EXAMPLE 10

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH 4-1BB OR CD28 COSTIMULATORY DOMAIN IN VIVO

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge and transmembrane domains anchoring a FKBP12 multimerization domain and one antigen targeting domain to a 4-1BB or a CD28 costimulatory domain (SR001, SR001-41BB, SR001-28) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 1L G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

Female NSG mice were dosed intravenously with a CD33+ HL-60 xenograft tumor cells expressing firefly luciferase. After 10 days of tumor growth, 10E6 untransduced, SR001, SR001-41BB, or SR001-28 T cells were administered intravenously without rapamycin (**Figure 32A**) or with rapamycin dosed three times per week (**Figure 32B**).

- 5 Alternatively, 3E6 untransduced, SR001, SR001-41BB or SR001-28 T cells were administered intravenously with rapamycin dosed three times per week (**Figure 32C**) and survival was monitored for 38 days (**Figure 32D**). In all instances, SR001 performed or trended better than SR001-41BB and SR001-28 T cells.

10

EXAMPLE 11

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH A CD4 OR CD8 CORECEPTOR DOMAIN

- In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge and transmembrane domains anchoring a FKBP12 multimerization domain and one antigen targeting domain to a CD4 or CD8 coreceptor domain (SR022, SR022+CD4 and SR022+CD8) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

- 25 SR-T cells transduced with lentiviral vectors described above (SR022, SR022+CD4 and SR022+CD8) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, specifically the FRB multimerization domain, using an anti-FRB antibody. FRB was highly expressed compared to control cells that were untransduced (**Figure 33**).

- 30 SR022, SR022+CD4 and SR022+CD8-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ and IL2 production was quantified using

MSD from supernatants of cultures with SR022, SR022+CD4 and SR022+CD8-T cells and a cell line endogenously expressing high levels of CD33 (**Figure 34**). SR022, SR022+CD4 and SR022+CD8-T cells released each of these 2 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD).

5

EXAMPLE 12

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH A TRANSGENIC TCR

In another experiment, T cells expressing rapamycin-inducible T cell receptors and a transgenic TCR (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge and transmembrane domains anchoring a FKBP12 multimerization domain and one antigen targeting domain. Additionally, the same lentiviral vector encodes a transgenic TCR (SR001 and TCR+SR001) This vector was used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR001 and TCR+SR001) were analyzed for transgene integration using a qPCR-based assay to determine vector copy number (**Figure 35A**) and extracellular expression of key components of the rapamycin-inducible + transgenic TCR system by flow cytometry, including the TCR, using the beta chain-specific antibody and an epitope-specific tetramer (**Figures 35B and 35C**), and the targeting domains using an anti-VHH. All components were highly expressed compared to control cells that were untransduced (**Figures 35D and 35E**).

SR001 and TCR+SR001-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ , IL2 and TNF α production was quantified using MSD from supernatants of cultures with SR001 and TCR+SR001-T cells and a cell line endogenously expressing high levels of the HLA-A2+TCR epitope, with and without rapamycin (**Figure**

36A). IFN γ production was also quantified using MSD from supernatants of cultures with SR001 and TCR+SR001-T cells and a cell line endogenously expressing high levels of CD33, with and without rapamycin (**Figure 36B**). In all cases, SR001 and TCR+SR001-T cells released each cytokine at levels that were highly distinguishable from baseline (untransduced control; UTD). Additionally, the combination of the transgenic TCR with SR001 in T cells did not diminish antigen-specific cytokine release compared to T cells expressing only TCR or SR001.

The cytotoxicity of SR001 and TCR+SR001-T cells to cells that express either target antigens was assessed using two target lines that expressed a nuclear red stain and tracked over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 120 hours. TCR or TCR+SR001-T cells effectively killed TCR epitope+ target cells (**Figure 36C, top panel**) while SR001 and TCR+SR001-T cell effectively killed CD33+ target cells (**Figure 36C, bottom panel**).

EXAMPLE 13

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS AT VERY LOW ANTIGEN DENSITY

In another experiment, T cells expressing rapamycin-inducible T cell receptors and a transgenic TCR (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge and transmembrane domains anchoring a FKBP12 multimerization domain and one antigen targeting domain (SR001) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR001-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, target cells were transfected with CD33- or CLL1-encoding mRNA to generate

target cells expressing less than 1500 molecules of each per cell. IL2 production was quantified using MSD from supernatants of cultures with SR001 (**Figures 37A and 37B**). SR001-T cells released IL2 at levels that were highly distinguishable from baseline (untransduced control; UTD).

5

EXAMPLE 14

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS IN VIVO TO CONTROL LOW ANTIGEN TUMORS

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge and transmembrane domains anchoring a FKBP12 multimerization domain and one antigen targeting domain (*i.e.*, a CD33 VHH or a CLL1 VHH) (SR001 and SR007, respectively) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 1L G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

Female NSG mice were dosed intravenously with a CD33+CLL1+ OCI-AML3 xenograft tumor cells expressing firefly luciferase. After 10 days of tumor growth, 10E6 untransduced, SR007-, or comparator regulated CAR-T cells were administered intravenously with rapamycin dosed three times per week (**Figure 38**). The comparator regulated CAR (Reg CAR 1) was a 2nd-generation 41BB-CD3ζ split into two, rapamycin regulated domains, using the same CLL1 binder as SR007 (see, *e.g.*, Leung *et al.*, *JCI Insight*. 2019 Apr 30;5(11), for general regulated CAR design). Mice treated with SR007-T cells controlled their tumors faster and more deeply than mice treated with comparator regulated CAR T cells.

EXAMPLE 15

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS TARGETING CD19

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge, transmembrane, and intracellular domains anchoring either a FKBP12 or FRB multimerization domain and two antigen targeting domains (SR10167 and SR10168; each having a CD19 VHH or a CD19 scFv, respectively) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system (Wilson Wolf) 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR10167- and SR10168-T cells) were analyzed for transgene integration using a qPCR-based assay to determine vector copy number (**Figure 39A**) and for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including targeting domains (*e.g.*, CD19 VHH or scFv) and the FRB multimerization domain, using a recombinant CD19-Fc fusion and anti-FRB antibody, respectively. FRB and anti-CD19 components were highly expressed compared to control cells that were untransduced (**Figures 39B and 39C**).

T cells were cultured alone with no antigen present, both without and in the presence of 1 nM of rapamycin. SR10167- and SR10168-T cells produced no IFN γ when rapamycin was absent and only small amounts comparable to untransduced when 1 nM of rapamycin was added to the culture. (**Figures 40A and 40B**). By comparison, comparator regulated CARs that were targeted using either the CD19 VHH (Reg CAR1) or the CD19 scFv (Reg CAR 2) produced IFN γ at levels significantly higher than baseline both with and without 1nM rapamycin in the cultures.

SR10167- and SR10168-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence or absence of

1 nM rapamycin. Specifically, IFN γ production was quantified using MSD from supernatants of cultures with SR10167- and SR10168-T cells and cell lines that endogenously express CD19 (**Figures 41A and 41B**). Additionally, TNF α and IL2 were quantified. SR10167- and SR10168-T cells released each of these 3 cytokines at levels that were
 5 distinguishable from baseline (untransduced control; UTD) but lower than comparable regulated CAR Ts. (**Figures 42A-42D**).

The cytotoxicity of SR10167 -T cells to cells that express target antigens was assessed using two target lines that expressed GFP and tracked over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing GFP (antigen positive target line) and cells not
 10 expressing GFP (SR-T cells) were both tracked over approximately 120 hours. SR10167 -T cells effectively kill CD19+ target cells (**Figures 43A and 43B**) For both CD19+ target cultures, SR10167-T cells trended to having superior cytotoxicity than the comparator regulated CAR (Reg CAR 1).

15

EXAMPLE 16

CONSTRUCTION AND EVALUATION OF CONSTITUTIVE T CELL RECEPTOR-LIKE ARCHITECTURES

To generate a rapamycin-independent, constitutive TCR-like architecture, the FRB and FKBP12 domains were substituted with heterodimerization domains derived from the
 20 CH3 region of Fc-engineered bispecific antibodies. Lentiviral vectors comprising constructs that include constitutive heterodimerization domain pairs, CD3 subunits and an antigen targeting domain were designed, cloned and sequences were verified. Constructs comprise a promoter driving expression of a combination of the following units: a CD8 α or IgKa signal sequence, antibody Fc CH3 heterodimerization domain pairs, an antibody derived targeting
 25 domain (*e.g.*, CD33 VHH), CD4 hinge, transmembrane and intracellular domains. (**Figure 44**; constructs SR292, SR293, and SR296). Specifically, for constructs SR292, SR293, and SR296, the CH3 heterodimerization domain pairs were derived using mutations from previously described knobs-in-holes antibodies, SEEDbody using chimeric IgA/IgG CH3 domains, and DEKK electrostatic pairs, respectively (see, *e.g.*, Merchant, A., Zhu, Z., Yuan,
 30 J. *et al.* An efficient route to human bispecific IgG. *Nat Biotechnol* 16, 677–681 (1998). Nardis, C., Hendriks, L., Poirier, E. *et al.* A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human

immunoglobulin G1. *J Biol Chem* 292, 14706-14717 (2017). Davis, J., Aperlo, C., Li, Y. *et al.* SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies *Protein Engineering, Design and Selection*, Volume 23, Issue 4, April 5 2010, Pages 195–202. While the pairs were tested in one orientation within the construct, it is anticipated that the opposite orientation would function similarly.

T cells expressing constitutive T cell receptor-like architectures (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood 10 mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding the constructs were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for antigen-dependent activity as well as antigen-independent 15 background activity. A standard CAR, regulated CAR, architecture comparator and SR001 targeting the same antigen were used as functional controls and comparators.

SR-T cells transduced with lentiviral vectors described above (SR292, SR293, and SR296 T cells) were analyzed by flow cytometry for extracellular expression of the targeting domain fused to one half of the CH3 heterodimerization domains linked to a transmembrane 20 domain using a recombinant anti-VHH antibody (**Figures 45A and 45B**). All constructs expressed and were evaluable.

SR292, SR293, and SR296 T cell antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells. The induced dimerization control constructs, regulated CAR and SR001 T cells, included the addition of a dimerization agent to promote 25 activity. Specifically, IFN γ and IL2 production was quantified using MSD from supernatants of co-cultures with T cells and a HL60 cell line expressing the target antigen CD33 (**Figures 46A and 46B**). SR292, SR293, and SR296-T cells released cytokines at levels that were amplified from baseline, untransduced control T cells, indicating antigen-dependent activation. SR292, SR293, and SR296 T cells did not exhibit robust cytokine secretion when 30 cultured alone with no antigen present and the levels were comparable to untransduced T cells (**Figure 47**).

The cytotoxicity of SR292, SR293, and SR296-T cells was assessed by co-culturing transduced SR-T cells with antigen positive tumor cells engineered to express a nuclear red fluorescent protein. Cells displaying nuclear fluorescence (antigen positive target line) and cells not expressing nuclear fluorescence (SR-T cells) were both tracked over approximately 5 140 hours using an Incucyte® live cell imaging system (Sartorius). SR292, SR293, and SR296 modified T cells effectively eliminated red-labeled antigen positive tumor cells and modified T cells expanded at levels comparable to a control anti-CD33 CAR molecule (Figures 48A and 48B).

Altogether, these data are indicative of the generation of a constitutive, antigen-10 dependent TCR-like architecture capable of re-directing T cell activity.

EXAMPLE 17

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS WITH CYTOKINE RECEPTOR DOMAINS

15 In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-20 inducible TCRs with CD4 hinge, transmembrane and intracellular domains anchoring an FKBP12 or FRB multimerization domain and antigen targeting domains to cytokine receptor intracellular signaling domains (SR001±IL7R α , IL2R β , common γ chain or both IL2R β and common γ chain) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system (Wilson Wolf) 48 hours later. 25 After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR001±IL7R α , IL2R β , common γ chain, or both IL2R β and common γ chain- T cells) were analyzed for 30 extracellular expression of key components of the rapamycin-inducible system by flow cytometry, specifically FRB dimerization domain using anti-FRB antibody. FRB

components were highly expressed compared to control cells that were untransduced (**Figure 49**).

SR001±IL7Rα, IL2Rβ, common γ chain, or both IL2Rβ and common γ chain-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence or absence of 1 nM rapamycin. Specifically, IFNγ and IL2 production was quantified using MSD from supernatants of cultures with SR001±IL7Rα, IL2Rβ, common γ chain, or both IL2Rβ and common γ chain-T cells and cell lines that endogenously express CD33. SR001±IL7Rα, IL2Rβ, common γ chain, or both IL2Rβ and common γ chain-T cells released each of these 2 cytokines at levels that were distinguishable from baseline (untransduced control) but lower than comparable regulated CAR Ts. (**Figures 50A-50D**).

Antigen-specific T cell proliferation of SR001±IL7Rα, IL2Rβ, common γ chain, or both IL2Rβ and common γ chain-T cells was assessed by culturing a CD33+ target line that expresses a red nuclear fluorescent stain and tracking T cell growth over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 100 hours. SR001±IL7Rα, IL2Rβ, common γ chain or both IL2Rβ and common γ chain -T cells proliferated in the presence of CD33+ target cells (**Figure 51**), particularly those that had IL7Rα and common γ chain signaling.

EXAMPLE 18

EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS TARGETING WITH NATURAL LIGANDS

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge, transmembrane and intracellular domains anchoring an FKBP12 or FRB multimerization domain and natural ligand antigen targeting domains (*e.g.*, high-affinity PD1 (see, *e.g.*, US20220378873A1) and PD1 ectodomains; SR300 and SR301, respectively) were used to transduce the PBMCs one day after culture initiation, then cells

were transferred to a 24-well G-REX® culture system (Wilson Wolf) 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

5 SR-T cells transduced with lentiviral vectors described above (SR300 and SR301) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including FRB multimerization domain and natural ligand, PD1 using anti-FRB and anti-PD1 antibodies, respectively. FRB and PD1 targeting components were highly expressed compared to control cells that were untransduced (**Figure 52**).

10 Antigen-specific cytotoxicity of SR300 and SR301-T cells was assessed by culturing a PDL1+ or PDL1/PDL2 knock-out target line that expresses a red nuclear fluorescent stain and tracking T cell growth over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain (SR-T cells) were both tracked over approximately 115 hours. SR300 and SR301-T
15 cells killed PDL1+ target cells only when rapamycin is present (**Figures 53A-53D**), but not when PDL1/PDL2 is knocked out. The high-affinity PD1-ectodomain (SR300-T cells) more efficiently killed PDL1+ target cells lines compared to natural PD1-ectodomain.

EXAMPLE 19

20 EVALUATION OF RAPAMYCIN-INDUCIBLE Fc RECEPTOR NK CELLS

 In another experiment, NK cells expressing rapamycin-inducible Fc receptors (SR-NK cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were activated with microbeads coated with anti-CD2 and
25 anti-NKp46, then cultured in growth media containing human serum, HEPES, glutamine and a NK-specific cocktail of cytokines, including IL2, IL15, IL18, IL21 and IL12. Lentiviral vectors encoding rapamycin-inducible Fc epsilon receptor gamma with CD4 hinge, transmembrane and intracellular domains anchoring an FKBP12 or FRB multimerization domain and antigen targeting domains (SR354) were used to transduce the PBMCs two days
30 after culture initiation. Cells were washed then transferred to a 24-well G-REX® culture system (Wilson Wolf) 48 hours later in NK growth medium containing IL2, IL15, IL18, IL21 and IL12. After a total of 10 days in culture, CD3+ T cells remaining in the culture were

removed using magnetic bead sorting, resulting in a population of only NK cells. SR-NK cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-NK cells transduced with lentiviral vectors described above (SR354) were
5 analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, including VHH targeting domain using an anti-VHH antibody. VHH targeting components were highly expressed compared to control cells that were untransduced (**Figure 54**).

SR354- NK cell rapamycin-dependent, antigen-dependent activity was evaluated in
10 co-cultures with target antigen positive tumor cells in the presence or absence of 1 nM rapamycin. Specifically, IFN γ production was quantified using MSD from supernatants of cultures with SR354-NK cells and cell lines that endogenously express CD33 or had CD33 knocked out. SR354-NK cells released cytokine at levels that were distinguishable from baseline (untransduced control) and were regulated completely by both rapamycin and
15 antigen. (**Figures 55A and 55B**).

Antigen-specific cytotoxicity of SR354-NK cells was assessed by culturing a CD33+ or CD33 knocked-out target line that expresses a red nuclear fluorescent stain and tracking cytotoxicity over time using an Incucyte® live cell imaging system (Sartorius). Cells expressing nuclear stain (antigen positive target line) and cells not expressing nuclear stain
20 (SR-NK cells) were both tracked over approximately 120 hours. SR354-NK cells killed CD33+ target cells only when rapamycin was present (**Figures 55C and 55D**), but not when CD33 is knocked out.

EXAMPLE 20

25 EVALUATION OF RAPAMYCIN-INDUCIBLE TCR T CELLS TARGETING ROR1

In another experiment, T cells expressing rapamycin-inducible T cell receptors (SR-T cells) were generated using a 10-day transduction and expansion process, then evaluated for expression and biological activity against specific target antigens. Briefly, peripheral blood mononuclear cells (PBMCs) were cultured in an IL-2 containing media and activated with
30 antibodies against human CD3 and human CD28. Lentiviral vectors encoding rapamycin-inducible TCRs with CD4 hinge and transmembrane domains anchoring a FKBP12

multimerization domain and one antigen targeting domain (SR303) were used to transduce the PBMCs one day after culture initiation, then cells were transferred to a 24-well G-REX® culture system 48 hours later. After a total of 10 days in culture, SR-T cells were evaluated for rapamycin-dependent, antigen-dependent activity, as well as rapamycin-independent, antigen-independent background activity.

SR-T cells transduced with lentiviral vectors described above (SR303) were analyzed for extracellular expression of key components of the rapamycin-inducible system by flow cytometry, specifically the ROR1-targeted targeting domain, using an anti-ROR1 scFv. ROR1 scFv was highly expressed compared to control cells that were untransduced (**Figure 56**).

SR303-T cell rapamycin-dependent, antigen-dependent activity was evaluated in co-cultures with target antigen positive tumor cells in the presence of 1 nM rapamycin. Specifically, IFN γ and IL2 production was quantified using MSD from supernatants of cultures with SR303-T cells and a cell line endogenously expressing high levels of human ROR1 (**Figure 57A and 57B**). SR303-T cells released each of these 2 cytokines at levels that were highly distinguishable from baseline (untransduced control; UTD). Additionally, T cells were cultured alone with no antigen present, both without and in the presence of 1 nM of rapamycin. SR303-T cells produced minimal IFN γ when rapamycin was absent or when 1 nM of rapamycin was added with no antigen present (**Figure 57C**).

EXAMPLE 21

ILLUSTRATIVE ENGINEERED IMMUNE RECEPTOR CONSTRUCTS

Contemplated herein are engineered immune receptors comprising signaling and targeting components that can redirect signaling of either a native or engineered/exogenous multimeric immune receptor complex in response to a selected antigen. Signaling components contemplated herein comprise a multimerization domain, an optional linker, and an actuator domain. Targeting components contemplated herein comprise an extracellular domain comprising one or more targeting domains (also referred to herein as “binders” or “antigen binders”), a multimerization domain, an optional hinge domain, a transmembrane domain, and an optional intracellular domain (e.g., truncated intracellular domain, intracellular signaling domain, or costimulatory domain). The engineered immune receptor

components and subunits/domains can be surprisingly combined to produce an engineered immune receptor having increased sensitivity over traditional CARs, low tonic or antigen-independent signaling, increased targeting capabilities, and optionally regulatability. In other words, the components can be combined without destroying the functionality of either the native or engineered/exogenous immune receptor complex or the targeting component(s) of the engineered immune receptor(s) described herein. Thus, the engineered immune receptors contemplated herein also surprisingly provide (1) multi-specificity, (2) increased sensitivity to non-MHC presented targets, (3) minimal tonic or antigen-independent signaling, and (4) the ability to simultaneously target both intracellular and extracellular targets.

Engineered immune receptors can be constructed in multiple formats and can be designed and constructed using known subunits/domains/polypeptides (*e.g.*, multimerization domains, polypeptide linkers, actuator domains, targeting domains, hinge domains, transmembrane domains, and intracellular domains) and techniques. For example, a signaling component can be constructed by linking a multimerization domain (*e.g.*, one or more “A” subunits) to an actuator domain (*e.g.*, one or more “C” subunits) with or without one or more polypeptide linkers (*e.g.*, with or without one or more “B” subunits) using standard cloning techniques.

Illustrative general signaling component formulas are provided below:

$$A - C$$

$$A - B - C$$

A targeting component can be constructed by linking an extracellular domain (*e.g.*, one or more “D” subunits), to a multimerization domain (*e.g.*, one or more “A” subunits), an optional hinge domain (*e.g.*, one or more “E” subunits), a transmembrane domain (*e.g.*, an “F” subunit), and an optional intracellular domain (*e.g.*, one or more “G” subunits), with or without one or more polypeptide linkers (*e.g.*, with or without one or more “B” subunits) using standard cloning techniques.

Illustrative general targeting component formulas are provided below:

$$D - A - E - F$$

D – B – A – E – F

D – A – E – F – G

D – B – A – E – F – G

D – D – A – E – F

5 D – D – B – A – E – F

D – D – A – E – F – G

D – D – B – A – E – F – G

D – B – D – A – E – F

D – B – D – B – A – E – F

10 D – B – D – A – E – F – G

D – B – D – B – A – E – F – G

In various embodiments, both components (*i.e.*, signaling and targeting) are expressed by a cell separately (*e.g.*, from different polynucleotides, RNA, or DNA) or together as a fusion protein from a single polynucleotide, RNA or DNA. The engineered immune
 15 receptors contemplated herein can be designed and constructed using known subunits/domains/polypeptides (*e.g.*, multimerization domains, polypeptide linkers, actuator domains, targeting domains, hinge domains, transmembrane domains, and intracellular domains) and techniques.

Table 3 provides an illustrative list of known multimerization domains. **Table 4**
 20 provides an illustrative list of known polypeptide linkers. **Table 5** provides an illustrative list of known actuators. **Table 6** provides an illustrative list of known targeting domains. **Table 7** provides an illustrative list of known hinge domains. **Table 8** provides an illustrative list of known transmembrane domains. **Table 9** provides an illustrative list of known intracellular domains. However, other known multimerization domains, polypeptide linkers, actuator
 25 domains, targeting domains, hinge domains, transmembrane domains, intracellular domains,

- and TCRs can be found throughout the literature, *e.g.*, including but not limited to US20120082661, WO2016014789, WO2022046730, WO2016033570, US8147832B2, WO2014026054, WO2018145649, WO2014065961, WO2020123947, WO2013049254, WO2019241685, WO2019241688, WO2016049214, WO2018236870, WO2020102240,
- 5 WO2018183888, US6217866B1, WO2008119566, WO2003055917, WO2018073680, WO2014146672, WO2019200007, WO2016016859, WO2018119279, WO2020227072, WO2020227073, WO2020227071, WO2017153402, WO2007042289, WO2018028647, WO2005113595, US20180273602, WO2019067242, WO2020193767, US10538572B2, US11078252B2, WO2019140100, WO2015009606, WO2021195503, WO2007131092,
- 10 US20190169260, WO2012045085, WO2016115559, and WO2016187220, each of which are incorporated by reference herein, in their entirety. Since other known multimerization domains, polypeptide linkers, actuator domains, targeting domains, hinge domains, transmembrane domains, intracellular domains, and TCRs are well known in the literature, the invention is not intended to be limited to the illustrative components disclosed in **Tables**
- 15 **3-9.**

Table 3 - Illustrative Multimerization Domains (“A” Subunits):

SUBUNIT REFERENCE	SUBUNIT NAME	SEQ ID NO:
A1	FRB*	1
A2	FRB	2
A3	FKBP12	3
A4	FKBP12 F36V	4
A5	CH3 AB (S354C T366W)	5
A6	CH3 IA (Y349C T366S L368A Y407V)	6
A7	CH3 DE (L351D L368E)	7
A8	CH3 KK (L351K T366K)	8
A9	CH3 GA (SEED 1)	9
A10	CH3 AG (SEED 2)	10

Table 4 - Illustrative Polypeptide Linkers (“B” Subunits):

SUBUNIT REFERENCE	SEQUENCE / NAME	SEQ ID NO:
B1	GGGS (G4S; 1xG4S)	11
B2	GGGSGGGGS (2xG4S)	12
B3	GGGSGGGSGGGGS (3xG4S)	13
B4	GGGSGGGSGGGSGGGGS (4xG4S)	14
B5	GGGSGGGSGGGSGGGSGGGGS (5xG4S)	15
B6	DGGGS	16
B7	TGEKP	17

B8	GRR	18
B9	EGKSSSGSGSESKVD	19
B10	KESGSVSSEQLAQFRSLD	20
B11	GRRGGGS	21
B12	LRQRDGERP	22
B13	LRQKDGGGGERP	23
B14	LRQKDGGGSGGGSERP	24
B15	GSTSGSGKPGSGEGSTKG	25
B16	GSTSGSGKSSESGSTKG	26
B17	GSTSGSGKSSEGGK	27
B18	GSTSGSGKPGSGEGS	28
B19	GGGS	29
B20	LEKT (yuTCR linker; uLNK)	30
B21	LEKTGGGGS (uLNK + G4S linker)	31
B22	none	

Table 5 – Illustrative actuators (“C” Subunits):

SUBUNIT REFERENCE	SUBUNIT NAME	SEQ ID NO:
C1	CD3 ϵ	55
C2	CD3 γ	57
C3	CD3 δ	59
C4	Fc ϵ R1 γ v1	61
C5	Fc ϵ R1 γ v2	63
C6	Ig α /CD79a (BCR)	65
C7	Ig β /CD79b (BCR)	67
C8	DAP10	69
C9	DAP12	71

Table 6 – Illustrative targeting domains (“D” Subunits):

SUBUNIT REFERENCE	TARGET / DOMAIN	TYPE	SEQ ID NO:
D1	BCMA	scFv	50, 51, OR 52
D2	CD19	scFv	53
D3	CD20	scFv	54, 55, OR 56
D4	CD22	scFv	57
D5	CD33	scFv	58
D6	CD79A	scFv	59
D7	CD79B	scFv	60 OR 61
D8	B7H3	scFv	62
D9	Muc16	scFv	63
D10	HER2	scFv	64
D11	EGFR	scFv	65
D12	FN-EDB	scFv	66
D13	CLDN18.2	scFv	67
D14	DLL3	scFv	68
D15	FLT3	scFv	69 OR 70
D16	ROR1	scFv	71
D17	CD33	VHH	72, 73, OR 74

D18	CLL1	VHH	75 OR 76
D19	CD123	VHH	77 OR 78
D20	CD20	VHH	79
D21	EGFR	VHH	80
D22	BCMA	VHH	81 OR 82
D23	CD19	VHH	83
D24	PD-L1 / PD1	ECTO	84 OR 85
D25	BCMA / APRIL	LIGAND	86 OR 87
D26	NKG2DLs / NKG2D	ECTO	88
D27	CD33	CDRs	89, 90, AND 91
D28	CLL1	CDRs	92, 93, AND 94

Table 7 - Illustrative Hinge Domains (“E” Subunits):

SUBUNIT REFERENCE	SUBUNIT NAME	SEQ ID NO:
E1	Minimal CD4 hinge	41
E2	Minimal CD28 hinge	42
E3	IgG4 hinge	43
E4	CD8 hinge	44
E5	Hinge linker; GGR	

Table 8 - Illustrative Transmembrane Domains (“F” Subunits):

SUBUNIT REFERENCE	SUBUNIT NAME	SEQ ID NO:
F1	CD4 transmembrane	45
F2	CD28 transmembrane	46
F3	CD8 transmembrane	47

5

Table 9 - Illustrative Intracellular Domains (“G” Subunits):

SUBUNIT REFERENCE	SUBUNIT NAME	SEQ ID NO:
G1	Truncated intracellular CD4 - v1	48
G2	Truncated intracellular CD4 - v2	49
G3	41BB intracellular signaling domain	98
G4	CD28 intracellular signaling domain	99
G5	CD4 coreceptor domain	100
G6	CD8 coreceptor domain	101
G7	LAT domain	102
G8	IL7 receptor alpha signaling domain	103
G9	IL2 receptor beta signaling domain, truncated	104
G10	IL2 receptor beta signaling domain	105
G11	Common gamma chain signaling domain	106
G12	none	

As one example of a signaling component, multimerization domain that pairs with a multimerization domain from a corresponding targeting component from **Table 3** (*e.g.*, an A1 subunit) can be combined with one or more polypeptide linkers from **Table 4** (*e.g.*, a B3 subunit) and an actuator domain from **Table 5** (*e.g.*, a C1 subunit), to produce a novel
5 signaling component (*e.g.*, a signaling component as shown in SEQ ID NO: 111). Other illustrative signaling components are shown in SEQ ID NOs: 107-110 and 112-115.

As one example of a targeting component, an extracellular or one or more targeting domains from **Table 6** (*e.g.*, a D17 subunit), can be combined with one or more optional polypeptide linkers from **Table 4** (*e.g.*, a B1 subunit), a multimerization domain that pairs
10 with a multimerization domain from a corresponding signaling component from **Table 3** (*e.g.*, an A3 subunit), a hinge domain from **Table 7** (*e.g.*, an E1 subunit), a transmembrane domain from **Table 8** (*e.g.*, an F1 subunit), and an intracellular domain from **Table 9** (*e.g.*, a G2 subunit), to produce a novel targeting component (*e.g.*, a targeting component as shown in SEQ ID NO: 117). Other illustrative targeting components are shown in SEQ ID NOs: 116
15 and 118-136.

Additionally, as further shown and contemplated herein, multiple “A” components can be combined to produce multi-specific extracellular domains (*e.g.*, tandem targeting domains), and multiple polypeptide linkers can be combined to produce functional linkers.

Moreover, one of skill in the art would understand that a signal sequence may be
20 linked to the N-terminus of the signaling and/or targeting components to enable efficient trafficking to the cell membrane compartment. Accordingly, in various embodiments, any of the signaling and targeting components disclosed herein comprise a signaling sequence. In some embodiments, the signaling sequence is a IgK, CD8, or PD1 signal sequence. In some embodiments, the signaling sequence is a IgK, CD8, or PD1 signal sequence as set forth in
25 any one of SEQ ID NOs: 95-97.

Tables 10 and 11 provide an illustrative, non-limiting list of signaling and targeting components, respectively, based on the multimerization domains, polypeptide linkers,

actuator domains, targeting domains, hinge domains, transmembrane domains, and intracellular domains provided in **Tables 3-9**.

Table 10 – Illustrative Signaling Components:

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
1	A1	B1	C1
2	A1	B1	C2
3	A1	B1	C3
4	A1	B1	C4
5	A1	B1	C5
6	A1	B1	C6
7	A1	B1	C7
8	A1	B1	C8
9	A1	B1	C9
10	A1	B2	C1
11	A1	B2	C2
12	A1	B2	C3
13	A1	B2	C4
14	A1	B2	C5
15	A1	B2	C6
16	A1	B2	C7
17	A1	B2	C8
18	A1	B2	C9
19	A1	B3	C1
20	A1	B3	C2
21	A1	B3	C3
22	A1	B3	C4
23	A1	B3	C5
24	A1	B3	C6
25	A1	B3	C7
26	A1	B3	C8
27	A1	B3	C9
28	A1	B4	C1
29	A1	B4	C2
30	A1	B4	C3
31	A1	B4	C4
32	A1	B4	C5

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
33	A1	B4	C6
34	A1	B4	C7
35	A1	B4	C8
36	A1	B4	C9
37	A1	ANY ONE OF B4-B22	C1
38	A1	ANY ONE OF B4-B22	C2
39	A1	ANY ONE OF B4-B22	C3
40	A1	ANY ONE OF B4-B22	C4
41	A1	ANY ONE OF B4-B22	C5
42	A1	ANY ONE OF B4-B22	C6
43	A1	ANY ONE OF B4-B22	C7
44	A1	ANY ONE OF B4-B22	C8
45	A1	ANY ONE OF B4-B22	C9
46	A2	B1	C1
47	A2	B1	C2
48	A2	B1	C3
49	A2	B1	C4
50	A2	B1	C5
51	A2	B1	C6
52	A2	B1	C7
53	A2	B1	C8
54	A2	B1	C9
55	A2	B2	C1
56	A2	B2	C2
57	A2	B2	C3
58	A2	B2	C4
59	A2	B2	C5
60	A2	B2	C6
61	A2	B2	C7
62	A2	B2	C8
63	A2	B2	C9
64	A2	B3	C1
65	A2	B3	C2
66	A2	B3	C3
67	A2	B3	C4
68	A2	B3	C5
69	A2	B3	C6
70	A2	B3	C7

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
71	A2	B3	C8
72	A2	B3	C9
73	A2	ANY ONE OF B4-B22	C1
74	A2	ANY ONE OF B4-B22	C2
75	A2	ANY ONE OF B4-B22	C3
76	A2	ANY ONE OF B4-B22	C4
77	A2	ANY ONE OF B4-B22	C5
78	A2	ANY ONE OF B4-B22	C6
79	A2	ANY ONE OF B4-B22	C7
80	A2	ANY ONE OF B4-B22	C8
81	A2	ANY ONE OF B4-B22	C9
82	A3	B1	C1
83	A3	B1	C2
84	A3	B1	C3
85	A3	B1	C4
86	A3	B1	C5
87	A3	B1	C6
88	A3	B1	C7
89	A3	B1	C8
90	A3	B1	C9
91	A3	B2	C1
92	A3	B2	C2
93	A3	B2	C3
94	A3	B2	C4
95	A3	B2	C5
96	A3	B2	C6
97	A3	B2	C7
98	A3	B2	C8
99	A3	B2	C9
100	A3	B3	C1
101	A3	B3	C2
102	A3	B3	C3
103	A3	B3	C4
104	A3	B3	C5
105	A3	B3	C6
106	A3	B3	C7
107	A3	B3	C8
108	A3	B3	C9

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
109	A3	ANY ONE OF B4-B22	C1
110	A3	ANY ONE OF B4-B22	C2
111	A3	ANY ONE OF B4-B22	C3
112	A3	ANY ONE OF B4-B22	C4
113	A3	ANY ONE OF B4-B22	C5
114	A3	ANY ONE OF B4-B22	C6
115	A3	ANY ONE OF B4-B22	C7
116	A3	ANY ONE OF B4-B22	C8
117	A3	ANY ONE OF B4-B22	C9
118	A4	B1	C1
119	A4	B1	C2
120	A4	B1	C3
121	A4	B1	C4
122	A4	B1	C5
123	A4	B1	C6
124	A4	B1	C7
125	A4	B1	C8
126	A4	B1	C9
127	A4	B2	C1
128	A4	B2	C2
129	A4	B2	C3
130	A4	B2	C4
131	A4	B2	C5
132	A4	B2	C6
133	A4	B2	C7
134	A4	B2	C8
135	A4	B2	C9
136	A4	B3	C1
137	A4	B3	C2
138	A4	B3	C3
139	A4	B3	C4
140	A4	B3	C5
141	A4	B3	C6
142	A4	B3	C7
143	A4	B3	C8
144	A4	B3	C9
145	A4	ANY ONE OF B4-B22	C1
146	A4	ANY ONE OF B4-B22	C2

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
147	A4	ANY ONE OF B4-B22	C3
148	A4	ANY ONE OF B4-B22	C4
149	A4	ANY ONE OF B4-B22	C5
150	A4	ANY ONE OF B4-B22	C6
151	A4	ANY ONE OF B4-B22	C7
152	A4	ANY ONE OF B4-B22	C8
153	A4	ANY ONE OF B4-B22	C9
154	A5	B1	C1
155	A5	B1	C2
156	A5	B1	C3
157	A5	B1	C4
158	A5	B1	C5
159	A5	B1	C6
160	A5	B1	C7
161	A5	B1	C8
162	A5	B1	C9
163	A5	B2	C1
164	A5	B2	C2
165	A5	B2	C3
166	A5	B2	C4
167	A5	B2	C5
168	A5	B2	C6
169	A5	B2	C7
170	A5	B2	C8
171	A5	B2	C9
172	A5	B3	C1
173	A5	B3	C2
174	A5	B3	C3
175	A5	B3	C4
176	A5	B3	C5
177	A5	B3	C6
178	A5	B3	C7
179	A5	B3	C8
180	A5	B3	C9
181	A5	ANY ONE OF B4-B22	C1
182	A5	ANY ONE OF B4-B22	C2
183	A5	ANY ONE OF B4-B22	C3
184	A5	ANY ONE OF B4-B22	C4

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
185	A5	ANY ONE OF B4-B22	C5
186	A5	ANY ONE OF B4-B22	C6
187	A5	ANY ONE OF B4-B22	C7
188	A5	ANY ONE OF B4-B22	C8
189	A5	ANY ONE OF B4-B22	C9
190	A6	B1	C1
191	A6	B1	C2
192	A6	B1	C3
193	A6	B1	C4
194	A6	B1	C5
195	A6	B1	C6
196	A6	B1	C7
197	A6	B1	C8
198	A6	B1	C9
199	A6	B2	C1
200	A6	B2	C2
201	A6	B2	C3
202	A6	B2	C4
203	A6	B2	C5
204	A6	B2	C6
205	A6	B2	C7
206	A6	B2	C8
207	A6	B2	C9
208	A6	B3	C1
209	A6	B3	C2
210	A6	B3	C3
211	A6	B3	C4
212	A6	B3	C5
213	A6	B3	C6
214	A6	B3	C7
215	A6	B3	C8
216	A6	B3	C9
217	A6	ANY ONE OF B4-B22	C1
218	A6	ANY ONE OF B4-B22	C2
219	A6	ANY ONE OF B4-B22	C3
220	A6	ANY ONE OF B4-B22	C4
221	A6	ANY ONE OF B4-B22	C5
222	A6	ANY ONE OF B4-B22	C6

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
223	A6	ANY ONE OF B4-B22	C7
224	A6	ANY ONE OF B4-B22	C8
225	A6	ANY ONE OF B4-B22	C9
226	A7	B1	C1
227	A7	B1	C2
228	A7	B1	C3
229	A7	B1	C4
230	A7	B1	C5
231	A7	B1	C6
232	A7	B1	C7
233	A7	B1	C8
234	A7	B1	C9
235	A7	B2	C1
236	A7	B2	C2
237	A7	B2	C3
238	A7	B2	C4
239	A7	B2	C5
240	A7	B2	C6
241	A7	B2	C7
242	A7	B2	C8
243	A7	B2	C9
244	A7	B3	C1
245	A7	B3	C2
246	A7	B3	C3
247	A7	B3	C4
248	A7	B3	C5
249	A7	B3	C6
250	A7	B3	C7
251	A7	B3	C8
252	A7	B3	C9
253	A7	ANY ONE OF B4-B22	C1
254	A7	ANY ONE OF B4-B22	C2
255	A7	ANY ONE OF B4-B22	C3
256	A7	ANY ONE OF B4-B22	C4
257	A7	ANY ONE OF B4-B22	C5
258	A7	ANY ONE OF B4-B22	C6
259	A7	ANY ONE OF B4-B22	C7
260	A7	ANY ONE OF B4-B22	C8

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
261	A7	ANY ONE OF B4-B22	C9
262	A8	B1	C1
263	A8	B1	C2
264	A8	B1	C3
265	A8	B1	C4
266	A8	B1	C5
267	A8	B1	C6
268	A8	B1	C7
269	A8	B1	C8
270	A8	B1	C9
271	A8	B2	C1
272	A8	B2	C2
273	A8	B2	C3
274	A8	B2	C4
275	A8	B2	C5
276	A8	B2	C6
277	A8	B2	C7
278	A8	B2	C8
279	A8	B2	C9
280	A8	B3	C1
281	A8	B3	C2
282	A8	B3	C3
283	A8	B3	C4
284	A8	B3	C5
285	A8	B3	C6
286	A8	B3	C7
287	A8	B3	C8
288	A8	B3	C9
289	A8	ANY ONE OF B4-B22	C1
290	A8	ANY ONE OF B4-B22	C2
291	A8	ANY ONE OF B4-B22	C3
292	A8	ANY ONE OF B4-B22	C4
293	A8	ANY ONE OF B4-B22	C5
294	A8	ANY ONE OF B4-B22	C6
295	A8	ANY ONE OF B4-B22	C7
296	A8	ANY ONE OF B4-B22	C8
297	A8	ANY ONE OF B4-B22	C9
298	A9	B1	C1

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
299	A9	B1	C2
300	A9	B1	C3
301	A9	B1	C4
302	A9	B1	C5
303	A9	B1	C6
304	A9	B1	C7
305	A9	B1	C8
306	A9	B1	C9
307	A9	B2	C1
308	A9	B2	C2
309	A9	B2	C3
310	A9	B2	C4
311	A9	B2	C5
312	A9	B2	C6
313	A9	B2	C7
314	A9	B2	C8
315	A9	B2	C9
316	A9	B3	C1
317	A9	B3	C2
318	A9	B3	C3
319	A9	B3	C4
320	A9	B3	C5
321	A9	B3	C6
322	A9	B3	C7
323	A9	B3	C8
324	A9	B3	C9
325	A9	ANY ONE OF B4-B22	C1
326	A9	ANY ONE OF B4-B22	C2
327	A9	ANY ONE OF B4-B22	C3
328	A9	ANY ONE OF B4-B22	C4
329	A9	ANY ONE OF B4-B22	C5
330	A9	ANY ONE OF B4-B22	C6
331	A9	ANY ONE OF B4-B22	C7
332	A9	ANY ONE OF B4-B22	C8
333	A9	ANY ONE OF B4-B22	C9
334	A10	B1	C1
335	A10	B1	C2
336	A10	B1	C3

SIGNALING COMPONENT #	"A" SUBUNIT	"B" SUBUNIT	"C" SUBUNIT
337	A10	B1	C4
338	A10	B1	C5
339	A10	B1	C6
340	A10	B1	C7
341	A10	B1	C8
342	A10	B1	C9
343	A10	B2	C1
344	A10	B2	C2
345	A10	B2	C3
346	A10	B2	C4
347	A10	B2	C5
348	A10	B2	C6
349	A10	B2	C7
350	A10	B2	C8
351	A10	B2	C9
352	A10	B3	C1
353	A10	B3	C2
354	A10	B3	C3
355	A10	B3	C4
356	A10	B3	C5
357	A10	B3	C6
358	A10	B3	C7
359	A10	B3	C8
360	A10	B3	C9
361	A10	ANY ONE OF B4-B22	C1
362	A10	ANY ONE OF B4-B22	C2
363	A10	ANY ONE OF B4-B22	C3
364	A10	ANY ONE OF B4-B22	C4
365	A10	ANY ONE OF B4-B22	C5
366	A10	ANY ONE OF B4-B22	C6
367	A10	ANY ONE OF B4-B22	C7
368	A10	ANY ONE OF B4-B22	C8
369	A10	ANY ONE OF B4-B22	C9

Table 11 – Illustrative Targeting Components:

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
1	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F1	G1
2	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F1	G2
3	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F1	ANY ONE OF G3-G12
4	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F2	G1
5	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F2	G2
6	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F2	ANY ONE OF G3-G12
7	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F3	G1
8	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F3	G2
9	ANY ONE OR MORE OF D1-D28	B1	A1	E1	F3	ANY ONE OF G3-G12
10	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F1	G1
11	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F1	G2
12	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F1	ANY ONE OF G3-G12
13	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F2	G1
14	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F2	G2
15	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F2	ANY ONE OF G3-G12
16	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F3	G1
17	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
18	ANY ONE OR MORE OF D1-D28	B1	A1	ANY ONE OF E2-E4	F3	ANY ONE OF G3-G12
19	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F1	G1
20	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F1	G2
21	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F1	ANY ONE OF G3-G12
22	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F2	G1
23	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F2	G2
24	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F2	ANY ONE OF G3-G12
25	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F3	G1
26	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F3	G2
27	ANY ONE OR MORE OF D1-D28	B1	A2	E1	F3	ANY ONE OF G3-G12
28	ANY ONE OR MORE OF D1-D28	B1	A2	ANY ONE OF E2-E4	F1	G1
29	ANY ONE OR MORE OF D1-D28	B1	A2	ANY ONE OF E2-E4	F1	G2
30	ANY ONE OR MORE OF D1-D28	B1	A2	ANY ONE OF E2-E4	F1	ANY ONE OF G3-G12
31	ANY ONE OR MORE OF D1-D28	B1	A2	ANY ONE OF E2-E4	F2	G1
32	ANY ONE OR MORE OF D1-D28	B1	A2	ANY ONE OF E2-E4	F2	G2
33	ANY ONE OR MORE OF D1-D28	B1	A2	ANY ONE OF E2-E4	F2	ANY ONE OF G3-G12
34	ANY ONE OR MORE OF D1-D28	B1	A2	ANY ONE OF E2-E4	F3	G1
35	ANY ONE OR MORE OF D1-D28	B1	A2	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
36	ANY ONE OR MORE OF D1- D28	B1	A2	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
37	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F1	G1
38	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F1	G2
39	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F1	ANY ONE OF G3- G12
40	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F2	G1
41	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F2	G2
42	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F2	ANY ONE OF G3- G12
43	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F3	G1
44	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F3	G2
45	ANY ONE OR MORE OF D1- D28	B1	A3	E1	F3	ANY ONE OF G3- G12
46	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F1	G1
47	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F1	G2
48	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
49	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F2	G1
50	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F2	G2
51	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
52	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F3	G1
53	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
54	ANY ONE OR MORE OF D1- D28	B1	A3	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
55	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F1	G1
56	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F1	G2
57	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F1	ANY ONE OF G3- G12
58	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F2	G1
59	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F2	G2
60	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F2	ANY ONE OF G3- G12
61	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F3	G1
62	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F3	G2
63	ANY ONE OR MORE OF D1- D28	B1	A4	E1	F3	ANY ONE OF G3- G12
64	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F1	G1
65	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F1	G2
66	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
67	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F2	G1
68	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F2	G2
69	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
70	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F3	G1
71	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
72	ANY ONE OR MORE OF D1- D28	B1	A4	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
73	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F1	G1
74	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F1	G2
75	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F1	ANY ONE OF G3- G12
76	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F2	G1
77	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F2	G2
78	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F2	ANY ONE OF G3- G12
79	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F3	G1
80	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F3	G2
81	ANY ONE OR MORE OF D1- D28	B1	A5	E1	F3	ANY ONE OF G3- G12
82	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F1	G1
83	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F1	G2
84	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
85	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F2	G1
86	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F2	G2
87	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
88	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F3	G1
89	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
90	ANY ONE OR MORE OF D1- D28	B1	A5	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
91	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F1	G1
92	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F1	G2
93	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F1	ANY ONE OF G3- G12
94	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F2	G1
95	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F2	G2
96	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F2	ANY ONE OF G3- G12
97	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F3	G1
98	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F3	G2
99	ANY ONE OR MORE OF D1- D28	B1	A6	E1	F3	ANY ONE OF G3- G12
100	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F1	G1
101	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F1	G2
102	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
103	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F2	G1
104	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F2	G2
105	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
106	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F3	G1
107	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
108	ANY ONE OR MORE OF D1- D28	B1	A6	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
109	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F1	G1
110	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F1	G2
111	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F1	ANY ONE OF G3- G12
112	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F2	G1
113	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F2	G2
114	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F2	ANY ONE OF G3- G12
115	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F3	G1
116	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F3	G2
117	ANY ONE OR MORE OF D1- D28	B1	A7	E1	F3	ANY ONE OF G3- G12
118	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F1	G1
119	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F1	G2
120	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
121	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F2	G1
122	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F2	G2
123	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
124	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F3	G1
125	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
126	ANY ONE OR MORE OF D1- D28	B1	A7	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
127	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F1	G1
128	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F1	G2
129	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F1	ANY ONE OF G3- G12
130	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F2	G1
131	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F2	G2
132	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F2	ANY ONE OF G3- G12
133	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F3	G1
134	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F3	G2
135	ANY ONE OR MORE OF D1- D28	B1	A8	E1	F3	ANY ONE OF G3- G12
136	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F1	G1
137	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F1	G2
138	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
139	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F2	G1
140	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F2	G2
141	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
142	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F3	G1
143	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
144	ANY ONE OR MORE OF D1- D28	B1	A8	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
145	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F1	G1
146	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F1	G2
147	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F1	ANY ONE OF G3- G12
148	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F2	G1
149	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F2	G2
150	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F2	ANY ONE OF G3- G12
151	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F3	G1
152	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F3	G2
153	ANY ONE OR MORE OF D1- D28	B1	A9	E1	F3	ANY ONE OF G3- G12
154	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F1	G1
155	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F1	G2
156	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
157	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F2	G1
158	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F2	G2
159	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
160	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F3	G1
161	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
162	ANY ONE OR MORE OF D1- D28	B1	A9	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
163	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F1	G1
164	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F1	G2
165	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F1	ANY ONE OF G3- G12
166	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F2	G1
167	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F2	G2
168	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F2	ANY ONE OF G3- G12
169	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F3	G1
170	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F3	G2
171	ANY ONE OR MORE OF D1- D28	B1	A10	E1	F3	ANY ONE OF G3- G12
172	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F1	G1
173	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F1	G2
174	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
175	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F2	G1
176	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F2	G2
177	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
178	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F3	G1
179	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
180	ANY ONE OR MORE OF D1- D28	B1	A10	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
181	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F1	G1
182	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F1	G2
183	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F1	ANY ONE OF G3- G12
184	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F2	G1
185	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F2	G2
186	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F2	ANY ONE OF G3- G12
187	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F3	G1
188	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F3	G2
189	ANY ONE OR MORE OF D1- D28	B2	A1	E1	F3	ANY ONE OF G3- G12
190	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F1	G1
191	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F1	G2
192	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
193	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F2	G1
194	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F2	G2
195	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
196	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F3	G1
197	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
198	ANY ONE OR MORE OF D1- D28	B2	A1	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
199	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F1	G1
200	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F1	G2
201	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F1	ANY ONE OF G3- G12
202	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F2	G1
203	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F2	G2
204	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F2	ANY ONE OF G3- G12
205	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F3	G1
206	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F3	G2
207	ANY ONE OR MORE OF D1- D28	B2	A2	E1	F3	ANY ONE OF G3- G12
208	ANY ONE OR MORE OF D1- D28	B2	A2	ANY ONE OF E2-E4	F1	G1
209	ANY ONE OR MORE OF D1- D28	B2	A2	ANY ONE OF E2-E4	F1	G2
210	ANY ONE OR MORE OF D1- D28	B2	A2	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
211	ANY ONE OR MORE OF D1- D28	B2	A2	ANY ONE OF E2-E4	F2	G1
212	ANY ONE OR MORE OF D1- D28	B2	A2	ANY ONE OF E2-E4	F2	G2
213	ANY ONE OR MORE OF D1- D28	B2	A2	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
214	ANY ONE OR MORE OF D1- D28	B2	A2	ANY ONE OF E2-E4	F3	G1
215	ANY ONE OR MORE OF D1- D28	B2	A2	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
216	ANY ONE OR MORE OF D1-D28	B2	A2	ANY ONE OF E2-E4	F3	ANY ONE OF G3-G12
217	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F1	G1
218	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F1	G2
219	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F1	ANY ONE OF G3-G12
220	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F2	G1
221	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F2	G2
222	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F2	ANY ONE OF G3-G12
223	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F3	G1
224	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F3	G2
225	ANY ONE OR MORE OF D1-D28	B2	A3	E1	F3	ANY ONE OF G3-G12
226	ANY ONE OR MORE OF D1-D28	B2	A3	ANY ONE OF E2-E4	F1	G1
227	ANY ONE OR MORE OF D1-D28	B2	A3	ANY ONE OF E2-E4	F1	G2
228	ANY ONE OR MORE OF D1-D28	B2	A3	ANY ONE OF E2-E4	F1	ANY ONE OF G3-G12
229	ANY ONE OR MORE OF D1-D28	B2	A3	ANY ONE OF E2-E4	F2	G1
230	ANY ONE OR MORE OF D1-D28	B2	A3	ANY ONE OF E2-E4	F2	G2
231	ANY ONE OR MORE OF D1-D28	B2	A3	ANY ONE OF E2-E4	F2	ANY ONE OF G3-G12
232	ANY ONE OR MORE OF D1-D28	B2	A3	ANY ONE OF E2-E4	F3	G1
233	ANY ONE OR MORE OF D1-D28	B2	A3	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
234	ANY ONE OR MORE OF D1- D28	B2	A3	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
235	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F1	G1
236	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F1	G2
237	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F1	ANY ONE OF G3- G12
238	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F2	G1
239	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F2	G2
240	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F2	ANY ONE OF G3- G12
241	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F3	G1
242	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F3	G2
243	ANY ONE OR MORE OF D1- D28	B2	A4	E1	F3	ANY ONE OF G3- G12
244	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F1	G1
245	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F1	G2
246	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
247	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F2	G1
248	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F2	G2
249	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
250	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F3	G1
251	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
252	ANY ONE OR MORE OF D1- D28	B2	A4	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
253	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F1	G1
254	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F1	G2
255	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F1	ANY ONE OF G3- G12
256	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F2	G1
257	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F2	G2
258	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F2	ANY ONE OF G3- G12
259	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F3	G1
260	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F3	G2
261	ANY ONE OR MORE OF D1- D28	B2	A5	E1	F3	ANY ONE OF G3- G12
262	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F1	G1
263	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F1	G2
264	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
265	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F2	G1
266	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F2	G2
267	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
268	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F3	G1
269	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
270	ANY ONE OR MORE OF D1- D28	B2	A5	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
271	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F1	G1
272	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F1	G2
273	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F1	ANY ONE OF G3- G12
274	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F2	G1
275	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F2	G2
276	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F2	ANY ONE OF G3- G12
277	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F3	G1
278	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F3	G2
279	ANY ONE OR MORE OF D1- D28	B2	A6	E1	F3	ANY ONE OF G3- G12
280	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F1	G1
281	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F1	G2
282	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
283	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F2	G1
284	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F2	G2
285	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
286	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F3	G1
287	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
288	ANY ONE OR MORE OF D1- D28	B2	A6	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
289	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F1	G1
290	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F1	G2
291	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F1	ANY ONE OF G3- G12
292	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F2	G1
293	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F2	G2
294	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F2	ANY ONE OF G3- G12
295	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F3	G1
296	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F3	G2
297	ANY ONE OR MORE OF D1- D28	B2	A7	E1	F3	ANY ONE OF G3- G12
298	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F1	G1
299	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F1	G2
300	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
301	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F2	G1
302	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F2	G2
303	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
304	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F3	G1
305	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
306	ANY ONE OR MORE OF D1- D28	B2	A7	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
307	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F1	G1
308	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F1	G2
309	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F1	ANY ONE OF G3- G12
310	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F2	G1
311	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F2	G2
312	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F2	ANY ONE OF G3- G12
313	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F3	G1
314	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F3	G2
315	ANY ONE OR MORE OF D1- D28	B2	A8	E1	F3	ANY ONE OF G3- G12
316	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F1	G1
317	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F1	G2
318	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
319	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F2	G1
320	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F2	G2
321	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
322	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F3	G1
323	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
324	ANY ONE OR MORE OF D1- D28	B2	A8	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
325	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F1	G1
326	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F1	G2
327	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F1	ANY ONE OF G3- G12
328	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F2	G1
329	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F2	G2
330	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F2	ANY ONE OF G3- G12
331	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F3	G1
332	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F3	G2
333	ANY ONE OR MORE OF D1- D28	B2	A9	E1	F3	ANY ONE OF G3- G12
334	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F1	G1
335	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F1	G2
336	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
337	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F2	G1
338	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F2	G2
339	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
340	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F3	G1
341	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
342	ANY ONE OR MORE OF D1- D28	B2	A9	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
343	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F1	G1
344	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F1	G2
345	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F1	ANY ONE OF G3- G12
346	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F2	G1
347	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F2	G2
348	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F2	ANY ONE OF G3- G12
349	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F3	G1
350	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F3	G2
351	ANY ONE OR MORE OF D1- D28	B2	A10	E1	F3	ANY ONE OF G3- G12
352	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F1	G1
353	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F1	G2
354	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
355	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F2	G1
356	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F2	G2
357	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
358	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F3	G1
359	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
360	ANY ONE OR MORE OF D1- D28	B2	A10	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
361	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F1	G1
362	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F1	G2
363	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F1	ANY ONE OF G3- G12
364	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F2	G1
365	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F2	G2
366	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F2	ANY ONE OF G3- G12
367	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F3	G1
368	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F3	G2
369	ANY ONE OR MORE OF D1- D28	B3	A1	E1	F3	ANY ONE OF G3- G12
370	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F1	G1
371	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F1	G2
372	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
373	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F2	G1
374	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F2	G2
375	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
376	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F3	G1
377	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
378	ANY ONE OR MORE OF D1- D28	B3	A1	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
379	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F1	G1
380	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F1	G2
381	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F1	ANY ONE OF G3- G12
382	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F2	G1
383	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F2	G2
384	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F2	ANY ONE OF G3- G12
385	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F3	G1
386	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F3	G2
387	ANY ONE OR MORE OF D1- D28	B3	A2	E1	F3	ANY ONE OF G3- G12
388	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F1	G1
389	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F1	G2
390	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
391	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F2	G1
392	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F2	G2
393	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
394	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F3	G1
395	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
396	ANY ONE OR MORE OF D1- D28	B3	A2	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
397	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F1	G1
398	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F1	G2
399	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F1	ANY ONE OF G3- G12
400	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F2	G1
401	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F2	G2
402	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F2	ANY ONE OF G3- G12
403	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F3	G1
404	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F3	G2
405	ANY ONE OR MORE OF D1- D28	B3	A3	E1	F3	ANY ONE OF G3- G12
406	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F1	G1
407	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F1	G2
408	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
409	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F2	G1
410	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F2	G2
411	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
412	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F3	G1
413	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
414	ANY ONE OR MORE OF D1- D28	B3	A3	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
415	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F1	G1
416	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F1	G2
417	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F1	ANY ONE OF G3- G12
418	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F2	G1
419	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F2	G2
420	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F2	ANY ONE OF G3- G12
421	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F3	G1
422	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F3	G2
423	ANY ONE OR MORE OF D1- D28	B3	A4	E1	F3	ANY ONE OF G3- G12
424	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F1	G1
425	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F1	G2
426	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
427	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F2	G1
428	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F2	G2
429	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
430	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F3	G1
431	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
432	ANY ONE OR MORE OF D1- D28	B3	A4	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
433	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F1	G1
434	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F1	G2
435	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F1	ANY ONE OF G3- G12
436	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F2	G1
437	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F2	G2
438	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F2	ANY ONE OF G3- G12
439	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F3	G1
440	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F3	G2
441	ANY ONE OR MORE OF D1- D28	B3	A5	E1	F3	ANY ONE OF G3- G12
442	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F1	G1
443	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F1	G2
444	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
445	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F2	G1
446	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F2	G2
447	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
448	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F3	G1
449	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
450	ANY ONE OR MORE OF D1- D28	B3	A5	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
451	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F1	G1
452	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F1	G2
453	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F1	ANY ONE OF G3- G12
454	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F2	G1
455	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F2	G2
456	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F2	ANY ONE OF G3- G12
457	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F3	G1
458	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F3	G2
459	ANY ONE OR MORE OF D1- D28	B3	A6	E1	F3	ANY ONE OF G3- G12
460	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F1	G1
461	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F1	G2
462	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
463	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F2	G1
464	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F2	G2
465	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
466	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F3	G1
467	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
468	ANY ONE OR MORE OF D1- D28	B3	A6	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
469	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F1	G1
470	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F1	G2
471	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F1	ANY ONE OF G3- G12
472	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F2	G1
473	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F2	G2
474	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F2	ANY ONE OF G3- G12
475	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F3	G1
476	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F3	G2
477	ANY ONE OR MORE OF D1- D28	B3	A7	E1	F3	ANY ONE OF G3- G12
478	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F1	G1
479	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F1	G2
480	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
481	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F2	G1
482	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F2	G2
483	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
484	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F3	G1
485	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
486	ANY ONE OR MORE OF D1- D28	B3	A7	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
487	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F1	G1
488	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F1	G2
489	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F1	ANY ONE OF G3- G12
490	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F2	G1
491	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F2	G2
492	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F2	ANY ONE OF G3- G12
493	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F3	G1
494	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F3	G2
495	ANY ONE OR MORE OF D1- D28	B3	A8	E1	F3	ANY ONE OF G3- G12
496	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F1	G1
497	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F1	G2
498	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
499	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F2	G1
500	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F2	G2
501	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
502	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F3	G1
503	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
504	ANY ONE OR MORE OF D1- D28	B3	A8	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
505	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F1	G1
506	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F1	G2
507	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F1	ANY ONE OF G3- G12
508	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F2	G1
509	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F2	G2
510	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F2	ANY ONE OF G3- G12
511	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F3	G1
512	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F3	G2
513	ANY ONE OR MORE OF D1- D28	B3	A9	E1	F3	ANY ONE OF G3- G12
514	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F1	G1
515	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F1	G2
516	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
517	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F2	G1
518	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F2	G2
519	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
520	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F3	G1
521	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
522	ANY ONE OR MORE OF D1- D28	B3	A9	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
523	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F1	G1
524	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F1	G2
525	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F1	ANY ONE OF G3- G12
526	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F2	G1
527	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F2	G2
528	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F2	ANY ONE OF G3- G12
529	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F3	G1
530	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F3	G2
531	ANY ONE OR MORE OF D1- D28	B3	A10	E1	F3	ANY ONE OF G3- G12
532	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F1	G1
533	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F1	G2
534	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
535	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F2	G1
536	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F2	G2
537	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
538	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F3	G1
539	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
540	ANY ONE OR MORE OF D1- D28	B3	A10	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
541	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F1	G1
542	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F1	G2
543	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F1	ANY ONE OF G3- G12
544	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F2	G1
545	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F2	G2
546	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F2	ANY ONE OF G3- G12
547	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F3	G1
548	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F3	G2
549	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	E1	F3	ANY ONE OF G3- G12
550	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F1	G1
551	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F1	G2
552	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
553	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F2	G1
554	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F2	G2
555	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
556	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F3	G1
557	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
558	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A1	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
559	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F1	G1
560	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F1	G2
561	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F1	ANY ONE OF G3- G12
562	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F2	G1
563	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F2	G2
564	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F2	ANY ONE OF G3- G12
565	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F3	G1
566	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F3	G2
567	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	E1	F3	ANY ONE OF G3- G12
568	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F1	G1
569	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F1	G2
570	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
571	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F2	G1
572	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F2	G2
573	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
574	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F3	G1
575	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
576	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A2	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
577	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F1	G1
578	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F1	G2
579	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F1	ANY ONE OF G3- G12
580	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F2	G1
581	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F2	G2
582	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F2	ANY ONE OF G3- G12
583	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F3	G1
584	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F3	G2
585	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	E1	F3	ANY ONE OF G3- G12
586	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F1	G1
587	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F1	G2
588	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
589	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F2	G1
590	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F2	G2
591	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
592	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F3	G1
593	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
594	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A3	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
595	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F1	G1
596	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F1	G2
597	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F1	ANY ONE OF G3- G12
598	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F2	G1
599	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F2	G2
600	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F2	ANY ONE OF G3- G12
601	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F3	G1
602	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F3	G2
603	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	E1	F3	ANY ONE OF G3- G12
604	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F1	G1
605	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F1	G2
606	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
607	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F2	G1
608	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F2	G2
609	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
610	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F3	G1
611	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
612	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A4	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
613	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F1	G1
614	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F1	G2
615	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F1	ANY ONE OF G3- G12
616	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F2	G1
617	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F2	G2
618	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F2	ANY ONE OF G3- G12
619	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F3	G1
620	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F3	G2
621	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	E1	F3	ANY ONE OF G3- G12
622	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F1	G1
623	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F1	G2
624	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
625	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F2	G1
626	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F2	G2
627	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
628	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F3	G1
629	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
630	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A5	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
631	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F1	G1
632	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F1	G2
633	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F1	ANY ONE OF G3- G12
634	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F2	G1
635	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F2	G2
636	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F2	ANY ONE OF G3- G12
637	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F3	G1
638	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F3	G2
639	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	E1	F3	ANY ONE OF G3- G12
640	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F1	G1
641	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F1	G2
642	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
643	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F2	G1
644	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F2	G2
645	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
646	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F3	G1
647	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
648	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A6	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
649	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F1	G1
650	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F1	G2
651	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F1	ANY ONE OF G3- G12
652	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F2	G1
653	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F2	G2
654	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F2	ANY ONE OF G3- G12
655	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F3	G1
656	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F3	G2
657	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	E1	F3	ANY ONE OF G3- G12
658	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F1	G1
659	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F1	G2
660	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
661	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F2	G1
662	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F2	G2
663	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
664	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F3	G1
665	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
666	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A7	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
667	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F1	G1
668	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F1	G2
669	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F1	ANY ONE OF G3- G12
670	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F2	G1
671	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F2	G2
672	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F2	ANY ONE OF G3- G12
673	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F3	G1
674	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F3	G2
675	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	E1	F3	ANY ONE OF G3- G12
676	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F1	G1
677	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F1	G2
678	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
679	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F2	G1
680	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F2	G2
681	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
682	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F3	G1
683	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
684	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A8	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
685	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F1	G1
686	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F1	G2
687	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F1	ANY ONE OF G3- G12
688	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F2	G1
689	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F2	G2
690	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F2	ANY ONE OF G3- G12
691	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F3	G1
692	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F3	G2
693	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	E1	F3	ANY ONE OF G3- G12
694	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F1	G1
695	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F1	G2
696	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
697	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F2	G1
698	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F2	G2
699	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
700	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F3	G1
701	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
702	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A9	ANY ONE OF E2-E4	F3	ANY ONE OF G3- G12
703	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F1	G1
704	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F1	G2
705	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F1	ANY ONE OF G3- G12
706	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F2	G1
707	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F2	G2
708	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F2	ANY ONE OF G3- G12
709	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F3	G1
710	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F3	G2
711	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	E1	F3	ANY ONE OF G3- G12
712	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F1	G1
713	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F1	G2
714	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F1	ANY ONE OF G3- G12
715	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F2	G1
716	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F2	G2
717	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F2	ANY ONE OF G3- G12
718	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F3	G1
719	ANY ONE OR MORE OF D1- D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F3	G2

TARGETING COMPONENT #	"D" SUBUNIT	"B" SUBUNIT	"A" SUBUNIT	"E" SUBUNIT	"F" SUBUNIT	"G" SUBUNIT
720	ANY ONE OR MORE OF D1-D28	ANY ONE OF B4-B22	A10	ANY ONE OF E2-E4	F3	ANY ONE OF G3-G12

As disclosed herein, signaling and targeting components having paired multimerization domains (*i.e.*, a multimerization domain pairs that dimerize/multimerize in the presence or absence of a bridging factor) can be combined to yield a functional engineered immune receptor. For example, a signaling component having an FRB (*e.g.*, FRB or FRB*) multimerization domain can be combined/paired with a targeting component having an FKBP (*e.g.*, FKBP or FKBP F36V) multimerization domain. As one example, any one of signaling constructs 1-81 are combined with any one of targeting components 37-72, 217-252, 397-432, and 577-612, to produce a novel engineered immune receptor. Other multimerization pairs include, but are not limited to, CH3_AB (S354C T366W) and CH3_IA (Y349C T366S L368A Y407V); CH3_DE (L351D L368E) and CH3_KK (L351K T366K); and CH3_GA (SEED 1) and CH3_AG (SEED 2).

In various embodiments, paired signaling and targeting components may be combined as a fusion polypeptide. Illustrative fusion polypeptides are shown in SEQ ID NOs: 139-170.

Additionally, any one of the engineered immune receptors disclosed herein can be combined with an engineered/exogenous antigen or lymphocyte receptor (*e.g.*, TCR, CAR, CCR, or flip receptor).

One of skill in the art would understand that other combinations are possible, including combinations using other multimerization domains, polypeptide linkers, actuator domains, targeting domains, hinge domains, transmembrane domains, intracellular domains, and exogenous antigen receptors either known to or newly developed by the skilled artisan.

In general, in the following claims, the terms used should not be construed to limit the claims to the specific embodiments disclosed in the specification and the claims, but should be construed to include all possible embodiments along with the full scope of equivalents to which such claims are entitled. Accordingly, the claims are not limited by the disclosure.

CLAIMS

What is claimed is:

1. A non-natural cell, comprising:

(a) a signaling component comprising (i) a first multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (ii) a first polypeptide linker, and (iii) a CD3 ϵ polypeptide or variant thereof; and

(b) a targeting component comprising (i) an anti-CLL1 scFv or single domain antibody (sdAb), (ii) an anti-CD33 scFv or single domain antibody (sdAb), (iii) a second polypeptide linker, (iv) a second multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (v) a CD4 hinge polypeptide, (vi) a CD4 transmembrane polypeptide, and (vii) a truncated CD4 intracellular polypeptide.

2. The non-natural cell of claim 1, wherein the targeting component does not comprise a functional intracellular domain or costimulatory domain having signaling capabilities.

3. The non-natural cell of any one of the preceding claims, wherein the CD4 hinge polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 41.

4. The non-natural cell of any one of the preceding claims, wherein the CD4 hinge polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 41.

5. The non-natural cell of any one of the preceding claims, wherein the CD3 ϵ polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 32.

6. The non-natural cell of any one of the preceding claims, wherein the CD3 ϵ polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 32.

7. The non-natural cell of any one of the preceding claims, wherein the CD3 ϵ polypeptide comprises both extracellular and intracellular portions.

8. The non-natural cell of any one of the preceding claims, wherein the FRB and FKBP polypeptides localize extracellularly when the signaling and targeting components are expressed.
9. The non-natural cell of any one of the preceding claims, wherein the first and second multimerization domains are different.
10. The non-natural cell of any one of the preceding claims, wherein the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP12 polypeptide or variant thereof.
11. The non-natural cell of any one of the preceding claims, wherein the first multimerization domain comprises an FKBP12 polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof.
12. The non-natural cell of any one of any one of the preceding claims, wherein the FRB polypeptide is an FRB T2098L variant.
13. The non-natural cell of any one of the preceding claims, wherein the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 1.
14. The non-natural cell of any one of the preceding claims, wherein the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 2.
15. The non-natural cell of any one of the preceding claims, wherein the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 3.
16. The non-natural cell of any one of the preceding claims, wherein the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 4.
17. The non-natural cell of any one of the preceding claims, wherein the multimerization domains of the signaling component and the targeting component associate with a bridging factor.

18. The non-natural cell of claim 17, wherein the bridging factor is selected from the group consisting of: rapamycin or a rapalog thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A or a derivative thereof, trimethoprim (Tnp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof, wherein the bridging factor promotes the formation of a polypeptide complex, with the bridging factor associated with and disposed between the multimerization domains of the signaling and targeting components.
19. The non-natural cell of claim 17 or claim 18, wherein the bridging factor is AP1903, AP20187, AP21967 (also known as C16-(S)-7-methylindolerapamycin), everolimus, novolimus, pimecrolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus, umirolimus, zotarolimus, or BPC015.
20. The non-natural cell of any one of the preceding claims, wherein the first polypeptide linker is a linker of 2 to 40 amino acids in length.
21. The non-natural cell of claim 20, wherein the first polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, 5xG4S, and any combination thereof.
22. The non-natural cell of claim 21, wherein the first polypeptide linker is a 3xG4S linker.
23. The non-natural cell of any one of the preceding claims, wherein the second polypeptide linker is a linker of 2 to 40 amino acids in length.
24. The non-natural cell of claim 23, wherein the second polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof.
25. The non-natural cell of claim 24, wherein the second polypeptide linker is a G4S linker.
26. The non-natural cell of any one of the preceding claims, wherein the anti-CLL1 scFv or sdAb and the anti-CD33 scFv or sdAb are separated by a third polypeptide linker.
27. The non-natural cell of claim 26, wherein the third polypeptide linker is a linker of 2 to 40 amino acids in length.

28. The non-natural cell of claim 27, wherein the third polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof.
29. The non-natural cell of claim 28, wherein the third polypeptide linker is a G4S linker.
30. The non-natural cell of any of the preceding claims, wherein the CD4 transmembrane domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 45.
31. The non-natural cell of any of the preceding claims, wherein the CD4 transmembrane polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 45.
32. The non-natural cell of any of the preceding claims, wherein the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 48.
33. The non-natural cell of any one of claims 1-31, wherein the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 49.
34. The non-natural cell of any one of the preceding claims, wherein the anti-CLL1 and anti-CD33 antibodies are each a sdAb.
35. The non-natural cell of claim 34, wherein the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb).
36. The non-natural cell of any one of the preceding claims, wherein the sdAb is a camelid VHH.
37. The non-natural cell of any one of the preceding claims, wherein the scFv or sdAb is human or humanized.
38. The non-natural cell of any one of the preceding claims, wherein the anti-CLL1 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 92, 93, and 94, respectively.
39. The non-natural cell of any one of the preceding claims, wherein the anti-CLL1 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 75.

40. The non-natural cell of any one of the preceding claims, wherein the anti-CLL1 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 75.
41. The non-natural cell of any one of the preceding claims, wherein the anti-CD33 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 89, 90, and 91, respectively.
42. The non-natural cell of any one of the preceding claims, wherein the anti-CD33 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72.
43. The non-natural cell of any one of the preceding claims, wherein the anti-CD33 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 72.
44. The non-natural cell of any one of the preceding claims, wherein the signaling component further comprises a signal sequence.
45. The non-natural cell of claim 44, wherein the signal sequence is a CD8 signal sequence.
46. The non-natural cell of claim 45, wherein the CD8 signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96.
47. The non-natural cell of claim 46, wherein the CD8 signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 96.
48. The non-natural cell of any one of the preceding claims, wherein the targeting component further comprises a signal sequence.
49. The non-natural cell of claim 48, wherein the signal sequence is an IgK signal sequence.
50. The non-natural cell of claim 49, wherein the IgK signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 95.
51. The non-natural cell of claim 50, wherein the IgK signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 95.
52. The non-natural cell of any one of the previous claims, wherein the signaling component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 111.

53. The non-natural cell of claim 52, wherein the signaling component comprises a sequence set forth as SEQ ID NO: 111.
54. The non-natural cell of any one of the previous claims, wherein the targeting component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth as SEQ ID NO: 122.
55. The non-natural cell of claim 54, wherein the targeting component comprises a sequence set forth as SEQ ID NO: 122.
56. The non-natural cell of any one of the previous claims, comprising a fusion polypeptide which comprises the targeting component and the signaling component.
57. The non-natural cell of claim 56, wherein the fusion polypeptide comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 151.
58. The non-natural cell of claim 57, wherein the fusion polypeptide comprises a sequence set forth as SEQ ID NO: 151.
59. The non-natural cell of any one of the preceding claims, wherein the cell comprises a first nucleic acid molecule encoding the signaling component.
60. The non-natural cell of any one of the preceding claims, wherein the cell comprises a second nucleic acid molecule encoding the targeting component.
61. The non-natural cell of any one of the preceding claims, wherein the cell comprises a nucleic acid molecule that encodes both the signaling component and the targeting component.
62. The non-natural cell of any one of the preceding claims, wherein the cell further expresses an exogenous costimulatory factor, immunomodulatory factor, agonist for a costimulatory factor, antagonist for an immunosuppressive factor, immune cell engager, flip receptor, or any combination thereof.
63. The non-natural cell of any one of the preceding claims, wherein the cell further expresses an exogenous lymphocyte receptor or co-receptor.
64. The non-natural cell of claim 63, wherein the exogenous lymphocyte receptor or co-receptor is selected from the group consisting of: TCR alpha (TCR α), TCR beta (TCR β), TCR gamma

(TCR γ), TCR delta (TCR δ), CD4, CD8, pre T cell receptor α (pT α), Fc receptor alpha (FcR α), Fc receptor beta (FcR β), Fc receptor gamma (FcR γ), natural killer group 2 member D (NKG2D), CD79A, CD79B, and any combination thereof.

65. The non-natural cell of any one of the preceding claims, wherein the cell further expresses an exogenous TCR.
66. The non-natural cell of claim 65, wherein the exogenous TCR binds a target antigen selected from the group consisting of: α -fetoprotein (AFP), B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CAIX), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human Epidermal Growth Factor Receptor 2 (HER-2), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, Wilms tumor protein (WT-1), X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).
67. The non-natural cell of claim 65 or claim 66, wherein the exogenous TCR is an $\alpha\beta$ -TCR or $\gamma\delta$ -TCR.

68. The non-natural cell of any one of the preceding claims, wherein the cell further expresses a CAR, CCR, or flip receptor.
69. The non-natural cell of any one of the preceding claims, wherein the cell further expresses a zetakine, immune cell engager, or BiTE.
70. The non-natural cell of any one of the preceding claims, wherein the cell is a hematopoietic cell.
71. The non-natural cell of any one of the preceding claims, wherein the cell is a T cell, an $\alpha\beta$ -T cell, or a $\gamma\delta$ -T cell.
72. The non-natural cell of any one of the preceding claims, wherein the cell is a CD3⁺, CD4⁺, and/or CD8⁺ cell.
73. The non-natural cell of any one of the preceding claims, wherein the cell is an immune effector cell.
74. The non-natural cell of any one of the preceding claims, wherein the cell is a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell.
75. The non-natural cell of any one of the preceding claims, wherein the cell is a natural killer (NK) cell or natural killer T (NKT) cell.
76. The non-natural cell of any one of the preceding claims, wherein the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.
77. The non-natural cell of any one of the preceding claims, wherein the non-natural cell is an isolated non-natural cell.
78. The non-natural cell of any one of the preceding claims, wherein the non-natural cell is obtained from a subject.
79. The non-natural cell of any one of the preceding claims, wherein the non-natural cell is a human cell.
80. A fusion polypeptide comprising:

(a) signaling component comprising (i) a first multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (ii) a first polypeptide linker, and (iii) a CD3 ϵ polypeptide or variant thereof; and

(b) a polypeptide cleavage signal; and

(c) a targeting component comprising (i) an anti-CLL1 scFv or single domain antibody (sdAb), (ii) an anti-CD33 scFv or single domain antibody (sdAb), (iii) a second polypeptide linker, (iv) a second multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (v) a CD4 hinge polypeptide, (vi) a CD4 transmembrane polypeptide, and (vii) a truncated CD4 intracellular polypeptide.

81. The fusion polypeptide of claim 80, wherein the targeting component does not comprise a functional intracellular domain or costimulatory domain having signaling capabilities.

82. The fusion polypeptide of any one of claims 80-81, wherein the CD4 hinge polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 41.

83. The fusion polypeptide of any one of claims 80-82, wherein the CD4 hinge polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 41.

84. The fusion polypeptide of any one of claims 80-83, wherein the CD3 ϵ polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 32.

85. The fusion polypeptide of any one of claims 80-84, wherein the CD3 ϵ polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 32.

86. The fusion polypeptide of any one of claims 80-85, wherein the CD3 ϵ polypeptide comprises both extracellular and intracellular portions.

87. The fusion polypeptide of any one of claims 80-86, wherein the FRB and FKBP polypeptides localize extracellularly when the signaling and targeting components are expressed.

88. The fusion polypeptide of any one of claims 80-87, wherein the first and second multimerization domains are different.

89. The fusion polypeptide of any one of claims 80-88, wherein the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP12 polypeptide or variant thereof.
90. The fusion polypeptide of any one of claims 80-89, wherein the first multimerization domain comprises an FKBP12 polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof.
91. The fusion polypeptide of any one of claims 80-90, wherein the FRB polypeptide is an FRB T2098L variant.
92. The fusion polypeptide of any one of claims 80-91, wherein the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 1.
93. The fusion polypeptide of any one of claims 80-92, wherein the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 2.
94. The fusion polypeptide of any one of claims 80-93, wherein the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 3.
95. The fusion polypeptide of any one of claims 80-94, wherein the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 4.
96. The fusion polypeptide of any one of claims 80-95, wherein the multimerization domains of the signaling component and the targeting component associate with a bridging factor.
97. The fusion polypeptide of claim 96, wherein the bridging factor is selected from the group consisting of: rapamycin or a rapalog thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A or a derivative thereof, trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof, wherein the bridging factor promotes the formation of a polypeptide complex, with the bridging factor

associated with and disposed between the multimerization domains of the signaling and targeting components.

98. The fusion polypeptide of claim 96 or claim 97, wherein the bridging factor is AP1903, AP20187, AP21967 (also known as C16-(S)-7-methylindolerapamycin), everolimus, novolimus, pimecrolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus, umirolimus, zotarolimus, or BPC015.
99. The fusion polypeptide of any one of claims 80-98, wherein the first polypeptide linker is a linker of 2 to 40 amino acids in length.
100. The fusion polypeptide of claim 99, wherein the first polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, 5xG4S, and any combination thereof.
101. The fusion polypeptide of claim 100, wherein the first polypeptide linker is a 3xG4S linker.
102. The fusion polypeptide of any one of claims 80-101, wherein the second polypeptide linker is a linker of 2 to 40 amino acids in length.
103. The fusion polypeptide of claim 102, wherein the second polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof.
104. The fusion polypeptide of claim 103, wherein the second polypeptide linker is a G4S linker.
105. The fusion polypeptide of any one of claims 80-104, wherein the anti-CLL1 scFv or sdAb and the anti-CD33 scFv or sdAb are separated by a third polypeptide linker.
106. The fusion polypeptide of claim 105, wherein the third polypeptide linker is a linker of 2 to 40 amino acids in length.
107. The fusion polypeptide of claim 106, wherein the third polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof.

108. The fusion polypeptide of claim 107, wherein the third polypeptide linker is a G4S linker.
109. The fusion polypeptide of any one of claims 80-108, wherein the CD4 transmembrane domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 45.
110. The fusion polypeptide of any one of claims 80-109, wherein the CD4 transmembrane polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 45.
111. The fusion polypeptide of any one of claims 80-110, wherein the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 48.
112. The fusion polypeptide of any one of claims 80-111, wherein the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 49.
113. The fusion polypeptide of any one of claims 80-112, wherein the anti-CLL1 and anti-CD33 antibodies are each a sdAb.
114. The fusion polypeptide of claim 113, wherein the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb).
115. The fusion polypeptide of any one of claims 80-114, wherein the sdAb is a camelid VHH.
116. The fusion polypeptide of any one of claims 80-115, wherein the scFv or sdAb is human or humanized.
117. The fusion polypeptide of any one of claims 80-116, wherein the anti-CLL1 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 92, 93, and 94, respectively.
118. The fusion polypeptide of any one of claims 80-117, wherein the anti-CLL1 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 75.
119. The fusion polypeptide of any one of claims 80-118, wherein the anti-CLL1 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 75.

120. The fusion polypeptide of any one of claims 80-119, wherein the anti-CD33 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 89, 90, and 91, respectively.
121. The fusion polypeptide of any one of claims 80-120, wherein the anti-CD33 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72.
122. The fusion polypeptide of any one of claims 80-121, wherein the anti-CD33 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 72.
123. The fusion polypeptide of any one of claims 80-122, wherein the signaling component further comprises a signal sequence.
124. The fusion polypeptide of claim 123, wherein the signal sequence is a CD8 signal sequence.
125. The fusion polypeptide of claim 124, wherein the CD8 signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96.
126. The fusion polypeptide of claim 125, wherein the CD8 signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 96.
127. The fusion polypeptide of any one of claims 80-126, wherein the targeting component further comprises a signal sequence.
128. The fusion polypeptide of claim 127, wherein the signal sequence is an IgK signal sequence.
129. The fusion polypeptide of claim 128, wherein the IgK signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 95.
130. The fusion polypeptide of claim 129, wherein the IgK signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 95.

131. The fusion polypeptide of any one of claims 80-130, wherein the signaling component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 111.
132. The fusion polypeptide of claim 131, wherein the signaling component comprises a sequence set forth as SEQ ID NO: 111.
133. The fusion polypeptide of any one of claims 80-132, wherein the targeting component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth as SEQ ID NO: 122.
134. The fusion polypeptide of claim 133, wherein the targeting component comprises a sequence set forth as SEQ ID NO: 122.
135. The fusion polypeptide of any one of claims 80-134, comprising a fusion polypeptide which comprises the targeting component and the signaling component.
136. The fusion polypeptide of claim 135, wherein the fusion polypeptide comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 151.
137. The fusion polypeptide of claim 136, wherein the fusion polypeptide comprises a sequence set forth as SEQ ID NO: 151.
138. The fusion polypeptide of any one of claims 80-137, wherein the polypeptide cleavage signal is a viral self-cleaving polypeptide.
139. The fusion polypeptide of any one of claims 80-138, wherein the polypeptide cleavage signal is a viral self-cleaving 2A polypeptide.
140. A nucleic acid molecule that encodes the fusion polypeptide of any one of claims 80-139.
141. A cell comprising the fusion polypeptide of any one of claims 80-139.
142. A cell comprising the nucleic acid molecule of claim 140.
143. The cell of claim 140 or claim 141, further expressing an exogenous costimulatory factor, immunomodulatory factor, agonist for a costimulatory factor, antagonist for an immunosuppressive factor, immune cell engager, flip receptor, or any combination thereof.

144. The cell of any one of claims 141-143, wherein the cell further expresses an exogenous lymphocyte receptor or co-receptor.
145. The cell of claim 144, wherein the exogenous lymphocyte receptor or co-receptor is selected from the group consisting of: TCR alpha (TCR α), TCR beta (TCR β), TCR gamma (TCR γ), TCR delta (TCR δ), CD4, CD8, pre T cell receptor α (pT α), Fc receptor alpha (FcR α), Fc receptor beta (FcR β), Fc receptor gamma (FcR γ), natural killer group 2 member D (NKG2D), CD79A, CD79B, and any combination thereof.
146. The cell of any one of claims 141-145, wherein the cell further expresses an exogenous TCR.
147. The cell of claim 146, wherein the exogenous TCR binds a target antigen selected from the group consisting of: α -fetoprotein (AFP), B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CA1X), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human Epidermal Growth Factor Receptor 2 (HER-2), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X 8 (SSX8), Thyroglobulin, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, Wilms

tumor protein (WT-1), X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).

148. The cell of claim 146 or claim 147, wherein the exogenous TCR is an $\alpha\beta$ -TCR or $\gamma\delta$ -TCR.
149. The cell of any one of claims 141-148, wherein the cell further expresses a CAR, CCR, or flip receptor.
150. The cell of any one of claims 141-149, wherein the cell further expresses a zetakine, immune cell engager, or BiTE.
151. The cell of any one of claims 141-150, wherein the cell is a hematopoietic cell.
152. The cell of any one of claims 141-151, wherein the cell is a T cell, an $\alpha\beta$ -T cell, or a $\gamma\delta$ -T cell.
153. The cell of any one of claims 141-152, wherein the cell is a CD3⁺, CD4⁺, and/or CD8⁺ cell.
154. The cell of any one of claims 141-153, wherein the cell is an immune effector cell.
155. The cell of any one of claims 141-154, wherein the cell is a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell.
156. The cell of any one of claims 141-155, wherein the cell is a natural killer (NK) cell or natural killer T (NKT) cell.
157. The cell of any one of claims 141-156, wherein the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.
158. The cell of any one of claims 141-157, wherein the cell is an isolated cell.
159. The cell of any one of claims 141-158, wherein the cell is obtained from a subject.
160. The cell of any one of claims 141-159, wherein the cell is a human cell.
161. A polypeptide complex, comprising:

(a) a signaling component comprising (i) a first multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (ii) a first polypeptide linker, and (iii) a CD3 ϵ polypeptide or variant thereof; and

(b) a targeting component comprising (i) an anti-CLL1 scFv or single domain antibody (sdAb), (ii) an anti-CD33 scFv or single domain antibody (sdAb), (iii) a second polypeptide linker, (iv) a second multimerization domain comprising an FRB polypeptide or variant thereof or a FKBP polypeptide or variant thereof, (v) a CD4 hinge polypeptide, (vi) a CD4 transmembrane polypeptide, and (vii) a truncated CD4 intracellular polypeptide.

162. The polypeptide complex of claim 161, wherein the targeting component does not comprise a functional intracellular domain or costimulatory domain having signaling capabilities.

163. The polypeptide complex of any one of claims 161-162, wherein the CD4 hinge polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 41.

164. The polypeptide complex of any one of claims 161-163, wherein the CD4 hinge polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 41.

165. The polypeptide complex of any one of claims 161-164, wherein the CD3 ϵ polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 32.

166. The polypeptide complex of any one of claims 161-165, wherein the CD3 ϵ polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 32.

167. The polypeptide complex of any one of claims 161-166, wherein the CD3 ϵ polypeptide comprises both extracellular and intracellular portions.

168. The polypeptide complex of any one of claims 161-167, wherein the FRB and FKBP polypeptides localize extracellularly when the signaling and targeting components are expressed.

169. The polypeptide complex of any one of claims 161-168, wherein the first and second multimerization domains are different.

170. The polypeptide complex of any one of claims 161-169, wherein the first multimerization domain comprises an FRB polypeptide or variant thereof, and the second multimerization domain comprises an FKBP12 polypeptide or variant thereof.
171. The polypeptide complex of any one of claims 161-170, wherein the first multimerization domain comprises an FKBP12 polypeptide or variant thereof, and the second multimerization domain comprises an FRB polypeptide or variant thereof.
172. The polypeptide complex of any one of claims 161-171, wherein the FRB polypeptide is an FRB T2098L variant.
173. The polypeptide complex of any one of claims 161-172, wherein the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 1.
174. The polypeptide complex of any one of claims 161-173, wherein the FRB polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 2.
175. The polypeptide complex of any one of claims 161-174, wherein the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 3.
176. The polypeptide complex of any one of claims 161-175, wherein the FKBP12 polypeptide comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, 99%, identity to, or comprising a sequence set forth as SEQ ID NO: 4.
177. The polypeptide complex of any one of claims 161-176, wherein the multimerization domains of the signaling component and the targeting component associate with a bridging factor.
178. The polypeptide complex of claim 177, wherein the bridging factor is selected from the group consisting of: rapamycin or a rapalog thereof, gibberellin or a derivative thereof, abscisic acid (ABA) or a derivative thereof, methotrexate or a derivative thereof, cyclosporin A or a derivative thereof, FK506/cyclosporin A or a derivative thereof, trimethoprim (Tmp)-synthetic ligand for FK506 binding protein (FKBP) (SLF) or a derivative thereof, wherein

the bridging factor promotes the formation of a polypeptide complex, with the bridging factor associated with and disposed between the multimerization domains of the signaling and targeting components.

179. The polypeptide complex of claim 177 or claim 178, wherein the bridging factor is AP1903, AP20187, AP21967 (also known as C16-(S)-7-methylindolerapamycin), everolimus, novolimus, pimecrolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus, umirolimus, zotarolimus, or BPC015.
180. The polypeptide complex of any one of claims 161-179, wherein the first polypeptide linker is a linker of 2 to 40 amino acids in length.
181. The polypeptide complex of claim 180, wherein the first polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2xG4S, 3xG4S, 4xG4S, 5xG4S, and any combination thereof.
182. The polypeptide complex of claim 181, wherein the first polypeptide linker is a 3xG4S linker.
183. The polypeptide complex of any one of claims 161-182, wherein the second polypeptide linker is a linker of 2 to 40 amino acids in length.
184. The polypeptide complex of claim 183, wherein the second polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof.
185. The polypeptide complex of claim 184, wherein the second polypeptide linker is a G4S linker.
186. The polypeptide complex of any one of claims 161-185, wherein the anti-CLL1 scFv or sdAb and the anti-CD33 scFv or sdAb are separated by a third polypeptide linker.
187. The polypeptide complex of claim 186, wherein the third polypeptide linker is a linker of 2 to 40 amino acids in length.

188. The polypeptide complex of claim 187, wherein the third polypeptide linker is selected from the group consisting of: GG, GS, SG, SS, GSS, SSG, GSG, SGS, SGG, G4S, 2x G4S, 3xG4s, 4xG4S, and any combination thereof.
189. The polypeptide complex of claim 188, wherein the third polypeptide linker is a G4S linker.
190. The polypeptide complex of any one of claims 161-189, wherein the CD4 transmembrane domain comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 45.
191. The polypeptide complex of any one of claims 161-190, wherein the CD4 transmembrane polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 45.
192. The polypeptide complex of any one of claims 161-191, wherein the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 48.
193. The polypeptide complex of any one of claims 161-191, wherein the truncated intracellular CD4 polypeptide comprises an amino acid sequence as set forth in SEQ ID NO: 49.
194. The polypeptide complex of any one of claims 161-193, wherein the anti-CLL1 and anti-CD33 antibodies are each a sdAb.
195. The polypeptide complex of claim 194, wherein the sdAb is a camelid VHH, nanobody, or heavy chain-only antibody (HcAb).
196. The polypeptide complex of any one of claims 161-195, wherein the sdAb is a camelid VHH.
197. The polypeptide complex of any one of claims 161-196, wherein the scFv or sdAb is human or humanized.
198. The polypeptide complex of any one of claims 161-197, wherein the anti-CLL1 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOS: 92, 93, and 94, respectively.

199. The polypeptide complex of any one of claims 161-198, wherein the anti-CLL1 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 75.
200. The polypeptide complex of any one of claims 161-199, wherein the anti-CLL1 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 75.
201. The polypeptide complex of any one of claims 161-200, wherein the anti-CD33 scFv or sdAb comprises CDR1, CDR2, and CDR3 amino acid sequences as set forth in SEQ ID NOs: 89, 90, and 91, respectively.
202. The polypeptide complex of any one of claims 161-201, wherein the anti-CD33 scFv or sdAb comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 72.
203. The polypeptide complex of any one of claims 161-202, wherein the anti-CD33 scFv or sdAb comprises a sequence as set forth SEQ ID NO: 72.
204. The polypeptide complex of any one of claims 161-203, wherein the signaling component further comprises a signal sequence.
205. The polypeptide complex of claim 204, wherein the signal sequence is a CD8 signal sequence.
206. The polypeptide complex of claim 205, wherein the CD8 signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 96.
207. The polypeptide complex of claim 206, wherein the CD8 signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 96.
208. The polypeptide complex of any one of claims 161-207, wherein the targeting component further comprises a signal sequence.
209. The polypeptide complex of claim 208, wherein the signal sequence is an IgK signal sequence.

210. The polypeptide complex of claim 209, wherein the IgK signal sequence comprises an amino acid sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 95.
211. The polypeptide complex of claim 210, wherein the IgK signal sequence comprises an amino acid sequence set forth as SEQ ID NO: 95.
212. The polypeptide complex of any one of claims 161-211, wherein the signaling component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 111.
213. The polypeptide complex of claim 212, wherein the signaling component comprises a sequence set forth as SEQ ID NO: 111.
214. The polypeptide complex of any one of claims 161-213, wherein the targeting component comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to a sequence set forth as SEQ ID NO: 122.
215. The polypeptide complex of claim 214, wherein the targeting component comprises a sequence set forth as SEQ ID NO: 122.
216. The polypeptide complex of any one of claims 161-215, comprising a fusion polypeptide which comprises the targeting component and the signaling component.
217. The polypeptide complex of claim 216, wherein the fusion polypeptide comprises a sequence having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 151.
218. The polypeptide complex of claim 217, wherein the fusion polypeptide comprises a sequence set forth as SEQ ID NO: 151.
219. A nucleic acid molecule that encodes both the signaling component and the targeting component of the polypeptide complex of any one of claims 161-218.
220. A cell comprising the polypeptide complex of any one of claims 161-219.
221. A cell comprising the nucleic acid molecule of claim 220.
222. The cell of any one of claim 220 or 221, wherein the cell further expresses an exogenous costimulatory factor, immunomodulatory factor, agonist for a costimulatory factor,

antagonist for an immunosuppressive factor, immune cell engager, flip receptor, or any combination thereof.

223. The cell of any one of claims 220-222, wherein the cell further expresses an exogenous lymphocyte receptor or co-receptor.

224. The cell of claim 223, wherein the exogenous lymphocyte receptor or co-receptor is selected from the group consisting of: TCR alpha (TCR α), TCR beta (TCR β), TCR gamma (TCR γ), TCR delta (TCR δ), CD4, CD8, pre T cell receptor α (pT α), Fc receptor alpha (FcR α), Fc receptor beta (FcR β), Fc receptor gamma (FcR γ), natural killer group 2 member D (NKG2D), CD79A, CD79B, and any combination thereof.

225. The cell of any one of claims 220-224, wherein the cell further expresses an exogenous TCR.

226. The cell of claim 225, wherein the exogenous TCR binds a target antigen selected from the group consisting of: α -fetoprotein (AFP), B Melanoma Antigen (BAGE) family members, Brother of the regulator of imprinted sites (BORIS), Cancer-testis antigens, Cancer-testis antigen 83 (CT-83), Carbonic anhydrase IX (CA1X), Carcinoembryonic antigen (CEA), Cytomegalovirus (CMV) antigens, Cytotoxic T cell (CTL)-recognized antigen on melanoma (CAMEL), Epstein-Barr virus (EBV) antigens, G antigen 1 (GAGE-1), GAGE-2, GAGE-3, GAGE-4, GAGE-5, GAGE-6, GAGE-7B, GAGE-8, Glycoprotein 100 (GP100), Hepatitis B virus (HBV) antigens, Hepatitis C virus (HCV) non-structure protein 3 (NS3), Human Epidermal Growth Factor Receptor 2 (HER-2), Human papillomavirus (HPV)-E6, HPV-E7, Human telomerase reverse transcriptase (hTERT), IGF2BP3/A3, K-Ras, K-Ras G12C, K-Ras G12D, K-Ras G12V, Latent membrane protein 2 (LMP2), Melanoma antigen family A, 1 (MAGE-A1), MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10, MAGE-A12, Melanoma antigen recognized by T cells (MART-1), Mesothelin (MSLN), Mucin 1 (MUC1), Mucin 16 (MUC16), New York esophageal squamous cell carcinoma-1 (NYESO-1), P53, P antigen (PAGE) family members, Placenta-specific 1 (PLAC1), Preferentially expressed antigen in melanoma (PRAME), Survivin, Synovial sarcoma X 1 (SSX1), Synovial sarcoma X 2 (SSX2), Synovial sarcoma X 3 (SSX3), Synovial sarcoma X 4 (SSX4), Synovial sarcoma X 5 (SSX5), Synovial sarcoma X

8 (SSX8), Thyroglobulin, Tyrosinase, Tyrosinase related protein (TRP)1, TRP2, Wilms tumor protein (WT-1), X Antigen Family Member 1 (XAGE1), and X Antigen Family Member 2 (XAGE2).

227. The cell of claim 225 or claim 226, wherein the exogenous TCR is an $\alpha\beta$ -TCR or $\gamma\delta$ -TCR.
228. The cell of any one of claims 220-227, wherein the cell further expresses a CAR, CCR, or flip receptor.
229. The cell of any one of claims 220-228, wherein the cell further expresses a zetakine, immune cell engager, or BiTE.
230. The cell of any one of claims 220-229, wherein the cell is a hematopoietic cell.
231. The cell of any one of claims 220-230, wherein the cell is a T cell, an $\alpha\beta$ -T cell, or a $\gamma\delta$ -T cell.
232. The cell of any one of claims 220-231, wherein the cell is a CD3⁺, CD4⁺, and/or CD8⁺ cell.
233. The cell of any one of claims 220-232, wherein the cell is an immune effector cell.
234. The cell of any one of claims 220-233, wherein the cell is a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell.
235. The cell of any one of claims 220-234, wherein the cell is a natural killer (NK) cell or natural killer T (NKT) cell.
236. The cell of any one of claims 220-235, wherein the source of the cell is peripheral blood mononuclear cells, bone marrow, lymph nodes tissue, cord blood, thymus issue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, or tumors.
237. The cell of any one of claims 220-236, wherein the cell is an isolated cell.
238. The cell of any one of claims 220-237, wherein cell is obtained from a subject.
239. The cell of any one of claims 220-238, wherein the cell is a human cell.

240. A polynucleotide encoding the signaling and targeting component of the fusion polypeptide of any one of claims 80-139 or the polypeptide complex of any one of claims 161-219.
241. A cDNA encoding the signaling and targeting component of the fusion polypeptide of any one of claims 80-139 or the polypeptide complex of any one of claims 161-219.
242. An RNA encoding the signaling and targeting component of any one of claims 1-79, 141-160, or 220-239, or the fusion polypeptide of any one of claims 80-139, or the polypeptide complex of any one of claims 161-218.
243. A vector comprising the polynucleotide of claim 240.
244. The vector of claim 243, wherein the vector is an expression vector.
245. The vector of claim 243, wherein the vector is a transposon.
246. The vector of claim 243, wherein the vector is a piggyBAC transposon or a Sleeping Beauty transposon.
247. The vector of claim 243, wherein the vector is a viral vector.
248. The vector of claim 247, wherein the vector is an adenoviral vector, an adeno-associated viral (AAV) vector, a herpes virus vector, a vaccinia virus vector, or a retroviral vector.
249. The vector of claim 248, wherein the retroviral vector is a lentiviral vector.
250. The vector of claim 249, wherein the lentiviral vector is selected from the group consisting of: human immunodeficiency virus 1 (HIV-1); human immunodeficiency virus 2 (HIV-2), visna-maedi virus (VMV) virus; caprine arthritis-encephalitis virus (CAEV); equine infectious anemia virus (EIAV); feline immunodeficiency virus (FIV); bovine immune deficiency virus (BIV); and simian immunodeficiency virus (SIV).
251. A cell comprising the fusion polypeptide of any one of claims 80-139, the polynucleotide of claim 240, or the vector of any one of claims 243-250.
252. The cell of claim 251, wherein the cell is a hematopoietic cell.
253. The cell of claim 251 or claim 252, wherein the cell is an immune effector cell.

254. The cell of any one of claims 251-253, wherein the cell is a T cell, an $\alpha\beta$ T cell, or a $\gamma\delta$ T cell.
255. The cell of any one of claims 251-244, wherein the cell expresses CD3⁺, CD4⁺, CD8⁺, or a combination thereof.
256. The cell of any one of claims 251-255, wherein the cell is a cytotoxic T lymphocyte (CTL), a tumor infiltrating lymphocyte (TIL), or a helper T cell.
257. The cell of any one of claims 251-266, wherein the cell is a natural killer (NK) cell or natural killer T (NKT) cell.
258. A composition comprising a cell according to any one of claims 1-79, 141-160, 220-239, or 251-257, or the vector of any one of claims 243-250.
259. A composition comprising a physiologically acceptable carrier and a cell according to any one of claims 1-79, 141-160, 220-239, or 251-257, or the vector of any one of claims 243-250.
260. A method of treating a subject in need thereof comprising administering the subject an effective amount of the composition of claim 258 or claim 259.
261. A method of treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith, comprising administering to the subject an effective amount of the composition of claim 258 or claim 259.
262. A method of treating a solid cancer comprising administering to the subject an effective amount of the composition of claim 258 or claim 259.
263. The method of claim 262, wherein the solid cancer is selected from the group consisting of: lung cancer, squamous cell carcinoma, colorectal cancer, pancreatic cancer, breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, or brain cancer.
264. The method of claim 262 or claim 263, wherein the solid cancer is a non-small cell lung carcinoma, head and neck squamous cell carcinoma, colorectal cancer, pancreatic cancer,

breast cancer, thyroid cancer, bladder cancer, cervical cancer, esophageal cancer, ovarian cancer, gastric cancer endometrial cancer, gliomas, glioblastomas, or oligodendroglioma.

265. A method of treating a hematological malignancy comprising administering to the subject an effective amount of the composition of claim 258 or claim 259.
266. The method of claim 265, wherein the hematological malignancy is a leukemia, lymphoma, or multiple myeloma.
267. The method of claim 265, wherein the hematological malignancy is acute myelogenous leukemia (AML).
268. The non-natural cell of any one of claims 1-79, wherein the cell further comprises a polypeptide having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 137.
269. The non-natural cell of any one of claims 1-79, wherein the cell further comprises a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 137.
270. The non-natural cell of any one of claims 1-79, wherein the cell further comprises a polypeptide having at least 90%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 138.
271. The non-natural cell of any one of claims 1-79, wherein the cell further comprises a polypeptide having an amino acid sequence as set forth in SEQ ID NO: 138.




FIG. 1A




FIG. 1B




FIG. 1C




FIG. 1D

5/78




FIG. 1E




FIG. 1F

7/78




FIG. 1G

8/78




FIG. 1H




FIG. 2




FIG. 3




FIG. 4




FIG. 5A




FIG. 5B





FIG. 6




FIG. 7A




FIG. 7B




FIG. 7C




FIG. 8




FIG. 9A




FIG. 9B

19/78





FIG. 10




FIG. 11




FIG. 12




FIG. 13A

FIG. 13B

23/78





FIG. 14




FIG. 15




FIG. 16

+ Rapamycin - Proliferation




FIG. 17B

+ Rapamycin - Cytotoxicity




FIG. 17A



FIG. 18




FIG. 19




FIG. 20




FIG. 21A

FIG. 21B




FIG. 22




FIG. 23




FIG. 24




FIG. 25A




FIG. 25B

35/78




FIG. 26B




FIG. 26A

36/78




FIG. 26D




FIG. 26C




FIG. 27A




FIG. 27B




FIG. 27C




FIG. 28A

FIG. 28B




FIG. 29




FIG. 30




FIG. 31B




FIG. 31A




FIG. 32B




FIG. 32A




FIG. 32D

FIG. 32C




FIG. 33




FIG. 34





FIG. 35A




FIG. 35B

Vβ1 gMFI
Gated within Vβ1+ cells




FIG. 35C




FIG. 35E





FIG. 35D



51/78




FIG. 36B




FIG. 36C




FIG. 37B




FIG. 37A




FIG. 38




FIG. 39A

FRB expression +/-Rapaycin




FIG. 39B

VHH expression +/-Rapamycin




FIG. 39C




FIG. 40B

FIG. 40A




FIG. 41B





FIG. 41A



58/78

FIG. 42B





FIG. 42A



59/78

FIG. 42D




FIG. 42C






FIG. 43A

FIG. 43B



CH3 and CH3* are CH3 heterodimerization domain pairs derived from bispecific antibody engineering

FIG. 44




FIG. 45B




FIG. 45A




FIG. 46B




FIG. 46A




FIG. 47




FIG. 48A

FIG. 48B




FIG. 49




FIG. 50A

FIG. 50B




FIG. 50C

FIG. 50D




FIG. 51




FIG. 52




FIG. 53B

FIG. 53A




FIG. 53D




FIG. 53C




FIG. 54




FIG. 55B

FIG. 55A




FIG. 55D

FIG. 55C




FIG. 56




FIG. 57B




FIG. 57A

78/78




FIG. 57C